AU2003263992A1 - Method of identifying compounds that modulate protein activity - Google Patents

Description

WO 2004/013347 PCT/US2003/024504 METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE PROTEIN ACTIVITY TECHNICAL FIELD 5 The present invention relates to novel polypeptides that are targets of small molecule drugs and that have properties related to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. More particularly, the novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use encompass screening, diagnostic, and prognostic 10 assay procedures as well as methods of treating diverse pathological conditions.

WO 2004/013347 PCTIUS2003/024504 BACKGROUND Obesity and diabetes are major public health concerns in the developed and developing world. It is estimated that over half of the adult US population is overweight. 2 WO 2004/013347 PCT/US2003/024504 This includes those with a body mass index (BMI) greater than the upper limit of normal (25) where the BMI is defined as the weight (Kg) / [height (n)] 2 . A common consequence of being overweight is hyperlipidemia and the development of insulin resistance. This is followed by the development of hyperglycemia, a hallmark of Type II diabetes. Left 5 untreated, the hyperglycemia leads to microvascular disease and end organ damage that includes retinopathy, renal disease, cardiac disease, peripheral neuropathy and peripheral vascular compromise. Currently, over 16 million adults in the US are affected by Type II diabetes and the condition has now become rampant among school-age children as a consequence of the epidemic of obesity in that age group. 10 Diabetes mellitus is a disorder in which blood levels of glucose (a simple sugar) are abnormally high because the body doesn't release or respond to insulin adequately. Blood sugar (glucose) levels vary throughout the day, rising after a meal and returning to normal within 2 hours. Blood sugar levels are normally between 70 and 110 milligrams per deciliter (mg/dL) of blood in the morning after an overnight fast. They are usually lower than 15 120 to 140 mg/dL 2 hours after eating foods or drinking liquids containing sugar or other carbohydrates. Insulin, a hormone released from the pancreas, is the primary substance responsible for maintaining appropriate blood sugar levels. Insulin allows glucose to be transported into cells so that they can produce energy or store glucose-derived enrgy until it's needed. The 20 rise in blood sugar levels after eating or drinking stimulates the pancreas to produce insulin, preventing a greater rise in blood sugar levels and causing them to fall gradually. Because muscles use glucose for energy, blood sugar levels can also fall during physical activity. Diabetes results when the body doesn't produce enough insulin to maintain normal blood sugar levels or when cells don't respond appropriately to insulin. In type II diabetes 25 mellitus, the pancreas continues to manufacture insulin, sometimes even at higher than normal levels. However, the body develops resistance to its effects, resulting in a relative insulin deficiency. The main goal of diabetes treatment is to keep blood sugar levels within the normal range as much as possible. Completely normal levels are difficult to maintain, but the more 30 closely they can be kept within the normal range, the less likely that temporary or long-term complications will develop. Therefore, a therapeutic that decreases insulin resistance and/or enhances insulin secretion would be beneficial in treatment of obesity and/or diabetes. Additionally, such a 3 WO 2004/013347 PCT/US2003/024504 therapeutic would be beneficial in treatment of insulin resistance, a condition that often leads to the development of diabetes. In order to treat diseases, pathologies and other abnormal states or conditions in which a mammalian organism has been diagnosed as being, or as being at risk for becoming, 5 other than in a normal state or condition, it is important to identify new therapeutic agents. Eukaryotic cells are characterized by biochemical and physiological processes which under normal conditions are exquisitely balanced to achieve the preservation and propagation of the cells. When such cells are components of multicellular organisms such as vertebrates, or more particularly organisms such as mammals, the regulation of the 10 biochemical and physiological processes involves intricate signaling pathways. Frequently, such signaling pathways involve extracellular signaling proteins, cellular receptors that bind the signaling proteins and signal transducing components located within the cells. Signaling proteins may be classified as endocrine effectors, paracrine effectors or autocrine effectors. Endocrine effectors are signaling molecules secreted by a given organ 15 into the circulatory system, which are then transported to a distant target organ or tissue. The target cells include the receptors for the endocrine effector, and when the endocrine effector binds, a signaling cascade is induced. Paracrine effectors involve secreting cells and receptor cells in close proximity to each other, for example two different classes of cells in the same tissue or organ. One class of cells secretes the paracrine effector, which then 20 reaches the second class of cells, for example by diffusion through the extracellular fluid. The second class of cells contains the receptors for the paracrine effector; binding of the effector results in induction of the signaling cascade that elicits the corresponding biochemical or physiological effect. Autocrine effectors are highly analogous to paracrine effectors, except that the same cell type that secretes the autocrine effector also contains the 25 receptor. Thus the autocrine effector binds to receptors on the same cell, or on identical neighboring cells. The binding process then elicits the characteristic biochemical or physiological effect. Signaling processes may elicit a variety of effects on cells and tissues including by way of nonlimiting example induction of cell or tissue proliferation, suppression of growth 30 or proliferation, induction of differentiation or maturation of a cell or tissue, and suppression of differentiation or maturation of a cell or tissue. Many pathological conditions involve dysregulation of expression of important effector proteins. In certain classes of pathologies the dysregulation is manifested as diminished or suppressed level of synthesis and secretion of protein effectors. In other 4 WO 2004/013347 PCT/US2003/024504 classes of pathologies the dysregulation is manifested as increased or up-regulated level of synthesis and secretion of protein effectors. In a clinical setting a subject may be suspected of suffering from a condition brought on by altered or mis-regulated levels of a protein effector of interest. Therefore there is a need to assay for the level of the protein effector of 5 interest in a biological sample from such a subject, and to compare the level with that characteristic of a nonpathological condition. There also is a need to provide the protein effector as a product of manufacture. Administration of the effector to a subject in need thereof is useful in treatment of the pathological condition. Accordingly, there is a need for a method of treatment of a pathological condition brought on by a diminished or suppressed 10 levels of the protein effector of interest. In addition, there is a need for a method of treatment of a pathological condition brought on by a increased or up-regulated levels of the protein effector of interest. Small molecule targets have been implicated in various disease states or pathologies. These targets may be proteins, and particularly enzymatic proteins, which are acted upon by 15 small molecule drugs for the purpose of altering target function and achieving a desired result. Cellular, animal and clinical studies can be performed to elucidate the genetic contribution to the etiology and pathogenesis of conditions in which small molecule targets are implicated in a variety of physiologic, pharmacologic or native states. These studies utilize the core technologies at CuraGen Corporation to look at differential gene expression, 20 protein-protein interactions, large-scale sequencing of expressed genes and the association of genetic variations such as, but not limited to, single nucleotide polymorphisms (SNPs) or splice variants in and between biological samples from experimental and control groups. The goal of such studies is to identify potential avenues for therapeutic intervention in order to prevent, treat the consequences or cure the conditions. 25 In order to treat diseases, pathologies and other abnormal states or conditions in which a mammalian organism has been diagnosed as being, or as being at risk for becoming, other than in a normal state or condition, it is important to identify new therapeutic agents. Such a procedure includes at least the steps of identifying a target component within an affected tissue or organ, and identifying a candidate therapeutic agent that modulates the 30 functional attributes of the target. The target component may be any biological macromolecule implicated in the disease or pathology. Commonly the target is a polypeptide or protein with specific functional attributes. Other classes of macromolecule may be a nucleic acid, a polysaccharide, a lipid such as a complex lipid or a glycolipid; in addition a target may be a sub-cellular structure or extra-cellular structure that is comprised 5 WO 2004/013347 PCT/US2003/024504 of more than one of these classes of macromolecule. Once such a target has been identified, it may be employed in a screening assay in order to identify favorable candidate therapeutic agents from among a large population of substances or compounds. In many cases the objective of such screening assays is to identify small molecule 5 candidates; this is commonly approached by the use of combinatorial methodologies to develop the population of substances to be tested. The implementation of high throughput screening methodologies is advantageous when working with large, combinatorial libraries of compounds. 10 SUMMARY OF THE INVENTION The invention includes nucleic acid sequences and the novel polypeptides they encode. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOVI, NOV2, NOV3, etc., nucleic acids and polypeptides. These nucleic acids and 15 polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as "NOVX" nucleic acid, which represents the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 85, or polypeptide sequences, which represents the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 85. 20 In one aspect, the invention provides an isolated polypeptide comprising a mature form of a NOVX amino acid. One example is a variant of a mature form of a NOVX amino acid sequence, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. The amino acid can be, for example, a NOVX amino acid 25 sequence or a variant of a NOVX amino acid sequence, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed. The invention also includes fragments of any of these. In another aspect, the invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative 30 thereof. Also included in the invention is a NOVX polypeptide that is a naturally occurring allelic variant of a NOVX sequence. In one embodiment, the allelic variant includes an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a NOVX nucleic acid sequence. In another embodiment, the NOVX 6 WO 2004/013347 PCT/US2003/024504 polypeptide is a variant polypeptide described therein, wherein any amino acid specified'in the chosen sequence is changed to provide a conservative substitution. In one embodiment, the invention discloses a method for determining the presence or amount of the NOVX polypeptide in a sample. The method involves the steps of: providing a sample; introducing 5 the sample to an antibody that binds immunospecifically to the polypeptide; and determining the presence or amount of antibody bound to the NOVX polypeptide, thereby determining the presence or amount of the:NOVX polypeptide in the sample. In another embodiment, the invention provides a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide in a mammalian subject. This method 10 involves the steps of: measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and comparing the amount of the polypeptide in the sample of the first step to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, the disease, wherein an alteration in the expression level of the polypeptide in the first subject as compared to the 15 control sample indicates the presence of or predisposition to the disease. In a further embodiment, the invention includes a method of identifying an agent that modulates a NOVX polypeptide. This method involves the steps of: introducing the polypeptide to the agent; and determining whether the agent binds to the polypeptide. In various embodiments, the agent is a cellular receptor or a downstream effector. 20 In another aspect, the invention provides a method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of a NOVX polypeptide. The method involves the steps of: providing a cell expressing the NOVX polypeptide and having a property or function ascribable to the polypeptide; contacting the cell with a composition 25 comprising a candidate substance; and determining whether the substance alters the property or function ascribable to the polypeptide; whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition devoid of the substance, the substance is identified as a potential therapeutic agent. In another aspect, the invention describes a method for screening for a modulator of activity or of latency or 30 predisposition to a pathology associated with the NOVX polypeptide. This method involves the following steps: administering a test compound to a test animal at increased risk for a pathology associated with the NOVX polypeptide, wherein the test animal recombinantly expresses the NOVX polypeptide. This method involves the steps of measuring the activity of the NOVX polypeptide in the test animal after administering the compound of step; and 7 WO 2004/013347 PCT/US2003/024504 comparing the activity of the protein in the test animal with the activity of the NOVX polypeptide in a control animal not administered the polypeptide, wherein a change in the activity of the NOVX polypeptide in the test animal relative to the control animal indicates that the test compound is a modulator of latency of, or predisposition to, a pathology 5 associated with the NOVX polypeptide. In one embodiment, the test animal is a recombinant test animal that expresses a test protein transgene or expresses the transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein the promoter is not the native gene promoter of the transgene. In another aspect, the invention includes a method for modulating the activity of the NOVX polypeptide, the 10 method comprising introducing a cell sample expressing the NOVX polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide. In order to treat diseases, pathologies and other abnormal states or conditions in which a mammalian organism has been diagnosed as being, or as being at risk for becoming, 15 other than in a normal state or condition, it is important to identify new therapeutic agents. Such a procedure includes at least the steps of identifying a target component within an affected tissue or organ, and identifying a candidate therapeutic agent that modulates the functional attributes of the target. The target component may be any biological macromolecule implicated in the disease or pathology. Commonly the target is a 20 polypeptide or protein with specific functional attributes. Other classes of macromolecule may be a nucleic acid, a polysaccharide, a lipid such as a complex lipid or a glycolipid; in addition a target may be a sub-cellular structure or extra-cellular structure that is comprised of more than one of these classes of macromolecule. Once such a target has been identified, it may be employed in a screening assay in order to identify favorable candidate therapeutic 25 agents from among a large population of substances or compounds. In many cases the purpose of such screening assays is to identify small molecule candidates; this is commonly approached by the use of combinatorial methodologies to develop the population of substances to be tested. The implementation of high throughput screening methodologies is advantageous when working with large, combinatorial libraries 30 of compounds. It is a purpose of this invention to provide cell lines that recombinantly or endogenously express the target biopolymer or an isolated target biopolymer that is intended to serve as the macromolecular component in a screening assay for identifying candidate pharmaceutical agents. 8 WO 2004/013347 PCT/US2003/024504 It is another purpose of the present invention to provide screening assays that positively identify candidate pharmaceutical agents from among a combinatorial library of low molecular weight substances or compounds. It is still a further aspect of this invention to employ the candidate pharmaceutical 5 agents in any of a variety of in vitro, ex vivo and in vivo assays in order to identify pharmaceutical agents with advantageous therapeutic applications in the treatment of a disease, pathology, or abnormal state or condition in a mammal. In another aspect, the present invention provides a method of identifying a test compound as a candidate therapeutic agent, for treating a disease, pathology, or an abnormal 10 state or condition using a target polypeptide (NOVX) having a specific association with the disease. This method includes: (a) combining a test compound with a target polypeptide and a substrate of the target polypeptide; and (b) determining whether the test compound modulates the activity of the target 15 polypeptide. In one embodiment of this method, the chemical compound is a member of a combinatorial library of compounds; the combining in step (a) is conducted on one or more replicate samples of the biopolymer; and the replicate sample is contacted with at least one member of the combinatorial library. In additional embodiments of this method, the 20 biopolymer is included within a cell and is functionally expressed therein. In still a further embodiment, the binding of the compound modulates the function of the biopolymer, and it is the modulation that provides the identification that the compound is a potential therapeutic agent. In yet further embodiments of this method, the target biopolymer is a polypeptide. As used herein, a "substrate" includes any compound capable of binding to or 25 interacting with a target polypeptide, including but not limited to a peptide, a polypeptide, a nucleic acid, a carbohydrate moiety, a lipid, a small molecule (e.g., cyclic AMP, ATP), an agonist, an antagonist, and an inhibitor. In another aspect of the invention, a method for identifying a pharmaceutical agent for treating a disease, pathology, or an abnormal state or condition is provided. The method 30 includes the steps of: (1) identifying a candidate therapeutic agent for treating said disease, pathology, or abnormal state or condition by the method described in the preceding paragraphs; 9 WO 2004/013347 PCT/US2003/024504 (2) contacting a biological sample associated with the disease, pathology, or abnormal state or condition with the candidate therapeutic agent; (3) determining whether the candidate induces an effect on the biological sample associated with a therapeutic response therein; and 5 (4) identifying a candidate exerting such an effect as a pharmaceutical agent. In significant embodiments of the method, the biological sample includes a cell, a tissue or organ, or is a nonhuman mammal. Several cellular, animal and clinical studies were performed to elucidate the genetic contribution to the etiology and pathogenesis of these conditions in a variety of physiologic, 10 pharmacologic or native states. These studies utilized the core technologies at CuraGen Corporation to look at differential gene expression, protein-protein interactions, large-scale sequencing of expressed genes and the association of genetic variations such as, but not limited to, single nucleotide polymorphisms (SNPs) or splice variants in and between biological samples from experimental and control groups. The goal of such studies is to 15 identify various therapeutic interventions in order to prevent, treat the consequences or cure the conditions of obesity and/or diabetes. The present invention discloses novel associations of proteins and polypeptides and the nucleic acids that encode them with various diseases or pathologies. The proteins and related proteins that are similar to them, are encoded by a cDNA and/or by genomic DNA. 20 The proteins, polypeptides and their cognate nucleic acids were identified by the inventors in certain cases. Additionally, the current invention embodies the use of recombinantly expressed and/or endogenously expressed protein in various screens to identify therapeutic antibodies and/or therapeutic small molecules which modulate activity of the disclosed NOVX polypeptides. 25 The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. In a preferred embodiment, the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant. In another embodiment, the nucleic acid encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a 30 naturally occurring polypeptide variant. In another embodiment, the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence. In one embodiment, the NOVX nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer 10 WO 2004/013347 PCT/US2003/024504 between 1 and 85, or a complement of the nucleotide sequence. In another aspect, the invention provides a vector or a cell expressing a NOVX nucleotide sequence. In one embodiment, the invention discloses a method for modulating the activity of a NOVX polypeptide. The method includes the steps of: introducing a cell sample expressing 5 the NOVX polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide. In another embodiment, the invention includes an isolated NOVX nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising a NOVX amino acid sequence or a variant of a mature form of the NOVX amino acid sequence, wherein any amino acid in the mature form of the 10 chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. In another embodiment, the invention includes an amino acid sequence that is a variant of the NOVX amino acid sequence, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the 15 sequence are so changed. In one embodiment, the invention discloses a NOVX nucleic acid fragment encoding at least a portion of a NOVX polypeptide or any variant of the polypeptide, wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed, In another 20 embodiment, the invention includes the complement of any of the NOVX nucleic acid molecules or a naturally occurring allelic nucleic acid variant. In another embodiment, the invention discloses a NOVX nucleic acid molecule that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the invention discloses a NOVX nucleic acid, 25 wherein the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence. In another aspect, the invention includes a NOVX nucleic acid, wherein one or more nucleotides in the NOVX nucleotide sequence is changed to a different nucleotide provided that no more than 15% of the nucleotides are so changed. In one embodiment, the invention 30 discloses a nucleic acid fragment of the NOVX nucleotide sequence and a nucleic acid fragment wherein one or more nucleotides in the NOVX nucleotide sequence is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed. In another embodiment, the invention includes a nucleic acid molecule wherein the nucleic acid molecule hybridizes 11 WO 2004/013347 PCT/US2003/024504 under stringent conditions to a NOVX nucleotide sequence or a complement of the NOVX nucleotide sequence. In one embodiment, the invention includes a nucleic acid molecule, wherein the sequence is changed such that no more than 15% of the nucleotides in the coding sequence differ from the NOVX nucleotide sequence or a fragment thereof. 5 In a further aspect, the invention includes a method for determining the presence or amount of the NOVX nucleic acid in a sample. The method involves the steps of: providing the sample; introducing the sample to a probe that binds to the nucleic acid molecule; and determining the presence or amount of the probe bound to the NOVX nucleic acid molecule, thereby determining the presence or amount of the NOVX nucleic acid molecule in the 10 sample. In one embodiment, the presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type. In another aspect, the invention discloses a method for determining the presence of or predisposition to a disease associated with altered levels of the NOVX nucleic acid molecule of in a first mammalian subject. The method involves the steps of: measuring the amount of 15 NOVX nucleic acid in a sample from the first mammalian subject; and comparing the amount of the nucleic acid in the sample of step (a) to the amount of NOVX nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the 20 disease. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are 25 described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. 30 Other features and advantages of the invention will be apparent from the following detailed description and claims. 12 WO 2004/013347 PCT/US2003/024504 BRIEF DESCRIPTION OF THE FIGURES Figure 1 is a schematic diagram of the non-oxidative stage of the pentose phosphate pathway indicating the function of transketolase in the pathway. Figure 2 is a schematic diagram illustrating the roles of SREBP-regulated genes during 5 excess citrate production. Figure 3 is a schematic diagram illustrating representative pathways relevant to the etiology and pathogenesis of obesity and/or diabetes. Figure 4 is a schematic diagram illustrating the pyruvate sythesis pathway. DETAILED DESCRIPTION OF THE INVENTION 10 The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences, their encoded polypeptides, antibodies, and other related compounds. The sequences are collectively referred to herein as "NOVX nucleic acids" or "NOVX polynucleotides" and the corresponding encoded polypeptides are referred to as "NOVX polypeptides" or "NOVX proteins." Unless indicated 15 otherwise, "NOVX" is meant to refer to any of the novel sequences disclosed herein. Table 1 provides a summary of the NOVX nucleic acids and their encoded polypeptides. TABLE 1. Sequences and Corresponding SEQ ID Numbers SEQ ID SEQ ID NOVX Internal NO NO Homology Assignment Identification (nucleic (amino acid) acid) NOVia CG101190-01 1 2 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] (EC 4.1.1.32) (Phosphoenolpyruvate carboxylase) (PEPCK-C) - Homo sapiens NOVlb 278992806 3 4 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] (EC 4.1.1.32) (Phosphoenolpyruvate carboxylase) (PEPCK-C) - Homo sapiens NOVlc 278992862 5 6 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] (EC 4.1.1.32) (Phosphoenolpyruvate carboxylase) (PEPCK-C) - Homo sapiens NOV2a CG175387-01 7 8 Transketolase (EC 2.2.1.1) (TK) - Homo a _sapiens NOV2b CG173387-03 9 10 Transketolase (EC 2.2.1.1) (TK) - Homo 13 WO 2004/013347 PCT/US2003/024504 sapiens NOV2c 267254044 11 12 Transketolase (EC 2.2.1.1) (TK) - Homo sapiens NOV2d CG175387-02 13 14 Transketolase (EC 2.2.1.1) (TK) - Homo sapiens NOV2e CG175387-04 15 16 Transketolase (EC 2.2.1.1) (TK) - Homo sapiens NOV3a CG180320-01 17 20 Hypothetical protein FLJ23378 - Homo sapiens NOV3b CG 180320-02 19 20 Hypothetical protein FLJ23378 - Homo sapiens NOV3c CG180320-03 21 22 Hypothetical protein FLJ23378 - Homo sapiens NOV3d 30563200 25 24 Hypothetical protein FLJ23378 -Homo sapiens NOV3e 305263028 25 26 Hypothetical protein FLJ23378 - Homo sapiens NOV3f CG 180320-05 27 28 Hypothetical protein FLJ23378 - omo sapiens NOV4a CG181387-01 29 30 3-ketoacyl-CoA thiolase, mitochondrial (EC 2.3.1.16) (Beta- ketothiolase) (Acetyl-CoA acyltransferase) (Mitochondrial 3-oxoacyl- CoA thiolase) (Ti) - Homo sapiens NOV4b 282274427 31 32 3-ketoacyl-CoA thiolase, mitochondrial (EC 2.3.1.16) (Beta- ketothiolase) (Acetyl-CoA acyltransferase) (Mitochondrial 3-oxoacyl- CoA thiolase) . (TI) - Homo sapiens NOV4c CG181387-02 33 34 3-ketoacyl-CoA thiolase, mitochondrial (EC 2.3.1.16) (Beta- ketothiolase) (Acetyl-CoA acyltransferase) (Mitochondrial 3-oxoacyl- CoA thiolase) (TI) - Homo sapiens NOV4d 306268235 35 36 3-ketoacyl-CoA thiolase, mitochondrial (EC 2.3.1.16) (Beta- ketothiolase) (Acetyl-CoA acyltransferase) (Mitochondrial 3-oxoacyl- CoA thiolase) (Ti) - Homo sapiens NOV4e CG181387-03 37 38 3-ketoacyl-CoA thiolase, mitochondrial (EC 2.3.1.16) (Beta- ketothiolase) (Acetyl-CoA acyltransferase) (Mitochondrial 3-oxoacyl- CoA thiolase) -- __----- __(TI) - Homo sapiens NOV4f CG181387-04 39 40 3-ketoacyl-CoA thiolase, mitochondrial (EC 2.3.1.16) (Beta- ketothiolase) (Acetyl-CoA acyltransferase) (Mitochondrial 3-oxoacyl- CoA thiolase) 14 WO 2004/013347 PCT/US2003/024504 (TI) - Homo sapiens NOV4g CG181387-05 41 42 3-ketoacyl-CoA thiolase, mitochondrial (EC 2.3.1.16) (Beta- ketothiolase) (Acetyl-CoA acyltransferase) (Mitochondrial 3-oxoacyl- CoA thiolase) (Ti) - Homo sapiens NOV4h CG181387-06 43 44 3-ketoacyl-CoA thiolase, mitochondrial (EC 2.3.1.16) (Beta- ketothiolase) (Acetyl-CoA acyltransferase) (Mitochondrial 3-oxoacyl- CoA thiolase) (TI) - Homo sapiens NOV5a CG186640-02 45 46 phosphoglycerate mutase (EC 5.4.2.1) M NOV5b 311980359 47 48 phosphoglycerate mutase (EC 5.4.2.1) M NOV~c CG186640-01 49 150 phosphoglycerate mutase (EC 5.4.2.1) M NOV5d CGI86640-03 51 52 phosphoglycerate mutase (EC 5.4.2.1) M NOV5e CG186640-04 53 54 phosphoglycerate mutase (EC 5.4.2.1) M NOV6a CG58655-01 55 56 Adenosine Al receptor - Homo sapiens NOV6b 268368558 57 58 Adenosine Al receptor - Homo sapiens NOV7a CG96859-03 59 60 Hydroxymethylglutaryl-CoA lyase, mitochondrial precursor (EC 4.1.3.4) (HMG-CoA lyase) (HL) (3-hydroxy-3 methylglutarate-CoA lyase) - Homo sapiens NOV7b 223317153 61 62 Hydroxymethylglutaryl-CoA lyase, mitochondrial precursor (EC 4.1.3.4) (HM4G-CoA lyase) (HL) (3-hydroxy-3 rnethylglutarate-CoA lyase) - Homo sapiens NOV7c CG96859-01 63 64 Hydroxymethylglutaryl-CoA lyase, mitochondrial precursor (EC 4.1.3.4) (HMG-CoA lyase) (HL) (3-hydroxy-3 methylglutarate-CoA lyase) - Homo sapiens NOV7f CG96859-025 69 6 Hydroxymethylglutaryl-CoA lyase, mitochondrial precursor (EC 4.1.3.4) (HMG-CoA lyase) (HL) (3-hydroxy-3 methylglutarate-CoA lyase) - Homo sapiens NOV7e CG96859-04 67 68 Hydroxymethylglutaryl-CoA lyase, mitochondrial precursor (EC 4.1.3.4) (HMG-CoA lyase) (HL) (3-hydroxy-3 methylglutarate-CoA lyase) - Homo I sapiens NOV7f CEG96859-05 69 70 Hydroxymnethylglutaryl-CoA lyase, mitochondrial precursor (EC 4.1.3.4) (HMG-CoA lyase) (HL) (3-hydroxy-3 methylglutarate-CoA lyase) - Homo 15 WO 2004/013347 PCT/US2003/024504 NOV7g CG96859-06 71 72 Hydroxymethylglutaryl-CoA lyase, mitochondrial precursor (EC 4.1.3.4) (HMG-CoA lyase) (HL) (3-hydroxy-3 methylglutarate-CoA lyase) - Homo sapiens NOV7h CG96859-07 73 74 Hydroxymethylglutaryl-CoA lyase, mitochondrial precursor (EC 4.1.3.4) (HMG-CoA lyase) (HL) (3-hydroxy-3 methylglutarate-CoA lyase) -Homo sapiens NOV7i CG96859-08 75 76 Hydroxymethylglutaryl-CoA lyase, mitochondrial precursor (EC 4.1.3.4) (HMG-CoA lyase) (HL) (3-hydroxy-3 methylglutarate-CoA lyase) - Homo sapiens NOV7j CG96859-09 77 78 Hydroxymethylglutaryl-CoA lyase, mitochondrial precursor (EC 4.1.3.4) (HMG-CoA lyase) (HL) (3-hydroxy-3 methylglutarate-CoA lyase) - Homo sapiens Table 1 indicates the homology of NOVX polypeptides to known protein families. Thus, the nucleic acids and polypeptides, antibodies and related compounds according to the invention corresponding to a NOVX as identified in column 1 of Table 1 will be useful in 5 therapeutic and diagnostic applications implicated in, for example, pathologies and disorders associated with the known protein families identified in column 5 of Table 1. Pathologies, diseases, disorders and condition and the like that are associated with NOVX sequences include, but are not limited to, e.g., cardiomyopathy, atherosclerosis, 10 hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, metabolic disturbances associated with obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, diabetes, metabolic disorders, neoplasm; 15 adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Ostoeodystrophy, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, 20 hematopoietic disorders, and the various dyslipidemias, the metabolic syndrome X and 16 WO 2004/013347 PCT/US2003/024504 wasting disorders associated with chronic diseases and various cancers, as well as conditions such as transplantation and fertility. NOVX nucleic acids and their encoded polypeptides are useful in a variety of 5 applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong. 10 Consistent with other known members of the family of proteins, identified in column 5 of Table 1, the NOVX polypeptides of the present invention show homology to, and contain domains that are characteristic of, other members of such protein families. Details of the sequence relatedness and domain analysis for each NOVX are presented in Examples for 15 identification of human sequence in individual sections for each NOVX polypeptide. The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small 20 molecules that modulate or inhibit diseases associated with the protein families listed in Table 1. The NOVX nucleic acids and polypeptides are also useful for detecting specific cell types. Details of the expression analysis for each NOVX are Examples showing expression profiles in 25 individual sections for each NOVX polypeptide. Accordingly, the NOVX nucleic acids, polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, e.g., detection of a variety of cancers. SNP analysis for each NOVX, if applicable, is presented in SNP Examples in individual 30 sections for each NOVX polypeptide. Additional utilities for NOVX nucleic acids and polypeptides according to the invention are disclosed herein. 17 WO 2004/013347 PCT/US2003/024504 NOVX clones NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and 5 sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong. The NOVX genes and their corresponding encoded proteins are useful for preventing, treating or ameliorating medical conditions, e.g., by protein or gene therapy. Pathological 10 conditions can be diagnosed by determining the amount of the new protein in a sample or by determining the presence of mutations in the new genes. Specific uses are described for each of the NOVX genes, based on the tissues in which they are most highly expressed. Uses include developing products for the diagnosis or treatment of a variety of diseases and disorders. 15 The NOVX nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule 20 drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) a biological defense weapon. In one specific embodiment, the invention includes an isolated polypeptide comprising an 25 amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 85; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 85, wherein any amino acid in the mature form is changed to a different amino acid, provided that no 30 more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) an amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 85; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 85 wherein any amino acid specified in the chosen sequence is changed to a different amino 18 WO 2004/013347 PCT/US2003/024504 acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and (e) a fragment of any of (a) through (d). In another specific embodiment, the invention includes an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid 5 sequence selected from the group consisting of: (a) a mature form of the amino acid sequence given SEQ ID NO: 2n, wherein n is an integer between 1 and 85; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 85 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of 10 the amino acid residues in the sequence of the mature form are so changed; (c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 85; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 85, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no 15 more than 15% of the amino acid residues in the sequence are so changed; (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 85 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid 20 residues in the sequence are so changed; and (f) the complement of any of said nucleic acid molecules. In yet another specific embodiment, the invention includes an isolated nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence selected from the group consisting of SEQ ID 25 NO: 2n-1, wherein n is an integer between 1 and 85; (b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 85 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; (c) a nucleic acid fragment of the sequence 30 selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 85; and (d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 85 is changed from that selected from the group consisting of the chosen 19 WO 2004/013347 PCT/US2003/024504 sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed. NOVX Nucleic Acids and Polypeptides One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX 5 polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (e.g., NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic 10 DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA. A NOVX nucleic acid can encode a mate NOVX polypeptide. As used herein, a "mature" 15 form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product 20 "mature" form arises, by way of nonlimiting example, as a result of one or more naturally occurring processing steps that may take place within the cell (e.g., host cell) in which the gene product arises. Examples of such processing steps leading to a "mature" form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader 25 sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terinal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues 30 from residue M+1 to residue N remaining. Further as used herein, a "mature" form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristylation or phosphorylation. In general, a mature polypeptide 20 WO 2004/013347 PCT/US2003/024504 or protein may result from the operation of only one of these processes, or a combination of any of them. The term "probe", as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), about 100 nt, or as many as 5 approximately, e.g., 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single stranded or double-stranded and designed to have specificity in PCR, membrane-based 10 hybridization technologies, or ELISA-like technologies. The term "isolated" nucleic acid molecule, as used herein, is a nucleic acid that is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA 15 of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (e.g., brain, heart, liver, spleen, etc.). Moreover, an "isolated" nucleic acid molecule, 20 such as a cDNA molecule, can be substantially free of other cellular material, or culture medium, or of chemical precursors or other chemicals. A nucleic acid molecule of the invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, or a complement of this nucleotide sequence, can be isolated using standard molecular biology techniques and 25 the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, et al., (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2 nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and 30 Ausubel, et al., (eds.), CURRENT PROTOCOLS I MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.) A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template with appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an 21 WO 2004/013347 PCT/US2003/024504 appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer. As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues. A 5 short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a 10 nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ D NO:2n-1, wherein n is an integer between 1 and 85, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes. In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID 15 NO:2n-1, wherein n is an integer between 1 and 85, or a portion of this nucleotide sequence (e.g., a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of a NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, is one that is sufficiently complementary to the nucleotide sequence of 20 SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, that it can hydrogen bond with few or no mismatches to the nucleotide sequence shown in SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, thereby forming a stable duplex. As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term "binding" means the 25 physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, 30 the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates. A "fragment" provided herein is defined as a sequence of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case 22 WO 2004/013347 PCT/US2003/024504 of amino acids, and is at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. A full-length NOVX clone is identified as containing an ATG translation start codon and an in-frame stop codon. Any disclosed NOVX nucleotide sequence lacking an ATG start 5 codon therefore encodes a truncated C-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 5' direction of the disclosed sequence. Any disclosed NOVX nucleotide sequence lacking an in-frame stop codon similarly encodes a truncated N-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 3' direction 10 of the disclosed sequence. A "derivative" is a nucleic acid sequence or amino acid sequence formed from the native compounds either directly, by modification or partial substitution. An "analog" is a nucleic acid sequence or amino acid sequence that has a structure similar to, but not identical to, the native compound, e.g., they differs from it in respect to certain components or side chains. 15 Analogs may be synthetic or derived from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. A "homolog" is a nucleic acid sequence or amino acid sequence of a particular gene that is derived from different species. Derivatives and analogs may be full length or other than full length. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules 20 comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of 25 hybridizing to the complement of a sequence encoding the proteins under stringent, moderately stringent, or low stringent conditions. See e.g., Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below. A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid 30 level as discussed above. Homologous nucleotide sequences include those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for a NOVX polypeptide of species other 23 WO 2004/013347 PCT/US2003/024504 than humans, including, but not limited to: vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence 5 does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below. 10 A NOVX polypeptide is encoded by the open reading frame ("ORF") of a NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or 15 TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bonafide cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more. The nucleotide sequences determined from the cloning of the human NOVX genes allows 20 for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e.g., from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 25 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85; or an anti-sense strand nucleotide sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85; or of a naturally occurring mutant of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85. Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or 30 genomic sequences encoding the same or homologous proteins. In various embodiments, the probe has a detectable label attached, e.g., the label can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express a NOVX protein, such as by measuring a level of a NOVX-encoding nucleic acid in a sample of cells from a subject 24 WO 2004/013347 PCT/US2003/024504 e.g., detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted. "A polypeptide having a biologically-active portion of a NOVX polypeptide" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a 5 polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically-active portion of NOVX" can be prepared by isolating a portion of SEQ U) NO:2n-1, wherein n is an integer between 1 and 85, that encodes a polypeptide having a NOVX biological activity (the biological activities of the NOVX proteins are described 10 below), expressing the encoded portion of NOVX protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of NOVX. NOVX Nucleic Acid and Polypeptide Variants The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, due to degeneracy 15 of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 85. 20 In addition to the human NOVX nucleotide sequences of SEQ D NO:2n-1, wherein n is an integer between 1 and 85, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (e.g., the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic 25 variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame (ORF) encoding a NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are 30 the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention. Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from a human SEQ ID NO:2n-1, wherein n is an 25 WO 2004/013347 PCT/US2003/024504 integer between 1 and 85, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe 5 according to standard hybridization techniques under stringent hybridization conditions. Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 10 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 65% homologous to each other typically remain hybridized to each other. 15 Homologs (i.e., nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning. As used herein, the phrase "stringent hybridization conditions" refers to conditions under 20 which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The 25 Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 30 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30 *C for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60 'C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide. 26 WO 2004/013347 PCT/US2003/024504 Stringent conditions are known to those skilled in the art and can be found in Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized 5 to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65'C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50*C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a 10 sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein). In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid 15 molecule comprising the nucleotide sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Reinhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55 *C, followed by one or more washes in IX SSC, 0.1% 20 SDS at 37 'C. Other conditions of moderate stringency that may be used are well-known within the art. See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Krieger, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY. In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule 25 comprising the nucleotide sequences of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) 30 dextran sulfate at 40'C, followed by one or more washes in 2X SSC, 25 mM Tris-HC1 (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50*C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & 27 WO 2004/013347 PCT/US2003/024504 Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. Proc Natl Acad Sci USA 78: 6789-6792. Conservative Mutations In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the 5 population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, thereby leading to changes in the amino acid sequences of the encoded NOVX protein, without altering the functional ability of that NOVX protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid 10 residues can be made in the sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 85. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an "essential" amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are not 15 particularly amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art. Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NO:2n-1, wherein n is an integer 20 between 1 and 85, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 40% homologous to the amino acid sequences of SEQ ID NO:2n, wherein n is an integer between 1 and 85. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID 25 NO:2n, wherein n is an integer between 1 and 85; more preferably at least about 70% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 85; still more preferably at least about 80% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 85; even more preferably at least about 90% homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 85; and most preferably at least about 95% 30 homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 85. An isolated nucleic acid molecule encoding a NOVX protein homologous to the protein of SEQ ID NO:2n, wherein n is an integer between I and 85, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ 28 WO 2004/013347 PCT/US2003/024504 ID NO:2n-1, wherein n is an integer between 1 and 85, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced any one of SEQ ID NO:2n-1, wherein n is an integer between I and 85, by standard techniques, such as site-directed mutagenesis and PCR-mediated 5 mutagenesis. Preferably, conservative amino acid substitutions are made at one or more non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), 10 acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a non-essential amino acid residue in 15 the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis of a nucleic acid of SEQ ID NO:2n-1, wherein n is an integer 20 between 1 and 85, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined. The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved "strong" residues or fully conserved "weak" residues. The "strong" group of conserved amino acid residues may be 25 any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the "weak" group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, HFY, wherein the letters within each group represent the single letter amino acid 30 code. In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein 29 WO 2004/013347 PCT/US2003/024504 and a NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g., avidin proteins). In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release). 5 Interfering RNA In one aspect of the invention, NOVX gene expression can be attenuated by RNA interference. One approach well-known in the art is short interfering RNA (siRNA) mediated gene silencing where expression products of a NOVX gene are targeted by specific double stranded NOVX derived siRNA nucleotide sequences that are complementary to at 10 least a 19-25 nt long segment of the NOVX gene transcript, including the 5' untranslated (UT) region, the ORF, or the 3' UT region. See, e.g., PCT applications WOOO/44895, W099/32619, WO01/75164, WO01/92513, WO 01/29058, WO01/89304, W002/16620, and WO02/29858, each incorporated by reference herein in their entirety. Targeted genes can be a NOVX gene, or an upstream or downstream modulator of the NOVX gene. Nonlimiting 15 examples of upstream or downstream modulators of a NOVX gene include, e.g., a transcription factor that binds the NOVX gene promoter, a kinase or phosphatase that interacts with a NOVX polypeptide, and polypeptides involved in a NOVX regulatory pathway. According to the methods of the present invention, NOVX gene expression is silenced using 20 short interfering RNA. A NOVX polynucleotide according to the invention includes a siRNA polynucleotide. Such a NOVX siRNA can be obtained using a NOVX polynucleotide sequence, for example, by processing the NOVX ribopolynucleotide sequence in a cell-free system, such as but not limited to a Drosophila extract, or by transcription of recombinant double stranded NOVX RNA or by chemical synthesis of 25 nucleotide sequences homologous to a NOVX sequence. See, e.g., Tuschl, Zamore, Lehmann, Bartel and Sharp (1999), Genes & Dev. 13: 3191-3197, incorporated herein by reference in its entirety. When synthesized, a typical 0.2 micromolar-scale RNA synthesis provides about 1 milligram of siRNA, which is sufficient for 1000 transfection experiments using a 24-well tissue culture plate format. 30 The most efficient silencing is generally observed with siRNA duplexes composed of a 21-nt sense strand and a 21-nt antisense strand, paired in a manner to have a 2-nt 3' overhang. The sequence of the 2-nt 3' overhang makes an additional small contribution to the specificity of siRNA target recognition. The contribution to specificity is localized to the unpaired 30 WO 2004/013347 PCT/US2003/024504 nucleotide adjacent to the first paired bases. In one embodiment, the nucleotides in the 3' overhang are ribonucleotides. In an alternative embodiment, the nucleotides in the 3' overhang are deoxyribonucleotides. Using 2'-deoxyribonucleotides in the 3' overhangs is as efficient as using ribonucleotides, but deoxyribonucleotides are often cheaper to synthesize 5 and are most likely more nuclease resistant. A contemplated recombinant expression vector of the invention comprises a NOVX DNA molecule cloned into an expression vector comprising operatively-linked regulatory sequences flanking the NOVX sequence in a manner that allows for expression (by transcription of the DNA molecule) of both strands. An RNA molecule that is antisense to 10 NOVX mRNA is transcribed by a first promoter (e.g., a promoter sequence 3' of the cloned DNA) and an RNA molecule that is the sense strand for the NOVX mRNA is transcribed by a second promoter (e.g., a promoter sequence 5' of the cloned DNA). The sense and antisense strands may hybridize in vivo to generate siRNA constructs for silencing of the NOVX gene. Alternatively, two constructs can be utilized to create the sense and anti-sense 15 strands of a siRNA construct. Finally, cloned DNA can encode a construct having secondary structure, wherein a single transcript has both the sense and complementary antisense sequences from the target gene or genes. In an example of this embodiment, a hairpin RNAi product is homologous to all or a portion of the target gene. In another example, a hairpin RNAi product is a siRNA. The regulatory sequences flanking the NOVX sequence may be 20 identical or may be different, such that their expression may be modulated independently, or in a temporal or spatial manner. In a specific embodiment, siRNAs are transcribed intracellularly by cloning the NOVX gene templates into a vector containing, e.g., a RNA pol III transcription unit from the smaller nuclear RNA (snRNA) U6 or the human RNase P RNA H1. One example of a vector 25 system is the GeneSuppressorm RNA Interference kit (commercially available from Imgenex). The U6 and H1 promoters are members of the type III class of Pol III promoters. The +1 nucleotide of the U6-like promoters is always guanosine, whereas the +1 for H1 promoters is adenosine. The termination signal for these promoters is defined by five consecutive thymidines. The transcript is typically cleaved after the second uridine. 30 Cleavage at this position generates a 3' UU overhang in the expressed siRNA, which is similar to the 3' overhangs of synthetic siRNAs. Any sequence less than 400 nucleotides in length can be transcribed by these promoter, therefore they are ideally suited for the expression of around 21-nucleotide siRNAs in, e.g., an approximately 50-nucleotide RNA stem-loop transcript. 31 WO 2004/013347 PCT/US2003/024504 A siRNA vector appears to have an advantage over synthetic siRNAs where long term knock-down of expression is desired. Cells transfected with a siRNA expression vector would experience steady, long-term mRNA inhibition. In contrast, cells transfected with exogenous synthetic siRNAs typically recover from mRNA suppression within seven days or 5 ten rounds of cell division. The long-term gene silencing ability of siRNA expression vectors may provide for applications in gene therapy. In general, siRNAs are chopped from longer dsRNA by an ATP-dependent ribonuclease called DICER. DICER is a member of the RNase III family of double-stranded RNA-specific endonucleases. The siRNAs assemble with cellular proteins into an 10 endonuclease complex. In vitro studies in Drosophila suggest that the siRNAs/protein complex (siRNP) is then transferred to a second enzyme complex, called an RNA-induced silencing complex (RISC), which contains an endoribonuclease that is distinct from DICER. RISC uses the sequence encoded by the antisense siRNA strand to find and destroy mRNAs of complementary sequence. The siRNA thus acts as a guide, restricting the ribonuclease to 15 cleave only mRNAs complementary to one of the two siRNA strands. A NOVX mRNA region to be targeted by siRNA is generally selected from a desired NOVX sequence beginning 50 to100 nt downstream of the start codon. Alternatively, 5' or 3' UTRs and regions nearby the start codon can be used but are generally avoided, as these may be richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation 20 complexes may interfere with binding of the siRNP or RISC endonuclease complex. An initial BLAST homology search for the selected siRNA sequence is done against an available nucleotide sequence library to ensure that only one gene is targeted. Specificity of target recognition by siRNA duplexes indicate that a single point mutation located in the paired region of an siRNA duplex is sufficient to abolish target mRNA degradation. See, 25 Elbashir et al. 2001 EMBO J. 20(23):6877-88. Hence, consideration should be taken to accommodate SNPs, polymorphisms, allelic variants or species-specific variations when targeting a desired gene. In one embodiment, a complete NOVX siRNA experiment includes the proper negative control. A negative control siRNA generally has the same nucleotide composition as the 30 NOVX siRNA but lack significant sequence homology to the genome. Typically, one would scramble the nucleotide sequence of the NOVX siRNA and do a homology search to make sure it lacks homology to any other gene. Two independent NOVX siRNA duplexes can be used to knock-down a target NOVX gene. This helps to control for specificity of the silencing effect. In addition, expression of two 32 WO 2004/013347 PCT/US2003/024504 independent genes can be simultaneously knocked down by using equal concentrations of different NOVX siRNA duplexes, e.g., a NOVX siRNA and an siRNA for a regulator of a NOVX gene or polypeptide. Availability of siRNA-associating proteins is believed to be more limiting than target mRNA accessibility. 5 A targeted NOVX region is typically a sequence of two adenines (AA) and two thymidines (TT) divided by a spacer region of nineteen (N19) residues (e.g., AA(N19)TT). A desirable spacer region has a G/C-content of approximately 30% to 70%, and more preferably of about 50%. If the sequence AA(N19)TT is not present in the target sequence, an alternative target region would be AA(N21). The sequence of the NOVX sense siRNA corresponds to 10 (N19)TT or N21, respectively. In the latter case, conversion of the 3' end of the sense siRNA to TT can be performed if such a sequence does not naturally occur in the NOVX polynucleotide. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and antisense 3' overhangs. Symmetric 3' overhangs may help to ensure that the siRNPs are formed with approximately 15 equal ratios of sense and antisense target RNA-cleaving siRNPs. See, e.g., Elbashir, Lendeckel and Tuschl (2001). Genes & Dev. 15: 188-200, incorporated by reference herein in its entirely. The modification of the overhang of the sense sequence of the siRNA duplex is not expected to affect targeted mRNA recognition, as the antisense siRNA strand guides target recognition. 20 Alternatively, if the NOVX target mRNA does not contain a suitable AA(N21) sequence, one may search for the sequence NA(N21). Further, the sequence of the sense strand and antisense strand may still be synthesized as 5' (NI 9)TT, as it is believed that the sequence of the 3'-most nucleotide of the antisense siRNA does not contribute to specificity. Unlike. antisense or ribozyme technology, the secondary structure of the target mRNA does not 25 appear to have a strong effect on silencing. See, Harborth, et al. (2001) J. Cell Science 114: 455 7-4565, incorporated by reference in its entirety. Transfection of NOVX siRNA duplexes can be achieved using standard nucleic acid transfection methods, for example, OLIGOFECTAMINE Reagent (commercially available from Invitrogen). An assay for NOVX gene silencing is generally performed approximately 30 2 days after transfection. No NOVX gene silencing has been observed in the absence of transfection reagent, allowing for a comparative analysis of the wild-type and silenced NOVX phenotypes. In a specific embodiment, for one well of a 24-well plate, approximately 0.84 jig of the siRNA duplex is generally sufficient. Cells are typically seeded the previous day, and are transfected at about 50% confluence. The choice of cell 33 WO 2004/013347 PCT/US2003/024504 culture media and conditions are routine to those of skill in the art, and will vary with the choice of cell type. The efficiency of transfection may depend on the cell type, but also on the passage number and the confluency of the cells. The time and the manner of formation of siRNA-liposome complexes (e.g., inversion versus vortexing) are also critical. Low 5 transfection efficiencies are the most frequent cause of unsuccessful NOVX silencing. The efficiency of transfection needs to be carefully examined for each new cell line to be used. Preferred cell are derived from a mammal, more preferably from a rodent such as a rat or mouse, and most preferably from a human. Where used for therapeutic treatment, the cells are preferentially autologous, although non-autologous cell sources are also contemplated as 10 within the scope of the present invention. For a control experiment, transfection of 0.84 pg single-stranded sense NOVX siRNA will have no effect on NOVX silencing, and 0.84 pig antisense siRNA has a weak silencing effect when compared to 0.84 pg of duplex siRNAs. Control experiments again allow for a comparative analysis of the wild-type and silenced NOVX phenotypes. To control for 15 transfection efficiency, targeting of common proteins is typically performed, for example targeting of lamin A/C or transfection of a CMV-driven EGFP-expression plasmid (e.g., commercially available from Clontech). In the above example, a determination of the fraction of lamin A/C knockdown in cells is determined the next day by such techniques as immunofluorescence, Western blot, Northern blot or other similar assays for protein 20 expression or gene expression. Lamin A/C monoclonal antibodies may be obtained from Santa Cruz Biotechnology. Depending on the abundance and the half life (or turnover) of the targeted NOVX polynucleotide in a cell, a knock-down phenotype may become apparent after 1 to 3 days, or even later. In cases where no NOVX knock-down phenotype is observed, depletion of the 25 NOVX polynucleotide may be observed by immunofluorescence or Western blotting. If the NOVX polynucleotide is still abundant after 3 days, cells need to be split and transferred to a fresh 24-well plate for re-transfection. If no knock-down of the targeted protein is observed, it may be desirable to analyze whether the target mRNA (NOVX or a NOVX upstream or downstream gene) was effectively destroyed by the transfected siRNA duplex. Two days 30 after transfection, total RNA is prepared, reverse transcribed using a target-specific primer, and PCR-amplified with a primer pair covering at least one exon-exon junction in order to control for amplification of pre-mRNAs. RT/PCR of a non-targeted mRNA is also needed as control. Effective depletion of the mRNA yet undetectable reduction of target protein may indicate that a large reservoir of stable NOVX protein may exist in the cell. Multiple 34 WO 2004/013347 PCT/US2003/024504 transfection in sufficiently long intervals may be necessary until the target protein is finally depleted to a point where a phenotype may become apparent. If multiple transfection steps are required, cells are split 2 to 3 days after transfection. The cells may be transfected immediately after splitting. 5 An inventive therapeutic method of the invention contemplates administering a NOVX siRNA construct as therapy to compensate for increased or aberrant NOVX expression or activity. The NOVX ribopolynucleotide is obtained and processed into siRNA fragments, or a NOVX siRNA is synthesized, as described above. The NOVX siRNA is administered to cells or tissues using known nucleic acid transfection techniques, as described above. A 10 NOVX siRNA specific for a NOVX gene will decrease or knockdown NOVX transcription products, which will lead to reduced NOVX polypeptide production, resulting in reduced NOVX polypeptide activity in the cells or tissues. The present invention also encompasses a method of treating a disease or condition associated with the presence of a NOVX protein in an individual comprising administering 15 to the individual an RNAi construct that targets the mRNA of the protein (the mRNA that encodes the protein) for degradation. A specific RNAi construct includes a siRNA or a double stranded gene transcript that is processed into siRNAs. Upon treatment, the target protein is not produced or is not produced to the extent it would be in the absence of the treatment. 20 Where the NOVX gene function is not correlated with a known phenotype, a control sample of cells or tissues from healthy individuals provides a reference standard for determining NOVX expression levels. Expression levels are detected using the assays described, e.g., RT-PCR, Northern blotting, Western blotting, ELISA, and the like. A subject sample of cells or tissues is taken from a mammal, preferably a human subject, suffering from a disease 25 state. The NOVX ribopolynucleotide is used to produce siRNA constructs, that are specific for the NOVX gene product. These cells or tissues are treated by administering NOVX siRNA's to the cells or tissues by methods described for the transfection of nucleic acids into a cell or tissue, and a change in NOVX polypeptide or polynucleotide expression is observed in the subject sample relative to the control sample, using the assays described. This NOVX 30 gene knockdown approach provides a rapid method for determination of a NOVX minus (NOVX~) phenotype in the treated subject sample. The NOVX~ phenotype observed in the treated subject sample thus serves as a marker for monitoring the course of a disease state during treatment. 35 WO 2004/013347 PCT/US2003/024504 In specific embodiments, a NOVX siRNA is used in therapy. Methods for the generation and use of a NOVX siRNA are known to those skilled in the art. Example techniques are provided below. Production of RNAs 5 Sense RNA (ssRNA) and antisense RNA (asRNA) of NOVX are produced using known methods such as transcription in RNA expression vectors. In the initial experiments, the sense and antisense RNA are about 500 bases in length each. The produced ssRNA and asRNA (0.5 pM) in 10 mM Tris-HCl (pH 7.5) with 20 mM NaCl were heated to 950 C for 1 min then cooled and annealed at room temperature for 12 to 16 h. The RNAs are 10 precipitated and resuspended in lysis buffer (below). To monitor annealing, RNAs are electrophoresed in a 2% agarose gel in TBE buffer and stained with ethidium bromide. See, e.g., Sambrook et al., Molecular Cloning. Cold Spring Harbor Laboratory Press, Plainview, N.Y. (1989). Lysate Preparation 15 Untreated rabbit reticulocyte lysate (Ambion) are assembled according to the manufacturer's directions. dsRNA is incubated in the lysate at 30* C for 10 min prior to the addition of mRNAs. Then NOVX mRNAs are added and the incubation continued for an additional 60 min. The molar ratio of double stranded RNA and mRNA is about 200:1. The NOVX mRNA is radiolabeled (using known techniques) and its stability is monitored by gel 20 electrophoresis. In a parallel experiment made with the same conditions, the double stranded RNA is internally radiolabeled with a 3P-ATP. Reactions are stopped by the addition of 2X proteinase-K buffer and deproteinized as described previously (Tuschl et al., Genes Dev., 13:3191-3197 (1999)). Products are analyzed by electrophoresis in 15% or 18% 25 polyacrylamide sequencing gels using appropriate RNA standards. By monitoring the gels for radioactivity, the natural production of 10 to 25 nt RNAs from the double stranded RNA can be determined. The band of double stranded RNA, about 21-23 bps, is eluded. The efficacy of these 21-23 mers for suppressing NOVX transcription is assayed in vitro using the same rabbit 30 reticulocyte assay described above using 50 nanomolar of double stranded 21-23 mer for each assay. The sequence of these 21-23 mers is then determined using standard nucleic acid sequencing techniques. 36 WO 2004/013347 PCT/US2003/024504 RNA Preparation 21 nt RNAs, based on the sequence determined above, are chemically synthesized using Expedite RNA phosphoramidites and thymidine phosphoramidite (Proligo, Germany). Synthetic oligonucleotides are deprotected and gel-purified (Elbashir, Lendeckel, & Tuschl, 5 Genes & Dev. 15, 188-200 (2001)), followed by Sep-Pak C18 cartridge (Waters, Milford, Mass., USA) purification (Tuschl, et al., Biochemistry, 32:11658-11668 (1993)). These RNAs (20 ptM) single strands are incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate) for 1 min at 90* C followed by 1 h at 370 C. 10 Cell Culture A cell culture known in the art to regularly express NOVX is propagated using standard conditions. 24 hours before transfection, at approx. 80% confluency, the cells are trypsinized and diluted 1:5 with fresh medium without antibiotics (1-3 X 105 cells/mil) and transferred to 24-well plates (500 ml/well). Transfection is performed using a commercially 15 available lipofection kit and NOVX expression is monitored using standard techniques with positive and negative control. A positive control is cells that naturally express NOVX while a negative control is cells that do not express NOVX. Base-paired 21 and 22 nt siRNAs with overhanging 3' ends mediate efficient sequence-specific mRNA degradation in lysates and in cell culture. Different concentrations of siRNAs are used. An efficient concentration for 20 suppression in vitro in mammalian culture is between 25 nM to 100 nM final concentration. This indicates that siRNAs are effective at concentrations that are several orders of magnitude below the concentrations applied in conventional antisense or ribozyme gene targeting experiments. The above method provides a way both for the deduction of NOVX siRNA sequence and the 25 use of such siRNA for in vitro suppression. In vivo suppression may be performed using the same siRNA using well known in-vivo transfection or gene therapy transfection techniques. Antisense Nucleic Acids Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide 30 sequence of SEQ 1D NO:2n-1, wherein n is an integer between I and 85, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (e.g., complementary to 37 WO 2004/013347 PCT/US2003/024504 the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding 5 fragments, homologs, derivatives and analogs of a NOVX protein of SEQ ID NO:2n, wherein n is an integer between 1 and 85, or antisense nucleic acids complementary to a NOVX nucleic acid sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, are additionally provided. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of 10 the coding strand of a nucleotide sequence encoding a NOVX protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding the NOVX protein. The term "noncoding region" refers to 5' and 3' sequences that 15 flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions). Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the 20 entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20,25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid 25 of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical-stability of the duplex formed between the antisense and sense 30 nucleic acids (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used). Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-carboxymethylaminomethyl-2-thiouridine, 5-(carboxyhydroxyhnethyl) 38 WO 2004/013347 PCT/US2003/024504 uracil, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 5-methoxyuracil, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5 5-methoxyaminomethyl-2-thiouracil, 2-thiouracil, 4-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 10 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection). The antisense nucleic acid molecules of the invention are typically administered to a subject 15 or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NOVX protein to thereby inhibit expression of the protein (e.g., by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in 20 the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed 25 on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred. 30 In yet another embodiment, the antisense nucleic acid molecule of the invention is an a-anomeric nucleic acid molecule. An a-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual p-units, the strands run parallel to each other. See, e.g., Gaultier, et al., 1987. NucL. Acids Res. 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 39 WO 2004/013347 PCT/US2003/024504 2'-o-methylribonucleotide (See, e.g., Inoue, et al. 1987. Nucl. Acids Res. 15: 6131-6148) or a chimeric RNA-DNA analogue (See, e.g., Inoue, et al., 1987. FEBS Lett. 215: 327-330. Ribozymes and PNA Moieties Nucleic acid modifications include, by way of non-limiting example, modified bases, and 5 nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are 10 catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an. mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. Nature 334: 585-59 1) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for a 15 NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of a NOVX cDNA disclosed herein (i.e., SEQ ID NO:2n-1, wherein n is an integer between I and 85). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NOVX-encoding mRNA. See, e.g., U.S. Patent 4,987,071 to Cech, et al. 20 and U.S. Patent 5,116,742 to Cech, et al. NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993) Science 261:1411-1418. Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (e.g., the NOVX 25 promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. See, e.g., Helene, 1991. Anticancer Drug Des. 6: 569-84; Helene, et al. 1992. Ann. N.Y. Acad. Sci. 660: 27-36; Maher, 1992. Bioassays 14: 807-15. In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of 30 the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, et al., 1996. Bloorg Med Chem 4: 5-23. As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a 40 WO 2004/013347 PCT/US2003/024504 pseudopeptide backbone and only the four natural nucleotide bases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomer can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. 5 supra; Perry-O'Keefe, et al., 1996. Proc. Nat?. Acad. Sci. USA 93: 14670-14675. PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations 10 in a gene (e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., Si nucleases (See, Hyrup, et al., 1996.supra); or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al., 1996, supra; Perry-O'Keefe, et al., 1996. supra). In another embodiment, PNAs of NOVX can be modified, e.g., to enhance their stability or 15 cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the 20 -PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleotide bases, and orientation (see, Hyrup, et al., 1996. supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. supra and Finn, et al., 1996. Nucl Acids Res 24: 3357-3363. For example, a DNA chain can 25 be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)-amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA. See, e.g., Mag, et al., 1989. NuclAcid Res 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. See, 30 e.g., Finn, et al., 1996. supra. Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, e.g., Petersen, et al., 1975. Bioorg. Med. Chem. Lett. 5: 1119-11124. In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across 41 WO 2004/013347 PCT/US2003/024504 the cell membrane (see, e.g., Letsinger, et al., 1989. Proc. Nvatl. Acad. Sci. U.S.A. 86: 6553-6556; Lemaitre, et al., 1987. Proc. Nati. Acad. Sci. 84: 648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, 5 e.g., Krol, et al., 1988. BioTechniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988. Pharm. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like. NOVX Polypeptides 10 A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in any one of SEQ ID NO:2n, wherein n is an integer between 1 and 85. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in any one of SEQ ID NO:2n, wherein n is an integer between 1 and 85, while still 15 encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof. - In general, a NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues 20 between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above. One aspect of the invention pertains to isolated NOVX proteins, and biologically-active 25 portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to 30 recombinant expression, a NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques. An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue 42 WO 2004/013347 PCT/US2003/024504 source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or 5 recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX 10 proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation. The language "substantially free of chemical precursors or other chemicals" includes 15 preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or 20 non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals. Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the 25 NOVX proteins (e.g., the amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 85) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of a NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of a NOVX protein can be a polypeptide which is, for example, 30 10, 25, 50, 100 or more amino acid residues in length. Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein. 43 WO 2004/013347 PCT/US2003/024504 In an embodiment, the NOVX protein has an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 85. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NO:2n, wherein n is an integer between 1 and 85, and retains the functional activity of the protein of SEQ ID NO:2n, wherein n is an integer 5 between 1 and 85, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO:2n, wherein n is an integer between I and 85, and retains the functional activity of the NOVX proteins of SEQ I) NO:2n, wherein n is an 10 integer between 1 and 85. Determining Homology Between Two or More Sequences To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second 15 amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic 20 acid "identity"). The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970. JMol Biol 48: 443-453. Using GCG GAP software with the following 25 settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85. 30 The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of 44 WO 2004/013347 PCT/US2003/024504 positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage 5 of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region. 10 Chimeric and Fusion Proteins The invention also provides NOVX chimeric or fusion proteins. As used herein, a NOVX "chimeric protein" or "fusion protein" comprises a NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An "NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a NOVX protein of SEQ ID NO:2n, wherein n is an 15 integer between 1 and 85, whereas a "non-NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, e.g., a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within a NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of a NOVX protein. In one 20 embodiment, a NOVX fusion protein comprises at least one biologically-active portion of a NOVX protein. In another embodiment, a NOVX fusion protein comprises at least two biologically-active portions of a NOVX protein. In yet another embodiment, a NOVX fusion protein comprises at least three biologically-active portions of a NOVX protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the 25 NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide. In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. 30 Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides. In another embodiment, the fusion protein is a NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), 45 WO 2004/013347 PCT/US2003/024504 expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence. In yet another embodiment, the fusion protein is a NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the 5 immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a NOVX ligand and a NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction in vivo. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of a NOVX 10 cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g., promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening 15 assays to identify molecules that inhibit the interaction of NOVX with a NOVX ligand. A NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction 20 enzyme digestion to provide for appropriate tennini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary 25 overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A NOVX-encoding nucleic acid can be cloned into such an expression 30 vector such that the fusion moiety is linked in-frame to the NOVX protein. NOVX Agonists and Antagonists The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists. Variants of the NOVX protein can be 46 WO 2004/013347 PCT/US2003/024504 generated by mutagenesis (e.g., discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of 5 the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to 10 treatment with the naturally occurring form of the NOVX proteins. Variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (e.g., truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial 15 mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NOVX 20 sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired 25 set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. See, e.g., Narang, 1983. Tetrahedron 39: 3; Itakura, et al., 1984. Annu. Rev. Biochem. 53: 323; Itakura, et al., 1984. Science 198: 1056; Ike, et al., 1983. Nucl. Acids Res. 11: 477. Polypeptide Libraries 30 In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of a NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a NOVX coding sequence 47 WO 2004/013347 PCT/US2003/024504 with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with Si nuclease, and ligating the resulting 5 fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins. Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene 10 products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most. widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the 15 combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992. Proc. Nati. Acad. Sci. USA 89: 7811-7815; 20 Delgrave, et al., 1993. Protein Engineering 6:327-331. Anti-NOVX Antibodies Included in the invention are antibodies to NOVX proteins, or fragments of NOVX proteins. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that 25 contain an antigen-binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab, Fab, and F(ab)2 fragments, and an Fab expression library. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes 30 have subclasses as well, such as IgGi, IgG 2 , and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species. 48 WO 2004/013347 PCT/US2003/024504 An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide 5 fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1 and 85, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the 10 epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions. In certain embodiments of the invention, at least one epitope encompassed by the antigenic 15 peptide is a region of NOVX that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human NOVX protein sequence will indicate which regions of a NOVX polypeptide are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity 20 may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doolittle 1982, J MoL. Biol. 157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or 25 derivatives, fragments, analogs or homologs thereof, are also provided herein. The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge 30 characteristics. A NOVX polypeptide or a fragment thereof comprises at least one antigenic epitope. An anti-NOVX antibody of the present invention is said to specifically bind to antigen NOVX when the equilibrium binding constant (KD) is 1 pM, preferably 5 100 nM, more preferably 10 nM, and most preferably 100 pM to about 1 pM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art. 49 WO 2004/013347 PCT/US2003/024504 A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components. Various procedures known within the art may be used for the production of polyclonal or 5 monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below. 10 Polyclonal Antibodies For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic 15 protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The 20 preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar 25 immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such 30 as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen that is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. 50 WO 2004/013347 PCT/US2003/024504 Purification of iminunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28). Monoclonal Antibodies 5 The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain 10 an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it. Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an 15 immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro. The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of 20 human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly 25 myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell . lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas 30 typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells. Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a 51 WO 2004/013347 PCT/US2003/024504 medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for 5 the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63). The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding 10. specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). It is an 15 objective, especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen. After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding,1986). Suitable culture media 20 for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal. The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional inimunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel 25 electrophoresis, dialysis, or affinity chromatography. The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the 30 heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA 52 WO 2004/013347 PCT/US2003/024504 also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a 5 non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody. Humanized Antibodies 10 The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric imnunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab') 2 or other 15 antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or 20 CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all 25 of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fe), typically that of a human immunoglobulin (Jones et 30 al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)). 53 WO 2004/013347 PCT/US2003/024504 Human Antibodies Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human 5 monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Inunuol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by 10 using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et 15 al., J. Mol. Biol., 222:5 81 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals. For example, mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. 20 This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison (iNature 368, 812-13 (1994)); Fishwild et al,(Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 25 65-93 (1995)). Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication W094/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman 30 host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full 54 WO 2004/013347 PCT/US2003/024504 complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the XenomouseTM as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after 5 immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for 10 example, single chain Fv molecules. An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement 15 of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker. A method for producing an antibody of interest, such as a human antibody, is disclosed in 20 U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain. 25 In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049. FAb Fragments and Single Chain Antibodies 30 According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of Fab expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective 55 WO 2004/013347 PCT/US2003/024504 identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F(ab')2 fragment produced by pepsin digestion of an antibody molecule; 5 (ii) an Fab fragment generated by reducing the disulfide bridges of an F(ab,)2 fragment; (iii) an Fab fragment generated by the treatment of the antibody molecule with papaia and a reducing agent and (iv) F, fragments. Bispecific Antibodies Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have 10 binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit. Methods for making bispecific antibodies are known in the art. Traditionally, the 15 recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the 20 correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991). Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion 25 preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are 30 co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986). According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers that are 56 WO 2004/013347 PCT/US2003/024504 recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). Compensatory "cavities" of identical or similar 5 size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers. Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., 10 F(ab') 2 bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab') 2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to 15 stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective 20 immobilization of enzymes. Additionally, Fab' fragments can be directly recovered from E. coli and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab') 2 molecule. Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to 25 form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the'lytic activity of human cytotoxic lymphocytes against human breast tumor targets. Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have 30 been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" 57 WO 2004/013347 PCT/US2003/024504 technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) by a linker that is too short to allow pairing between the two domains on the 5 same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994). 10 Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991). Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering 15 molecule on a leukocyte such as a T-cell receptor molecule (e.g., CD2, CD3, CD28, or B7), or Fe receptors for IgG (FcyR), such as FcyRI (CD64), FcyRII (CD32) and FeyRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds 20 a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF). Heteroconjugate Antibodies Heteroconjugate antibodies are also within the scope of the present invention. 25 Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking 30 agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include ininothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980. 58 WO 2004/013347 PCT/US2003/024504 Effector Function Engineering It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fe region, thereby allowing interchain 5 disulfide bond formation in this region. The homodineric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional 10 cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fe regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989). Immunoconjugates 15 The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate). Chemotherapeutic agents useful in the generation of such immunoconjugates have been 20 described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, 25 gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include 2 12 Bi, 1311 mIn, 90 Y, and 186 Re. Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), 30 iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as 59 WO 2004/013347 PCT/US2003/024504 tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 23: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an 5 exemplary chelating agent for conjugation of radionucleotide to the antibody. See W094/11026. In another embodiment, the antibody can be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a 10 clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent. Immunoliposomes The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in 15 Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556. Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized 20 phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al.,_J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. 25 National Cancer Inst., 81(19): 1484 (1989). Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme linked iimunosorbent assay (ELISA) and 30 other immunologically mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of an NOVX protein is facilitated by generation of hybridomas that bind to the fragment of an NOVX protein 60 WO 2004/013347 PCT/US2003/024504 possessing such a domain. Thus, antibodies that are specific for a desired domain within an NOVX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein. Antibodies directed against a NOVX protein of the invention may be used in methods known 5 within the art relating to the localization and/or quantitation of a NOVX protein (e.g., for use in measuring levels of the NOVX protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies specific to a NOVX protein, or derivative, fragment, analog or homolog thereof, that contain the antibody derived antigen binding domain, are utilized as pharmacologically 10 active compounds (referred to hereinafter as "Therapeutics"). An antibody specific for a NOVX protein of the invention (e.g., a monoclonal antibody or a polyclonal antibody) can be used to isolate a NOVX polypeptide by standard techniques, such as immunoaffinity, chromatography or immunoprecipitation. An antibody to a NOVX polypeptide can facilitate the purification of a natural NOVX antigen from cells, or of a 15 recombinantly produced NOVX antigen expressed in host cells. Moreover, such an anti-NOVX antibody can be used to detect the antigenic NOVX protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic NOVX protein. Antibodies directed against a NOVX protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., 20 to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, 25 3-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include 30 luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 1251 1311 35 S or 3 H. 61 WO 2004/013347 PCT/US2003/024504 Antibody Therapeutics Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one 5 having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to 10 which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible. Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a 15 receptor having an endogenous ligand that may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor. A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding 20 interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. 25 Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week. Pharmaceutical Compositions of Antibodies 30 Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components 62 WO 2004/013347 PCT/US2003/024504 are provided, for example, in Remington: The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa. : 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In 5 Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York. If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target 10 protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active compound as necessary for the 15 particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended. 20 The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methyhnethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in 25 macroemulsions. The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes. Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the 30 antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and y ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON 63 WO 2004/013347 PCT/US2003/024504 DEPOT m (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. 5 ELISA Assay An agent for detecting an analyte protein is an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab)2) can be used. The term "labeled", with regard to the probe or antibody, is intended to 10 encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with 15 fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term "biological sample", therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an 20 analyze mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an 25 analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in "ELISA: Theory and Practice: Methods in Molecular Biology", Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995; "Immunoassay", E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, CA, 1996; and "Practice and Theory of Enzyme Immunoassays", P. Tijssen, Elsevier Science 30 Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-an analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. 64 WO 2004/013347 PCT/US2003/024504 NOVX Recombinant Expression Vectors and Host Cells Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of 5 transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a 10 bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors". In general, 15 useful expression vectors in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent 20 functions. The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid 25 sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). 30 The term "regulatory sequence" is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of 65 WO 2004/013347 PCT/US2003/024504 host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors 5 of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.). The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be 10 expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and 15 T7 polymerase. Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion 20 vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety 25 subsequent to purification of the fusion protein. Such enzymes, and their cognate . recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or 30 protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 1 ld (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89). 66 WO 2004/013347 PCT/US2003/024504 One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif (1990) 119-128. Another strategy is to alter the nucleic 5 acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (see, e.g., Wada, et al., 1992. Nucl. Acids Res. 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques. In another embodiment, the NOVX expression vector is a yeast expression vector. Examples 10 of vectors for expression in yeast Saccharomyces cerivisae include pYepSecl (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kurijan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.). Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. 15 Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39). In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include 20 pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of 25 Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. In another embodiment,. the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific 30 regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Banerji, et al., 1983. Cell 33: 729-740; Queen and 67 WO 2004/013347 PCT/US2003/024504 Baltimore, 1983. Cell 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. NatL. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European 5 Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. Science 249: 374-379) and the a-fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3: 537-546). The invention further provides a recombinant expression vector comprising a DNA molecule 10 of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense 15 RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can 20 be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, et al., "Antisense RNA as a molecular tool for genetic analysis," Reviews-Trends in Genetics, Vol. 1(1) 1986. Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host 25 cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. 30 A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art. 68 WO 2004/013347 PCT/US2003/024504 Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium 5 chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals. 10 For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that 15 confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die). 20 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable 25 medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell. Transgenic NOVX Animals The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an 30 embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful 69 WO 2004/013347 PCT/US2003/024504 for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of 5 transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant 10 animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal. A transgenic animal of the invention can be created by introducing a NOVX-encoding 15 nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences, i.e., any one of SEQ ID NO:2n- 1, wherein n is an integer between 1 and 85, can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX 20 gene, can be isolated based on hybridization to the human NOVX cDNA (described further supra) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic 25- animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be 30 identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes. 70 WO 2004/013347 PCT/US2003/024504 To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (e.g., the cDNA of any one of SEQ ID NO:2n-1, wherein n is an integer 5 between 1 and 85), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the 10 endogenous NOVX gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the 15 endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous 20 recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3-termini) are included in the vector. See, e.g., Thomas, et al., 1987. Cell 51: 503 for a description of homologous recombination vectors. The vector is ten introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. 25 See, e.g., Li, et al., 1992. Cell 69: 915. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal 30 and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are 71 WO 2004/013347 PCT/US2003/024504 described further in Bradley, 1991. Curr. Opin. Biotechnol. 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169. In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a 5 system is the cre/loxP recombinase system of bacteriophage PL. For a description of the cre/loxP recombinase system, see, e.g., Lakso, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae. See, O'Gorman, et al., 1991. Science 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals 10 containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase. Clones of the non-human transgenic animals described herein can also be produced 15 according to the methods described in Wilmut, et al., 1997. Nature 385:'810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter Go phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops 20 to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated. Pharmaceutical Compositions The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also 25 referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion 30 media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers 72 WO 2004/013347 PCT/US2003/024504 or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible 5 with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions. A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), 10 transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating 15 agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. 20 Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should 25 be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The 30 proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, 73 WO 2004/013347 PCT/US2003/024504 for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin. 5 Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients 10 from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. Oral compositions generally include an inert diluent or an edible carrier. They can be 15 enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, 20 and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal 25 silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser that contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. 30 Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal 74 WO 2004/013347 PCT/US2003/024504 sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal 5 delivery. In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, 10 collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods 15 known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811. It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the 20 desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals. 25 The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Patent No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994. Proc. Nati. Acad. Sci. USA 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the 30 gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system. 75 WO 2004/013347 PCT/US2003/024504 The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration. Screening and Detection Methods The isolated nucleic acid molecules of the invention can be used to express NOVX protein 5 (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (e.g., in a biological sample) or a genetic lesion in a NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production 10 of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (e.g.; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and 15 the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion. The invention further pertains to novel agents identified by the screening assays described 20 herein and uses thereof for treatments as described, supra. Screening Assays The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a 25 stimulatory or inhibitory effect on, e.g., NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein. In one embodiment, the invention provides assays for screening candidate or test compounds that bind to or modulate the activity of the membrane-bound form of a NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the 30 invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 76 WO 2004/013347 PCT/US2003/024504 "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997. Anticancer Drug Design 12: 145. 5 A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can 10 be screened with any of the assays of the invention. Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al., 1993. Proc. Nati. Acad. Sci. U.S.A. 90: 6909; Erb, et al., 1994. Proc. Natl. Acad. Sci. U.S.A. 91: 11422; Zuckermann, et al., 1994. J. Med. Chem. 37: 2678; Cho,'et al., 1993. Science 261: 1303; Carrell, et al., 1994. Angew. Chen. Int. Ed. Engl. 33: 15 2059; Carell, et al., 1994. Angew. Chen. Int. Ed. Engl. 33: 2061; and Gallop, et al., 1994. J Med. Chem. 37: 1233. Libraries of compounds may be presented in solution (e.g., Houghten, 1992. Biotechniques 13: 412-421), or on beads (Lam, 1991. Nature 354: 82-84), on chips (Fodor, 1993. Nature 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, 20 U.S. Patent 5,233,409), plasmids' (Cull, et al., 1992. Proc. Nat. Acad. Sci. USA 89: 1865-1869) or on phage (Scott and Smith, 1990. Science 249: 386-390; Devlin, 1990. Science 249: 404-406; Cwirla, et al., 1990. Proc. Nat. Acad. Sci. U.S.A. 87: 6378-6382; Felici, 1991. J. Mol. Biol. 222: 301-3 10; Ladner, U.S. Patent No. 5,233,409.). In one embodiment, an assay is a cell-based assay in which a cell which expresses a 25 membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a NOVX protein determined. The cell, for example, can be of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic 30 label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with 125L 35 8 14 C, or 3 H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for 77 WO 2004/013347 PCT/US2003/024504 example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known 5 compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound. 10 In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to 15 modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule. As used herein, a "target molecule" is a molecule with which a NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a NOVX interacting protein, a molecule on the surface of a second cell, a 20 molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A NOVX target molecule can be a non-NOVX molecule or a NOVX protein or polypeptide of the invention. In one embodiment, a NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g., a signal generated by binding of a compound to a 25 membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX. Determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by one of the methods described above for determining 30 direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i.e., intracellular Ca 2 +, diacylglycerol, IP 3 , etc.), detecting catalytic/enzymatic activity of the target an appropriate 78 WO 2004/013347 PCT/US2003/024504 substrate, detecting the induction of a reporter gene (comprising a NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation. 5 In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting a NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the 10 assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and'determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially 15 bind to NOVX or biologically-active portion thereof as compared to the known compound. In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test 20 compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to a NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate a NOVX 25 target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, supra. In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and 30 determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of a NOVX target molecule. 79 WO 2004/013347 PCT/US2003/024504 The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples 5 of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylnaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton* X-1 14, Thesit*, Isotridecypoly(ethylene glycol ether)a, N-dodecyl--NN-dimethyl-3 -ammonio-1 -propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 10 3-(3-cholamidopropyl)dimethylammniniol-2-hydroxy-1 -propane sulfonate (CHAPSO). In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed -from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or 15 interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or 20 GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the 25 beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques. 30 Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, 80 WO 2004/013347 PCT/US2003/024504 Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein 5 trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule. 10 In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate 15 compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less 20 (statistically significantly less) in the presence of the candidate compound tha in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein. In yet another aspect of the invention, the NOVX proteins can be used as "bait 25 proteins" in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos, et al., 1993. Cell 72: 223-232; Madura, et al., 1993. J. Biol. Chem. 268: 12046-12054; Bartel, et al., 1993. Biotechniques 14: 920-924; Iwabuchi, et al., 1993. Oncogene 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX ("NOVX-binding proteins" or "NOVX-bp") and modulate NOVX 30 activity. Such NOVX-binding proteins are also involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway. The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a 81 WO 2004/013347 PCT/US2003/024504 gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to 5 interact, in vivo, forming a NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and 10 used to obtain the cloned gene that encodes the protein which interacts with NOVX. In yet another aspect of the invention a method for identifying compounds that modulate target polypeptide (NOVX) activity is disclosed wherein the method comprises: (a) combining a test compound with a target polypeptide and a substrate of the target 15 polypeptide; and (b) determining whether the test compound modulates the activity of the target polypeptide; wherein the target polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 85, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at 20 least 95% identical to the at least one domain of SEQ ID NO:2n. The method further comprising a step of identifying the test compound that modulates the target polypeptide activity by modulating the target polypeptide activity as modulator of the target polypetide. Such modulator could be an inhibitor, an activator, an 25 antagonist, or an agonist of NOVX target polypeptide. The method also further comprising a step of identifying the test compound that modulates the target polypeptide activity as an enhancer of insulin secretion, or as a therapeutic for treatment of insulin resistance, obesity and/or diabetes. 30 In the above described method, the target polypeptide (NOVX) could be an isolated polypetide. 82 WO 2004/013347 PCT/US2003/024504 The target polypeptide could be produced by a process comprising culturing a recombinant host cell, the recombinant host cell comprising a nucleic acid encoding the target polypeptide, under conditions promoting expression of the target polypeptide. In such a method, the nucleic acid comprises a nucleotide sequence selected from the group 5 consisting of: (a) SEQ ID NO:2n-1, wherein n is an integer between 1 and 85; (b) nucleotides encoding an amino acid sequence of the at least one domain of SEQ ID NO:2n; and (c) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO:2n, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino 10 acid sequence that is at least 95% identical to the at least one domain of SEQ ID NO:2n. Alternatively, the target polypeptide could be produced by expression of a recombinant vector comprising a nucleic acid, the nucleic acid encoding an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer 15 between 1 and 85, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at least 95% identical to the at least one domain of SEQ ID NO:2n. Here, the test compound could be combined with the target polypeptide in a mammalian cell grown in culture. Also, the test compound could be combined with the target polypeptide in vitro. 20 In this method, the nucleic acid comprises a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:2n-1, wherein n is an integer between 1 and 85; (b) nucleotides encoding an amino acid sequence of the at least one domain of SEQ ID NO:2n; and (c) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO:2n, the amino acid sequence that is at least 95% identical to SEQ 25 ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence thatis at least 95% identical to the at least one domain of SEQ ID NO:2n. In yet another embodiment, the target polypeptide is produced by expression of an endogenous nucleic acid, the endogenous nucleic acid encoding an amino acid sequence 30 selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 85, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at least 95% identical to the at least one domain of SEQ ID NO:2n. Here as well, the test compound could be combined with the target polypeptide in a mamnialian cell grown in 83 WO 2004/013347 PCT/US2003/024504 culture. Also, the test compound could be combined with the target polypeptide in vitro. in this method, the nucleic acid comprises a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:2n-1, wherein n is an integer between 1 and 85; (b) nucleotides encoding an amino acid sequence of the at least one domain of SEQ ID NO:2n; 5 and (c) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ED NO:2n, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at least 95% identical-to the at least one domain of SEQ ID NO:2n. 10 The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein. Detection Assays Portions or fragments of the cDNA sequences identified herein (and the 15 corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are 20 described in the subsections, below. Chromosome Mapping Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences 25 of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease. Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers 30 (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then 84 WO 2004/013347 PCT/US2003/024504 be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment. Somatic cell hybrids are prepared by fusing somatic cells from different mammals 5 (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can 10 be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, et al., 1983. Science 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and 15 deletions. PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific 20 chromosomes. Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes 25 can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. 30 Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, et al., HUMAN CHROMOSOMEs: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988). Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for 85 WO 2004/013347 PCT/US2003/024504 marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping. 5 Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, e.g., in McKusick, MENDELIAN INERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage 10 analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland, et aL, 1987. Nature, 325: 783-787. Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, 15 then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a 20 mutation and to distinguish mutations from polymorphisms. Tissue Typing The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for 25 identification.' The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057). Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an 30 individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it. 86 WO 2004/013347 PCT/US2003/024504 Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX 5 sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction 10 fragment length polymorphisms (RFLPs). Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide 15 positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If coding sequences, such as those of SEQ ID NO:2in-1, wherein n is an integer between 1 and 85, are used, a more appropriate number of primers for positive individual identification would be 500-2,000. Predictive Medicine 20 The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a 25 biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, 30 and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder 87 WO 2004/013347 PCT/US2003/024504 associated with NOVX protein, nucleic acid expression or activity. For example, mutations in a NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid 5 expression, or biological activity. Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharnacogenomics"). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or 10 prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.) Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX in clinical trials. 15 These and other agents are described in further detail in the following sections. Diagnostic Assays An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or 20 nucleic acid (e.g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NO:2n-1, wherein n is an integer between 1 25 and 85, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein. An agent for detecting NOVX protein is an antibody capable of binding to NOVX 30 protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab') 2 ) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a 88 WO 2004/013347 PCT/US2003/024504 detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with 5 fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fliids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of NOVX mRNA include Northern 10 hybridizations and in situ hybridizations. In vitro techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX 15 antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a 20 peripheral blood leukocyte sample isolated by conventional means from a subject. In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing 25 the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, niRNA or genomic DNA in the test sample. The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the 30 amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid. 89 WO 2004/013347 PCT/US2003/024504 Prognostic Assays The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding 5 diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in 10 which a test sample is obtained from a subject and NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological 15 fluid (e.g., serum), cell sample, or tissue. Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods 20 can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e.g., wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that 25 can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity). The methods of the invention can also be used to detect genetic lesions in a NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, 30 the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from a NOVX gene; (ii) an addition of one or more 90 WO 2004/013347 PCT/US2003/024504 nucleotides to a NOVX gene; (iii) a substitution of one or more nucleotides of a NOVX gene, (iv) a chromosomal rearrangement of a NOVX gene; (v) an alteration in the level of a messenger RNA transcript of a NOVX gene, (vi) aberrant modification of a NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type 5 splicing pattern of a messenger RNA transcript of a NOVX gene, (viii) a non-wild-type level of a NOVX protein, (ix) allelic loss of a NOVX gene, and (x) inappropriate post-translational modification of a NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional 10 means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells. In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, 15 e.g., Landegran, et al., 1988. Science 241: 1077-1080; and Nakazawa, et al., 1994. Proc. Nati. Acad. Sci. USA 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, et al., 1995. Nucl. Acids Res. 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting 20 the nucleic acid sample with one or more primers that specifically hybridize to a NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification 25 step in conjunction with any of the techniques used for detecting mutations described herein. Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990. Proc. Natl. A cad. Sci. USA 87: 1874-1878), transcriptional amplification system (see, Kwoh, et al., 1989. Proc. Nati. Acad. Sci. USA 86: 1173-1177); Qp Replicase (see, Lizardi, et al, 1988. BioTechnology 6: 1197), or any other nucleic acid 30 amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In an alternative embodiment, mutations in a NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and 91 WO 2004/013347 PCT/US2003/024504 control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., 5 U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, et al., 1996. Human 10 Mutation 7: 244-255; Kozal, et al., 1996. Nat. Med. 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping 15 probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene. 20 In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. Proc. Natl. Acad. Sci. USA 74: 560 or Sanger, 1977. Proc. Nati. Acad. 25 Sci. USA 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 1995. Biotechniques 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, et al., 1996. Adv. Chromatography 36: 127-162; and Griffin, et al., 1993. Apple. Biochem. Biotechnol. 38: 147-159). 30 Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, et al., 1985. Science 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with 92 WO 2004/013347 PCT/US2003/024504 potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated 5 with Si nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al., 1988. Proc. 10 Natl. Acad. Sci. USA 85: 4397; Saleeba, et al., 1992. Methods Enzymol. 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection. In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in 15 NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al., 1994. Carcinogenesis 15: 1657-1662. According to an exemplary embodiment, a probe based on a NOVX sequence, e.g., a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test 20 cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039. In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) 25 may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al., 1989. Proc. Nat!. Acad. Sc. USA: 86: 2766; Cotton, 1993. Mutat. Res. 285: 125-144; Hayashi, 1992. Genet. Anal. Tech. Apple. 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids 30 varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded 93 WO 2004/013347 PCT/US2003/024504 heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991. Trends Genet. 7: 5. In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient 5 gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985. Nature 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, 10 e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753. Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that 15 pennit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA. 20' - Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448) or at the extreme 3'-terminus of one primer where, 25 under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993. Tibtech. 11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al., 1992. Mol. Cell Probes 6: 1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 30 -1991. Proc. Nati. Acad. Sci. USA 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification. 94 WO 2004/013347 PCT/US2003/024504 The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a NOVX 5 gene. Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells. 10 Pharmacogenomics Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (e.g.,.NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed 15 above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table 1. In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of 20 therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and 25 therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. 30 See e.g., Eichelbaum, 1996. Clin. Exp. PharmacoL Physiol., 23: 983-985; Linder, 1997. Clin. Chen., 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the 95 WO 2004/013347 PCT/US2003/024504 way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, 5 sulfonamides, analgesics, nitrofurans) and consumption of fava beans. As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome pregnancy zone protein precursor enzymes CYP2D6 and CYP2C19) has 10 provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly 15 polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine-mediated by its CYP2D6-formed metabolite 20 morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification. Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate 25 agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when 30 treating a subject with a NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein. 96 WO 2004/013347 PCT/US2003/024504 Monitoring of Effects During Clinical Trials Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For 5 example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or 10 downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell. 15 By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates NOVX activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of 20 expression of NOVX and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative 25 of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent. In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, 30 peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the 97 WO 2004/013347 PCT/US2003/024504 level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the 5 administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, i.e., to decrease the effectiveness of the agent. 10 Methods of Treatment The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or-activity. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, 15 disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table 1. These methods of treatment will be discussed more fully, below. Diseases and Disorders Diseases and disorders that are characterized by increased (relative to a subject not 20 suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) 25 nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (i.e., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989. Science 244: 1288-1292); or (v) modulators ( i.e., 30 inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner. 98 WO 2004/013347 PCT/US2003/024504 Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i.e., are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may 5 be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability. Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of 10 an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like). 15 Prophylactic Methods In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression 20 or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, a NOVX agonist or NOVX antagonist agent can 25 be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections. Therapeutic Methods Another aspect of the invention pertains to methods of modulating NOVX expression 30 or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an 99 WO 2004/013347 PCT/US2003/024504 agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a NOVX protein, a peptide, a NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding 5 NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such-inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the invention provides methods of treating 10 an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering a 15 NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity. Stimulation of NOVX activity is desirable in situations in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder 20 characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia). Determination of the Biological Effect of the Therapeutic In various embodiments of the invention, suitable in vitro or in vivo assays are 25 performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue. In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy 30 may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects. 100 WO 2004/013347 PCT/US2003/024504 Prophylactic and Therapeutic Uses of the Compositions of the Invention The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and 5 more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table 1. As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have 10 efficacy for treatment of patients suffering from diseases, disorders, conditions and the like, including but not limited to those listed herein. Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use 15 could be as an anti-bacterial molecule (i.e., some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods. The invention will be further described in the following examples, which do not limit 20, the scope of the invention described in the claims. NOVX Polypeptides 25 The following sections describe in detail the NOVX polypeptides of the invention and methods of screening for modulators of NOVX polypeptides. A. NOVI -- Cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK) 30 The cytosolic isoform of PEPCK regulates glyceroneogenesis in adipose tissue. Glyceroneogenesis is an abbreviated version of gluconeogenesis in which glycerol-3 phosphate is produced from substrates such as pyruvate, lactate and alanine. The glycerol-3 phosphate thus produced is used in triglyceride synthesis. The role of glyceroneogenesis in maintaining the deposition of triglycerides in adipose tissue has been uncovered recently. 101 WO 2004/013347 PCT/US2003/024504 Cytosolic PEPCK is also the rate-limiting enzyme for gluconeogenesis, the pathway in which glucose is produced in the liver from pyruvate, lactate and alanine. The process of hepatic gluconeogenesis is upregulated in Type 2 diabetes and is believed to contribute to the fasting hyperglycemia characteristic of this disease. The genetic and environmental causes of 5 the complex metabolic disturbances of Type 2 diabetes, including increased hepatic glucose production, are incompletely understood. CuraGen's GeneCalling@ studies have shown that cytosolic PEPCK is upregulated in adipose tissue of obese AKR versus normal C57BI mice. This result suggests that 10 upregulation of PEPCK may contribute to the obese phenotype. This hypothesis is supported by the fact that transgenic overexpression of cytosolic PEPCK in adipose is associated with increased glyceroneogenesis, increased adipocyte (fat cell) size and fat mass, and higher body weight (Franckhauser S, Munoz S, Pujol A, Casellas A, Riu E, Otaegui P, Su B, Bosch F. Increased fatty acid re-esterification by PEPCK overexpression in adipose tissue leads to 15 obesity without insulin resistance. Diabetes. 2002 Mar;51(3):624-30. PMID: 11872659). Furthermore, a mutation in the PPARgamma-binding site in the gene for cytosolic PEPCK reduces the activity of PEPCK, with a concomitamt increase in adiposity and body weight in mice (Olswang Y, Cohen H, Papo 0, Cassuto H, Croniger CM, Hakimi P, Tilghman SM, Hanson RW, Reshef L. A mutation in the peroxisome proliferator-activated receptor 20 gamma-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice. Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):625-30. PMID: 11792850). Thus, a reduction in the expression of cytosolic PEPCK reduced triglyceride deposition in adipose tissue, while an increase in adipose expression of PEPCK increased fat mass in mice. 25 Diet-induced obesity is a popular model for the study of pathways involved in the evolution of weight gain due to increased caloric intake. Mice are fed a high-fat diet (- 30 45% of calories from fat) for 12-16 weeks and then tissues are analyzed for changes in metabolic pathways as compared to control animals fed a normal rodent diet. CuraGen's 30 GeneCalling@ studies of adipose tissue from high fat-fed versus normal chow-fed mice have given results contradictory to those discussed above. Contrary to expectations, cytosolic PEPCK is downregulated in multiple adipose depots of high fat versus normal chow-fed mice. Downregulation of adipose PEPCK was documented at multiple time points in the course of the diet-induced obesity protocol. Our interpretation of these results is that 102 WO 2004/013347 PCT/US2003/024504 downregulation of PEPCK maybe a compensatory response to limit triglyceride deposition. In support of this hypothesis, a number of additional lipogenic genes are downregulated in adipose tissue under conditions of diet-induced obesity, including diacylglycerol transferase 2, monoglyceride lipase, lipoprotein lipase and aquaporin adipose. 5 The discordance in PEPCK gene expression in diet-induced obesity versus a genetic model of obesity may be explained by the differences in the two models. In genetic obesity, the pathophysiology is static because it is hard-wired into the organism. In contrast, in diet induced obesity, the increase in fat mass evolves over a period of 12-16 weeks, and is a 10 result of the increase in high-fat calories. The response to the caloric overload is dynamic (as seen in CuraGen's GeneCalling@ studies), and includes compensatory responses by the organism to maintain energy homeostasis and body weight. Such a compensatory response to caloric overload appears to include a downregulation of PEPCK in adipose tissue. 15 CuraGen's GeneCalling@ studies have also shown an upregulation of cytosolic PEPCK in the liver of mice in the diet-induced obesity model (data included below). The gene is upregulated 1.8-fold in the transition from normoglycemia to hyperglycemia in obese mice. This data strongly supports a pathogenic role for cytosolic PEPCK in the increased hepatic glucose production and hyperglycemia of Type 2 diabetes. It is important to note that 20 more than 90% of patients with Type 2 diabetes are obese. In the diet-induced obesity model, a proportion of the obese mice also develop hyperglycemia and other metabolic disturbances characteristic of Type 2 diabetes. Thus cytosolic PEPCK is also a therapeutic target for Type 2 diabetes. 25 The following summarizes the biochemistry surrounding the human cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK) and potential assays that may be used to screen for antibody therapeutics or small molecule drugs to treat obesity and/or diabetes. Cytosolic Phosphoenolpyruvate carboxykinase (PEPCK) is an important enzyme in 30 whole-body energy homeostasis and catalyzes the following reaction: GTP + oxaloacetate = GDP + phosphoenolpyravate + CO 2 103 WO 2004/013347 PCT/US2003/024504 It is the rate-limiting enzyme in gluconeogenesis in liver and glyceroneogenesis in adipose tissue, participating in the glyceroneogenic pathway in adipocytes when glucose is limiting. Adipose tissue glyceroneogenesis produces glycerol 3-phosphate, which is the substrate for triglyceride deposition. Phosphoenolpyruvate carboxykinase (PEPCK) activity is affected 5 by a number of hormones that regulate this metabolic process, including glucagon, insulin, and glucocorticoids. Taken in total, the data indicates that a modulator such as an inhibitor/antagonist of the human cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK) would be beneficial in 10 the treatment of obesity and/or diabetes. Furthermore, our results indicate that a modulator of cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK) activity, such as an inhibitor, activator, antagonist, or agonist of PEPCK may be useful for treatment of such disorders as obesity, diabetes, and insulin 15 resistance, as well as for enhancement of insulin secretion. Discovery Process The following sections describe the study design(s) and the techniques used to 20 identify the Cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK) - encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for Obesity and Diabetes. 25 Example Al. Genetically Obese Mice vs Genetically Lean Mice Study A protocol for Genetically Obese Mice vs Genetically Lean Mice Study is disclosed in Example Q6. 30 A fragment of the mouse cytosolic Phosphoenolpyruvate carboxykinase (PEPCK) 1 gene (mouse strains AKR, C57BL) was initially found to be up-regulated by 3-fold in the adipose tissue of obese AKR mice relative to lean C57L/J mice using CuraGen's GeneCalling@ method of differential gene expression (described in Example Q7). A 104 WO 2004/013347 PCT/US2003/024504 differentially expressed mouse gene fragment migrating, at approximately 254 nucleotides in length was definitively identified as a component of the mouse Cytosolic Phosphoenolpyruvate carboxykinase (PEPCK) 1 cDNA. The method of competitive PCR was used for confirmation of the gene assessment. The electropherographic peaks 5 corresponding to the gene fragment of the mouse cytosolic Phosphoenolpyruvate carboxykinase (PEPCK) 1 were ablated when a gene-specific primer (shown in Table Al) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 254 nt in length were ablated in the sample from both the obese AKR mice and the normal C57L/J mice. 10 Table Al. The direct sequence of the 254 nucleotide-long gene fragment and the gene specific primers used for competitive PCR are indicated on the cDNA sequence of Cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK) 1 fragment (SEQ ID NO:171) are shown in bold. The gene-specific primers at the 5' and 3' ends of the fragment are underlined. Gene Sequence (fragment from 1442 to 1695 in bold. band size: 254) 961 AAGGCAAGAA GAAATACCTG GCCGCAGCCT TCCCTAGTGC CTGTGGGAAG ACTAACTTGG 1021 CCATGATGAA CCCCAGCCTG CCCGGGTGGA AGGTCGAATG TGTGGGCGAT GACATTGCCT 1081 GGATGAAGTT TGATGCCCAA GGCAACTTAA GGGCTATCAA CCCAGAAAAC GGGTTTTTTG 1141 GAGTTGCTCC TGGCACCTCA GTGAAGACAA ATCCAAATGC CATTAAAACC ATCCAGAAAA 1201 ACACCATCTT CACCAACGTG GCCOAGACTA GCGATGGGGG TGTTTACTGG GAAGGCATCG 1261 ATGAGCCGCT GGCCCCGGGA GTCACCATCA CCTCCTGGAA GAACAAGGAG TGGAGACCGC 1321 AGGACGCGGA ACCATGTGCC CATCCCAACT CGAGATTCTG CACCCCTGCC AGCCAGTGCC 1381 CCATTATTGA CCCTGCCTGG GAATCTCCAG AAGGAGTACC CATTGAGGGT ATCATCTTTG 1441 GTGGCCGTAG ACCTGAAGGT GTCCCCCTTG TCTATGAAGC CCTCAGCTGG CAGCATGGGG 1501 TGTTTGTAGG AGCAGCCATG AGATCTGAGG CCACAGCTGC TGCAGAACAC AAGGGCAAGA 1561 TCATCATGCA CGACCCCIT GCCATGCGAC CCTTCTTCGG CTACAACTTC GGCAAATACC 1621 TGGCCCACTG GCTGAGCATG GCCCACCGCC CAGCAGCCAA GTTGCCCAAG ATCTTCCATG 1681 TCAACTGGTT CCGGAAGGAC AAAGATGGCA AGTTCCTCTG GCCAGGCTTT GGCGAGAACT 1741 CCCGGGTGCT GGAGTGGATG TTCGGGCGGA TTGAAGGGGA AGACAGCGCC AAGCTCACGC 1801 CCATCGGCTA CATCCCTAAG GAAAACGCCT TGAACCTGAA AGGCCTGGGG GGCGTCAACG 1861 TGGAGGAGCT GTTTGGGATC TCTAAGGAGT TCTGGGAGAA GGAGGTGGAG GAGATCGACA 1921 GGTATCTGGA GGACCAGGTC AACACCGACC TCCCTTACGA AATTGAGAGG GAGCTCCGAG 1981 CCCTGAAACA GAGAATCAGC CAGATGTAAA TCCCAATGGG GGCGTCTCGA GAGTCACCCC 2041 TTCCCACTCA CAGCATCGCT GAGATCTAGG AGAAAGCCAG CCTGCTCCAG CTTTGAGATA 2101 GCGGCACAAT CGTGAGTAGA TCAGAAAAGC ACCTTTrAAT AGTCAGTTGA GTAGCACAGA 2161 GAACAGGCTA GGGGC (gene length is 2617, only region from 961 to 2175 shown) 105 WO 2004/013347 PCT/US2003/024504 Example A2. Mouse Dietary-Induced Obesity Study A protocol for Mouse Dietary-Induced Obesity study is disclosed in Example Q1. 5 A large number of mouse strains have been identified that differ in body mass and composition. The AKR and NZB strains are obese, the SWR, C57BL and C57BL/6 strains are of average weight whereas the SM/J and Cast/Ei strains are lean. Understanding the gene expression differences in the major metabolic tissues from these strains will elucidate the pathophysiologic basis for obesity. These specific strains of rat were chosen for differential 10 gene expression analysis because quantitative trait loci (QTL) for body weight and related traits had been reported in published genetic studies. Tissues included whole brain, skeletal muscle, visceral adipose, and liver. The predominant cause for obesity in clinical populations is excess caloric intake. 15 This so-called diet-induced obesity (DIO) is mimicked in animal models by feeding high fat diets of greater than 40% fat content. The DIO study was established to identify the gene expression changes contributing to the development and progression of diet-induced obesity. In addition, the study design sought to identify the factors that lead to the ability of certain individuals to resist the effects of a high fat diet and thereby prevent obesity. The sample 20 groups for the study had body weights +1 S.D., + 4 S.D. and + 7 S.D. of the chow-fed controls. In addition, the biochemical profile of the +7 S.D. mice revealed a further stratification of these animals into mice that retained a normal glycemic profile in spite of obesity and mice that demonstrated hyperglycemia. Tissues examined included hypothalamus, brainstem, liver, retroperitoneal white adipose tissue (WAT), epididymal 25 WAT, brown adipose tissue (BAT), gastroenemius muscle (fast twitch skeletal muscle) and soleus muscle (slow twitch skeletal muscle). The differential gene expression profiles for these tissues revealed genes and pathways that can be used as therapeutic targets for obesity. Protocol for differential gene expression analysis, GeneCalling@, is disclosed in Example Q7. 30 Results A gene fragment of mouse cytosolic Phosphoenolpyruvate carboxykinase (PEPCK) was found to be down-regulated by 7-fold in the epididymal fat pad (efp) of Ngsd7 (normal 35 glycemic, obese) vs. chow-fed mice in a diet-induced obesity study using CuraGen's 106 WO 2004/013347 PCT/US2003/024504 GeneCalling@ method of differential gene expression. A differentially expressed mouse gene fragment migrating, at approximately 349 nucleotides in length was definitively identified as a component of the mouse cytosolic Phosphoenolpyravate carboxykinase (PEPCK) cDNA. The method of competitive PCR was used for confirmation of the gene 5 assessment. The electropherographic peaks corresponding to the gene fragment of the mouse cytosolic Phosphoenolpyruvate carboxykinase (PEPCK) were ablated when a gene-specific primer (shown in Table A2) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 349 nt in length were ablated in the sample from both the Ngsd7 and chow-fed mice. In addition, the mouse cytosolic Phosphoenolpyruvate carboxykinase 10 (PEPCK) gene is down-regulated in the retroperitoneal fat pad (rfp) ofNgsd7 (normal glycemic, obese) and Hgsd7 (hyperglycemic, obese) versus Sdl or chow-fed mice. It should be noted that the downregulation of this gene in adipose in a dietary-induced obesity model may be a compensatory response to limit triglyceride deposition and adiposity. Table A2. The direct sequence of the 349 nucleotide-long gene fragment and the gene specific primers used for competitive PCR are indicated on the cDNA sequence of the cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK) fragment (SEQ ID NO:172) are shown in bold. The gene-specific primers at the 5' and 3' ends of the fragment are underlined. Gene Sequence (fragment from 2077 to 2425 in bold. band size: 349) 1596 CCATGCGACC CTrCTTCGGC TACAACTTCG GCAAATACCT GGCCCACTGG CTGAGCATGG 1656 CCCACCGCCC AGCAGCCAAG TTGCCCAAGA TCTTCCATGT CAACTGGTTC CGGAAGGACA 1716 AAGATGGCAA GTTCCTCTGG CCAGGCTTTG GCGAGAACTC CCGGGTGCTG GAGTGGATGT 1776 TCGGGCGGAT TGAAGGGGAA GACAGCGCCA AGCTCACGCC CATCGGCTAC ATCCCTAAGG 1836 AAAACGCCTT GAACCTGAAA GGCCTGGGGG GCGTCAACGT GGAGGAGCTG TTTGGGATCT 1896 CTAAGGAGTT CTGGGAGAAG GAGGTGGAGG AGATCGACAG GTATCTGGAG GACCAGGTCA 1956 ACACCGACCT CCCTTACGAA ATTGAGAGGG AGCTCCGAGC CCTGAAACAG AGAATCAGCC 2016 AGATGTAAAT CCCAATGGGG GCGTCTCGAG AGTCACCCCT TCCCACTCAC AGCATGCGCT 2076 GAGATCTAGG AGAAAGCCAG CCTGCTCCAG CTrrGAGATA GCGGCACAAT GCTGAGTAGA 2136 TCAGAAAAGC ACCTTTTAAT AGTCAGITGA GTAGCACAGA GAACAGGCTA GGGGCAAATA 2196 AGATTGGGAG GGGAAATCAC CGCATAGTCT CTGAAGTTrG CATTTGACAC CAATGGGGGT 2256 TTTGGTTCCA CTTCAAGGTC ACTCAGGAAT CCAGTrCTTC ACGTTAGCTG TAGCAGTTAG 2316 CTAAAATGCA CAGAAAACAT ACTTGAGCTG TATATATGTG TGTGAACGTG TCTCTGTGTG 2376 AGCATGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTGTACA TGCCTGTCTG 2436 TCCCATTGTC CACAGTATAT TTAAAACCTT TGGGGAAAAA TCTTGGGCAA ATTTGTAGCT 2496 GTAACTAGAG AGTCATGTTG CTTTGTTGCT AGTATGTATG TTTAAATTAT TTTTATACAC 2556 CGCCCTTCCT TACCTTTCTT TACATAA1rG AAATTGGTAT CCGGACCACT TCTTGGGAAA 107 WO 2004/013347 PCT/US2003/024504 2616 AAAATTACAA AATAAACITT TATAGAAAAA GTAAAAAAAA AAAAAAAA (gene length is 2663, only region from 1596 to 2663 shown) Our data also showed that cytosolic PEPCK is downregulated 1.8-fold in the liver of Ngsd7 (normal glycemia and obese) versus Hgsd7 (hyperglycemic and obese) mice in the diet-induced obesity study. Identitiy of the PEPCK as the downregulated gene was then 5 confirmed by TrapPing technology (disclosed in Example Q7). Therefore, PEPCK is upregulated in Hgsd7 liver versus Ngsd7 liver. Thus, PEPCK upregulation occurs at the transition between normal glycemia and the pathologic change to hyperglycemia. Since PEPCK is the rate-controlling step in the process of hepatic gluconeogenesis (production of glucose from non-glucose substrates), the data suggests that upregulation of PEPCK is a 10 critical step in the evolution to hyperglycemia and Type 2 diabetes. Example A3. Identification of Human PEPCK Sequence The sequence of Human PEPCK (Acc. No. CG101 190-01) was derived by laboratory 15 cloning of cDNA fragments, by in silicon prediction of the sequence. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were cloned. In silicon prediction was based on sequences available in CuraGen's proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof. The protocol for identification of human 20 sequence(s) is disclosed in Example Q8. Table A3 shows an alignment (ClustalW) of the protein sequences of the human (CG101190-01), rat (PPCCMOUSE = Q9Z2V4) and mouse (PPCCRAT = P07379) versions of the cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK). Table A4 shows 25 sequences of rat (PPCCMOUSE = Q9Z2V4; SEQ ID NO:174) and mouse (PPCC RAT P07379; SEQ ID NO: 173) versions of the cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK). 108 WO 2004/013347 PCT/US2003/024504 .. .. i ... ..... 6muuM TableoAS >PPCC MOSE (SEQimO:7 MPPLHNLDFAKVQGSDSLQAVKFV mAllQPEIIDGSEEEYGQLAHMQEEG1RKL KYDNWLA~hPRVARESKVIITEQRTVPPKTGSQLRWMSEDFKAFARFPC ;allM VIPFMGPGSPAIiEl DPVAMITMIVELDEIMCHVCLPKPV" ACNELTIAHPDREISFGGYGNSLGKCFLR1SRLKOWLAEM 41140 EGKKY AAFPACKTLAMNSLGWVEVGDIWMFDQGL WIpmNFGAGSVTFAK >PPCC MATUSE Q ID NO:173) MPPQLHNGLDFSAKVIQGSLDSLPQAVRKFVEGNAQLCQPEYIHICDGSEEEYGRLLAHMQEEGVlRKLK KYDNCWLALTDPRDVARIESKTVIITQEQRDTVPIPKSGQSQLGRWMSEEDFEKAFNARFPGCMKGRTMY VIPFSMGPLGSPLAICIGIELTDSPYVVASMRIMTRMGISVLEALGDGEFIKCLHSVGCPLPLKKPLVNNW ACNPELTLIAHLPDRREIISFGSGYGGNSLLGKKCFALRIASRLAKEEGWLAEHMLILGITNT'EGKKKYL AAAFPSACGKTNLAMMNPSLPGWKVECVGDDIAWMK1FDAQGNLRAINPENGFFGjVAPGTSVKTNPNAIKT IQKNnT1VAETSDGGVYWEGIDEPLAPGVTITSWKN.KEWRPQDEEPCAHPNSRFCTPASQCPIIDPAW ESPEGVPIEGIIFGGRRPEGVPLVYEALSWQHGVFVGAAMRSEATAAAEHiKGKVIMHDPFAMRPFFGYNF GKYLAHWLSMAH-RPAAKLPKIFHVNWFRKDKDGKFLWPGFGENSRVLEWMFGRIEGEDSAKLTPIGYIPK EDALNLKGLGDVNYEELFGISKEFWEKLEVEEIDKYLEDQVNADLPYEIERELRALKQRJSQM >PPCCRAT(E IDN:109 WO 2004/013347 PCT/US2003/024504 The laboratory cloning was performed using one or more of the methods summarized in Example Q8. The NOV1 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table A6. Table A6. NOVI Sequence Analysis NOVla, CG101190-01 ISEQ ID NO: 1 2070 bp DNA Sequence ORF Start: ATG at 119 ORF Stop: TAA at 1985 GAACACAAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAA A GAGAAGAAAGGTGACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTGCA A AACGGCCTGAACCTCTCGGCCAAAGTTGTCCAGGGAAGCCTGGACAGCCTGCCCCAGGCAGTGAGGG A GTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGATCACATCCACATCTGTGACGGCTCTGAGGAG G AGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGCGGCTGAAGAGTATGACAA C TGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATCGTCACCC A AGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCAGAG AGGATTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTACGTCAT C CCATTCAGCATGGGGCCGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGACGGATTCGCCCT A CGTGGTGGCCAGCATGCGGATCATGACGCGGATGGGCACGCCCGTCCTGGAAGCACTGGGCGATGGG G AGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTGCCTTTACAAAAGCCTTTGGTCAACAACTG G CCCTGCAACCCGGAGCTGACGCTCATCGCCCACCTGCCTGACCGCAGAGAGATCATCTCCTTTGGCA G TGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTGGCC A AGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAA G TACCTGGCGGCCGCATTTCCCAGCGCCTGCGGGAAGACCAACCTGGCCATGATGAACCCCAGCCTCC C CGGGTGGAAGGTTGAGTGCGTCGGGGATGACATTGCCTGGATGAAGTTTGACGCACAAGGTCATTTA A GGGCCATCAACCCAGAAAATGGCTTTTTCGGTGTCGCTCCTGGGACTTCAGTGAAGACCAACCCCAA T GCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGCCGAGACCAGCGACGGGGGCGTTT A CTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGTCACCATCACGTCCTGGAAGAATAAGGAGTGG A GCTCAGAGGATGGGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCC C ATCATTGATGCTGCCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTA G ACCTGCTGGTGTCCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGGCGGCC A TGAGATCAGAGGCCACAGCGGCTGCAGAACATAAAGGCAAAATCATCATGCATGACCCCTTTGCCAT G CGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTGGCCCACTGGCTTAGCATGGCCCAGCACCCAG C AGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGACAAGGAAGGCAAATTCCTCTGG C CAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATGTTCAACCGGATCGATGGAAAAGCCAGCAC C AAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCA 110 WO 2004/013347 PCT/US2003/024504 CATGATGGAGCTTTTCAGCATCTCCAAGGAATTCTGGGAGAAGGAGGTGGAAGACATCGAGAAGTAT C TGGAGGATCAAGTCAATGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAG A ATAAGCCAGATGTAATCAGGGCCTGAGTGCTTTACCTTTAAAATCATTCCCTTTCCdATCCATAAGG T GCAGTAGGAGCAAGAGAGGGCAAGTGTTCC NOVIa, CG1O1190-01 ISEQ ID NO: 2 1622 aa 1MW at 07.8kD Protein Sequence MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILR R LKKYDNCWLALTDPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFEKAFNARFPGCMK G RTMYVIPFSMGPLGSPLSKIGIELTDSPYVVASMRIMTRMGTPVLEALGDGEFVKCLHSVGCPLPLQ K PLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSLLGKKCFALRMASRLAKEEGWLAEHMLILGIT N PEGEKKYLAAAFPSACGKTNLAMMNPSLPGWKVECVGDDIAWMKFDAQGHLRAINPENGFFGVAPGT S VKTNPNAIKTIQKNqTIFTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCAHPNSRFC T PASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKII M HDPFAMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRVLEWMFNR I DGKASTKLTPIGYTPKEDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIERE I LALKQRISQM NOVb, 278992806 SEQ ID NO: 3 1888 bp DNA Sequence ORF Start: at 2 ORF Stop: end of sequence CACCGGATCCACCATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGCCAAAOTTGTCCAGGGA A GCCTGGACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGA T CACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTCGCCAGATGGAGGAAGAGG G CATCCTCAGGCGACTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCC A GGATCGAAAGCAAGACGGTTATCGTCACCCAAGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGG C CTCAGCCAGCTCGGTCGCTGGATGTCAGAGGAGGATTTTGAGAAAGCGTTCAATGCCAGGTTCCCAG G GTGCATGAAAGGTCGCACCATGTACGTCATCCCATTCAGCATGGGGCCGCTGGGCTCACCTCTGTCG A AGATCGGCATCGAGCTGACGGATTCGCCCTACGTGGTGGCCAGCATGCGGATCATGACGCGGATGGG C ACGCCCGTCCTGGAAGCACTGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTC T GCCTTTACAAAACCCTTTGGTCAACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCGCCCACCTG C CTGACCGCAGAGAGATCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTG C TTTGCTCTCAGGATGGCCAGCCGGCTGGCCAAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTC T GGGTATAACCAACCCTGAGGGTGAGAAGAAGTACCTGGCGGCCGCATTTCCCAGCGCCTGCGGAAG A CCAACCTGGCCATGATGAACCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCGTCGGGGATGACATTGC C TGGATGAAGTTTGACGCACAAGGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGTGTCG 111 WO 2004/013347 PCT/US2003/024504 C TCCTGGGACTTCAGTGAAGACCAACCCCAATGCCATCAAGACCATCCAGGACACAATCTTTACC A ATGTGGCCGAGACCAGCGACGGGGGCGTTTACTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGT C ACCATCACGTCCTGGAAGAATAAGGAGTGGAGCTCAGAGGATGGGGAACCTTGTGCCCACCCCAACT C GAGGTTCTGCACCCCTGCCAGCCAGTGCCCCATCATTGATGCTGCCTGGGAGTCTCCGGAAGGTGTT C CCATTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGTGTCCCTCTAGTCTATGAAGCTCTCAG C TGGCAACATGGAGTCTTTGTGGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTGCAGAACATAAAG G CAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG G CCCACTGGCTTAGCATGGCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTT C CGGAAGGACAAGGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGA T GTTCAACCGGATCGATGGAAAAGCCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGAT G CCCTGAACCTGAAAGGCCTGGGGCACATCAACATGATGGAGCTTTTCAGCATCTCCAAGGAATTCTG G GAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGGATCAAGTCAATGCCGACCTCCCCTGTGAAA T CGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGCCAGATGGTCGACGGC NOVib, 278992806 SEQ ID NO: 4 629 aa MW at 69825.4kD Protein Sequence TGSTMPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEE G ILRRLKKYDNCWLALTDPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFEKAFNARFP G CMKGRTMYVIPFSMGPLGSPLSKIGIELTDSPYVVASMRIMTRMGTPVLEALGDGEFVKCLHSVGCP L PLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSLLGKKCFALRMASRLAKEEGWLAEHMLI L GITNPEGEKKYLAAAFPSACGKTNLAMMNPSLPGWKVECVGDDIAWMKFDAQGHLRAINPENGFFGV A PGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCAHPN S RFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHK G KIIMHDPFAMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRVLEW M FNRIDGKASTKLTPIGYIPKEDALNLKGLGHINMMELFS ISKEFWEKEVEDIEKYLEDQVNADLPCE I EREILALKQRISQMVDG NOVlc, 278992862 SEQ ID NO: 5 1801bp DNA Sequence ORF Start: at 2 ORF Stop: end of sequence CACCGGATCCGAGTTTCTCGAGATAACGCTGAGCTGTGTCAGCCTGATCACATCCACATCTGTGAC G GCTCTGAAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGCGACTGAA G AAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGG T TATCGTCACCCAAGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGC T GGATGTCAGAGGAGGATTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCAC C ATGTACGTCATCCCATTCAGCATGGGGCCGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGA 112 WO 2004/013347 PCT/US2003/024504 GGATTCGCCCTACGTGGTGGCCAGCATGCGGATCATGACGCGGATGGGCACGCCCGTCCTGGAA GCA TGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTGCCTTTACAA-AAGCCTTT GTC2AACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCGCCCACCTGCCTGACCGCAGAGAGATCA CTCCTTTGCAGTGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCC GCCGGCTGGCCAAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGA GGTGAGAAGAAGTACCTGGCGGCCGCATTTCCCAGCGCCTGCGGGAAGACCAACCTGGCCATGATGA CCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCGTCGGGGATGACATTGCCTGGATGAAGTTTGACGCA AAGGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGTGTCGOTCCTGGGACTTCAGTGAA G ACCDAACCCCAATGCCATCAAGACCATCCAG74AGAACACAATCTTTACCAATGTGGCCGAGACCAGCG A CGGGGOGTTTACTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGTCACCATCACGTCCTGGAAG A ATAAGGAGTGGAGCTCAGAGGATGrGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTGC AGCCAGTGCCCCATCATTGATGCTGCCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCT T TGGAGGCCGTAGACCTGCTGGTGTCCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTT G TGGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTGCAGAACATAGGCAAAATCATCATGCATGA C CCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTGGCCCACTGGCTTAGCATGG C CCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGACAAGGAAGGC A AATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATGTTCAACCGGATCGATGG A AAAGCCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAXGGCC T GGGGCACATCAACATGATGGAGCTTTTCAGCATCTCCAAGGAATTCTGGGAGAAGGAGGTGGAAGAC A TCGAGAAGTATCTGGAGGATCAAGTCAATGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGC C TTGAAGCAAAGAATAAGCCAGATGGTCGACGGC NOVIc, 278992862 SEQ ID NO:6, O ajWa 68.k Protein Sequence TGSEFLENNAELCQPDHIHICDGSEEENGRLLGQEEGLRRLKKYDNCWLALTDPRDVARIESKT V IVTQEQIRDTVPIPKTGLSQLGRWMSEEDFEKAFNARF'PGCMKGRTMYVIFSMGPLGSPLSKIGIEL T DSPYVNASMkIMTRMGTPVLEALGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREI I SFGSGYGGNSLLGKKCFAMR1ASRLACEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLIMM N PSI.PGWKVECVGDDIAWMKFDAQGLRAINPENGFFGVAPGTSVKTNPAIKTIQMcTIFTNVAETS D GGVYWEGIDEPI.ASGVTITSWI1NKEWSSEDGEPCAHPNSRFCTPASQCPI IDAAWESPEGVPIEGII GGRRPAGVPLVYEALSWQIGVFVGA4RSEATAHKGKII14DPFRPFFGYFGKYLAWLSM IGHINMMELFS ISKEFWEKEVEDIEKYILEDQVINAfLPCEIERSILALKQRISQMVDG 113 WO 2004/013347 PCT/US2003/024504 A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table A7. Table A7. Comparison of the NOVI protein sequences. NOVIa ---- MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRL NOV~b TGSTMPPQLQNGLNL5AKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRL NOVIc-----------------------------TGSEFLENNAELCQPDHIHICDGSEEENGRL NOVla LGQMEEEGILRRLKKYDNCWLALTDPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRW NOVIb LGQMEEEGILRRLKKYDNCWLALTDPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRW NOVIc LGQMEEEGILRRLKKYDNCWLALTDPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRW NOVIa MSEEDFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIELTDSPYVVASMRIMTRM NOVib MSEEDFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIELTDSPYVVASMRIMTRM NOVIc MSEEDFEKAFNARFPGCMKORTMYVIPFSMGPLGSPLSKIGIELTDSPYVVASMRIMTRM NOVIa GTPVLEALGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYG NOVIb GTPVLEALGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYG NOVic GTPVLEALGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYG NOVIa GNSLLGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMM NOV1b GNSLLGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMM NOVic GNSLLGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMM NOVla NPSLPGWKVECVGDDIAWMKFDAQGHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTI NOVib NPSLPGWKVECVGDDIAWMKFDAQGHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTI NOVIc NPSLPGWKVECVGDDIAWMKFDAQGHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTI NOVIa FTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCAHPNSRFCTPASQCPII NOVIb FTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCAHPNSRFCTPASQCPII NOV1c FTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCAHPNSRFCTPASQCPII NOVia DAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIM NOVIb DAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIM NOV1c DAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIM NOVia HDPFAMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRV NOV~b HDPFAMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRV NOV1c HDPFAMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRV NOVIa LEWMFNRIDGKASTKLTPIGYIPKEDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYL NOVIb LEWMFNRIDGKASTKLTPIGYIPKEDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYL NOV1c LEWMFNRIDGKASTKLTPIGYIPKEDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYL NOVIa EDQVNADLPCEIEREILALKQRISQM-- NOV1b EDQVNADLPCEIEREILALKQRISQMVDG NOVic EDQVNADLPCEIEREILALKQRISQMVDG NOVla (SEQ ID NO: 2) NOVIb (SEQ ID NO: 4) NOVIc (SEQ ID NO: 6) Further analysis of the NOV1a protein yielded the following properties shown in Table A8. Table A8. Protein Sequence Properties NOVia SignalP analysis: No Known Signal Sequence Predicted PSORT II analysis: 114 WO 2004/013347 PCT/US2003/024504 PSG: a new signal peptide prediction method N-region: length 0; pos.chg 0; neg.chg 0 H-region: length 13; peak value -1.95 PSG score: -6.35 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -10.13 possible cleavage site: between 17 and 18 >>> Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood= 6.42 (at 280) ALOM score: 6.42 (number of TMSs: 0) MITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment(75): 3.20 Hyd Moment(95): 6.24 G content: 2 D/E content: 1 S/T content: 2 Score: -5.73 Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not found NUCDISC: discrimination ofnuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 10.6% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: found KLPK at 507 RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern: none Prenylation motif; none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none 115 WO 2004/013347 PCT/US2003/024504 checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 89 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues Final Results (k = 9/23): 43.5 %: nuclear 34.8 %: cytoplasmic 17.4 %: mitochondrial 4.3 %: vacuolar >> prediction for CG101190-01 is nuc (k=23) A search of the NOVla protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table A9. Table A9. Geneseq Results for NOVIa NOVia Identities/ Geneseq Protein/Organism/Length [Patent Residues/ Similarities for Expect Identifier #, Date] Match the Matched Value Residues Region AAB71880 Human PEPCK-cytosolic protein - 1..622 617/622 (99%) 0.0 Homo sapiens, 622 aa. [US6187545- 1..622 620/622 (99%) B1, 13-FEB-2001] AAB71890 Mouse PEPCK-cytosolic protein - 1..622 566/622 (90%) 0.0 Mus musculus, 622 aa. [US6187545- 1..622 596/622 (94%) BI, 13-FEB-2001] AAY80296 Human mitochondrial 14..622 437/610 (71%) 0.0 phosphoenolpyruvate carboxykinase 31..640 514/610 (83%) SEQ ID NO:1 - Homo sapiens, 640 aa. [US6030837-A, 29-FEB-2000] ABJ37938 NOVX protein sequence SEQ ID No 14..622 411/610 (67%) 0.0 121 - Unidentified, 608 aa. 31..608 485/610 (79%) [W0200281517-A2, 17-OCT-2002] ABB65318 Drosophila melanogaster polypeptide 18..622 397/610(65%) 0.0 SEQ ID NO 22746 - Drosophila 43..647 477/610 (78%) melanogaster, 647 aa. [WO200171042-A2, 27-SEP-2001] 116 WO 2004/013347 PCT/US2003/024504 In a BLAST search of public sequence databases, the NOVIa protein was found to have homology to the proteins shown in the BLASTP data in Table A10. Table Al0. Public BLASTP Results for NOVIa Protein NOVIa Identities/ Accession Protein/Organism/Length Residues/ Similarities for Expect Number Match the Matched Value Residues Portion P35558 Phosphoenolpyruvate carboxykinase, 1..622 622/622 (100%) 0.0 cytosolic [GTP] (EC 4.1.1.32) 1..622 622/622 (100%) (Phosphoenolpyruvate carboxylase) (PEPCK-C) - Homo sapiens (Human), 622 aa. A45746 phosphoenolpyruvate carboxykinase 1..622 620/622 (99%) 0.0 (GTP) (EC 4.1.1.32) 1 - human, 622 1..622 621/622 (99%) aa. P07379 Phosphoenolpyruvate carboxykinase, 1..622 566/622 (90%) 0.0 cytosolic [GTP] (EC 4.1.1.32) 1..622 596/622 (94%) (Phosphoenolpyruvate carboxylase) (PEPCK-C) - Rattus norvegicus (Rat), 622 aa. Q9Z2V4 Phosphoenolpyruvate carboxykinase, 1..622 566/622 (90%) 0.0 cytosolic [GTP] (EC 4.1.1.32) 1..622 596/622 (94%) (Phosphoenolpyruvate carboxylase) (PEPCK-C) - Mus musculus (Mouse), 622 aa. Q8BSX3 Phosphoenolpyruvate carboxykinase 1..622 566/622 (90%) 0.0 1 - Mus musculus (Mouse), 622 aa. 1 ..622 5 95/622 (94%) PFam analysis predicts that the NOVia protein contains the domains shown in the Table A1. Table All. Domain Analysis of NOVia Identities/ Pfam Domain NOVIa Match Region Similarities Expect Value for the Matched Region PEPCK 29..622 434/612 (71%) 0 567/612 (93%) 5 Example A4. Human Cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK) Gene Variants and SNPs 117 WO 2004/013347 PCT/US2003/024504 Variant sequences are included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one 5 nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at 10 the position of the SNP. Intragenic SNPs may also be silent, however, in the case that a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern for example, alteration in temporal expression, 15 physiological response regulation, cell type expression regulation, intensity of expression, stability of transcribed message. Method of novel SNP Identification: SNPs are identified by analyzing sequence assemblies using CuraGen's proprietary SNPTool algorithm. SNPTool identifies variation in assemblies 20 with the following criteria: SNPs are not analyzed within 10 base pairs on both ends of an alignment; Window size (number of bases in a view) is 10; The allowed number of mismatches in a window is 2; Minimum SNP base quality (PHRED score) is 23; Minimum number of changes to score an SNP is 2/assembly position. SNPTool analyzes the assembly and displays-SNP positions, associated individual variant sequences in the assembly, the 25 depth of the assembly at that given position, the putative assembly allele frequency, and the SNP sequence variation. Sequence traces are then selected and brought into view for manual validation. The consensus assembly sequence is imported into CuraTools along with variant sequence changes to identify potential amino acid changes resulting from the SNP sequence variation. Comprehensive SNP data analysis is then exported into the SNPCalling database. 30 Method of novel SNP Confirmation: SNPs are confirmed employing a validated method know as Pyrosequencing. Detailed protocols for Pyrosequencing can be found in: Alderborn et al. Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA 118 WO 2004/013347 PCT/US2003/024504 Sequencing. (2000). Genome Research. 10, Issue 8, August. 1249-1265. In brief, Pyrosequencing is a real time primer extension process of genotyping. This 5 protocol takes double-stranded, biotinylated PCR products from genomic DNA samples and binds them to streptavidin beads. These beads are then denatured producing single stranded bound DNA. SNPs are characterized utilizing a technique based on an indirect bioluminometric assay of pyrophosphate (PPi) that is released from each dNTP upon DNA chain elongation. Following Klenow polymerase-mediated base incorporation, PPi is 10 released and used as a substrate, together with adenosine 5'-phosphosulfate (APS), for ATP sulfurylase, which results in the formation of ATP. Subsequently, the ATP accomplishes the conversion of luciferin to its oxi-derivative by the action of luciferase. The ensuing light output becomes proportional to the number of added bases, up to about four bases. To allow processivity of the method dNTP excess is degraded by apyrase, which is also present in the 15 starting reaction mixture, so that only dNTPs are added to the template during the sequencing. The process has been fully automated and adapted to a 96-well format, which allows rapid screening of large SNP panels. Results 20 The DNA and protein sequences for the novel single nucleotide polymorphic variants of the phosphoenolpyruvate carboxykinase-like gene of CuraGen Acc. No. CG101 190-01 are reported in Table A12. Variants are reported individually but any combination of all or a select subset of variants are also included. In Table A12, the positions of the variant bases 25 and the variant amino acid residues are underlined. In summary, there are 16 variants reported in Table A12. Variant 13374203 is a G to A SNP at 187 bp of the nucleotide sequence that results in no change in the protein sequence (silent), variant 13374204 is a G to A SNP at 322 bp of the nucleotide sequence that results in no change in the protein sequence (silent), variant 13374205 is a C to T SNP at 400 bp of the nucleotide sequence that results in 30 no change in the protein sequence (silent), variant 13374206 is a C to G SNP at 668 bp of the nucleotide sequence that results in a Leu to Val change at amino acid 184 of protein sequence, variant 13378862 is a G to A SNP at 868 bp of the nucleotide sequence that results in a Met to Ile change at amino acid 250 of protein sequence, variant 13380271 is an A to G SNP at 917 bp of the nucleotide sequence that results in an Ile to Val change at amino acid 119 WO 2004/013347 PCT/US2003/024504 267 of protein sequence, variant 13378861 is a G to A SNP at 944 bp of the nucleotide sequence that results in a Glu to Lys change at amino acid 276 of protein sequence, variant 13379542 is a C to T SNP at 1258 bp of thenucleotide sequence that results in no change in the protein sequence (silent), variant 13378352 is a C to A SNP at 1339 bp of the nucleotide 5 sequence that results in a Cys to Stop change at amino acid 407 of protein sequence, variant 13375322 is an A to G SNP at 1680 bp of the nucleotide sequence that results in a Lys to Arg change at amino acid 521 of protein sequence, variant 13375321 is an A to G SNP at 1731 bp of the nucleotide sequence that results in a Glu to Gly change at amino acid 538 of protein sequence, variant 13375320 is a T to C SNP at 1773 bp of the nucleotide sequence 10 that results in a Leu to Pro change at amino acid 552 of protein sequence, variant 13375319 is a T to C SNP at 1848 bp of the nucleotide sequence that results in a Leu to Pro change at amino acid 577 of protein sequence, variant 13375318 is a T to C SNP at 1857 bp of the nucleotide sequence that results in an le to Thr change at amino acid 580 of protein sequence, variant 13377375 is an A to G SNP at 1887 bp of the nucleotide sequence that 15 results in a Glu to Gly change at amino acid 590 of protein sequence, and variant 13377374 is a T to C SNP at 1929 bp of the nucleotide sequence that results in a Leu to Pro change at amino acid 604 of protein sequence. Table A12. Variants of nucleotide sequence of Acc. No. CG1O1190-01 (SEQ ID NO:1) Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13374203 187 G A 23 Leu Leu 13374204 322 G A 68 Arg Arg 13374205 400 C T 94 Me Ile 13374206 668 C G 184 Leu Val 13378862 868 G A 250 Met Ile 13380271 917 A G 267 Be Val 13378861 944 G A 276 Glu Lys 13379542 1258 C T 380 Gly Gly 13378352 1339 C A 407 Cys STOP 13375322 1680 A G 521 Lys Arg 13375321 1731 A G 538 Glu Gly 13375320 1773 T C 552 Leu Pro 13375319 1848 T C 577 Leu Pro 120 WO 2004/013347 PCT/US2003/024504 13375318 1857 T C 580 Ie Thr 13377375 1887 A G 590 Glu Gly 13377374 1929 T C 604 Leu Pro Table A13. Variant Sequences Table A13A1. Nucleotide sequence of variant 13374203 NOV1aln (underlined). G/A (SEQ ID NO:79) 1 GAACACAAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAA 161 GTTGTCCAGGGAAGCCTGGACAGCCTACCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGA 241 TCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGC 321 GGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATC 401 GTCACCCAAGAGCAAAcGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCAGAGGAGGA 481 TTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTACGTCATCCCATTCAGCATGGGGC 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGACGGATTCGCCCTACGTGGTGGCCAGCATGCGGATCATGACG 641 CGGATGGGCACGCCCGTCCTGGAAGCACTGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTGCC 721 TTTACAAAAGCCTTTGGTCAACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCGCCCACCTGCCTGACCGCAGAGAGA 801 TCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTG 881 GCCAAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAAGTACCTGGC 961 GGCCGCATTTCCCAGCGCCTGCGGGAAGACCAACCTGGCCATGATGAACCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCG 1041 TCGGGGATGACATTGCCTGGATGAAGTTTGACGCACAAGGTCATTTA AGGGCCATCAACCCAGAAAATGGCTTTTTCGGT 1121 GTCGCTCCTGGGACTTCAGTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGC 1201 CGAGACCAGCGACGGGGGCGTTTACTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGTCACCATCACGTCCTGGAAGA 1281 ATAAGGAGTGGAGCTCAGAGGATGGGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCC 1361- ATCATTGATGCTGCCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGTGT 1441 CCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGGCGGCCATGAGATCAGAGGCCACAGCGCCTG 1521 CAGAACATAAAGGCAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGCCAAATACCTG 1601 GCCCACTGGCTTAGCATGGCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGACAA 1681 GGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATGTTCAACCGGATCGATGGAAAAG 1761 CCACCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAACGCCTGGGGCACATCAACATG 1841 ATGGAGCTTTTCAGCATCTCCAAGGAATTCTGGGAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGGATCAAGTCAA 1921 TGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGCCAGATCTAATCAGGGCCTGAGT 2001 GCTTTACCTTTAAAATCATTCCCTTTCCCATCCATAAGGTGCAGTAGGAGCAAGAGAGGGCAAGTGTTCC Table A13A2. Protein sequence of variant NOVialp (underlined). (SEQ ID NO:80) 1 MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALT 81 DPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRMSEEDFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIEL 161 TDSPYVVASMRIMTRMGTPVLEALGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL 241 LGKIKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMMNPSLPGWKVECVGDDIAWMKFDAQ 321 GHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCA 401 HPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF 481 AMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNNFRKDKEGKFLWPGFGENSRVLEWMFNRIDGKASTKLTPIGYIPK 561 EDALNLKGLGHINMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM Table A13A3. Alteration effect No change. Table A13B1. Nucleotide sequence of variant 13374204 NOVla2n (underlined). G/A (SEQ ID NO:81) 1 CAACACAAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAA 161 GTTGTCCAGGGAAGCCTGGACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGA 241 TCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGC 321 GACTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATC 401 GTCACCCAAGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCAGAGGAGGA 481 TTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTACGTCATCCCATTCAGCATGGGGC 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGACGGATTCGCCCTACGTGGTGGCCAGCATGCGGATCATGACG 641 CGGATGGGCACGCCCGTCCTGGAAGCACTGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTGCC 721 TTTACAAAAGCCTTTGGTCAACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCGCCCACCTGCCTGACCGCAGAGAGA 801 TCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTG 881 GCCAAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAAGTACCTGGC 961 GGCCGCATTTCCCAGCGCCTGCGGGAAGACCAACCTGGCCATGATGAACCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCG 1041 TCGGGGATGACATTGCCTGGATGAAGTTTGACGCACAAGGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGT 1121 GTCGCTCCTGGGACTTCAGTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGC 1201 CGAGACCAGCGACGGGGGCGTTTACTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGTCACCATCACGTCCTGGAAGA 1281 ATAAGGAGTGGAGCTCAGAGGATGGGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCC 1361 ATCATTGATGCTGCCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGTGT 121 WO 2004/013347 PCT/US2003/024504 1441 CCCTCTAGTCIATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTG 1521 CAGAACATAAAGGCAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG 1601 GCCCACTGGCTTAGCATGGCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGACAA 1681 GGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATGTTCAACCGGATCGATGGAAAAG 1761 CCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATG 1841 ATGGAGCTTTTCAGCATCTCCAAGGAATTCTGGGAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGGATCAAGTCAA 1921 TGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGCCAGATGTAATCAGGGCCTGAGT 2001 GCTTTACCTTTAAAATCATTCCCTTTCCCATCCATAAGGTGCAGTAGGAGCAAGAGAGGGCAAGTGTTCC Table A13B2. Protein sequence of variant NOVla2p (underlined). (SEQ ID NO:82) 1 MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALT 81 DPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIEL 161 TDSPYVVASMRIMTRMGTPVLEALGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL 241 LGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAFPSACGKTMLAMPSLPGWKVECVGDDIAWMKPDAQ 321 GHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCA 401 HPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF 481 AMRPFFGYNFGKYLAHWLSMAQHPPAAKLPKIFHVNWFRKDRECKFLWPGFGENSRVLEWMFNRIDGASTKLTPIGYIPK 561 EDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM Table A13B3. Alteration effect No change. Table A13CL. Nucleotide sequence of variant 13374205 NOVla3n (underlined). C/T (SEQ ID NO:83) 1 GAACACAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAA 161 GTTGTCCAGGGAAGCCTGGACAGCCTCCCCAGCCATGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCACCCTGA 241 TCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAACAGCGCATCCTCAGCC 321 GGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATT 401 GTCACCCAAGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCAGAGGAGGA 481 TTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATAAAGTCGCACCATGTACGTCATCCCATTCAGCATGGGGC 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGACGGATTCCCCCTACGTGGTGGCCAGCATCCGGATCATGACG 641 CGGATGGGCACGCCCGTCCTGGAAGCACTGGGCATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTCC 721 TTTACAAACCCTTTGGTCAACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCGCCCACCTGCCTGACCGAGACAGA 801 TCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATCGCCAGCCGGCTG 881 CCCAAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAAGTACCTGGC 961 COCCGCATTTCCCAGCGCCTGCGGAAGACCAACCTGGCCATGATAACCCCAGCCTCCCCGCGTGCAAGGTTOACTCCG 1041 TCGCGATGACATTGCCTGGATGAAGTTTGACGCACAAGCTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGT 1121 GTCGCTCCTGGGACTTCAGTGAAGACCAACCCCAATCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGC 1201 CGAGACCAGCGACGGGGG3CGTTTACTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGTCACCATCACGTCCTGGAAGA 1281 ATAAGGAGTGGAGCTCAGAGGATCGGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTGCCACCCAGTGCCCC 1361 ATCATTGATGCTGCCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTACACCTGCTGOTGT 1441 CCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTG 1521 CAGAACATAAAGGCAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTCGCTACAACTTCGGCAAATACCTG 1601 GCCCACTGGCTTAGCATCGCCCAGCACCCAGCACCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCCGAAGGACAA 1681 CGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATGTTCAACCGGATCGATGGAAAAG 1761 CCAGCACCAAGCTCACCCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAACCCTGGCCACATCAACATG 1841 ATGGAOCTTTTCAGCATCTCCAAGGAATTCTGGCAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGATCAAGTCAA 1921 TGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGCCAGATGTAATCAGGGCCTGAGT 2001 GCTTTACCTTTAAAATCATTCCCTTTCCCATCCATAAGGTGCATAGGAGCAAGAGAGGGCAAGTGTTCC Table A13C2. Protein sequence of variant NOVla3p (underlined). (SEQ ID NO:84) 1 MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALT 81 DPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIEL 161 TDSPYVVASMRIMTRMGTPVLEALGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL 241 LGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMMNPSLPGWKVECVGDDIAWMKFDAQ 321 GHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCA 401 HPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF 481 AMPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHWFRKDKEGFLWPGFGENSRVLEWMFNRIDGKASTKLTPIGYIPK 561 EDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM Table A13C3. Alteration effect No change. Table A13D1. Nucleotide sequence of variant 13374206 NOVla4n (underlined). C/G (SEQ ID NO:85) 1 GAACACAAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAA 161 GTTGTCCAGGGAAGCCTGGACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGA 122 WO 2004/013347 PCT/US2003/024504 241 TCACATCCACATCTGTGACGGCTCTGAGGAGGAGATGGGCGGCTTCTGGCCAATO32AGGAAGAG2ATCCTCAGGC 321 GGCTGAAGAAGTAT9ACAACTGCTGGTTGGCTC:TCACTGACCCCAGGATTGGCCAGGATCGAAAGCAAGACGGTTATC 401 GTACAGCAAAAAATCCTCCAAAGCCGrACCGCCGAGCGGAG 481. TTTA~A TCPTCAGTCAGTC~AAGCCCAGAGCTCATACTGG 561 CGTGCCCTTTGAACGACACGCGTCCCAGGT CACTCGTAGC 641 CGAGGAGCGCTGACGGGGTGGATTTAAGCCATTTGGGCTTC 721 TTAAAGCTGTACATGCTMCGACG~.T!T!CCCTCTACCGGG 801 TCTTCTGCGGGAGCGACCCGTCGAGATCTGTTAGTGCGCG~ 881 GCCAAGGAc2GAAGGGTGGCTGGCAGAGCAr-ATSCTGATTCTGGGTATAACCAACCCTCAGGGTAGAAG2AAGTACCTGGC 961 2GCCGCATTTCCCAGCGCCTGCG22GAAGACCACCTGGCCATGATGAACCCCAGCCTCCCCGGTGGAAGlGTTGAGTCCG 1041 TCCGGGATGACATTcCCTGGATGAAGTTTCACGCACAAGGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGT 1121 GTCCCTCCTGcGACTTCAGTG7AACACCACCCCAATGCCATCAAGACCATCCAAAGAACACAAT'CTTTACCAATGTG2GC 1201 CGAGACCAGCGACGGGGCGTTTACTGGAG9TATTGAAGCC2CTAGC7TCAGGGTCACCATCACTCCTGG7AAGA 1281 ATAACaAGTGGAGCTCAGAGGATGGGAACCTMTGCCACCCAACTCGAGGTTCTCACCCCTGCACCAG'GCCCC 1361 ATCATTGATGCTGCCTGGGAGTCrCCcGGAGGTGTfTCCCATTGAAGGCATTATCTTTGAGGCCGTAW3ACCTGCTGGTGT 1441 CCTCTAGTCTATAACTCTCACTaCGACATGAGTCTTTTGoocCaGCCAT2AGATCAGAL12CcACAGCGCco 1521 CAGAACATAAAGCAAATCATCArGCATGACCCCTTTCCATGCGGCCCTTCTTTG2CTACAACTTCGGCAAATACCTO 1601 GCCCGCTCAGCCCACACCCACTCCAACTCTTACGTCGAGAA 1681 GCAAcGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGTGCTGGAGTGGATGTCAACCGACGATGGAAAAG 1761 CCAGCACCAAGCTCACCCCCATAGGCTACATcCcCAAGGAGQATGCCCTGAACCTGAAAGGCCTGGGGcACATCAACATG 1841 ATGGAGCTTTTCAGCATCTCCAAGGAATTCTGOAGAAGGTGGAA.GACATCGAGAAGTATCTGGAGGATC!AAGTCAA 1921 TGCCGACCTCCCCTG'GAAATCcAGAGAGAGATCCTTGCCTTAACAAAAATAA~cCAGAT7TAATCAGGGCCTGAGT 2001 GCT7TACCTTTAAATCATTCCCTTTCCCATCCATAAGTGCAGTAGGAGCAAGAGAGGGCAAQTG2TTCC Table A13D2. Protein sequence of variant NOVi a4p (underlined). (SEQ ID NO:86) I MPPQLQNGIMLSAKVQGSLDSLPQAVRFLENALCQPDHIHICDGSEEENGRLLGQMEEGILRLXYDNCWLALT 81 DPRDVARIESKTVIVTQEQRDTVPIPTGLSLGRWMSEEDFEKAFIARPGCMKGRTMYVIPFSMGPLGSPLSICIGIEL 161 TDSPYVVASMRIMTRMGT'PVLEAVGDGEFVTCLSVGCPLPLQKPLVNNwPPELTLIR~.LPDRRsIISGSGYGGNSL 2 41 LGKFLMSLK:GLiMIGTPG=AMPAGTLMNSPWnVIDAMPA 321 GHRIPNFGAGSMPAKIKTPNATDGYEIELSVISKKWSDEC 401 HPNSRFCTPASQCPIIDAAWESPEGVPIEGIFGGRRPAGVPLVYEALSWQHGVFVGAAIRSEATAAAEHKGI(IIMHDPF 481 ARPFFGYNFGKYLAHWSMAQHPAALPKIHVFRKDKEGKFPGGNSRVLEWMFNRIDGKASTKLTPIGYIPK 561 EDALNLKGLGHINMELFSIS1EFE16VDIELEDQVNADLPCIEREIALKQRISQM Table A13D3. Alteration effect Leu to Val Table Al 3E1. Nucleotide sequence of variant 13378862 NOVl a5n (underlined). G/A (SEQ ID NO:87) 1 0 AACACAAACTTGCTGcCGGAAGAGCCCGGAAcGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAAGGT 81 GACCTCAC!ATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTCAAAACGG2CCTGAACCTCTCGGCCAAA 161 GTGCAGACCGAACTCCAGATAGATTTGGAACCG4CGGCGCG 241 TCCTCCTTTAGCCGGAGGAGGGCTTGCAAGAGAAGCTCCAG 321 GOTAGATTAACGTGTGTTATACCGGTTGCGACAACAAGT~X 401 GTACACGAAAAAATCC~CCAACGCTACACCGCCOAGCGGAG 481 TTTTGAGAAAGCGTTCAATGCCAaGTTCCr-AGGGTGCATGAAGGTCGCACCATGTACGTCATCCCATTCAGeATGGC 561 COCTGCTCACCTCTGTCGGATCGGATCAGCTGACGATTCGCCCTACGTGGTGGCAGCATGCGATCATGACG 641 CGgATgGCACcCCCGTCCGGAAATGGCATG GAGTTTGTCAAATGCCTCCATTCGTGGGGTGCCCTCTGCC 721 TTTACAA-'ACCTTTGTCAAGCCTGCTGCAACCCAGCTGACGCTCATCGCC-ACCTGCCTGACCGCAGAGAGA 801 TCATCTCCTTTGGCAGTcGGTACAGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATAGCCAGCCGGCIG 861 GCCAA~GAGGAAGcGGTGGCTGGCAGA~rCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAAGTACCTGGC 961 GGCCGCATTTCCr-AGCGCCTGCGGGAAG~kCCAACCTGCCATATGAACCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCG 1041 TCGGGGATACATTGCCTGGATGAAGTTTGACGCACAA(GTCATTTAAGGGCCATCAACCCAGAAAITGGCTTTTTCGGT 1121 GTCG2CTCCTGGGACTTCAG1GAAGACCA1ACCCCAATGCC!ATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGC 1201 CGAGACCAGCGACGGGGGCGTTTACTGGGAGcTATTGATGAGCCCTAGCTTAGGCGTCACCAECACGTCCTGGAAGA 1281 ATAAGGAGTGGAGCTCAGAGGATGGGc3AACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCC 1361 ATCATTGATGCTGCCTGGGAGrCTCCGGAGGT1TTCCMTTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGTGT 1441 CCCTCTACTCTATGAAGCTCTCAGCTGGCAACATGcAGTCTTTGTGGGGGCGGCCAGAGATCAGAGGCCACAGCGGC1G 1521 CAGAACATAAAr.GCAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG 1601 GCCCACTGGC VTAGCATGGCCCAGCACCCAGCAcGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGACAA, 1681 GA2CAATTCCTCTGGCCAGGCTTTGGAGGAACTCCAGGGTCTGGAGTGGATGTTCAACCGGATCGATGGAAAG 1761 CCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATG 1641 AT~GAGCTTTTCAGCATCTCCAGGAATTCTGGGAAGAGTGGAAGACATCGAGAAGTATCTGGAGQA'rCAAcTCAA 1921 T0CCGACCTCCCCTGTGAATCGAGAGAGAGATCCTTCCTTG4AGCAAAGAATAAGCCAGATGTAATCAGGGCCTGAGT 2001 OCcTTTACCTTTAAATCATTCCCTTTCCCATCCATAAGTGCAGTAGAGCAAGAGAGGGCAAGTGTTc Table A13E2. Protein sequence of variant (underlined) NOVla5p. (SEQ ID NO:88) 1 MPPQLQNGLNLSAICVQ2SLDSLPQAVREFL1ThAELCQPDHIHICDGSEEENGRLLGQMEEEGILRLKMYNCWNALT 81 DPRUVARIESKTVIVTQEOflTVPIP(T2.LSQLGRWMSE6DFEKAFNARFPGCMEGRTMVIPF6MGPLGSPLSKIOIEL 161 TDSPYVASH IMTRMT:LEALGDGEFVCSVCPLPLQKPLVNWPCNPELTLIAHLPDRREIISGS7YGG3NSL 241 LGKKCFALRIASRLKEEWLAEILGITPGELAAAPSACGKTLAMNPSLPWKECVGDIAWMC6DAQ 321. GHLRAfINPEGFFGVAPQTSVRTqPN4AIKTIQKNTFTNVAETSDGGVYWIEGIDEPLASGVTITSWKNCEWS6DGEPCA 401 HPN6RFCTPASQCPIIDAAWESPEGVPIEGIIFCGPI1PAGVPLVYEALSWQHGVFVGAMRSATAAAERKGKIIMHDPF 481 AMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFVNWPRKDKEG;KFLWPGFGEMSRVLEWMFNRIDGKASTXCLTPIGYIPR 123 WO 2004/013347 PCT/US2003/024504 561 EDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM Table A13E3. Alteration effect Met to Ile Table Al3F1. Nucleotide sequence of variant 13380271 NOVIa6n (underlined). A/G (SEQ ID NO:89) 1 GAACACAAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAA 161 GTTGTCCAGGGAAGCCTGGACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTCA 241 TCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGC 321 GGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATC 401 GTCACCCAAGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCAGAGGAGGA 481 TTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTACGTCATCCCATTCAGCATGGGGC 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGACGGATTCGCCCTACGTGGTGGCCAGCATGCGGATCATGACG 641 CGGATGGGCACGCCCGTCCTGGAAGCACTGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTGCC 721 TTTACAAAAGCCTTTGGTCAACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCGCCCACCTGCCTGACCGCAGAGAGA 801 TCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTG 881 GCCAAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGGTTCTGGGTATAACCAACCCTGAGGGTGAGAAGAAGTACCTGGC 961 GGCCGCATTTCCCAGCGCCTGCGGGAAGACCAACCTGGCCATGATGAACCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCG 1041 TCGGGGATGACATTGCCTGGATGAAGTTTGACGCACAAGGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGT 1121 -GTCGCTCCTGGGACTTCAGTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGC 1201 CGAGACCAGCGACGGGGGCGTTTACTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGTCACCATCACGTCCTGGAAGA 1281 ATAAGGAGTGGAGCTCAGAGGATGGGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCC 1361 ATCATTGATGCTGCCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGTGT 1441 CCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTG 1521 CAGAACATAAAGOCAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG 1601 GCCCACTGGCTTAGCATGGCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGACAA 1681 GGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATGTTCAACCGGATCGATGGAAAAG 1761 CCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATG 1841 ATGGAGCTTTTCAGCATCTCCAAGGAATTCTGGGAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGGATCAAGTCAA 1921 TGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGCCAGATGTAATCAGGGCCTGAGT 2001 GCTTTACCTTTAAAATCATTCCCTTTCCCATCCATAAGGTGCAGTAGGAGCAAGAGAGGGCAAGTGTTCC Table A13F2. Protein sequence of variant NOVla6p (underlined). (SEQ ID NO:90) 1 MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALT 81 DPRfDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFEKAFNARPPGCMKGRTMYVIPFSMGPLGSPLSKIGIEL 161 TDSPYVVASMRIMTRMGTPVLEALGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL 241 LGKKCFALRMASRLAKEEGWLAEHMLVLGITNPEGEKKYLAAAFPSACGKTLAMMNPSLPGWKVECVGDDIAWMKFDAQ 321 GHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCA 401 HPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF 481 AMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKECKFLWPGENSRVLEWMFNRIDGKASTKLTPIGYIPK 561 EDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM Table A13F3. Alteration effect Ile to Val Table A13G1. Nucleotide sequence of variant 13378861 NOVla7n (underlined). G/A (SEQ ID NO:91) 1 GAACACAAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAAAATGCCTCCTCAGCTGCAAACGGCCTGAACCTCTCGGCCAAA 161 GTTGTCCAGGGAAGCCTGGACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGA 241 TCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGC 321 GGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATC 401 GTCACCCAAGAGCAAAGAGACACAGTCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCAGAGGAGGA 481 TTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTACGTCATCCCATTCAGCATGGGGC 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGACGGATTCGCCCTACGTGGTGGCCAGCATGCGGATCATGACG 641 CGGATGGGCACGCCCGTCCTGGAAGCACTGGGCGATCGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTGCC 721 TTTACAAAAGCCTTTGGTCAACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCCCCACCTGCCTGACCGCAGAGAGA 801 TCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTG 881 GCCAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTCTGGTATAACCAACCCTGAGGGTAAGAAGAAGTACCTGGC 961 GGCCGCATTTCCCAGCCCTGCCGAAGACCAACCTCGCCATGATGAACCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCG 1041 TCGGGGATOACATTGCCTGGATGAAGTTTGACGCACAAGOTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGT 1121 GTCGCTCCTGGGACTTCACTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGC 1201 CGAGACCAGCGACGCGGGCGTTTACTGGGAACGTATTGATGAOCCCCTAGCTTCAGGCGTCACCATCACGTCCTGGAAGA 1281 ATAAGGAGTCGAGCTCAGAGGATGGGGAACCTTGTCCCCACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCC 1361 ATCATTGATGCTGCCTGGGAGTCTCCGGAAGTCTTCCCATTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGTGT 1441 CCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTG 1521 CAGAACATAAAGGCAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG 124 WO 2004/013347 PCT/US2003/024504 1601 GCCCACTGGCTTAGCATGGCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGACAA 1681 GGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATGTTCAACCGGATCGATGGAAAAG 1761 CCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATG 1841 ATGGAGCTTTTCAGCATCTCCAAGGAATTCTGGGAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGGATCAAGTCAA 1921 TGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGCCAGATGTAATCAGGGCCTGAGT 2001 GCTTTACCTTTAAAATCATTCCCTTTCCCATCCATAAGGTGCAGTAGGAGCAAGAGAGGGCAAGTGTTCC Table A13G2. Protein sequence of variant NOVIa7p (underlined). (SEQ ID NO:92) 1 MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALT 81 DPRDVARIESKTVIVTQEQRTVPIPKTTSQLGRWMSEDFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIEL 161 TDSPYVVASMRIMTRMGTPVLEALGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL 241 LGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGKKKYLAAAPSACGKTNLAMIPSLPGWKVECVGDDIAWMKFDAQ 321 GHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCA 401 HPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF 481 AMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKPLWPGFGENSRVLEWMFNRIDGKASTKLTPIGYIPK 561 EDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM Table A13G3. Alteration effect Glu to Lys Table A13H1. Nucleotide sequence of variant 13379542 NOVla8n (underlined). C/T (SEQ ID NO:93) 1 GAACACAAACTTCCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAACGT 81 GACCTCACATTCGTGCCCCTTACCAGCACTCTGCAGAAATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGOCCAAA 161 GTTGTCCAGGGAAGCCTGGACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTTCAGCCTGA 241 TCACATCCACATTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGC 321 GGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGCCAGGATCGAAAGCAAACGGTTATC 401 GTCACCCAAGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGOTCGCTGGATGTCAGAGGAGGA 481 TTTTGAGAAAGCGTTCAATGCCACGTTCCCAGGGTGCATGAAAGGTCGCACCATGTACGTCATCCCATTCAGCATGGGGC 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAOCTGACGGATTCGCCCTACGTGGTGGCCAGCATGCGGATCATGACG 641 CGGATGGGCACGCCCGTCCTGGAAGCACTGGCCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTGCC 721 TTTACAAAAGCCTTTGGTCAACAACTGGCCCTCCAACCCGGAGCTGACGCTCATCCCCACCTGCCTGACCGCAGAGAGA 801 TCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTG 881 GCCAAGGAGGAACGGTCGCTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAAGTACCTGGC 961 GGCCGCATTTCCCAGCGCCTCCGCGAAGACCAACCTGOCCATGATGAACCCCATCTCCCCGGGTGGAAGGTTGAGTCG 1041 TCGGGGATGACATTGCCTGGATGAAGTTTGACGCACAAGGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGT 1121 GTCGCTCCTGGGACTTCAGTGAAGACCAACCCCAATCCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGC 1201 CGAGACCAGCGACGGGCCGTTTACTGGGAAGGTATTGATCAGCCGCTAGCTTCAGGTGTCACCATCACGTCCTGGAAGA 1281 ATAAGGAGTGGAGCTCAGAGGATGGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCC 1361 ATCATTGATGCTCcCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGTGT 1441 CCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGACTCTTTGTGGGGGCGOCCATGAGATCAGAGGCCACAGCGGCTG 1521 CAGAACATAAACGCAAAATCATCATGCATCACCCCTTTGCCATCCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG 1601 GCCCACTGGCTTAGCATGGCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGACAA 1681 GGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATGTTCAACCGGATCGATGGAAAAG 1761 CCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATG 1841 ATGGAGCTTTTCAGCATCTCCAAGGAATTCTGGGAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGGATCAAGTCAA 1921 TGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGCCAGATGTAATCAGGGCCTGAGT 2001 GCTTTACCTTTAAAATCATTCCCTTTCCCATCCATAAGGTOCAGTAGGAGCAAGAGAGGGCAAGTGTTCC Table A13H2. Protein sequence of variant NOVla8p (underlined). (SEQ ID NO:94) 1 MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALT 81 DPRDVARIESKTVIVTQEQRDTVPPKTGLSQLGRWMSEEDFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIEL 161 TDSPYVVASMRIMTRMGTPVLEALGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL 241 LGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMNPSLPGWKVECVGDDIAWMKFDAQ 321 GHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCA 401 HPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF 481 AMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRVLEWMFNRIDGKASTKLTPIGYIPK 561 EDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM Table A13113. Alteration effect No change. Table A1311. Nucleotide sequence of variant 13378352 NOVla9n (underlined). C/A (SEQ ID NO:95) 1 GAACACAAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAA 161 GTTGTCCAGGGAAGCCTGGACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGN 241 TCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGC 321 GGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATC 125 WO 2004/013347 PCT/US2003/024504 401 GTCACCCAAGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCGAGAGGA 481 TTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTACGTCATCCCATTCAGCATGGGGC 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGACGGATTCCCCTACGTGGTGGCCAGCATGCGGATCATGACG 641 CGGATGGGCACGCCCGTCCTGGAAGCACTGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGOGTGCCCTCTGCC 721 TTTACAAAAGCCTTTGGTCAACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCGCCCACCTGCCTGACCGCAGAGAGA 801 TCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTG 881 GCCAAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAAGTACCTGGC 961 GGCCGCATTTCCCAGCGCCTGCGGGAAGACCAACCTGGCCATGATGAACCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCG 1041 TCGGGGATGACATTGCCTGGATGAAGTTTGACGCACAAGGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGT 1121 GTCGCTCCTGGGACTTCAGTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGC 1201 CGAGACCAGCGACGGGGGCGTTTACTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGTCACCATCACGTCCTGGAAGA 1281 ATAAGGAGTGGAGCTCAGAGGATGGGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGAACCCCTGCCAGCCAGTGCCCC 1361 ATCATTGATGCTGCCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGTGT 1441 CCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTG 1521 CAGAACATAAAGGCAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG 1601 GCCCACTGGCTTAGCATGGCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGACAA 1681 GGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATGTTCAACCGGATCGATGGAAAAG 1761 CCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATG 1841 ATGGAGCTTTTCAGCATCTCCAAGGAATTCTGGGAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGGATCAAGTCAA 1921 TGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGCCAGATGTAATCAGGGCCTGAGT 2001 GCTTTACCTTTAAAATCATTCCCTTTCCCATCCATAAGGTGCAGTAGGAGCAAGAGAGGGCAAGTGTTCC Table A1312. Protein sequence of variant NOVla9p (underlined). (SEQ ID NO:96) 1 MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDEIHICDGSEEENGRLLGQMBEEGILRRLKKYDNCWLALT 81 DPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFEKAFNARFPGCMKGRTMYVIPSMGPLGSPLSKIGIEL 161 TDSPYVVASMRIMTRMGTPVLEALGDGEFVKCISVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL 241 LGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMMNPSLPGWKVECVGDDIAWMKFDAQ 321 GHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCA 401 HPNSRF*TPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF 481 AMRPFFNYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRVLEWMFNRIDGKASTKLTPIGYIPK 561 EDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM Table Al 313. Alteration effect Cys to STOP Table A13J1. Nucleotide sequence of variant 13375322 NOVialOn (underlined). A/G (SEQ ID NO:97) 1 GAACACAAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAAGAAGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAA 161 GTTGTCCAGGGAAGCCTGGACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGA 241 TCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGC 321 GGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATC 401 GTCACCCAAGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCAGAGGAGGA 481 TTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTACGTCATCCCATTCAGCATGGGGC 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGACGGATTCGCCCTACGTGGTGGCCAGCATGCGGATCATGACG 641 CGGATGGGCACGCCCGTCCTGGAAGCACTGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTGCC 721 TTTACAAAAGCCTTTGGTCAACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCGCCCACCTGCCTGACCCCAGAGAGA 801 TCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTG 881 GCCAAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAAGTACCTCC 961 GGCCGCATTTCCCAGCGCCTGCGGGAAGACCAACCTGGCCATGATGAACCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCG 1041 TCGGGATGACATTGCCTGGATGAAGTTTGACGCACAAGGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGT 1121 GTCGCTCCTGGGACTTCAGTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGC 1201 CGAGACCAGCGACGGGGGCGTTTACTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGTCACCATCACGTCCTGGAAGA 1281 ATAAGGAGTGGAGCTCAGAGGATGGGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCC 1361 ATCATTGATGCTGCCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGTGT 1441 CCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTG 1521 CAGAACATAAAGGCAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG 1601 GCCCACTCGCTTAGCATGGCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGACAG 1681 GGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATGTTCAACCGGATCGATGGAAAAG 1761 CCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATG 1841 ATGGAGCTTTTCAGCATCTCCAAGGAATTCTGGGAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGGATCAAGTCAA 1921 TGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGCCAGATGTAATCAGGGCCTGAGT 2001 GCTTTACCTTTAAAATCATTCCCTTTCCCATCCATAAGGTGCAGTAGGAGCAAGAGAGGGCAAGTGTTCC Table A13J2. Protein sequence of variant NOVialOp (underlined). (SEQ ID NO:98) 1 MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALT 81 DPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFFKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIEL 161 TDSPYVVASMRIMTRMGTPVLEALGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL 241 LGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGRTNLAMMNPSLPGWKVECVGDDIAWMKFDAQ 321 GHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCA 401 HPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF 481 AMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDREGKFLWPGFGENSRVLEWMFNRIDGKASTKLTPIGYIPK 561 EDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM 126 WO 2004/013347 PCT/US2003/024504 Table A13J3. Alteration effect Lys to Arg Table A13K1. Nucleotide sequence of variant 13375321 NOVIalIn (underlined). A/G (SEQ ID NO:99) 1 GAACACAAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATCCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAA 161 GTTGTCCAGGAAGCCTGGACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGA 241 TCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGC 321 GGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATC 401 GTCACCCAAGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTCGATGTCAGAGGAGGA 481 TTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTACGTCATCCCATTCAGCATGGGGC 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGACGGATTCCCCCTACGTGGTGGCCAGCATGCGGATCATGACG 641 CGGATGGGCACGCCCGTCCTGGAAGCACTGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTCCC 721 TTTACAAAAGCCTTTGGTCAACAACTGGCCCTGCAACCCGGACCTGACGCTCATCGCCCACCTGCCTGACCGCAGAGAGA 801 TCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCCCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTG 881 GCCAAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTCTGGCTATAACCAACCCTCAGGGTGAGAAGAAGTACCTGGC 961 GGCCGCATTTCCCAGCGCCTGCGGGAAGACCAACCTGGCCATGATGAACCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCG 1041 TCGGGGATGACATTGCCTGGATGAAGTTTGACGCACAAGGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGT 1121 GTCGCTCCTGGGACTTCAGTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGC 1201 CGAGACCAGCGACGGGGGCGTTTACTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGTCACCATCACGTCCTGGAAGA i281 ATAAGGAGTGGAGCTCAGAGGATGGGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCC 1361 ATCATTGATGCTGCCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGTGT 1441 CCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTG 1521 CAGAACATAAAGGCAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG 1601 GCCCACTGGCTTAGCATGGCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGACAA 1681 GGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGGGTGGATGTTCAACCGGATCGATGGAAAAG 1761 CCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATG 1841 ATGGAGCTTTTCAGCATCTCCAAGGAATTCTGGGAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGGATCAAGTCAA 1921 TGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGCCAGATGTAATCAGGGCCTGAGT 2001 GCTTTACCTTTAAAATCATTCCCTTTCCCATCCATAAGGTGCAGTAGGAGCAAGAGAGGGCAAGTGTTCC Table A13K2. Protein sequence of variant NOVlallp (underlined). (SEQ ID NO:100) 1 MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALT 81 DPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIEL 161 TDSPYVVASMRIMTRMCTPVLEALGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL 241 LGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMMNPSLPGWKVECVGDDIAWMKFDAQ 321 GHLRAINPENGFFGVAPIGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCA 401 HPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF 481 AMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRVLGWMFNRIDGKASTKLTPIGYIPK 561, EDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM Table Al 3K3. Alteration effect Glu to Gly Table Al3L1. Nucleotide sequence of variant 13375320 NOVIal2n (underlined). TIC (SEQ ID NO: 101) 1 GAACACAAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAA 161 GTTGTCCAGGGAAGCCTGGACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGA 241 TCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGC 321 GGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATC 401 GTCACCCAAGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCAGAGGAGGA 481 TTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTACGTCATCCCATTCAGCATGGGGC 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGACGGATTCGCCCTACGTGGTGGCCAGCATGCGGATCATGACG 641 CGGATGGGCACGCCCGTCCTGGAAGCACTGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTGCC 721 TTTACAAAAGCCTTTGGTCAACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCGCCCACCTGCCTGACCGCAGAGAGA 801 TCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTG 881 GCCAAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAAGTACCTGGC 961 GGCCGCATTTCCCAGCGCCTGCGGGAAGACCAACCTGGCCATGATGAACCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCG 1041 TCGGGGATGACATTGCCTGGATGAAGTTTGACGCACAAGGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGT 1121 GTCGCTCCTCGGACTTCAGTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGC 1201 CGAGACCAGCGACGGGGGCGTTTACTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGTCACCATCACGTCCTGGAAGA 1281 ATAAGGAGTGGAGCTCAGAGCATGGGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTCCCAGCCAGTGCCCC 1361 ATCATTGATGCTCCCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGAGGCCGTAGACCTGCTGGTGT 1441 CCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTG 1521 CAGAACATAAAGGCAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG 1601 GCCCACTGGCTTAGCATGCCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGACAA 127 WO 2004/013347 PCT/US2003/024504 1681 GGAAGGCAAATTCCTCTCCCAGGCTTTGGAGAGAACTCCAGOGTGCTGGAGTGGATGTTCAACCGGATCGATGGAAAAG 1761 CCAGCACCAAGCCCACCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATG 1841 ATGGAGCTTTTCAGCATCTCCAAGGAATTCTGGGAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGGATCAAGTCAA 1921 TGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGCCAGATGTAATCAGGGCCTGAGT 2001 GCTTTACCTTTAAATCATTCCCTTTCCCATCCATAAGGTGCAGTAGGAGCAAGAGAGGGCAAGTGTTCC Table A13L2. Protein sequence of variant NOVlal2p (underlined). (SEQ ID NO:102) 1 MPPQLQNGLNLSAKVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALT 81 DPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFEKAFNARFPGCMKGRTMYVI PFSMGPLGSPLSKIGIEL 161 TDSPYVVASMRIMTRMGTPVLEALGDGEFKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL 241 LGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMMNPSLPGWKVECVGDDIAWMKFDAQ 321 GHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYWEGIDEPLASGTITSNKNKEWSSEDGEPCA 401 HPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF 481 AMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRVLEWMFNRIDGKASTKPTPIGYIPK 561 EDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALICQRISQM Table A13L3. Alteration effect Leu to Pro Table A13M1. Nucleotide sequence of variant 13375319 NOVlal3n (underlined). T/C (SEQ ID NO:103) 1 GAACACAAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCOGCCAAA 161 GTTGTCCAGGGAAGCCTGGACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGA 241 .TCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGC 321 GGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGCCCAGGATCGAAAGCAAGACGGTTATC 401 GTCACCCAAGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCCCTCGATGTCAGAGGAGGA 481 TTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTACGTCATCCCATTCAGCATGGGGC 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGACGGATTCGCCCTACGTGGTGGCCAGCATCGGATCATGACG 641 CGGATGGGCACGCCCGTCCTGGAAGCACTGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTGCC 721 TTTACAAAAGCCTTTGGTCAACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCGCCCACCTGCCTGACCGCAGAGAGA 801 TCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTG 881 GCCAAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAACTACCTGGC 961 GGCCGCATTTCCCAGCGCCTGCGGGAAGACCAACCTGGCCATGATGAACCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCG 1041 TCGGGGATGACATTGCCTGGATGAAGTTTGACGCACAAGGTCATTTAAGGGCCATCAACCCAGAAAATGCTTTTTCGGT 1121 GTCGCTCCTGGGACTTCAGTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGC 1201 CGAGACCAGCGACGGGGGCGTTTACTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGTCACCATCACGTCCTGGAAGA 1281 ATAAGGAGTGGAGCTCAGAGGATGGGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCC 1361 ATCATTGATGCTGCCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTAACCTGCTCGTGT 1441 CCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTG 1521 CAGAACATAAAGGCAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG 1601 GCCCACTGGCTTAGCATGGCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTCGTTCCGGAAGGACAA 1681 GGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATGTTCAACCGGATCCATGGAAAAG 1761 CCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATG 1841 ATGGAGCCTTTCAGCATCTCCAAGGAATTCTGGGAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGGATCAAGTCAA 1921 TGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTCAAGCAAAGAATAAGCCAGATGTAATCAGGCCTGAGT 2001 GCTTTACCTTTAAAATCATTCCCTTTCCCATCCATAAGGTGCAGTAGGAGCAAGAGAGGGCAAGTGTTCC Table A13M2. Protein sequence of variant (underlined) NOV1al3p. (SEQ ID NO: 104) 1 MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALT 81 DPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIEL 161 TDSPYVVASMRIMTRMGTPVLEALGDGEFVKCLHSVgCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL 241 LGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKYLAAAFPSACGKTLAMNPSLPGWKVECVGDDIAWMKFDAQ 321 GHLRAINPENGPFGVAPGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVYNEGIDEPLASGVTITSWKNKEWSSEDGEPCA 401 HPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVPVGAAMRSEATAAAEHKGKIIMHDPF 481 AMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIPHVNWFRKDKEGKFLWPGFGENSRVLEWMFNRIDGKASTKLTPIGYIPK 561 EDALNLKGLGHINMMEPFSISKEFWEKEVEDIEKYLEDQVNADLPCEIEREILALKQRISQM Table A13M3. Alteration effect Leu to Pro Table A13N1. Nucleotide sequence of variant 13375318 NOVI al4n (underlined). T/C (SEQ ID NO:105) 1 CAACACAAACTTGCTGGCGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGANGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAA 161 GTTGTCCAGGGAAGCCTGGACACCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGA 241 TCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGCCAGATGGAGGAAGAGGGCATCCTCAGGC 321 GGCTGAAGAAGTATGACAACTGCTCGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATC 401 GTCACCCAAGAGCAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCAGAGGAGGA 128 WO 2004/013347 PCT/US2003/024504 481 TTTAA7GGTATCAGTCAGTCTAAGTGACTTCTACCNTACTOG 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAOCTCACCGATTCGCCCTACGTGGTGGCCAGCATGCGGACATACG 641 CCCATGGCACCCC2TCCTGAACACTGGCGATGGGAGTTTTCAAATGCCTCCATTCTGTGGTCCCTCTGCC 721 TTACAAAAGCCTTTGGTCACACTGGCCCTGCAACCCGGACTCACCTCACGCCCACCTGCCTGACCGCAGACAGA 801 TCATCTCCTTTOGCAGTGGGTACCCGGGOACTCOCTGCTCCGAGAAGTCTTTGCTCTCAGGATGGCCAGCCGGCTO 881 GCCAAGGAGGAAGGGTGGCTGGCAGAG3CACATCCTGATTCTGGTATAACCAACCCTGAGGTGAGAAAATACCTGGC 961 GGCCGCATTTCCCAGCGCCTGCGG2AACACCAACCT~CCCATCATaAACCcCAGCCTCCCCGGTGAAGG~TTcAGTGCc 1041 TrCGGG2ATGACATTGCCTGGATGAAGTTTGACGCACAAGGTCATTTAAGGGCCATCAACCCAGAAAATGGCTT7TTTCGGT 1121 GTCGCTCCTGGGACTTCAGTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATG'rGGC 1201 CGAGACCAGCGACGGGGGCGTTTACTGGGAAGGTATTGATGAGCCGCTAGCTTCAGGCGTCACCATACGTCCTGGAAGA 1281 ATAAGGAGTGGAGCTCAGAGGATGGGGAACCTTGTGCCCACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCC 1361 ATCATTGATGCTGCCTGGGAGTCTCCGGAAGGTGTTCCCATTGAAGGCA'ITATCTTTGGAGGCCGTAGACCTCTGGTGT 1441 CCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTO 1521 CAGAACATAAAGGCAAAATCATCATGCATGACCCCTTTGCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG 1601 GCCCACTGGCTTAGCATGGCCCAGCACCCAGC-AGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTCCGGAAGGACAA 1681 GGAAGGCAATTCCTCTGGCCAGGCTTGGAGAGAACTCCAGGGTGCTGAGTGGATGTTCAACCGGATCGATGGAAAAG 1761 CCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATG 1841 ATGGAGCTTTTCGCACCTCCAAGGAATCTGGAGAAGGAGGTGGAAGACATCGAGAAGTATCTGGAGGATCAAGTcPAA 1921 TGCCGACCTCCCCTGT GAAATCGAGAGAGAGATCCTGCCTTGAAGCAAAGAATAAGCCAGATGTAATcAGGGCCTGAGT 2001 GCTTTACCTTTAAAATCATTCCCTTTCCCATCCATAGGTGCAGTAGGAGCAAGAGAGGGCAAGTGTTCC Table A13N2. Protein sequence of variant NOVlal4p (underlined). (SEQ IIDNO:106) 1 MPQQGNSKVGLSPARFENECPDIIDSENRLQEEIRLKDCLL 81- DPRrDVARIESICTVIVT0EQRDTVPIPKGLSQLGRWMSEEDFEKAFNARIPPGCMKGRTMYVIPFSMr.PLGSPLSKIGIEL 161 TDSPYNASMRI4TRMGTPVLEALCIlGEFKCLHSVGCPLPLQ1(PLVNNWPCNPELTLIAXLPDRREIISFGSGYGGUSL 241 LGKKCFALRNASRLTEEGWLAEMLLGITNPEGEKYAAATSACGKTNLAMMPSLPGWKVCVGDDIAWMKDAQ 321 0HLRAII4PENGFFGVAPGTSVKTb3PNAII(TIQKTITNVAESDGVYWEGIDEPLASGVTTSWKNKBWSSEDGEPCA 401 -HPNSRFCTPASQCPIIIAAWESPEVPIEIIFGGRRPAGVPLVYEALSWQHGVFVGAA4RSEATAAEEI(GIDHDPF 481. A34RPFFG3YNFGKYLA11ILSMAQHPALPKIFHVNWPRIW1EGFLwpr.FGENSRVLEWMF8RIDGKASTI(LTPIGYIPK 561 EDA&L(CLGHINMMELFSTSKEFWEKEVEDIEKYLEDQV3NAfLPCEIEREILA.KQRISQM Table A13N3. Alteration effect Ile to Thr Table A1301. Nucleotide sequence of variant 13377375 NOVlal5n (underlined). A/U (SEQ lID NO: 107) 1 GACCACTCGCGAGGCGAAAACTTGTTCTCAACTCAGGAAAG 81 GACCCTCTCCTACGATTCGATGCCTACGAACGCGACCCGCA 161 GTGCAGAGCGAACTCCAGATAGGGTCCAATAGTACGGCGCC 241 TCCTCCTTTAGCCGGAGGAGGGCTTGCAGTGGAGGGACTAG 321. GGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGATGTGCCAGACGAAACAAACXATTATC 401 GTACAGGAAAA~-GGCACCAACAGCCGrACCGCCGAGCGGAG 481 TTTAAACTCAGCGTCCGGGAGAAGCCCAGAGCTCATACTGG 561 CGCTGGCTCACCTCTGTCGATCGGCATCAGCGACATTCGCCCTACGTGTGGCACATCGGATATGACC 641 caAGa~ccrC~.ArATGCAGGATTTAAGCCATTTGGGCTTC 721 TTTACAAAGCCTTTGTCAACAACTGCCCTCAACCCGACT2ACCTCATCCCCACCTGCCTGACCCAAGAGA 801 TATCTCCTTGGCAGTGGTACGCGGGCTCGCTGCCGGGAAGAAGTGCTTTGCTCTCAGATGCCAGCCGGCTG 881 GCCAAGAGAAGGTGGCTGGCAGAGCACATGCTATTCTGGTATAACCAACCCTGAGGGGAGAAGAAGTCCTGGC 962. GGCCCCATTCCCAGCGCCTCGGAAACCACCTGCCATAT3AACCCCAGCCTCCCCGGTGAAGGTTAGTGCG 1041 TCOGTAATCTGTAGTGCCCAGCTTAGCACACAAATGTTT~. 1121 GTGTCGGCTATjAACACCAGCTAGCACAACACCACTACAGG; 1201 CGAGACCAQCGACrGQGGCGTTTACTOG;GGTATTGATACCCTACTTCAGCGTCACCATCCTCCTGAAGA 1281 ATAAGAGTGAGCTCAGAGAT2GGGACCTTGTGccCCCCCAACTCGAGGTTCTGCACcCCTGCCAGCCAGTGCCCe 1361 ATATAGTCTGATTCGAGGTCATG-CCTACTGAGCTGCTCG3G 1441 CCC'rCTAGTCTATG~AA2CTCTCAGCTGGCACATGGAGTCTTTGT2GGGCCGCCATAGATCAGAGCCACAGCGGCTO 1521 CACAACATAAAOGCAAAATCATCATGCATGACCCCTTTGCCATGCc3GCCCTTCTTTGGCTACAACTTCGGCAAATACCTr. 1601 GCCCACTGOCTTAGCATG3QCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAACGACAA 1681 CGAGAATCCGCAGTTGGGATCAGTCOATGTTCACGTGTGAA 1761 CCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGATGCCCTGAACCTGAAACCCTGGGCACATCAACATO 1841 ATOGAGCTTTTCAGCATCTCCAA(GATTCT~CGAGAAGGAGTGcAGACATCGAGAACTATCTGAGATCAAGTCAA 1921 TGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTeAA2CCAAAGAATAACACATGTAATCAGGCCTAGT 2001 GCTTTACCTTTAAAMTCATTCCCTTTCCCATCCAAAGGTGCAGTAGGAGCAAGAGAGGCAAGTGTTCC Table A1302. Protein sequence of variant NOVI al5p (underlined). (SEQ ED) NO:108) 1 MPPQLQNGLIILSAKCVVQGSLDSLPQAVREFLENNAELCQPDHICDGSEEENGRLLGQMEEEGILRRLKYDNCWLALT 81 DPDAISTITERTPPTLQGWSEPKFAFG1KRMVPSGLSLKGE 161 TDS'YVASRMrRGTPVLALGDGEFVKCLIISVGCPLPLQKPVNNIWPCNPLTLAHLPDRREIISFGSGYGGNSL 241 LGKFLMSLKEWAHLLINEEKLAFSCKNAMPLGKE!GDAMFA 321 GHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKTIFTNVAETSDGGVYWEGIDPLASGVTITSKNKEWSSEDGEPCA 401 ZiPNSRFCTPASQCPIIDAAWESPEGVPIEGIIGGRRPAGVPLVYEASWQHGVFVGAARSEATAAAEHKGKIINHDPF 481 AMPFYFKLHLMQPALKFVWRDKGFWGGNRLWFRDKSKTIYP 561 EDMALLGLGHINMELFSISEFWEKEVGDEKYLEDOVADLPCIERI.ALKORISON FTable Al 3 03. Alteration effect 129 WO 2004/013347 PCT/US2003/024504 Glu to Gly Table A13Pl. Nucleotide sequence of variant 13377374 NOV1 al6n (underlined). T/C (SEQ ID NO:109) 1 GAACACAAACTTGCTGGCGGGAAGAGCCCGGAAAGAAACCTGTGGATCTCCCTTCGAGATCATCCAAAGAGAAGAAAGGT 81 GACCTCACATTCGTGCCCCTTAGCAGCACTCTGCAGAAATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAA 161 GTTGTCCAGGGAAGCCTGGACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCTGA 241 TCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATGGAGGAAGAGGGCATCCTCAGGC 321 GGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACTGACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATC 401 GTCACCCAAGAGCAAAGAGACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCAGAGGAGGA 481 TTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTACGTCATCCCATTCAGCATGGGGC 561 CGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTGACGGATTCGCCCTACGTGGTGGCCAGCATGCGGATCATGACG 641 CGGATCGGCACOCCCGTCCTGGAAGCACTGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTGCC 721 TTTACAAACCTTTGGTCAACAACTGCCCTGCAACCCGGAGCTGACGCTCATCGCCCACCTGCCTGACCGCAOAGAGA 801 TCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTGCTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTG 881 GCCAAGGAGGAAGGGTGGCTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAACTACCTGGC 961 GGCCGCATTTCCCAGCOCCTGCGGGAAGACCAACCTGGCCATGATCAACCCCAGCCTCCCCGGGTGGAAGGTTGAGTGCG 1041 TCGGGGATGACATTGCCTGGATGAAGTTTGACGCACAAGGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGT 1121 GTCCCTCCTGGGACTTCAGTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTGGC 1201 COAGACCAGCOACGGGGGCGTTTACTGGGAAGGTATTGATGAGCCCTAGCTTCAGGCGTCACCATCACGTCCTGGAAGA 1281 ATAAGGAGTGGAGCTCAGAGGATGGGGAACCTTGTOCCCACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCC 1361 ATCATTGATGCTGCCTOGGAGTCTCCCGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGTGT 1441 CCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGOAGTCTTTGTGGGGCGGCCATGAGATCAGAGGCCACAGCGGCTG 1521 CAGAACATAAACGCAAAATCATCATCCATGACCCCTTTOCCATCCCGCCCTTCTTTGGCTACAACTTCGGCAAATACCTG 1601 GCCCACTGGCTTAGCATGGCCCACCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGACAA 1681 GOAAGOCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTOATGTTCAACCGGATCGATGAAAAG 1761 CCAGCACCAAGCTCACGCCCATAGGCTACATCCCCAAGGAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATG 1841 ATGGAGCTTTTCAGCATCTCCAAGGAATTCTGOGAGAAGCAGGTGAAGACATCGAGAAGTATCTGGAGGATCAATCAA 1921 TGCCGACCCCCCCTGTGAAATCCAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGCCAGATGTAATCAGOCCTCAOT 2001 GCTTTACCTTTAAAATCATTCCCTTTCCCATCCATAAGGTGCAGTAGGAGCAAGAGAGGGCAAGTGTTCC Table A13P2. Protein sequence of variant NOVlal6p (underlined). (SEQ ID NO:1 10) 1 MPPQLQNGLNLSAVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQMEEEGILRRLKKYDNCWLALT 81 DPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEEDFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIEL 161 TDSPYVVASMRIMTRMGTPVLEALGDGEFVKCLSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL 241 LGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMMNPSLPGWKVECVGDDIAWMKFDAQ 321 GHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNVAETSDGGVIWEGIDEPLASGVTITSWKNKEWSSEDGEPCA 401 HPNSRFCTPASQCPIIDAAWESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF 481 AMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEKFLWPGFGENSRVLEWMFNRIDGKASTKLTPIGYIPK 561 EDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQVNADPPCEIEREILALKQRISQM Table A13P3. Alteration effect Leu to Pro Example A5. Expression Profile of the Human Cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK) Gene The protocol for quantitative expression analysis is disclosed in Example Q9. 5 Expression of gene CG101190-01 was assessed using the primer-probe set Ag1769, described in Table A14. Results of the RTQ-PCR runs are shown in Tables A15, A16, and A17. Table A14. Probe Name Ag1769 Primers Sequences Length Start SEQ ID Position No Forward s -gcagaacataaaggcaaaatca-3' 22 1520 175 Probe TET-5'-tcatgcatgaccctttgccatg-3'- 23 1542 176 1TAMRA 130 WO 2004/013347 PCT/US2003/024504 Reverse i5 caggtatttgccgaagttgtag-3' 22 1579 177 Table A15. Panel 1.3D Rel. Exp.(%) Rel. Exp.(%) Tissue Name Ag1769, Run Tissue Name Ag1769, Run 156228299 156228299 Liver adenocarcinoma 0.0 Kidney (fetal) 32.3 Pancreas 0.0 Renal ca. 786-0 0.0 Pancreatic ca. CAPAN 2 0.0 Renal ca. A498 0.0 Adrenal gland 0.7 Renal ca. RXF 393 0.0 Thyroid 0.1 Renal ca. ACHN 0.0 Salivary gland 0.0 Renal ca. UO-31 0.0 Pituitary gland 5.0 Renal ca. TK-10 0.0 Brain (fetal) 0.0 Liver 100.0 Brain (whole) 0.1 Liver (fetal) 34.6 Brain (amygdala) 0.0 Liver ca. (hepatoblast) 0.6 _________________ ________HepG2 Brain (cerebellum) 0.0 Lung 0.3 Brain (hippocampus) 0.0 Lung (fetal) 0.1 Brain (substantia nigra) 0.0 Lung ca. (small cell) LX-1 0.3 Brain (thalamus) 0.1 Lung ca. (small cell) NCI- 0.0 H69 Cerebral Cortex 0.0 Lung ca. (s.cell var.) SHP-77 0.0 Spinal cord 0.0 Lung ca. (large cell)NCI- 0.0 H460 glio/astro U87-MG 0.0 Lung ca. (non-sm. cell) 0.1 A549 glio/astro U-i 18-MG 0.0 Lung ca. (non-s.cell) NCI- 0.0 ___ __ __ ___ __ __ ___ a__ ___ __ __H23 astrocytoma SW1783 0.0 Lung ca. (non-s.cell) HOP- 0.0 I_________62 neuro*; met SK-N-AS 0.0 Lung ca. (non-s,cl) NCI- 0.0 H522 astrocytoma SF-539 0.0 Lung ca. (squam.) SW 900 0.0 astrocytoma SNB-75 0.0 Lung ca. (squam.) NCI- 0.0 H596 glioma SNB-19 0.0 Mammary gland 4.4 glioma U251 0.0 Breast ca.* (pl.ef) MCF-7 0.1 glioma SF-295 0.0 Breast ca.* (pl.ef) MA- 0.0 __________________ a__________MB-23 1 Heart (fetal) 0.0 Breast ca.* (pl.ef) T47D 0.0 Heart 0.3 Breast ca. BT-549 0.0 Skeletal muscle (fetal) 0.2 Breast ca. MDA-N 0.0 131 WO 2004/013347 PCT/US2003/024504 Skeletal muscle 0.0 Ovary 0.3 Bone marrow 0.1 Ovarian ca. OVCAR-3 0.5 Thymus 0.2 Ovarian ca. OVCAR-4 0.0 Spleen 0.0 Ovarian ca. OVCAR-5 0.1 Lymph node 0.2 Ovarian ca. OVCAR-8 0.0 Colorectal 11.7 Ovarian ca. IGROV-1 0.0 Stomach 0.1 Ovarian ca.* (ascites) SK- 0.0 Stomach_0.1 OV-3 0.0 Small intestine 2.0 Uterus 0.0 Colon ca. SW480 0.0 Placenta 0.0 Colon ca.* SW620(SW480 0.1 Prostate 0.0 met) Colon ca. HT29 .0.0 Prostate ca.* (bone met)PC- 0.0 3 Colon ca. HCT-116 0.0 Testis 0.0 Colon ca. CaCo-2 0.2 Melanoma Hs688(A).T 0.0 Colon ca. tissue(OD03866) 1.0 Melanoma (met) 0.0 Hs688(B).T Colon ca. HCC-2998 0.0 Melanoma UACC-62 0.0 Gastric ca.* (liver met) NCI- 0.0 Melanoma M14 0.0 N87 Bladder 0.0 Melanoma LOX IMVI 0.0 Trachea*** 0.8 Melanoma* (met) SK-MELi 0.0 Kidney 29.5 Adipose .8 Table A16. Panel 5 Islet Rel. Rel. Exp.(%) Exp.(%) Tissue Name Ag1769, Run Tissue Name Ag1769, 174269005 Run 174269005 97457_Patient-O2go _adipose 3.1 94709_Donor 2 AM A adipose 97476mPatient-07sk skeletal 0.1 94710_Donor 2 AM - 0.7 muscle B adipose 97477 Patient-07ut uterus 0.0 947 11_Donor 2 AM - 0.7 C adipose 97478 Patient-07pl placenta 0.0 94712Donor 2 AD- 3.1 _Patiet-O~pplacena 0.0 A,.adipose ____ 99167_Bayer Patient 1 1.4 94713Donor2AD- 5.8 97482_Patient-08ut uterus 0.0 9471Donor 2 AD-4.3 132 WO 2004/013347 PCT/US2003/024504 97483Patient-08plplacenta4742Donor 3 U - 0.0 Patint-~pllacnta0.0 A Mesenchymnal Stem Cells 97486 Patient-09sk skeletal 0.0 94743Donor 3 U muscle 0B Mesenchymal Stem Cells 97487_Patient-09ututerus 0.0 94730_Donor 3 AM - 0.3 A adipose. 97488-Patient-09plplacenta 0.0 73 Donor 3 AM - 0.0 97492 Patient-10ut uterus 0.1 94732_Donor 3 AM - 0.0 ___________C adipose_____ 97493_Patient-10plplacenta 0.0 94733_Donor 3 AD Aadipose 97495_Patient-11go _adipose 3.2 94734_Donor 3 AD - 0.4 B adipose 97496_Patient- 11sk skeletal 0.0 94735_Donor 3 AD - 0.5 muscle C adipose 97497_Patient-1lut uterus 0.0 77138 Liver HepG2untreate 18.7 97498_Patient-i lpl3lacenta 0.0 73556_HeartCardiac stromal 0.0 cells (primary) 97500 Patient-12goadipose 6.4 81735 Small Intestine 16.6 97501_Patient-12sk skeletal 0.2 72409_KidneyProximal muscle Convoluted Tubule 97502_Patient-12ututerus 0.0 182685 Small 100.0 intestine-Duodenum 97503_Patient-12p1J3lacenta 0.0 90650_AdrenalAdrenocortic 0.0 -_ al adenoma, 94721_Donor 2 U - 0.0 72410 Kidney HRCE 0.2 A Mesenchymal Stem Cells 0 94722_Donor 2 U - 0.0 72411_Kidney HRE 0.0 B Mesenchymal Stem Cells 0 94723 Donor 2 U - 0.0 73139_UterusUterine 0.0 CMesenchymal Stem Cells smooth muscle cells Table A17. General screeningpanelvl.7 Column A - Rel. Exp.(%) Ag1769, Run 317617203 Tissue Name A Tissue Name A Adipose 13.4 Gastric ca. (liver met.) NCI-N87 0.0 HUVEC 0.0 Stomach 0.0 Melanoma* Hs688(A).T 0.0 Colon ca. SW-948 2.0 Melanoma* Hs688(B).T 0.0 Colon ca. SW480 0.0 Melanoma (met) SK-MEL-5 0.0 Colon ca. (SW480 met) SW620 1.3 Testis 0.2 Colon ca. HT29 0.0 Prostate ca. (bone met) PC-3 0.0 Colon ca. HCT-116 0.0 133 WO 2004/013347 PCT/US2003/024504 Prostate ca. DU145 0.0 Colon cancer tissu 0.1 0.0 Colon ca. SW1116 0.0 Uterus pooi 0.0 Colon ca. Colo-205 11.5 Ovarian ca. OVCAR-3 0.1 Colon ca. SW-48 0.1 Ovarian ca. (ascites) SK-OV-3 0.0 Colon 19.6 Ovarian ca. OVCAR-4 0.4 Small Intestine 0.6 Ovarian ca. OVCAR-5 0.0 Fetal Heart 0.1 Ovarian ca. IGROV-1 0.0 Heart 0.1 Ovarian ca. OVCAR-8 0.0 Lymph Node Pool 0.0 Ovary 0.1 Lymph Node pool 2 10.2 Breast ca. MCF-7 0.0 Fetal Skeletal Muscle 0.5 Breast ca. MDA-MB-231 0.0 Skeletal Muscle pool 0.0 Breast ca. BT 549 0.0 Skeletal Muscle 0.1 Breast'ca. T47D 0.0 Spleen 0.2 113452 mammary gland 0.0 Thymus 0.3 Trachea' 2.1 CNS cancer (glio/astro) SF-268 0.0 Lung 0.2 CNS cancer (glio/astro) T98G 0.0 Fetal Lung 1.1 CNS cancer (neuro;met) SK-N-AS 0.0 Lung ca. NCI-N417 0.0 CNS cancer (astro) SF-539 0.0 Lung ca. LX-1 0.1 CNS cancer (astro) SNB-75 0.0 Lung ca. NCI-H146 0.3 CNS cancer (glio) SNB-19 0.0 Lung ca. SHP-77 0.0 CNS cancer (glio) SF-295 0.0 Lung ca. NCI-H23 0.0 Brain (Amygdala) 0.0 Lung ca. NCI-H460 0.0 Brain (Cerebellum) 0.2 Lung ca. HOP-62 0.0 Brain (Fetal) 0.0 Lung ca. NCI-H522 0.0 Brain (Hippocampus) 0.0 Lung ca. DMS-l 14 0.0 Cerebral Cortex pool 0.0 Liver 65.1 Brain (Substantia nigra) 0.0 Fetal Liver 100.0 Brain (Thalamus) 0.0 Kidney pool 55.5 Brain (Whole) 0.3 Fetal Kidney 2.7 Spinal Cord 0.0 Renal ca. 786-0 0.0 Adrenal Gland 0.8 Renal ca. A498 0.0 Pituitary Gland 9.3 Renal ca. ACHN 0.0 Salivary Gland 0.2 Renal ca. UO-31 0.0 Thyroid 0.4 Renal ca. TK-10 0.3 Pancreatic ca. PANC-1 0.0 Badder 10.1 |Pancreas pool 0.1 Panel 1.3D Summary: Expression of the human cytosolic PEPCK gene was highest in liver (CT = 24.6). Cytosolic PEPCK was expressed at moderate to high levels in adipose, 134 WO 2004/013347 PCT/US2003/024504 mammary gland, kidney, colon, small intestine, heart, and adrenal gland. This expression pattern is consistent with the GeneCalling@ results and with reports from the literature. Panel 5 Islet Summary: Among the samples on this panel, expression of the human cytosolic PEPCK gene was highest in small intestine (CT = 28.3). Lower levels of 5 expression were also detected in liver, adipose and pancreatic islets of Langerhans. General_screening_panel-v1.7 Summary: Agl769 Highest expression of this gene was detected in liver (CT=23.4), kidney (CT=24.6), adipose (CT=26.3 1), colon (CT=25.7), lymph node (CT=26.7), and pituitary gland (CT=26.83). This gene encodes phosphoenolpyruvate carboxykinase (PEPCK). The cytosolic isoform of PEPCK regulates 10 glyceroneogenesis in adipose tissue. The glycerol-3-phosphate product of glyceroneogenesis is used in triglyceride synthesis. Cytosolic PEPCK is upregulated in adipose tissue of obese AKR versus normal C57B1 adipose and may contribute to the obese phenotype. This hypothesis is supported by the fact that transgenic overexpression of cytosolic PEPCK in adipose is associated with increased glyceroneogenesis, increased adipocyte (fat cell) size 15 and fat mass, and higher body weight (Sun Y, Liu S, Ferguson S, Wang L, Klepcyk P, Yun JS, Friedman JE. Phosphoenolpyruvate carboxykinase over-expression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice. J Biol Chem. 2002). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of 20 endocrine/metabolically related diseases, such as obesity and diabetes. Example A6. Pathways Relevant to the Etiology and Pathogenesis of Obesity and/or Diabetes 25 PathCalling screening identified significant protein-protein interactions for cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK) with stathmin-like 4 and heme regulated initiation factor 2-alpha kinase (HRI). Protocol for PathCalling is disclosed in Example Q10. 30 Stathmin is a ubiquitous phosphorylated protein thought to act as an intracellular relay for diverse regulatory pathways (Sobel A. Stathmin: a relay phosphoprotein for multiple signal transduction? Trends Biochem Sci 1991 Aug;16(8):301-5. PMID: 1957351). 135 WO 2004/013347 PCT/US2003/024504 HRI is also widely expressed with significant transcript levels in adipose, muscle and liver and is activated by oxidative stress (Hwang SY, Kim MK, Kim JC. Cloning of hHRI, human heme-regulated eukaryotic initiation factor 2alpha kinase: down-regulated in epithelial ovarian cancers. Mol Cells 2000 Oct 31;10(5):584-91 PMID: 11101152). Oxidative stress 5 has been associated with diabetes. It is possible that under conditions of oxidative stress, HRI will phosphorylate and activate cytosolic Phosphoenolpyruvate Carboxykinase. The outcome of inhibiting the action of the human cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK) gene would be a potential reduction of glyceroneogenesis, 10 triglyceride deposition in adipose tissue, adipocyte (fat cell) size and fat mass, and a reduction in body weight. Inhibition of cytosolic PEPCK would also reduce hepatic gluconeogenesis and ameliorate the fasting hyperglycemia of Type 2 diabetes. Example A7. Assays Screening for Modulators of Phosphoenolpyruvate carboxykinase 15 A non-exhaustive list of cell lines that express the Phosphoenolpyruvate carboxykinase (PEPCK) gene can be obtained from the RTQ-PCR results shown herein. These and other Phosphoenolpyruvate carboxykinase (PEPCK) expressing cell lines could be used for screening purposes. 20 Screening for an inhibitor/antagonist of PEPCK could be accomplished with an in vitro glucose production assay. H4IIE cells transfected with recombinant cytosolic PEPCK would be tested for glucose production as described in Materials and Methods in Wang JC, Stafford JM, Scott DK, Sutherland C, Granner DK. The molecular physiology of hepatic 25 nuclear factor 3 in the regulation of gluconeogenesis. J Biol Chem 275:14717-21, 2000, PMID: 10799560. Our results indicate that a modulator of cytosolic Phosphoenolpyruvate Carboxykinase (PEPCK) activity, such as an inhibitor, activator, antagonist, or agonist of 30 PEPCK may be useful for treatment of such disorders as obesity, diabetes, and insulin resistance, as well as for enhancement of insulin secretion. 136 WO 2004/013347 PCT/US2003/024504 B. NOV2 -- Transketolase Transketolase is a thiamine-dependent enzyme that links the pentose phosphate pathway with the glycolytic pathway. The pentose phosphate pathway, which is active in most tissues, provides sugar phosphates for intermediary biosynthesis, especially nucleotide 5 metabolism. The pentose pathway also generates the biosynthetic reducing power for the cell in the form of NADPH. Transketolase is directly involved in the branch of the pathway that channels excess sugar phosphates to glycolysis, enabling the production of NADPH to be maintained under different metabolic conditions. The pentose phosphate pathway is especially active in sites where production of fatty acids and steroid synthesis occurs because 10 they require the reducing power of NADPH (Lewandowski PA, Cameron-Smith D, Jackson CJ, Kultys ER, Collier GR. The role of lipogenesis in the development of obesity and diabetes in Israeli sand rats (Psammomys obesus). J Nutr 1998 Nov;128(11):1984-8. PMID: 9808653; Parks EJ, Krauss RM, Christiansen MP, Neese RA, Hellerstein MK. Effects of a low-fat, high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance.J 15 Clin Invest. 1999 Oct;104(8):1087-9 6 . PMID: 10525047; Marques-Lopes I, Ansorena D, Astiasaran I, Forga L, Martinez JA. Postprandial de novo lipogenesis and metabolic changes induced by a high-carbohydrate, low-fat meal in lean and overweight men. Am J Clin Nutr. 2001 Feb;73(2):253-61. PMID: 11157321) 20 We found transketolase to be down-regulated in brown adipose tissue derived from mice with various body weights ranging from obese (sd4 compared to chow-fed mice) to heavily obese (ngsd7 compared to chow-fed mice) and hyperglycemic, heavily obese mice (hgsd7+ compared to chow-fed mice) on a high fat diet; transketolase remained unchanged in white adipose from the same groups of mice. This down-regulation of transketolase is in 25 conjunction with a down-regulation of several enzymes in the fatty acid synthesis pathway and the anaplerotic pathway, including ATP citrate lyase, fatty acid elongase, and malic enzyme, as well as, SREBP. This suggests that in brown adipose, fatty acid synthesis and lipogenesis are down-regulated as a compensatory mechanism to the high fat diet. Such a compensatory mechanism is not present in white adipose (Swierczynski J, Goyke E, Wach 30 L, Pankiewicz A, Kochan Z, Adamonis W, Sledzinski Z, Aleksandrowicz Z. Comparative study of the lipogenic potential of human and rat adipose tissue. Metabolism. 2000 May;49(5):594-9. PMID: 10831168; Hellerstein MK. De novo lipogenesis in humans: 137 WO 2004/013347 PCT/US2003/024504 metabolic and regulatory aspects. Eur J Clin Nutr. 1999 Apr;53 Suppl 1:S53-65. Review. PMID: 10365981) Figure 1 summarizes the biochemistry surrounding the human Transketolase and 5 potential assays that may be used to screen for antibody therapeutics or small molecule drugs to treat obesity and/or diabetes. Figure 1 shows pentose phosphate pathway generating NADPH for fatty acid and steroid biosynthesis. The pathway has 1st oxidative and 2nd non oxidative stage. The non-oxidative stage is link between pentose phosphate pathway and glycolysis. reactions of the pathway are cytoplasmic. Transketolase cofactors are thiamine 10 pyrophosphate and Mg 2 +. (Frank T, Bitsch R, Maiwald J, Stein G. Alteration of thiamine pharmacokinetics by end-stage renal disease (ESRD). Int J Clin Pharmacol Ther 1999 Sep;37(9):4 4 9-55; Pietrzak I, Baczyk K. Erythrocyte transketolase activity and guanidino compounds in hemodialysis patients. Kidney Int Suppl 2001 Feb;78:S97-101) 15 Figure 2 suggests how alterations in expression of the human Transketolase and associated gene products function in the etiology and pathogenesis of obesity and/or diabetes. The scheme incorporates the unique findings of these discovery studies in conjunction with what has been reported in the literature. The outcome of inhibiting the action of the human Transketolase would be a reduction of Insulin Resistance, a major 20 problem in obesity and/or diabetes. Therefore, mimicking brown adipose in white adipose, by inhibiting transketolase, may decrease the amount of NADPH necessary for fatty acid synthesis and lipogenesis. The decrease of NADPH available for fatty acid synthesis and lipogenesis may force utilization 25 of fat stores. Thus, a modulator of transketolase such as an antagonist or an inhibitior for transketolase may be beneficial for the treatment of obesity an/or diabetes. Furthermore, ihibition of production of fructose-6-phosphate through inhibition of transketolase may decrease the hexosamine pathway and may also have beneficial effects for insulin resistance. Cell lines expressing the Transketolase can be obtained from the RTQ-PCR results disclosed 30 herein. These and other Transketolase expressing cell lines could be used for screening purposes. Furthermore, our results indicate that a modulator of Transketolase activity, such as an inhibitor, activator, antagonist, or agonist of Transketolase may be useful for treatment of 138 WO 2004/013347 PCT/US2003/024504 such disorders as obesity, diabetes, and insulin resistance, as well as for enhancement of insulin secretion. Discovery Process 5 The following sections describe the study design(s) and the techniques used to identify the Transketolase encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for Obesity and Diabetes. Obesity and Diabetes are major public health concerns in the developed and 10 developing world. It is estimated that over half of the adult US population is overweight with a body mass index (BMI) greater than the upper limit of normal (25) where the BMI is defined as the weight (Kg) / [height (m)]. A common consequence of being overweight is hyperlipidemia and the development of insulin resistance. This is followed by the development of hyperglycemia, a hallmark of Type II diabetes. Left untreated, the 15 hyperglycemia leads to microvascular disease and end organ damage that includes retinopathy, renal disease, cardiac disease, peripheral neuropathy and peripheral vascular compromise. Currently, over 16 million adults in the US are affected by Type I diabetes and the condition has now become rampant among school-age children as a consequence of the epidemic of obesity in that age group. 20 Diabetes mellitus is a disorder in which blood levels of glucose (a simple sugar) are abnormally high because the body doesn't release or respond to insulin adequately. Blood sugar (glucose) levels vary throughout the day, rising after a meal and returning to normal within 2 hours. Blood sugar levels are normally between 70 and 110 milligrams per deciliter (mg/dL) of blood in the morning after an overnight fast. They are usually lower than 25 120 to 140 mg/dL 2 hours after eating foods or drinking liquids containing sugar or other carbohydrates. Insulin, a hormone released from the pancreas, is the primary substance responsible for maintaining appropriate blood sugar levels. Insulin allows glucose to be transported into cells so that they can produce energy or store glucose-derived enrgy until it's needed. The 30 rise in blood sugar levels after eating or drinking stimulates the pancreas to produce insulin, preventing a greater rise in blood sugar levels and causing them to fall gradually. Because muscles use glucose for energy, blood sugar levels can also fall during physical activity. Diabetes results when the body doesn't produce enough insulin to maintain normal blood sugar levels or when cells don't respond appropriately to insulin. In type II diabetes 139 WO 2004/013347 PCT/US2003/024504 mellitus, the pancreas continues to manufacture insulin, sometimes even at higher than normal levels. However, the body develops resistance to its effects, resulting in a relative insulin deficiency. The main goal of diabetes treatment is to keep blood sugar levels within the normal 5 range as much as possible. Completely normal levels are difficult to maintain, but the more closely they can be kept within the normal range, the less likely that temporary or long-term complications will develop. Therefore, a therapeutic that decreases insulin resistance and/or enhances insulin secretion would be beneficial in treatment of obesity and/or diabetes. Additionally, such a 10 therapeutic would be beneficial in treatment of insulin resistance, a condition that often leads to the development of diabetes. 15 Example B1. Mouse Dietary - Induced Obesity A protocol for Mouse Dietary-Induced Obesity study is disclosed in Example Q1. The predominant cause for obesity in clinical populations is excess caloric intake. 20 This so-called diet-induced obesity (DIO) is mimicked in animal models (mouse strain C57BL/6) by feeding high fat diets of greater than 40% fat content. The DIO study was established to identify the gene expression changes contributing to the development and progression of diet-induced obesity. In addition, the study design sought to identify the factors that lead to the ability of certain individuals to resist the effects of a high fat diet and 25 thereby prevent obesity. The sample groups for the study had body weights +1 S.D., + 4 S.D. and +7 S.D. of the chow-fed controls (below). In addition, the biochemical profile of the + 7 S.D. mice revealed a further stratification of these animals into mice that retained a normal glycemic profile in spite of obesity and mice that demonstrated hyperglycemia. Tissues examined included hypothalamus, brainstem, liver, retroperitoneal white adipose 30 tissue (WAT), epididymal WAT, brown adipose tissue (BAT), gastrocnemius muscle (fast twitch skeletal muscle) and soleus muscle (slow twitch skeletal muscle). The differential gene expression profiles for these tissues revealed genes and pathways that can be used as therapeutic targets for obesity and/or diabetes. Protocol for differential gene expression analysis, GeneCalling@, is disclosed in Example Q7. 140 WO 2004/013347 PCT/US2003/024504 Results A fragment of the mouse (mouse strain C57BL/6) Transketolase gene was initially 5 found to be down-regulated by 1.7 fold in the brown adipose tissue of mice fed a high fat diet who reach 4 standard deviations of body weight when compared to chow fed mice relative. to. brown adipose of chow fed mice using CuraGen's GeneCalling@ method of differential gene expression. A differentially expressed human gene fragment migrating, at approximately 385 nucleotides in length was definitively identified as a component of the 10 human Transketolase cDNA. The method of competitive PCR was used for confirmation of the gene assessment. The electropherographic peaks corresponding to the gene fragment of the human Transketolase were ablated when a gene-specific primer (shown in Table B1) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 385 nt in length were ablated in the sample from both the chow fed mice and the mice on a high 15 fat diet. Table Bl. The direct sequence of the 385 nucleotide-long gene fragment and the gene specific primers used for competitive PCR are indicated on the cDNA sequence of the Transketolase fragment (SEQ ID NO: 178) are shown in bold. The gene-specific primers at the 5' and 3' ends of the fragment are underlined. Mouse transketolase (scmgb-u05809_4) (fragment from 1151 to 1536 in bold. band size: 386) 670 ACATCAACCG CCTCGGCCAG AGCGACCCAG CCCCGCTCCA GCACCAGGTG GACATCTACC 730 AGAAGCGCTG TGAGGCCTTT GGCTGGCACA CCATCATCGT GGACGGACAC AGCGTGGAGG 790 AGCTGTGCAA GGCCTTTGGT CAGGCCAAGC ACCAACCAAC AGCCATCATT GCCAAGACCT 850 TCAAGGGCCG AGGGATCACA GGGATTGAAG ACAAGGAGGC GTGGCACGGG AAGCCCCTCC 910 CCAAAAACAT GGCCGAGCAG ATTATCCAGG AGATTTACAG CCAGGTTCAG AGCAAAAAGA 970 AGATCCTGGC CACGCCCCCT CAGGAGGATG CCCCATCCGT GGACATTGCT AACATCCGAA 1030 TGCCTACGCC ACCCAGCTAC AAAGTGGGGG ACAAGATAGC CACCCGGAAG GCCTATGGAC 1090 TGGCCCTCGC TAAGCTGGGC CACGCCAGTG ACCGTATCAT TGCCCTGGAT GGAGACACCA 1150 AGAATTCCAC CTTCTCGGAG CTCTTCAAAA AGGAGCACCC AGACCGGTTC ATTGAGTGCT 1210 ACATTGCCGA GCAAAACATG GTGAGCATTG CCGTGGGCTG TGCCACACGT GACCGGACAG 1270 TGCCCTTCTG CAGTACTTTC GCGGCCTTCT TCACACGGGC CTTCGACCAG ATTCGCATGG 1330 CCGCCATCTC TGAGAGCAAC ATCAACCTCT GTGGCTCCCA CTGTGGTGTG TCCATTGGGG 1390 AAGACGGGCC CTCTCAGATG CCCTCGAAG ACCTGGCCAT GTTCCGGTCA GTCCCCATGT 1450 CCACCGTCTT TTACCCAAGC GATGGAGTTG CAACAGAGAA GGCAGTGGAG TTAGCAGCCA 141 WO 2004/013347 PCT/US2003/024504 1510 ACACAAAGGG CATTTGCTTC ATCCGGACCA GCCGCCCAGA GAATGCCATT ATTTATAGCA 1570 ACAATGAGGA TTTCCAGGTC GGCCAAGCCA AGGTGGTCCT GAAGAGCAAG GATGACCAAG 1630 TGACAGTGAT CGGGGCTGGT GTAACTCTGC ATGAGGCCTT GGCTGCTGCA GAGAGTCTAA 1690. AGAAAGATAA GATCAGCATC CGGGTGCTGG ATCCCTTCAC TATCAAGCCC CTGGACAGGA 1750 AACTCATCCT AGACTCTGCC CGAGCAACCA AAGGCAGGAT CCTCACCGTG GAGGACCACT 1810 ACTACGAAGG TGGCATAGGA GAGGCAGTGT CTGCTGCCGT AGTGGGTGAA CCTGGAGTGA 1870 CGGTCACTCG CCTGGCTGTC AGCCAAGTAC CACGAAGTGG CAAGCCAGCT GAGCTACTGA 1930 AGATGTTCGG TATTGACAAG GACGCCATTG TGCAAGCTGT GAAAGGCCTT GTCACCAAGG 1990 GCTAGGGAGG GCATGGGATG CTGGGTG (gene length is 2516, only region from 670 to 2016 shown) Example B2. Identification of Human Transketolase Sequences. 5 The sequence of Human Transketolase (Acc. No. CG175387-01) was derived by laboratory cloning of cDNA fragments, by in silico prediction of the sequence. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were cloned. In silico prediction was based on sequences available in CuraGen's proprietary sequence databases or in the public human sequence databases, and provided 10 either the full-length DNA sequence, or some portion thereof. The protocol for identification of human sequence(s) is disclosed in Example Q8. Table B2 shows protein alignment (ClustalW) of Human Transketolase sequence (CG175387-01; SEQ ID NO:8) and Mouse Transketolase sequence (SEQ ID NO:179) Table 15 B3 shows sequence of Mouse Transketolase (SEQ ID NO:179). Table B2. Protein alignment (ClustalW) of Human Transketolase sequence (CG175387 01; SEQ ID NO:8) and Mouse Transketolase sequencen (SEQ ID NO: 179). 142 WO 2004/013347 PCT/US2003/024504 "M 301 ,sw/)O~ -6 L N dd 9 t~Not" >U0am-OR Mous AEl KDQLAKTARRSIALAGGHTCSAIALFHMYADtPID FVLSGHAPQILALKWANRGLRISAELLNLRKISDLGHPSCCSAEITDVLGQGfMYLDACGMAYT YFDKASYRVYCMLGDGEVSEGSVWEAMAFAGIYKLDNLVAIFDJNRLGQSDPAPLQHQVDIYQKRCEAFG WI-ITIIVDGHSVEELCKAFGQAYKHQPTAIIAKTFKGRGITGIEDKEAWHGKPLPKNMAEQIIQEISQVQS KKKILATPPQEDAPSVDIANRMNP1PSYKVGDKIATRKAYGLALAKLGHASDRIIALDGDTKNSTFSEL FKKEHPDRFIECYIAEQNMVSIAVGCATRDRTVPFCSTFAAFFTRAFDQIRMAAKSESNILCGSHCGVS IGEDGPSQMALEDLAMFRSVPMSTFYPSDGVATEKAVELAANTKGICFIRTSRPENAIWSNEDFQVG QAKVVLKSKDDQVTVIGAGVTLHEALAAAESLKKDKISIRVLDPFTIKPLDRKLILDSARATKGRILTVE DHYYEGGIGEAVSAAVVGEPGVTVTLAVSQVPRSGKPAELLKMFGIDKDAIVQAVKGLVTKG The laboratory cloning was performed using one or more of the methods surmmarized in Example Q8. The NOV2 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table B4. Table B4. NOV2 Sequence Analysis NOV2a, CG175387-01 ISEQ ID NO: 7 2078 bp DNA Sequence JORF Start: ATG at 80 ORF Stop: TAG at 1949 GAGGGCCTGTCGCCGCGCGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCC G CCTGCCGCACCATGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAGGACACGGC C AACCGCCTACGTATCAGCTCCATCCAGGCCACCACTGCGCCCGGCTCTGGCCACCCCACGTCATGCT G CAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCACACCATGCGCTACAAGTCCCAGGACCCCCGG A ATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCATCCTCTACGCGGTCTCGC 143 WO 2004/013347 PCT/US20031024504 T GAAGCTGGTTTCCTGCCCGAGGCGGAGCTGCTACCTGAGGAAGATCAGCTCCGACTTGGACGGGC A CCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCT T GTGGGATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGA T GGGGAGCTGTCAGAGGGCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACC T TGTcGGCCATTCTAGACATCAATCGCCTGGGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGAC A TCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCATCATCGTGGATGGACACAGCGTGGAGGA G CTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCAAGACCTTCAAGGGCC AGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCTGAG AGATCATCCAGGAGATCTACAGCCAGATCCAGAGCA-AAAAGAAGATCCTGGCAACCCCTCCACAGGAz G GACGCACCCTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACA AI GATAGCCACCCGCAAGGCCTACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATC G CCCTGGATGGGGACACCAAAAATTCCACCTTCTCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTT C ATCGAGTGCTACATTGCCGACCAGAACATGGTGAGCATCGCGGTGGGCTGTGCCACCCGCACAGGA C GGTGCCCTTCTGCAGCACTTTTGCAGC.CTTCTTCACGCGGGCCTTTGACCAGATTCGCATGGCCGCC A TCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTC C CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTG A TGGCGTTGCTACAGAGAAGGCAGTGGAACTAGCCCCCAATACAAAGGGTATCTGCTTCTCCGGACC A GCCGCCCAGAAATGCCATCATCTATAACAACAATGAGGACTTCCAGGTCGGACA.GCCAAGGTGGT C CTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGGGCTCGGCGTGACCCTGCACGAGGCCTTGGCCG C TGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCCCTTCACCATCAGCCCCTG G ACAG-AAPLACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGGACCATTA T TATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTCGCATCACTGTCACCC A CCTGGCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGAC A GCGATGCCATTGCACAAGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGG c GGGGGTCTATACATTCCTGAGATTCTGGGAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATA T ATGTTTTGAGAAAAATGAAAAAAA NOV2a, CG175387-01 fSEQ ID NO:863a Wa 6786AD Protein Sequence MESYHKPDQQKLQALDTANRLRISSIQATTAAGSGHPTSCCSAFIMVLFFHTMRYKSQDPRNPH N DRFM SKGHAAPILYAVWBAGFLAAELLNLRKISSDLDCHPVPKQAFTDVATGSLGQGLGACGM A YTGKYFDKASYRVYCLLGDGELSEGSVWAAFASYLDNLVAILDIRLGQSDPAPLQNQMIYQ K RCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAI IAKTFKGPRGITGVEDI(ES WHGKPLPKNM7XEQI I.,I 144 WO 2004/013347 PCT/US20031024504 Q G DTKNSTFBEIFKKHPDRFIECYIEQNAVGCATRTVPFCSTFAAFTAFDQIRAAISE NINLCGSHCGVSIGEDGPSQMALEDIAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRP E NAIIYNNNEDFQVGQAKLSIDDQVTVIGAGVTLHEAALLKjEKNIRVLDPFTIKPLDRK L IlDSARATIKGRIJTVEDHYYEGGIGBAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLd(MFGIDRDA I AQAVRGLITKA NOV2b, CG175387-03 ISEQ ID NO: 9 j1927 bp DNA Sequence IORF Start: at 2 JORF Stop: TAG at 1886 T:CATCATCACCCCATCACGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGAC A CGGCCACCGCCTACGTATCAGCTCCATCCAGGCCAC-ACTGCGGCGGGCTCTGGCCACCCCACGTC A TGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCACACCATGCGCTACAGTCCCAGGACC C CCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAA.GGCCCATGCAGCTCCCATCCTCTACCGTC T GGGCTGAGCTGGTTTCCTGCCGAGCGAGCTGCTA&CCTGAGGAAGATCAGCTCCGACTTGGA C GGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGG C CGCTTGTCGGATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTG GAGACGGGGAGCTGTCAGACGGCTCTGTATCGGAGGCCATGGCCTTCGCCAGCATCTATAGCTGGA C AACCTTGTGGCCATTCTAGACATCAATCGCCTGGGCCAGAGTGACCCGGCCCCACTGCAGCACCAGA T GGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCATCATCGTGGATGGACACAGCGTG G AGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCAAGACCTTCA G GGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAACATGG C TGAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCA C AGGAGGACGCACCCTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTAAAATTGG GACAGATAGCCACCCGCAAGGCCTACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCA T CATCGCCCTGGATGGGGACACCAAAALATTCCACCTTCTCGGAGATCTTCAAAAAGGAGCACCCGGAC C GCTTCATCGAGTGCTACATTGCTGAGCAGAACATGGTGAGCATCGCGGTGGGCTGTGCCACCCGCAA C AGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTCGCATcG C CGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGC3GAGACGG C CCTCCCAGATGGCCCTAGAA4GATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCC A AGTGATGGCGTTGCTACAGAGAAGGCAGTGGAACTAGCCCCCAATACAAAGGGTATCTGCTTCATCC G GACCAGCCGCCCAGAAAATGCCATCATCTATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAG G TGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGGCTGCGGTGACCCTGCACGAGOCCTT G IGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCCCTTCACCATCAAGC 145 WO 2004/013347 PCT/US2003/024504 C CCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGGAC C ATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGT C ACCCACCTGGCAGTTAACCGGGTACCAAGAAGTGGGAAGCCGGCTGAGCTGCTGAAGATGTTTGGTA T CGACAGGGATGCCATTGCACAAGCTGTGAGGGGCCTCATCACCAAGGCCTAGGCAGGTGCGGCCGCA C TCGAGCACCACCACCACCACCAC NOV2b, CG175387-03 SEQ ID NO: 10 628 aa MW at 68568.4kD Protein Sequence HHHHIIESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQD p RNPHNDRFVLSKGHAAPILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLG A ACGMAYTGKYFDKASYRVYCLLGDGELSEGSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQ M DIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIAKTFKGRGITGVEDKESWHGKPLPKNM A EQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKAYGQALAKLGHASDR I IALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVS IAVGCATRNRTVPFCSTFAAFFTRAFDQIRM A AISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFI R TSRPENAIIYNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIK p LDRKLILDSARATKGRILTVEDHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFG I DRDAIAQAVRGLITKA NOV2c, 267254044 .SEQ ID NO: 11 1897 bp DNA Sequence IORF Start: at 3 ORF Stop: TAG at 1884 CACCGAATTCCACCATGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACAC G GCCAACCGCCTACGTATCAGCTCCATCCAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCAT G CTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCACACCATGCGCTACAAGTCCCAGGACCCC C GGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCATCCTCTACGCGGTCTG G GCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTGGACG G GCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCC C CTTGTGGGATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGG A GATGGGGAGCTGTCAGAGGGCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACA A CCTTGTGGCCATTCTAGACATCAATCGCCTGGGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATG G ACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCATCATCGTGGATGGACACAGCGTGGA G GAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCAAGACCTTCAAGG G CCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT G AGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACA G GAGGACGCACCCTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGG 146 WO 2004/013347 PCT/US2003/024504 A CAAGATAGCCACCCGCAAGGCCTACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATC A TCGCCCTGGATGGGGACACCAAAAATTCCACCTTCTCGGAGATCTTCAAAAAGGAGCACCCGGACCG C TTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCOGTGGGCTGTGCCACCCGCAACA G GACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTCGCATGGCC G CCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCC C TCCCAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAA G TGATGGCGTTGCTACAGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGG A CCAGCCGCCCAGAAAATGCCATCATCTATAACAACAATGAGGACTTCCAGGT CGGACAAGCCAAGGT G GTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGGGCTGGGGTGACCCTGCACGAGGCCTTGG C CGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCCCTTCACCATCAAGCCC C TGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGGACCA T TATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCA C CCACCTGGCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATC G ACAGGGATGCCATTGCACAAGCTGTGAGGGGCCTCATCACCAAGGCCTAGGCGGCCGCTAT NOV2c, 267254044 SEQ ID NO: 12 627 aa MW at 68276.2kD Protein Sequence PNSTMESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDP R NPHNDRFVLSKGHAAPILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGA A CGMAYTGKYFDKASYRVYCLLGDGELSEGSVWEAMAFAS IYKLDNLVAILDINRLGQSDPAPLQHQM D IYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIAKTFKGRGITGVEDKESWHGKPLPKNMA E QIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKAYGQALAKLGHASDRI ALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQIRMA A ISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIR T SRPENAIIYNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKP L DRKLILDSARATKGRILTVEDHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGI D RDAIAQAVRGLITKA NOV2d, CG175387-02 ISEQ ID NO: 13 |1897 bp DNA Sequence IORF Start: at 3 lORF Stop: TAG at 1884 CACCGAATTCCACCATGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACAC G GCCAACCGCCTACGTATCAGCTCCATCCAGGCCACCACTGCGGCOGGCTCTGGCCACCCCACGTCAT G CTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCACACCATGCGCTACAAGTCCCAGGACCCC C GGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCATCCTCTACCCGGTCTG G GCTGAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAGATCAGCTCCGACTTGGACG 147 WO 2004/013347 PCTIUS2003/024504 G GCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCC G CTTGTGGGATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGG A GATGGGGAGCTGTCAGAGGGCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACA A CCTTGTGGCCATTCTAGACATCAATCGCCTGGGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATG G ACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCATCATCGTGGATGGACACAGCGTGGA G GAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCAAGACCTTCAAGG G CCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT G AGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACA G GAGGACGCACCCTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGG A CAAGATAGCCACCCGCAAGGCCTACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATC A TCGCCCTGGATGGGGACACCAAAAATTCCACCTTCTCGGAGATCTTCAAAAAGGAGCACCCGGACCG C TTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGTGGGCTGTGCCACCCGCAACA G GACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTCGCATGGCC G CCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCC C TCCCAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAA G TGATGGCGTTGCTACAGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGG A CCAGCCGCCCAGAAAATGCCATCATCTATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGT G GTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGGGCTGGGGTGACCCTGCACGAGGCCTTGG C CGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCCCTTCACCATCAAGCCC C TGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGGACCA T TATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCA C CCACCTGGCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATC G ACAGGGATGCCATTGCACAAGCTGTGAGGGGCCTCATCACCAAGGCCTAGGCGGCCGCTAT NOV2d, CG175387-02 SEQ D 14627 aa MW at 68276.2kD Protein Sequence -7826k PNSTMESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAABIMAVLFFHTMRYKSQDP R NPHNDRFVLSKGHAAPILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGA A CGMAYTGKYFDKASYRVYCLLGDGELSEGSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQM D IYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIAKTFKGRGITGVEDKESWHGKPLPKNMA E QIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKAYGQALAKLGHASDRI I ALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNVSIAVGCATRNRTVPFCSTFAAFFTRAFDQIRMA A ISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIR 148 WO 2004/013347 PCT/US2003/024504 T SRPENAIIYNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKP L DRKLII DSARATKGRILTVEDHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGI D RDAIAQAVRGLITKA NOV2e, CG175387-04 SEQ ID NO: 15 11942 bp DNA Sequence |ORF Start: ATG at 138 JORF Stop: TAG at 1884 AGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTAT C AGCTCCATCCAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGA T CATGGCTGTCCTCTTTTTCCACACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGAC C GCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCATCCTCTACGCGGTCTGGCCTGAAGCTGGTTTCCT G GCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTGOACGGGCACCCGGTCCCGAAAC A AGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGGGATGGCCTAC A CCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGA G GGCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAG A CATCAATCGCCTGGGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGG T GCGAGGCCTTCGGTTGGCATGCCATCATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTT T GGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCAAGACCTTCAAGGGCCGAGGGATCACGGGGG T AGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCTGAGCAGATCATCCAGGAG A TCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACCCTCAGT G GACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCA A GGCCTACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGAC A CCAAAAATTCCACCTTCTCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACAT T GCCGAGCAGAACATGGTGAGCATCGCGGTGGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCA G CACTTTTGCAGCCTTCTTCACGCGCGCCTTTGACCAGATTCGCATGGCCGCCATCTCCGAGAGCAAC A TCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCCCAGATGGCCCTAGA A GATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTACAG A GAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAAT. G CCATCATCTATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAAGA T GACCAGGTGACCGTTATCGGGGCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGA A GAAAGAAAAGATCAACATCCGCGTGCTGGACCCCTTCACCATCAAGCCCCTGGACAGAAAACTCATT C TCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGGACCATTATTATGAAGGTGGCAT T GGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTGGCAGTTAACC G GGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCA 149 WO 2004/013347 PCT/US2003/024504 C AAGCTGTGAGGGGCCTCATCACCAAGGCCCATCATCACCACCATCACTAGGCAGGTGCGGCCGCTCT C GAGCACCACCACCACCACCACTGGAGATCCCGGCTGCT NOV2e, CG175387-04 SEQ ID NO:16 1582aa MW at 63701.1kD Protein Sequence MAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAPILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPK Q AFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSEGSVWEAMAFASIYKLDNLVAIL D INRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIAKTFKGRGITG EDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATR K AYGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFC S TFAAFFTRAFDQIRMAAISESNINLCGSHCGVS IGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVAT E KAVELAANTKGICFIRTSRPENAIIYNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELL K KEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVEDHYYEGGIGEAVSSAVVGEPGITVTHLAVN R VPRSGKPAELLKMFGIDRDAIAQAVRGLITKAHHHHHH A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table B5. Table B5. Comparison of the NOV2 protein sequences. NOV2 a ----- -- MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHT NOV2b HHHHHHESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHT NOV2c -PNSTMESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHT NOV2d -PNSTMESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHT NOV2e ---------------------------------------------------- MAVLFFHT NOV2a MRYKSQDPRNPHNDRFVLSKGHAAPILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQ NOV2b MRYKSQDPRNPHNDRFVLSKGHAAPILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQ NOV2c MRYKSQDPRNPHNDRFVLSKGHAAPILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQ NOV2d MRYKSQDPRNPHNDRFVLSKGHAAPILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQ NOV2e MRYKSQDPRNPHNDRFVLSKGHAAPILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQ NOV2a AFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSEGSVWEAMAFASIYKL NOV2b AFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSEGSVWEAMAFASIYKL NOV2c AFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSEGSVWEAMAFASIYKL NOV2d AFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSEGSVWEAMAFASIYKL NOV2e AFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSEGSVWEAMAFASIYKL NOV2a DNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQP NOV2b DNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQP NOV2c DNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQP NOV2d DNLVAILDINRLCQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQP NOV2e DNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQP NOV2a TAIIAKTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPS NOV2b TAIIAKTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPS NOV2c TAIIAKTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPS NOV2d TAIIAKTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPS NOV2e TAIIAKTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPS 150 WO 2004/013347 PCT/US2003/024504 NOV2a VDIANIRMPSLPSYKVGDKIATRKAYGQALAKLGHASDRIIALDGDTKSTFSEIFKKEH NOV2b VDIANIRMPSLPSYKVGDKIATRKAYGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEH NOV2c VDIANIRMPSLPSYKVGDKIATRKAYGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEH NOV2d VDIANIRMPSLPSYKVGDKIATRKAYGQALAKLGHASDRIIALDGDTKSTFSEIFKKEH NOV2e VDIANIRMPSLPSYKVGDKIATRKAYGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEH NOV2a PDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQIRMAAISESNINLCGS NOV2b PDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQIRMAAISESNINLCGS NOV2c PDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDIRMAAISESNINLCGS NOV2d PDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQIRMAAISESNINLCGS NOV2e' PDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQIRMAAISESNINLCGS NOV2a HCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRP NOV2b HCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICPIRTSRP NOV2c HCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRP NOV2d HCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRP NOV2e HCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRP NOV2a ENAT IYNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPF NOV2b ENAIIYNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPF NOV2c ENAIIYNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPF NOV2d ENAIIYNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPF NOV2e ENAIIYNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPF NOV2a TIKPLDRKLILDSARATKGRILTVEDHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRS NOV2b TIKPLDRKLILDSARATKGRILTVEDHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRS NOV2c TIKPLDRKLILDSARATKGRILTVEDHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRS NOV2d TIKPLDRKLILDSARATKGRILTVEDHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRS NOV2e TIKPLDRKLILDSARATKGRILTVEDHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRS NOV2a GKPAELLKMFGIDRDAIAQAVRGLITKA ---- NOV2b GKPAELLKMFGIDRDAIAQAVRGLITKA -- NOV2c GKPAELLKMFGIDRDAIAQAVRGLITKA----- NOV2d GKPAELLKFGIDRDAIAQAVRGLITKA----- NOV2e GKPAELLKMFGIDRDAIAQAVRGLITKAHHHHHH NOV2a (SEQ ID NO: 8) NOV2b (SEQ ID NO: 10) NOV2c (SEQ ID NO: 12) NOV2d (SEQ ID NO: 14) NOV2e (SEQ ID NO: 16) Further analysis of the NOV2a protein yielded the following properties shown in Table B6. Table B6. Protein Sequence Properties NOV2a SignalP analysis:j No Known Signal Sequence Predicted PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 11; pos.chg 2; neg.chg 2 H-region: length 4; peak value -6.34 PSG score: -10.74 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -6.01 possible cleavage site: between 41 and 42 151 WO 2004/013347 PCT/US2003/024504 > Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood= 1.11 (at 503) ALOM score: 1.11 (number of TMSs: 0) MITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment(75): 4.90 Hyd Moment(95): 4.71 G content: 0 D/E content: 2 S/T content: 1 Score: -7.08 Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not found NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 11.4% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: KKXX-like motif in the C-terminus: LITK SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 76.7 152 WO 2004/013347 PCT/US2003/024504 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues Final Results (k =9/23): 60.9 %: cytoplasmic 26.1 %: nuclear 4.3 %: mitochondrial 4.3 %: vacuolar 4.3 %: peroxisomal >> prediction for CG175387-01 is cyt (k=-23) A search of the NOV2a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table B7. Table B7. Geneseq Results for NOV2a NOV2a Identities/ Geneseq Protein/Organism/Length [Patent Residues/ Similarities for Expect Identifier #, Date] Match the Matched Value Residues Region ABB08374 Mouse transkelotase-like enzyme L..622 590/622 (94%) 0.0 amino acid sequence - Mus sp, 623 1..622 610/622 (97%) aa. [W0200192310-A2, 06-DEC 2001] ABU53000 Human metabolism-associated 6..616 582/611 (95%) 0.0 DKFZphtes3_17117 homologue #1 - 1..611 600/611 (97%) Homo sapiens, 611 aa. [W0200112659-A2, 22-FEB-2001] AAE33377 Human DME-3 protein - Homo 6..616 416/614 (67%) 00 sapiens, 738 aa. [W0200290521-A2, 119..732 499/614 (80%) 14-NOV-2002] ABU52999 Human metabolism-associated 6..616 415/614 (67%) 0.0 protein from DKFZphtes3_17117 - 7..620 498/614 (80%) Homo sapiens, 626 aa. [W0200112659-A2, 22-FEB-2001] ABB08373 Human transkelotase-like enzyme 6..616 415/614 (67%) 0.0 amino acid sequence - Homo sapiens, 6..619 498/614 (80%) 625 aa. [WO200192310-A2, 06 DEC-2001] In a BLAST search of public sequence databases, the NOV2a protein was found to have 5 homology to the proteins shown in the BLASTP data in Table B8. 153 WO 2004/013347 PCT/US2003/024504 Table B8. Public BLASTP Results for NOV2a Protein NOV2a Identities/ Exp Accession Protein/Organism/Length Residues/ Similarities for ect. Number Match the Matched Val Residues Portion ue P29401 Transketolase (EC 2.2.1.1) (TK) - 1..623 623/623 (100%) 0.0 Homo sapiens (Human), 623 aa. 1..623 623/623 (100%) A45050, transketolase (EC 2.2.1.1) - 1..623 619/623 (99%) 0.0 human, 623 aa. 1..623 621/623 (99%) P40142 Transketolase (EC 2.2.1.1) (TK) 1..622 590/622 (94%) 0.0 (P68) - Mus musculus (Mouse), 1..622 610/622 (97%) 623 aa. P50137 Transketolase (EC 2.2.1.1) (TK) - 1..622 586/622 (94%) 0.0 Rattus norvegicus (Rat), 623 aa. 1..622 609/622 (97%) Q9ESAO Transketolase - Mus musculus 65..622 529/558 (94%) 0.0 (Mouse), 559 aa (fragment). 1..558 548/558 (97%) PFam analysis predicts that the NOV2a protein contains the domains shown in the Table B9. Table B9. Domain Analysis of NOV2a Identities/ Pfam Domain NOV2a Match Region Similarities Expect Value for the Matched Region El_dehydrog 58..302 59/329 (18%) 0.011 150/329 (46%) transketolase 14..304 108/339 (32%) 3.9e-159 290/339 (86%) transketpyr 314..479 53/188 (28%) 1.3e-56 143/188 (76%) transketolaseC 490.612 41/136 (30%) 4.9e-34 105/136 (77%) Example B3. Transketolase Gene Variants and SNPs Variant sequences are included in this application. A variant sequence can include a 5 single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a 10 nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which 154 WO 2004/013347 PCT/US2003/024504 one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, however, in the case that a codon including a SNP encodes the same amino acid as a result of the redundancy of the 5 genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern for example, alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, stability of transcribed message. 10 Method of novel SNP Identification: SNPs are identified by analyzing sequence assemblies using CuraGen's proprietary SNPTool algorithm. SNPTool identifies variation in assemblies with the following criteria: SNPs are not analyzed within 10 base pairs on both ends of an alignment; Window size 15 (number of bases in a view) is 10; The allowed number of mismatches in a window is 2; Minimum SNP base quality (PHRED score) is 23; Minimum number of changes to score an SNP is 2/assembly position. SNPTool analyzes the assembly and displays SNP positions, associated individual variant sequences in the assembly, the depth of the assembly at that given position, the putative assembly allele frequency, and the SNP sequence variation. 20 Sequence traces are then selected and brought into view for manual validation. The consensus assembly sequence is imported into CuraTools along with variant sequence changes to identify potential amino acid changes resulting from the SNP sequence variation. Comprehensive SNP data analysis is then exported into the SNPCalling database. 25 Method of novel SNP Confirmation: SNPs are confirmed employing a validated method know as Pyrosequencing. Detailed protocols for Pyrosequencing can be found in: Alderborn et al. Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. (2000). Genome Research. 10, Issue 8, August. 1249-1265. In brief, Pyrosequencing is ayreal time primer extension process of genotyping. This 30 protocol takes double-stranded, biotinylated PCR products from genomic DNA samples and binds them to streptavidin beads. These beads are then denatured producing single stranded bound DNA. SNPs are characterized utilizing a technique based on an indirect bioluminometric assay of pyrophosphate (PPi) that is released from each dNTP upon DNA 155 WO 2004/013347 PCT/US2003/024504 chain elongation. Following Klenow polymerase-mediated base incorporation, PPi is released and used as a substrate, together with adenosine 5'-phosphosulfate (APS), for ATP sulfurylase, which results in the formation of ATP. Subsequently, the ATP accomplishes the conversion of luciferin to its oxi-derivative by the action of luciferase. The ensuing light 5 output becomes proportional to the number of added bases, up to about four bases. To allow processivity of the method dNTP excess is degraded by apyrase, which is also present in the starting reaction mixture, so that only dNTPs are added to the template during the sequencing. The process has been fully automated and adapted to a 96-well format, which allows rapid screening of large SNP panels. 10 Results The DNA and protein sequences for the novel single nucleotide polymorphic variants of the transketolase-like gene of CuraGen Acc. No. CG175387-01 are reported in Table B10. 15 Variants are reported individually but any combination of all or a select subset of variants are also included. In Table B10, the positions of the variant bases and the variant amino acid residues are underlined. In summary, there are 22 variants reported in Table B10. Variant 13377687 is a G to A SNP at 134 bp of the nucleotide sequence that results in an Ala to Thr change at amino acid 19 of protein sequence, variant 13377688 is a C to T SNP at 287 bp of 20 the nucleotide sequence that results in an Arg to Cys change at amino acid 70 of protein sequence, variant 13377684 is a G to T SNP at 566 bp of the nucleotide sequence that results in a Val to Leu change at amino acid 163 of protein sequence, variant 13377689 is an A to G SNP at 651 bp of the nucleotide sequence that results in an Asp to Gly change at amino acid 191 of protein sequence, variant 13380050 is an A to T SNP at 699 bp of the nucleotide 25 sequence that results in a Glu to Val change at amino acid 207 of protein sequence, variant 13380051 is a T to C SNP at 741 bp of the nucleotide sequence that results in a Val to Ala change at amino acid 221 of protein sequence, variant 13377683 is an A to G SNP at 747 bp of the nucleotide sequence that results in a Glu to Gly change at amino acid 223 of protein sequence, variant 13377690 is an A to G SNP at 894 bp of the nucleotide sequence that 30 results in a Gn to Arg change at amino acid 272 of protein sequence, variant 13377682 is a T to C SNP at 1253 bp of the nucleotide sequence that results in a Phe to Leu change at amino acid 392 of protein sequence, variant 13380092 is an A to G SNP at 1307 bp of the nucleotide sequence that results in an Ile to Val change at amino acid 410 of protein sequence, variant 13380073 is an A to G SNP at 1441 bp of the nucleotide sequence that 156 WO 2004/013347 PCT/US2003/024504 results in no change in the protein sequence (silent), variant 13380072 is a C to T SNP at 1519 bp of the nucleotide sequence that results in no change in the protein sequence (silent), variant 13380093 is an A to G SNP at 1529 bp of the nucleotide sequence that results in an Asn to Asp change at amino acid 484 of protein sequence, variant 13380094.is a C to T SNP 5 at 1550 bp of the nucleotide sequence that results in a Gln to Stop change at amino acid 491 of protein sequence, variant 13380095 is a T to C SNP at 1603 bp of the nucleotide sequence that results in no change in the protein sequence (silent), variant 13380052 is a G to T SNP at 1645 bp of the nucleotide sequence that results in no change in the protein sequence (silent), variant 13377691 is a T to C SNP at 1683 bp of the nucleotide sequence that results in a Phe 10 to Ser change at amino acid 535 of protein sequence, variant 13380053 is a T to C SNP at 1783 bp of the nucleotide sequence that results in no change in the protein sequence (silent), variant 13377686 is a G to A SNP at 1802 bp of the nucleotide sequence that results in an Ala to-Thr change at amino acid 575 of protein sequence, variant 13380055 is a C to T SNP at 1813 bp of the nucleotide sequence that results in no change in the protein sequence 15 (silent), variant 13377685 is an A to G SNP at 1832 bp of the nucleotide sequence that results in a Thr to Ala change at amino acid 585 of protein sequence, and variant 13380056 is an A to G SNP at 1862 bp of the nucleotide sequence that results in a Ser to Gly change at amino acid 595 of protein sequence. Table B10. Variants of nucleotide sequence of Acc. No. CG175387-01 (SEQ ID NO:7) Variant Nucleotides Amino Acids Position Initial Modified Position Initial Modified 13377687 134 G A 19 Ala Thr 13377688 287 C T 70 Arg Cys 13377684 566 G T 163 Val Leu 13377689 651 A G 191 Asp Gly 13380050 699 A T 207 Glu Val 13380051 741 T C 221 Val Ala 13377683 747 A G 223 Glu Gy 13377690 894 A G 272 Gin Arg 13377682 1253 T C 392 Phe Leu 13380092 1307 A G 410 Ile Val 13380073 1441 A G 454 Tbr Thr 13380072 1519 C T 480 Ile ile 13380093 1529 A G 484 Asn Asp 157 WO 2004/013347 PCT/US2003/024504 13380094 1550 C T 491 Gln STOP 13380095 1603 T C 508 Ala Ala 13380052 . 1645 G T 522 Leu Leu 13377691 1683 T C 535 Phe Ser 13380053 1783 T C 568 Ile Ile 13377686 1802 G A 575 Ala Thr 13380055 1813 C T 578 Gly Gly 13377685 1832 A G 585 Thr Ala 13380056 1862 A G 595 Ser Gly Table Bl. Variant Sequences Table BI1AL. Nucleotide sequence of variant 13377687 NOV2aln (underlined). G/A (SEQ ID NO:111) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTCCCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTCCAGGCCTTGAAGGACACGACCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATCCTGCACCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCddGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGATGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATCGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 ACACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCCACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATG Table 1B11A2. Protein sequence of variant NOV2alp (underlined). (SEQ ID NO: 112) 1 MESYHKPDQQKLQALKDTTRLRISSIQATTAAGSGRPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAPGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGRPAELLKMFGIDRDAIAQAVRGLITKA Table B 11A3. Alteration effect Ala to Thr Table 1311B1. Nucleotide sequence of variant 13377688 NOV2a2n (underlined). C/T (SEQ ID NO:113) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACTGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 158 WO 2004/013347 PCT/US2003/024504 321 TCCTCTACGCGCTGCTOAACTGGTTTCCTGGCCAGGCGGAGCTGCTGAACCTGAGGAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGCCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTCCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCCTGCAGCACCAGATGCACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACCAGCGTCCAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTCGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAA Table B11B2. Protein sequence of variant NOV2a2p (underlined). (SEQ ID NO:114) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAABIMAVLFFHTMRYKSQDPRNPHNDCFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDHPVPQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 CSVWEAMAFASIYK DNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 1 1B3. Alteration effect Arg to Cys Table B 1 IC 1. Nucleotide sequence of variant 13377684 NOV2a3n (underlined). G/T (SEQ ID NO:115) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGCCACCACTGCGCCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCCOTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 4D1 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTTTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAAAAA Table B 11C2. Protein sequence of variant NOV2a3p (underlined). (SEQ ID NO:116) 1 MESYHKDDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSLWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA 159 WO 2004/013347 PCT/US2003/024504 Table B 11 C3. Alteration effect Val to Leu Table B1 ID. Nucleotide sequence of variant 13377689 NOV2a4n (underlined). A/G (SEQ ID NO:117) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCACCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGCCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTC-AGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGATGGCCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCC-ATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTG.CCGAGC-AGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCG.T'ITCCATCGGGGAAGACGGGCCCTCC 1.361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAC-AAGGATGACCAGCGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTCCTGAAGATGTTTGGTATCGACAGGGATGCCA*TTGCACA 1921 AGCTGTGAGGG3GCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTCGGCGGGGGTCTATAC-ATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTG3AGAAAAATGAAAAAAAAAAAAAAAAAAAAA Table B11D32. Protein sequence of variant NOV2a4p (underlined). (SEQ ID NO: 118) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLD)NLVAILDINRLGQSCGPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLMGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECTIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTlRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITK Table B 11 D3. Alteration effect Asp to Gly Table B311E1. Nucleotide sequence of variant 13380050 NOV2a5n (underlined). A/T (SEQ ID NO: 119) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGG.CCATTCTAGACATCAATCGCCTG .641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGTGCCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCArCCAACAGCC-ATCATTGCC-A 801 AGACCTTCAAGGGCCGAGGGATCACGG;GGGTAGAAGATAAGGAGTCTTGG3CATGGGAAGCCCCTCCCCAAAACATGGCT 881 GAGCAGATCATCCAG;GAGATCTACAGCCAGATCCAGAGCAAAAGAAGATCCTGGCAACCCCTCCACAkGGAGGACGCACC 961 CTCAGTGGAC-ATTGCCAACATCCCCATGCCCAGCCTCCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTACAAGATCTCGCTATCTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGG;ACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTCCACGAGGCCTTGGCCGCTCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 160 WO 2004/013347 PCT/US2003/024504 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAAAAA Table B11E2. Protein sequence of variant NOV2a5p (underlined). (SEQ ID NO:120) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCVAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLLDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 1E3. Alteration effect Glu to Val Table B1 IF1. Nucleotide sequence of variant 13380051 NOV2a6n (underlined). T/C (SEQ ID NO:121) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCCCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG ,.481 GATGGCCTACACCGGCAAATACTTCGACAACCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTCGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGCGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAATAGCCCCCGCAACGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGOAAGACGGOCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATCGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATCCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTCGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGdTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAAAAA Table B 11F2. Protein sequence of variant NOV2a6p (underlined). (SEQ ID NO:122) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSAEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 11 F3. Alteration effect Val to Ala Table B11 G1. Nucleotide sequence of variant 13377683 NOV2a7n (underlined). A/G (SEQ ID NO:123) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTCCTGAACCTCACGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTC GCTGCCAGGGCCTCGGGGCCGCTTGTGG 161 WO 2004/013347 PCT/US2003/024504 481 GATGGCCTACACCGGCAAATACTTCGACAAGCCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTA TAAGCTGGACAACCTTGTGGCC!ATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCCGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGGGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAG-ATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGC-ACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCACCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGG.CAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTAC-ATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATCCCGCCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATG3CCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCrGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTCCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGA4TGTTTGGTATCGACAGGGATCCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAA-AAAAAAAAAAA Table B 11G 2. Protein sequence of variant NOV2a7p (underlined). (SEQ IID NO: 124) 1 MESYHKPDQQKLQALKDTANRZLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRZNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEGLCKAFGQAKHQPTAIIA 241 K(TFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGD)TKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVG3CATRNRTVPFCSTFAAFFTRAFDQI -401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFTPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 -YNNNEDFQVGQAKVVLKSKDD)QVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 11 G3. Alteration effect -Glu to Gly Table B11H1. Nucleotide sequence of variant 13377690 NOV2agn (underlined). A/G (SEQ ID NO: 125) 1 GG;CACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCACCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGGTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 4 01 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTG 481 GAzTGGCCTACACCGGCAAATACTTCGACAAGGCC-AGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCC!A 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 8 81 GAGCAGATCATCCGGGAGATCTACAGCCAGATCCAGAGCAAAAAGAzAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 963. CTCAGTGGACATT GCCAACATCCGCATGCCCAGCCTGCCCACCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGCTACATTGCCGAGCAGAACATG-GTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGC.CCTTCTCCCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGCTCAGTCCCCACATCALACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGG;ACTTCCAGGTCGGACAACCCAAGGTGGTCCTGAAGA.GCAAG;GATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACC-ATCAAGCCCCTG-GACAGAAAACTCATTCTCGACACGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTG.GCATTGGTGAGG0CTGTGTCCAGTGCAGT.AGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGG3GGCCTCATC-ACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAAAA Table B11IH2. Protein sequence of variant NOV2a8p (underlined). (SEQ ID NO:126) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQD)PRNPHNDRPVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIREIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLD)RKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRZGLITKA Table B11 IH3. Alteration effect 162 WO 2004/013347 PCT/US2003/024504 GIn to Arg Table BI 1I1. Nucleotide sequence of variant 13377682 NOV2a9n (underlined). T/C (SEQ ID NO:127) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCCCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGAT'CAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTCGCCACTCGCTCCCTGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAA(GCCAGCTACCGAGTCTATTGCTTGCTGGG.AGATGGGGAGCTGTCAGAGG 561 GCTCTGTATCGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTCCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCG;TGGATGGACACAGCCTGGAGGAGCTCTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 ,AGACCTTCAAGGGCCGAGGGATCACGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 161 1041 1121 1201 1281 1361 1521 1601 1041 A 1121 111TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTAC-ATTGCCGAGC-AGAACATGGTGAG;CATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCCTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 44 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAATCAACATCCGCGTCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTCCACCAAGGGCAGGATCCTCACCGTGAGG 171 ACCATTATTATGAAGGATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCT GATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCCGGTATG TCGGGGG TCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAA-AAAAAAAAAAAAAAAAA Table B11112. Protein sequence of variant NOV2a9p (underlined). (SEQ ID NO:128) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTPKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKLATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAALFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 1113. Alteration effect Phe to Leu Table B11 IJI. Nucleotide sequence of variant 13380092 NOV2a1On (underlined). A/G (SEQ ID NO: 129) 1 GGCACGAGGOCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTCCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAACACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGACCGCTTCATCGAGTCTACATTGCCGAGCAAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTCCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACGTCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAACCAGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACACAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 163 WO 2004/013347 PCT/US2003/024504 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAACCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTTGGCGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAAAA Table B1J2. Protein sequence of variant NOV2alOp (underlined). (SEQ ID NO:130) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNVNLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAlI 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 11 J3. Alteration effect Ile to Val Table B1IK1. Nucleotide sequence of variant 13380073 NOV2al1n (underlined). A/G (SEQ ID NO:131) 1 GGCACCAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCCCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCACGACCCCCCGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTCTTGCTGGGAGATGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCACCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGCCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 GGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGA A A A Table B 11K2. Protein sequence of variant NOV2a11 p (underlined). (SEQ ID NO:132) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 1K3. Alteration effect No change. Table B1 Ll. Nucleotide sequence of variant 13380072 NOV2al2n (underlined). C/T (SEQ ID NO:133) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 164 WO 2004/013347 PCT/US2003/024504 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTCAGCCTTCTTCACGCGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATTT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAAAAA Table B 11L2. Protein sequence of variant NOV2al2p (underlined). (SEQ ID NO:134) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPEMAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 1L3. Alteration effect No change. Table B1 1M1. Nucleotide sequence of variant 13380093 NOV2al3n (underlined). A/G (SEQ ID NO:135) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTGTGTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401. GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 104i ACGGGCAGCCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACGATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTCGGTGACCCTGCACGAGGCCTTGCCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGCCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAAAA Table BI 1M2. Protein sequence of variant NOV2a13p (underlined). (SEQ ID NO:136) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNDEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B1 1M3. Alteration effect 165 WO 2004/013347 PCT/US2003/024504 Asn to Asp Table B I1NI. Nucleotide sequence of variant 13380094 NOV2a14n (underlined). C/T (SEQ ID NO:137) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCCAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTCGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTCCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAACACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATCGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 CCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGATAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATG Table B11N2. Protein sequence of variant NOV2al4p (underlined). (SEQ ID NO:138) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVG*AKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 1 1N3. Alteration effect Gln to STOP Table B1101. Nucleotide sequence of variant 13380095 NOV2a15n (underlined). T/C (SEQ ID NO:139) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATCCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTOCCAAGCTCGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGACCAAGGATGACCAGGTGACCGTTATCOGG 1601 GCCGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 166 WO 2004/013347 PCT/US2003/024504 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGA A A Table B 1102. Protein sequence of variant NOV2al5p (underlined). (SEQ ID NO:140) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 1103. Alteration effect No change. Table B11P1. Nucleotide sequence of variant 13380052 NOV2al6n (underlined). G/T (SEQ ID NO:141) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTCGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTCGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTCGTCCTGAAGACCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTTAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACACGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCCACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAAA Table B 1P2. Protein sequence of variant NOV2al6p (underlined). (SEQ ID NO:142) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITK Table B 11P3. Alteration effect No change. Table BI1 Q1. Nucleotide sequence of variant 13377691 NOV2al7n (underlined). T/C (SEQ ID NO:143) 1 GGCACCAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTQTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 167 WO 2004/013347 PCT/US2003/024504 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCA-GATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCC:TGGCAACCCCTCCAC-AGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGG'GACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTCCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTG(GCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGCGGGTATGAAGTGTCGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAA Table B1Q2. Protein sequence of variant NOV2al7p (underlined). (SEQ ID NO: 144) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241. KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAATKGICFIRTSRPENAII 481 YNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPSTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 11Q3. Alteration effect Phe to Ser Table B 1 RL. Nucleotide sequence of variant 13380053 NOV2al 8n (underlined). T/C (SEQ ID NO:145) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACcACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGCCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTCCTTGCTGGGAGATG(GAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCCCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGACTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCCCATCTCCGAAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAACCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATCGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAA Table B1 1R2. Protein sequence of variant NOV2al8p (underlined). (SEQ ID NO:146) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAPGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMDSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B11 R3. Alteration effect No change. 168 WO 2004/013347 PCT/US2003/024504 3S1. Nucleotide sequence of variant 13377686 NOV2al9n (underlined). G/A (SEQ ID NO:147) - -GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGCCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAACCTCGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTCGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGCTCAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTACAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1341 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATG Table B 11S2. Protein sequence of variant NOV2al9p (underlined). (SEQ ID NO:148) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMR4YKSQDPRNPHNDRFVLSKGHAAP B1 ILYAVWAEAGFLABAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSTVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 11S3. Alteration effect Ala to Thr Table B1 IT. Nucleotide sequence of variant 13380055 NOV2a2On (underlined). C/T (SEQ ID NO:149) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCOCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTCACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 CCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGTGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGACGGGCCTCATCACCAAGGCCTAGGCCG GTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 169 WO 2004/013347 PCT/US2003/024504 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAAAAA Table B11T2. Protein sequence of variant NOV2a2Op (underlined). (SEQ ID NO:150) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDICASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 11T3. Alteration effect No change. Table B 1U1. Nucleotide sequence of variant 13377685 NOV2a2ln (underlined). A/G (SEQ ID NO:151) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCA.CAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCCCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCcGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGTCCCGAAACAAGCTTTCACCGACGTGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGCCcAGCTACCGAGTCTATTGCTTGCTGGAGATGGAGCTGTCAAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCACCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGCACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGGACATTGCCAACATCCGCATGCCCAGCCTGCCCAGCTACAAAGTTGGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCGAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTGCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCAGCCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCGCCCACCTG 1841 GCAGTTAACCGGGTACCAAGAAGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAAAAA Table B 1U2. Protein sequence of variant NOV2a2lp (underlined). (SEQ ID NO:152) 1 MESYHKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFFHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYFDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYKLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAIIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHEALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVAHLAVNRVPRSGKPAELLKMFGIDRDAIAQAVRGLITKA Table B1 1U3. Alteration effect Thr to Ala Table B11 V1. Nucleotide sequence of variant 13380056 NOV2a22n (underlined). A/G (SEQ ID NO:153) 1 GGCACGAGGGCCTGTCGCCGCGGGAGCAGCCGCTATCTCTGTGTGTCCGCGTGTGCGCCCGGTCCCCGCCTGCCGCACCA 81 TGGAGAGCTACCACAAGCCTGACCAGCAGAAGCTGCAGGCCTTGAAGGACACGGCCAACCGCCTACGTATCAGCTCCATC 161 CAGGCCACCACTGCGGCGGGCTCTGGCCACCCCACGTCATGCTGCAGCGCCGCAGAGATCATGGCTGTCCTCTTTTTCCA 241 CACCATGCGCTACAAGTCCCAGGACCCCCGGAATCCGCACAATGACCGCTTTGTGCTCTCCAAGGGCCATGCAGCTCCCA 321 TCCTCTACGCGGTCTGGGCTGAAGCTGGTTTCCTGGCCGAGGCGGAGCTGCTGAACCTGAGGAAGATCAGCTCCGACTTG 401 GACGGGCACCCGGTCCCGAAACAAGCTTTGACCGACGTGGCCACTGGCTCCCTGGGCCAGGGCCTCGGGGCCGCTTGTGG 481 GATGGCCTACACCGGCAAATACTTCGACAAGGCCAGCTACCGAGTCTATTGCTTGCTGGGAGATGGGGAGCTGTCAGAGG 561 GCTCTGTATGGGAGGCCATGGCCTTCGCCAGCATCTATAAGCTGGACAACCTTGTGGCCATTCTAGACATCAATCGCCTG 641 GGCCAGAGTGACCCGGCCCCGCTGCAGCACCAGATGGACATCTACCAGAAGCGGTGCGAGGCCTTCGGTTGGCATGCCAT 721 CATCGTGGATGGACACAGCGTGGAGGAGCTGTGCAAGGCCTTTGGCCAGGCCAAGCACCAGCCAACAGCCATCATTGCCA 170 WO 2004/013347 PCT/US2003/024504 801 AGACCTTCAAGGGCCGAGGGATCACGGGGGTAGAAGATAAGGAGTCTTGGCATGGGAAGCCCCTCCCCAAAAACATGGCT 881 GAGCAGATCATCCAGGAGATCTACAGCCAGATCCAGAGCAAAAAGAAGATCCTGGCAACCCCTCCACAGGAGGACGCACC 961 CTCAGTGACATTGCCAACATCCCATGCCCAGCCTGCCCAGCTACAAAGTTGGGACAAGATAGCCACCCGCAAGGCCT 1041 ACGGGCAGGCACTGGCCAAGCTGGGCCATGCCAGTGACCGCATCATCGCCCTGGATGGGGACACCAAAAATTCCACCTTC 1121 TCGGAGATCTTCAAAAAGGAGCACCCGGACCGCTTCATCGAGTGCTACATTGCCCAGCAGAACATGGTGAGCATCGCGGT 1201 GGGCTGTGCCACCCGCAACAGGACGGTGCCCTTCTGCAGCACTTTTGCAGCCTTCTTCACGCGGGCCTTTGACCAGATTC 1281 GCATGGCCGCCATCTCCGAGAGCAACATCAACCTCTCGGCTCCCACTGCGGCGTTTCCATCGGGGAAGACGGGCCCTCC 1361 CAGATGGCCCTAGAAGATCTGGCTATGTTTCGGTCAGTCCCCACATCAACTGTCTTTTACCCAAGTGATGGCGTTGCTAC 1441 AGAGAAGGCAGTGAACTAGCCGCCAATACAAAGGGTATCTGCTTCATCCGGACCACCGCCCAGAAAATGCCATCATCT 1521 ATAACAACAATGAGGACTTCCAGGTCGGACAAGCCAAGGTGGTCCTGAAGAGCAAGGATGACCAGGTGACCGTTATCGGG 1601 GCTGGGGTGACCCTGCACGAGGCCTTGGCCGCTGCCGAACTGCTGAAGAAAGAAAAGATCAACATCCGCGTGCTGGACCC 1681 CTTCACCATCAAGCCCCTGGACAGAAAACTCATTCTCGACAGCGCTCGTGCCACCAAGGGCAGGATCCTCACCGTGGAGG 1761 ACCATTATTATGAAGGTGGCATTGGTGAGGCTGTGTCCAGTGCAGTAGTGGGCGAGCCTGGCATCACTGTCACCCACCTG 1841 GCAGTTAACCGGGTACCAAGAGGTGGGAAGCCAGCTGAGCTGCTGAAGATGTTTGGTATCGACAGGGATGCCATTGCACA 1921 AGCTGTGAGGGGCCTCATCACCAAGGCCTAGGGCGGGTATGAAGTGTGGGGCGGGGGTCTATACATTCCTGAGATTCTGG 2001 GAAAGGTGCTCAAAGATGTACTGAGAGGAGGGGTAAATATATGTTTTGAGAAAAATGAAAAAAAAAAAAAAAAAAAAA Table B11V2. Protein sequence of variant NOV2a22p (underlined). (SEQ ID NO:154) 1 MESKPDQQKLQALKDTANRLRISSIQATTAAGSGHPTSCCSAAEIMAVLFPHTMRYKSQDPRNPHNDRFVLSKGHAAP 81 ILYAVWAEAGFLAEAELLNLRKISSDLDGHPVPKQAFTDVATGSLGQGLGAACGMAYTGKYPDKASYRVYCLLGDGELSE 161 GSVWEAMAFASIYLDNLVAILDINRLGQSDPAPLQHQMDIYQKRCEAFGWHAIIVDGHSVEELCKAFGQAKHQPTAITIA 241 KTFKGRGITGVEDKESWHGKPLPKNMAEQIIQEIYSQIQSKKKILATPPQEDAPSVDIANIRMPSLPSYKVGDKIATRKA 321 YGQALAKLGHASDRIIALDGDTKNSTFSEIFKKEHPDRFIECYIAEQNMVSIAVGCATRNRTVPFCSTFAAFFTRAFDQI 401 RMAAISESNINLCGSHCGVSIGEDGPSQMALEDLAMFRSVPTSTVFYPSDGVATEKAVELAANTKGICFIRTSRPENAII 481 YNNNEDFQVGQAKVVLKSKDDQVTVIGAGVTLHALAAAELLKKEKINIRVLDPFTIKPLDRKLILDSARATKGRILTVE 561 DHYYEGGIGEAVSSAVVGEPGITVTHLAVNRVPRGGKPAELLKMFGIDRDAIAQAVRGLITKA Table B 11V3. Alteration effect Ser to Gly 171 WO 2004/013347 PCT/US2003/024504 Example B4. Expression Profiles of Transketolase. The protocol for quantitative expression analysis is disclosed in Example Q9. Expression of gene CG175387-01 and G175387-03 was assessed using the primer probe set Ag6328, described in Table B12. Results of the RTQ-PCR runs are shown in 5 Tables B13, B14 and B15. Table B12. Probe Name Ag6328 Primers Sequences Length Start SEQ ID Position No Forward 5'~cctagggcgggtatgaagt -3 19 1947 180 Probe TET-5 -ccagaatctcaggaatgtatagacccc-3 ' 27 1974 181 -TAMRA -- I-I Reverse 5' -teagtacatctttgagcacctttc-3' 241 2001 182 Table B13. General screening panel v1.5 Rel. Exp.(%) Ag6328 Rel. Exp.(%) Tissue Name Run 259211050 Tissue Name Ag6328, Run 259211050 Adipose 4.1 Renal ca. TK-10 6_9 Melanoma* Hs688(A).T 7.6 Bladder Melanoma* Gastric ca. (liver met.) Hs688(B).T 8.2 NCI-N87 3.7 Melanoma* M14 17.9 Gastric ca. KATO I1 29.7 Melanoma* 13.1 Colon ca. SW-948 2.6 LOXIMVI _______ Me-lanoma* SK- 10.5 Colon ca. SW480 20.6 MEL-5 Squamous cell 0Colon ca.* (SW480 met) carcinoma SCC-4 8.0 SW620 7.6 Testis Pool 2.0 Colon ca. HT29 8.8 Prostate ca.* (bone 2.6 Colon ca. HCT-116 30.1 met) PC-3 2.6_Colon ca._HCT-116_30.1 Prostate Pool 1.6 Colon ca. CaCo-2 12.3 Placenta 3.0 Colon cancer tissue 7.9 Uterus Pool 0.6 Colon ca. SW1116 5.2 Ovarian ca. OVCAR 5.4 Colon ca. Colo-205 5 0 3 Ovarian ca. S 13.6 Colon ca. SW-48 3.7 Ovrinca. OVCAR- 5.1 Colon Pool 0.8 172 WO 2004/013347 PCT/US2003/024504 Ovarian ca. OVCAR 11.7 Small Intestine Pool 1.3 Ovarian ca. IGROV- 29.1 Stomach Pool 1.1 Ovarian ca. OVCAR- 10.6 Bone Marrow Pool 1.3 8 Ovary 1.8 Fetal Heart 0.4 Breast ca. MCF-7 4.5 Heart Pool 0.6 Breast ca. MDA-MB- 19.2 Lymph Node Pool 2.6 231_________ _ Breast ca, BT 549 55.1 Fetal Skeletal Muscle 1.0 Breast ca. T47D 7.9 Skeletal Muscle Pool 0.6 Breast ca. MDA-N 85.9 Spleen Pool 1.7 Breast Pool 1.1 Thymus Pool 2.6 Trachea 1.2 CNS cancer (glio/astro) 16.6 U87-MG Lung 2.1 CNS cancer (glio/astro) 10.9 U-118-MG Fetal Lung 5.3 CNS cancer (neuro;met) 6.0 SK-N-AS Lung ca. NCI-N417 6.3 CNS cancer (astro) SF- 3.9 539 Lung ca. LX-1 9.5 cancer (astro) 100.0 SNB-75 Lung ca. NCI-H146 2.7 NS cancer (glio) SNBj 36.1 19 Lung ca. SBP-77 12.4 CNS cancer (glio) SF- 16.3 295 Lung ca. A549 92.0 Brain (Amygdala) Pool 3.4 Lung ca. NCI-H526 1.9 Brain (cerebellum) 8.0 Lung ca. NCI-H23 2.6 Brain (fetal) 3.6 Lung ca. NCI-H460 6.7 Brain (Hippocampus) 1.4 Pool Lung ca. HOP-62 9.5 ~ Cerebral Cortex Pool 3.9______ Lung ca. NCI-H522 2.0 2.4 CerblCotxPl3. Liver 0.3 ~ Brain (Thalamus) Pool 5.1 Fetal Liver 2.4 Brain (whole) 3.0 Liver ca. HepG2 7.6 Spinal Cord Pool 3.6 Kidney Pool 1.4 Adrenal Gland 4.5 Fetal Kidney 1.4 Pituitary gland Pool 1.0 Renal ca. 786-0 10.8 Salivary Gland 0.9 Renal ca. A498 27.4 Thyroid (female) 0.5 Renal ca. ACHN 18.8 Pancreatic ca. CAPAN2 27.9 173 WO 2004/013347 PCT/US2003/024504 Renal ca. UO-31 10.4 Pancreas Pool 3.6 Table B14. Panel 5 Islet Rel. Exp.(%) Rel. Exp.(%) Tissue Name Ag6328, Run Tissue Name Ag6328, Run 259232256 259232256 97457 Patient- 19.6 94709 D 15.3 02go adipose _Donor2 AM- _adipose 97476 Patient 07sk skeletal muscle 25.0 94710_Donor 2 AM - B adipose 18.3 97477_Patient- 8.4 94711_Donor 2 AM - C adipose 15.3 O7ut uterus_ 97478 Patient- 26.8 94712_Donor 2 AD -A adipose 12.9 07pljilacenta, _ aioe1. 99167 Bayer Patient 1 91.4 94713_Donor 2 AD -B adipose 19.2 97482_Patient- 6.7 94714_Donor 2 AD - C adipose 23.8 0811t uterus _______ 97483 Patient- 4.3 94742_Donor 3 U - 6 08plplacenta A Mesenchymal Stem Cells 97486 Patient- 94743 Donor 3 U 09sk skeletal muscle B Mesenchymal Stem Cells 28.1 97487_Patient- 6.9 94730_Donor 3 AM - A adipose 25.3 O9ut uterus _ 97488 Patient 09p8_patent- 5.0 94731 Donor 3 AM - B adipose 22.4 9placenta 97492Patient- 19.6 94732_Donor 3 AM - Cadipose 24.0 l Out uterus 97493_Patient- 26.8 94733_Donor 3 AD - A adipose 26.4 I Oplplacenta_______________________ 97495 Patient 9749_aient- 10.7 94734_Donor 3 AD - B adipose 13.7 11 igo adipose _ 97496 Patient- 4 11sk sikeletal muscle 4.2 94735_Donor 3 AD - C adipose 23.5 97497 Patient 9747Ptnte 14.8 77138_Liver HepG2untreated 43.5 11ut uterus _p 97498 Patient- 10.2 73556_HeartCardiac stromal, 11plplacenta cells (primary) 97500_Patient- 29.1 81735_Small Intestine 21.8 1 2go adipose I_____________________ 97501_Patient- 10.0 72409_Kidney Proximal 12sk skeletal muscle Convoluted Tubule 29.5 97502_Patient- 21.2 8268 5 Small intestine Duodenum 5.1 l2ut uterus_ 97503 Patient- 12.3 90650 AdrenalAdrenocortical 13.3 12pl_placenta 12.3 adenoma 174 WO 2004/013347 PCT/US2003/024504 94721_Donor 2 U A_Mesenchymal Stem 38.4 72410_Kidney HRCE 100.0 Cells 94722_Donor 2 U B_Mesenchymal Stem 32.3 72411 Kidney_IRE 39.5 Cells 94723_Donor 2 U - 73139 Uterus Uterine smooth C_Mesenchymal Stem 27.4 muscle cells 12.9 Cells Table B15. Generalscreening_panelvl.6 Column A - Rel. Exp.(%) Ag6328, Run 277234226 Tissue Name A Tissue Name A Adipose 3 7 Renal ca. TK-10 7.4 Melanoma* Hs688(A).T 6.9 Bladder 2.6 Melanoma* Hs688(B).T 7.0 Gastric ca. (liver met.) NCI-N87 3.1 Melanoma* M14 21.5 Gastric ca. KATO III 25.3 Melanoma* LOXIMVI 9.6 Colon ca. SW-948 6.2 Meloa SK-MEL-5 10.6 Colon ca. SW480 16.2 Squamous cell carcinoma SCC-4 13.8 jolon ca.* (SW480 met) SW620 5.3 Testis Pool 1.2 Colon ca. HT29 10.7 Prostate ca.* (bone met) PC-3 3.7 Colon ca. HCT-1 16 24.5 Prostate Pool 1.7 Colon ca. CaCo-2 12.9 Placenta 3.1 Colon cancer tissue 7.3 Uterus Pool 0.4 Colon ca. SWI 116 5.4 Ovarian ca. OVCAR-3 6.3 Colon ca. Colo-205 6.4 Ovarian ca. SK-OV-3 29.3 Colon ca. SW-48 3.6 Ovarian ca. OVCAR-4 9.6 Colon Pool 1.6 Ovarian ca. OVCAIR-5 23.0 Small Intestine Pool 1.3 Ovarian ca. IGROV-1 25.7 Stomach Pool 1.4 Ovarian ca. OVCAR-8 13.4 IBone Marrow Pool 1.1 Ovary 1.4 Fetal Heart 0.4 Breast ca. MCF-7 7.4 Heart Pool 0.7 Breast ca. MDA-MB-231 21.6 Lymph Node Pool 1.8 Breast ca. BT 549 100.0 Fetal Skeletal Muscle 0.9 Breast ca. T47D 11.7 Skeletal Muscle Pool 0.2 Breast ca. MDA-N 11.7 Spleen Pool 1.8 Breast Pool 1.9 Thymus Pool 2.3 Trachea 1.7 CNS cancer (glio/astro) U87-MG 14.0 Lung 1.0 CNS cancer (glio/astro) U-1 18-MG 9.5 Fetal Lung 5.4 NS cancer (neuro;met) SK-N-AS 5.4 175 WO 2004/013347 PCT/US2003/024504 Lung ca. NCI-N417 5.7 CNS cancer (astro) SF-539 8.2 Lung ca. LX-1 8.2 CNS cancer (astro) SNB-75 92.0 Lung ca. NCI-H146 1.7 CNS cancer (glio) SNB-19 27.2 Lung ca. SIP-77 17.2 CNS cancer (glio) SF-295 13.3 Lung ca. A549 81.2 Brain (Amygdala) Pool 2.2 Lung ca. NCI-H526 2.0 Brain (cerebellum) 6.3 Lung ca. NCI-H23 4.3 Brain (fetal) 3.3 Lung ca. NCI-H460 10.2 Brain (Hippocampus) Pool 3.0 Lung ca. HOP-62 6.8 Cerebral Cortex Pool 3.0 Lung ca. NCI-H522 2.8 Brain (Substantia nigra) Pool 2.2 Liver 0.2 Brain (Thalamus) Pool 4.5 Fetal Liver 3.1 Brain (whole) 2.9 Liver ca. HepG2 4.6 Spinal Cord Pool 3.5 Kidney Pool 3.2 Adrenal Gland 3.3 Fetal Kidney 1.3 Pituitary gland Pool 1.1 Renal ca. 786-0 11.0 Salivary Gland 0.9 Renal ca. A498 28.5 Thyroid (female) 1.9 Renal ca. ACIH N 15.9 Pancreatic ca. CAPAN2 15.9 Renal ca. UO-31 16.0 Pancreas Pool 2.7 General screening panel v1.5 Summary: Transketolase is abundantly expressed in all tissues. Transketolase is highly expressed in adipose (CT=27.42), which is the target tissue. Panel 5 Islet Summary: Panel 51 shows the highest expression in placenta with a good expression in adipose tissue and supports the data of panel 1.5. 5 General screening panel v1.6 Summary: (Ag6328) High expression of this gene was detected ubiquitously in all tissues (CT=26-30). This ubiquitous pattern of expression indicates that this gene product is involved in homeostatic processes for these and other cell types and tissues. Its expression was elevated in all the cancer cell lines (melanoma, ovarian cancer, breast 10 cancer, lung cancer, renal cancer, pancreatic cancer, and CNS cancer) with CT=22-26. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of melanoma, ovarian cancer, breast cancer, lung cancer, renal cancer, pancreatic cancer, and CNS cancer. In addition, the expression of this gene can be used as a detection marker for those cancers. 176 WO 2004/013347 PCT/US2003/024504 This gene was highly expressed in adipose tissue (CT27.42). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product are useful in the treatment of obesity and diabetes. 5 Example B5. PathCalling@ PathCalling@ screening showed that Transketolase (TKT) interacts with transcriptional factor (TIFl) and the extracellular domain of semaforin (CG51896-04, See 10 Table EB5). Both interactions have been detected several times in the screening process with different libraries. Protocol for PathCalling@ technoogy is disclosed in Example Q10. Table EB5: CG51896-04-prot 1047 aa (SEQ ID NO:221) MRSEALLLYFTLLHFAGAGFPEDSEPISISHCNYTKQYPVFVGHKPGRNTTQRHRLDIQM IMIMNGTLYIAARDHIYTVDIDTSHTEEIYCSKKLTWKSRQADVDTCRMKGKHKDECHNF IKVLLKKNDDALFVCGTNAFNPSCRNYKMDTLEPFGDEFSGMARCPYDAKHANVALFADG KLYSATVTDFLAIDAVIYRSLGESPTLRTVKHDSKWLKEPYFVQAVDYGDYIYFFFREIA VEYNTMGKVVFPRVAQVCKNDMGGSQRVLEKQWTSFLKARLNCSVPGDSHFYFNILQAVT DVIIUNGRDVVLATFSTPYNSIPGSAVCAYDMLDIASVFTGRFKEQKSPDSTWTPVPDER VPKPRPGCCAGSSSLERYATSNEFPDDTLNFIKTHPLMDEAVPSIFNRPWFLRTMVRYRL TKIAVDTAAGPYQNHTVVFLGSEKGIILKFLARIGNSGFLNDSLFLEEMSVYNSEKCSYD GVEDKRIMGMQLDRASSSLYVAFSTCVIKVPLGRCERHGKCKKTCIASRDPYCGWIKEGG ACSHLSPNSRLTFEQDIERGNTDGLGDCHNSFVALNDISTPLPDNEMSYNTVYGHSSSLL PSTTSDSTAQEGYESRGGMLDWKHLLDSPDSTDPLGAVSSHNHQDKKGVIRESYLKGHD QLVPVTLLAIAVILAFVMGAVFSGITVYCVCDHRRKDVAVVQRKEKELTHSRRGSMSSVT KLSGLFGDTQSKDPKPEAILTPLMHNGKLATPGNTAKMLIKADQHHLDLTALPTPESTPT LQQKRKPSRGSREWERNQNLINACTKDMPPMGSPVIPTDLPLRASPSHIPSVVVLPITQQ GYQHEYVDQPKMSEVAQMALEDQAATLEYKTIKEHLSSKSPNHGVNLVENLDSLPPKVPQ REASLGPPGASLSQTGLSKRLEMHHSSSYGVDYKRSYPTNSLTRSHQATTLKRNNTNSSN SSHLSRNQSFGRGDNPPPAPQRVDSIQVHSSQPSGQAVTVSRQPSLNAYNSLTRSGLKRT PSLKPDVPPKPSFAPLSTSMKPNDACT 15 Example B6. Assays Screening for Modulators of Transketolase A non-exhaustive list of cell lines that express the Transketolase gene can be obtained from the RTQ-PCR results shown herein. These and other Transketolase expressing cell lines could be used for screening purposes. 20 Screening for a modulator of Transketolase may be accomplished by measurement of generated NADPH from the reaction in which Transketolase participates as outlined above. Additionally, Transketolase activity could be measured by a method outlined in Frank et al, High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis 177 WO 2004/013347 PCT/US2003/024504 patients by oral administration of benfontiamine, Eur J Clin Pharmacol. 2000 Jun;56(3):25 1 7). Functional/mechanistic assay for the effectiveness of the modulator of Transketolase can be 5 performed by measurement of effect of transketolase 1 inhibitors on TG synthesis/accumulation in 3T3-L1 mouse adipocytes, human adipocytes or hepatocytes by Oil Red 0 staining. Alternatively measurement could be made of post treatment TG accumulation in cells transfected with Transketolase 1. 10 Our results indicate that a modulator of Transketolase activity, such as an inhibitor, activator, antagonist, or agonist of Transketolase may be useful for treatment of such disorders as obesity, diabetes, and insulin resistance, as well as for enhancement of insulin secretion. 15 C. NOV3 - Long Chain Fatty Acyl Elongase Long chain fatty acyl elongase (LCE) is an enzyme that uses malonyl-CoA as a 2 carbon donor for elongation of the 16-carbon fatty acid palmitic acid to the 1 8-carbon fatty 20 acid stearic acid. The elongation of fatty acids occurs in the endoplasmic reticulum, where each 2-carbon addition requires 4 sequential reactions: (1) condensation between a fatty acyl CoA and malonyl-CoA to form a 3-ketoacyl-CoA, (2) reduction of the 3-ketoacyl-CoA using NADPH to form a 3-hydroxyacyl-CoA, (3) dehydration of the 3-hydroxyacyl-CoA to trans 2-enoyl-CoA, and (4) reduction of the trans-2-enoyl-CoA to the saturated acyl-CoA. It has 25 been shown that LCE is essential for the condensation step of fatty acid elongation, which is the rate-limiting step. LCE is regulated by SREBP, as are many enzymes in fatty acid synthesis and lipogenesis (Moon YA, Shah NA, Mohapatra S, Warrington JA, Horton JD. Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins J Biol Chem 2001 Nov 30;276(48):45358-66. PMID: 11567032). 30 We found LCE to be down-regulated in brown adipose tissue from mice on a high fat diet with various body weights, ranging from obese (sd4 compared to chow-fed mice), heavily obese (sd7 compared to chow-fed mice), and hyperglycemic, heavily obese mice (sd7+ compared to chow-fed mice). However, LCE remained unchanged in white adipose 178 WO 2004/013347 PCT/US2003/024504 from the same groups of mice. This down-regulation of LCE is in conjunction with a down regulation of several enzymes in the fatty acid synthesis pathway and the anaplerotic pathway, including ATP citrate lyase, transketolase, malic enzyme, and SREBP. This suggests that in brown adipose, fatty acid synthesis and lipogenesis are down-regulated in 5 compensation to the high fat diet. Such a compensatory mechanism is not present in white adipose. It has been clearly shown in the literature that long chain fatty acids are oxidized less than short chain fatty acids (DeLany JP, Windhauser MM, Champagne CM, Bray GA. Differential oxidation of individual dietary fatty acids in humans. Am J Clin Nutr. 2000 Oct;72(4):905-1 1. 10. PMID: 11010930) and that they are more prone to be retained in muscle and liver, which may contribute to insulin resistance (Bessesen DH, Vensor SH, Jackman MR. Trafficking of dietary oleic, linolenic, and stearic acids in fasted or fed lean rats.Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E1 124-32. PMID: 10827016). Therefore, mimicking brown adipose in white adipose, by inhibiting LCE, will decrease the amount of long chain fatty acids and 15 therefore, potentially promote more fatty acid oxidation of short chain fatty acids. Thus, a modulator of LCE such as an antagonist or inhibitor for LCE may be beneficial for the treatment of obesity and/or diabetes. Potential assays are used to screen for antibody therapeutics or small molecule drugs associated with the human Long Chain Fatty 20 Acyl Elongase that are useful to treat obesity and/or diabetes. In a screening assay for inhibitors of LCE, radiolabelled malonyl-CoA plus palmitate will yield radiolabelled stearate that can be detected by partition assay. A non-exhaustive list of cell lines that express the long chain fatty acyl elongase can be obtained from the differential gene expression (RTQ PCR) results presented herein. These and other Long Chain Fatty Acyl Elongase expressing 25 cell lines could be used for screening purposes. Furthermore, our results indicate that a modulator of Long Chain Fatty Acyl Elongase activity, such as an inhibitor, activator, antagonist, or agonist of Long Chain Fatty Acyl Elongase may be useful for treatment of such disorders as obesity, diabetes, and insulin 30 resistance, as well as for enhancement of insulin secretion. Discovery Process 179 WO 2004/013347 PCT/US2003/024504 The following sections describe the study designs and the techniques used to identify the Long Chain Fatty Acyl Elongase-encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for Obesity and/or Diabetes. 5 Example C1. Mouse Dietary-Induced Obesity A protocol for Mouse Dietary-Induced Obesity study is disclosed in Example Q1. 10 The predominant cause for obesity in clinical populations is excess caloric intake. This so-called diet-induced obesity (DIO) is mimicked in animal models by feeding high fat 'diets of greater than 40% fat content. The DIO study was established to identify the gene expression changes contributing to the development and progression of diet-induced obesity. In addition, the study design sought to identify the factors that lead to the ability of certain 15 individuals to resist the effects of a high fat diet and thereby prevent obesity. The sample groups for the study had body weights +1 S.D., + 4 S.D. and +7 S.D. of the chow-fed controls. In addition, the biochemical profile of the + 7 S.D. mice revealed a further stratification of these animals into mice that retained a normal glycemic profile in spite of obesity and mice that demonstrated hyperglycemia. Tissues examined included 20, hypothalamus, brainstem, liver, retroperitoneal white adipose tissue (WAT), epididymal WAT, brown adipose tissue (BAT), gastrocnemius muscle (fast twitch skeletal muscle) and soleus muscle (slow twitch skeletal muscle). The differential gene expression profiles for these tissues revealed genes and pathways that can be used as therapeutic targets for obesity. Protocol for differential gene expression analysis, GeneCalling@, is disclosed in Example 25 Q7. Results A fragment of the mouse (mouse strain C57BL/6J) Long Chain Fatty Acyl Elongase 30 (LCE) gene was initially found to be down-regulated by 2-fold in the brown adipose tissue of obese mice on a high fat diet (sd4) relative to normal weight mice (chow-fed) using CuraGen's GeneCalling@ method of differential gene expression. A differentially expressed mouse gene fragment migrating, at approximately 285 nucleotides in length was definitively identified as a component of the mouse Long Chain Fatty Acyl Elongase cDNA. 180 WO 2004/013347 PCT/US2003/024504 The method of competitive PCR was used for confirmation of the gene assessment. The electropherographic peaks corresponding to the gene fragment of the mouse Long Chain Fatty Acyl Elongase were ablated when a gene-specific primer (shown in Table Cl) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 285 5 nt in length were ablated in the sample from both the brown adipose tissue of obese mice on a high fat diet (sd4) and the normal weight mice (chow-fed). In addition, LCE was found to be down-regulated in brown adipose tissue of hyperinsulinemic (ngsd7) and hyperglycemic obese mice on a high fat diet compared to normal weight mice (chow-fed). 10 Table Cl. The direct sequence of the 285 nucleotide-long gene fragment and the gene specific primers used for competitive PCR are indicated on the cDNA sequence of the Long Chain Fatty Acyl Elongase fragment (SEQ ID NO:183) are shown in bold. The gene-specific primers at the 5' and 3' ends of the fragment are underlined. Gene Sequence (fragment from 5292 to 5576 in bold. band size: 285) 4811 CACACAGCTC CCATTTCCTG GTGCCTGAGA TCCCAGCCAT CAGAAAGTGA TTTGGGTGAG 4871 AATTCACAAC ATATATGTCA CCTCTGCATA TTGAAGTGAC ATCTAATAAA ACAAGGACGT 4931 CCTATTrTGT CTGAACCCGC TGAATGAAGC TCTGTTATCC TAGTTAGTCA TTGGGCCGCC 4991 ATCCTCTGTA CCCGATAGTG ACACAAAACA GATGTCGGTG CCTGTACAAG AATTCTCAGT 5051 GCCTGTTGTG ACAGACTGTG CTTAGAAGAA ACATrCGTGA GCCATAAAGC AGGAACCACA 5111 GATGAAAGGG CCAGTTAAAA GTCCACCTGC TCCAAGTATC ATAGAAAACC CAAAAGCCTG 5171 TTGTATAATC TGGTATTGTC CCCATCCCCA GATGCTTTGA AAACTAGGAT TCTCAGAGCA 5231 TGGATACCCA CGCTTCCATC TTCCCACAAA CATTrCCTAG AGTTGTACTG GTGGGTGCAG 5291 CCCTAGGTGG TrIGGTTGGGG GAAGTCTTGG AAGCTGTACT TrGATrGCAG GTCAAGCAAA 5351 GCCAAATCCA GATATrCTG TGTCACTCAC CAGTrGTCCA TGTCCACCCA CAAAACAATT 5411 GTATTATAGT CAAGTTGTCC TAGCTGATTG GTCCTCAAAT AAGGATGCAA CTATGTrTGC 5471 AACCCAGTTA GGACACATTr GAAAGAACCT GACTCACTAG CATCTAAACA ATATCATTTC 5531 CCCAATGCTT GGTGGCACTT CAGACTTTTG TTCTCCTGGT TGATCAAGGT GTTGCCTGGT 5591 GGTGCCGCCT CCTAGTGTGA ATATTTCAGT TAAGTGTGGG TCTGAGCATG ACCGGGCTGG 5651 GCTTAGCTCA CTGCTACTTG GAAAATGACT GGCATTCTGC TTCCTAGGCC CTAAACCCAT 5711 ATTCAGAGGG AAAATTCACT ATCAAGCCTC ACAGCGAAAT CACAGCAGTG TTGGAATTCT 5771 TATTTTCAAG TGCTTATCTC ACAACATTGA AAAATATTrT TGGTGTATTA AGATTTAAAA 5831 TAAAGTCATC ATAAACTTTT GAATTTAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 5891 AA (gene length is 5892, only region from 4811 to 5892 shown) Example C2. Identification of Human Long Chain Fatty Acyl Elongase Sequences 181 WO 2004/013347 PCT/US2003/024504 The sequence of Human Long Chain Fatty Acyl Elongase (Acc. No. CG180320-01) was derived by laboratory cloning of cDNA fragments, by in silico prediction of the sequence. cDNA fragments covering either the full length of the DNA sequence, or part of 5 the sequence, or both, were cloned. In silico prediction was based on sequences available in CuraGen's proprietary sequence databases or in the public human sequence databases, and provided either the full-length DNA sequence, or some portion thereof. The protocol for identification of human sequence(s) is disclosed in Example Q8. 10 Table C2 shows protein alignment (ClustalW) of Human Long Chain Fatty Acyl Elongase Protein Sequence (CG180320-01; SEQ ID NO:18) against Mouse Long Chain Fatty Acyl Elongase (Q920L5; SEQ ID NO: 184) and Rat Long Chain Fatty Acyl Elongase (Q920L6; SEQ ID NO:185). Table C3 shows sequences of Mouse Long Chain Fatty Acyl Elongase (Q920L5; SEQ ID NO:184) and Rat Long Chain Fatty Acyl Elongase (Q920L6; 15 SEQ ID NO:185). Table C2. Protein alignment (ClustalW) of Human Long Chain Fatty Acyl Elongase Protein Sequence (CG180320-01; SEQ ID NO:18) against Mouse Long Chain Fatty Acyl Elongase (Q920L5; SEQ ID NO: 184) and Rat Long Chain Fatty Acyl Elongase (Q920L6; SEQ ID NO:185). FattyacyLelongasemouse I Fattyacid elongas_2_rt I C0180320-01 INMSIA Fatty acyLelongase mouse Fattyacid elongas2_rat C0180320-01 KQ GV FWAL FattyacyLelongasemouse A Fatty_acid-elongase_2_rat A LD I LW CG180320-01 A Fatty_acyelongaseamuse Fattyacid elongasae_2_rat YFTLn CG180320-01 YARAFWRKAFTLQITMMV"YLFNQD 201m HFQIWSL Fatty-acy1_elongase-mouseYLSYL LeFFFEYIGKKKATKAE Fatty acid elongas_2 rat CG180320-01 YLSYVLFCFFF AYG KT KrAE Table C3. Sequences of Mouse Long Chain Fatty Acyl Elongase (Q920L5; SEQ ID NO:184) and Rat Long Chain Fatty Acyl Elongase (Q920L6; SEQ ID NO:185). Mouse Long Chain Fatty Acyl Elongase (Q920L5; SEQ ID NO:184) MNMSVLTLQEYEFEKQFNENEAIQWMQENWKKSFLFSALYAAFIFGGRHLMNKRAKFELRKPLVLWSLTL AVFSIFGALRTGAYMLYILMTKGLKQSVCDQSFYNGPVSKFWAYAFVLSKAPELGDTIFIILRKQKLIFL HWYHHITVLLYSWYSYKDMVAGGGWFMTMNYGVHAVMYSYYALRAAGFRVSRKFAMFITLSQITQMLMGC VINYLVFNWMQHDNDQCYSHFQNIFWSSLMYLSYLVLFCHFFFEAYIGKVKKATKAE Rat Long Chain Fatty Acyl Elongase (Q920L6; SEQ ID NO:185) MNMSVLTLQEYEFEKQFNENEAIQWMQENWKKSFLFSALYAAFIFGGRHLMNKRAKFELRKPLVLWSLTL AVFSIFGALRTGAYMLYILMTKGLKQSVCDQSFYNGPVSKFWAYAFVLSKAPELGDTIFHLRKQKLIFL 182 WO 2004/013347 PCT/US2003/024504 HWYHHITVLLYSWYSYKDMVAGGGWFMTMNYGVAVMYSYYALRAAGFRVSRKFAMFITLSQITQMLMGC VINYLVFNWMQHDNDQCYSHFQNIFWSSLMYLSYLLLFCHFFFEAYIGKVKKATKAE The laboratory cloning was performed using one or more of the methods summarized in Example Q8. The NOV3 clone was analyzed, and the nucleotide and encoded polypeptide 5 sequences are shown in Table C4. Table C4. NOV3 Sequence Analysis NOV3a, CG180320-01 SEQ ID NO: 17 3047 bp DNA Sequence ORF Start: ATG at 281 ORF Stop: TAG at 1076 ACTAAGACCGCAAGGCATTCATTTCCTCCTACGGTGGATGCGGACGCCGGGAGGGAGAGCCCCAG A GAGAGGAGCTGGGAGCGGAGGCGCAGGCAATGCTCAGCCCTGGATGTAGCTGAGAGGCTGGGAGAAG A GACGACCGCTGGAGACCGAGCGGCGTGGGGAAGACCTAGGGGGGTGGGTGGGGGAAGCAGACAGGAG A ACACTCGAAATCAAGCGCTTTACAGATTATTTTATTTTGTATAGAGAACACGTAGCGACTCCGAAGA T, CAGCCCCAATGAACATGTCAGTGTTGACTTTACAAGAATATGAATTCGAAAAGCAGTTCAACGAGAA T GAAGCCATCCAATGGATGCAGGAAAACTGGAAGAAATCTTTCCTGTTTTCTGCTCTGTATGCTGCCT T TATATTCGGTGGTCGGCACCTAATGAATAAACGAGCAAAGTTTGAACTGAGGAAGCCATTAGTGCTC T GGTCTCTGACCCTTGCAGTCTTCAGTATATTCGGTGCTCTTCGAACTGGTGCTTATATGGTGTACAT T TTGATGACCAAAGGCCTGAAGCAGTCAGTTTGTGACCAGGGTTTTTACAATGGACCTGTCAGCAAAT T CTGGGCTTATGCATTTGTGCTAAGCAAAGCACCCGAACTAGGAGATACAATATTCATTATTCTGAGG A AGCAGAAGCTGATCTTCCTGCACTGGTATCACCACATCACTGTGCTCCTGTACTCTTGGTACTCCTA C AAAGACATGGTTGCCGGGGGAGGTTGGTTCATGACTATGAACTATGGCGTGCACGCCGTGATGTACT C TTACTATGCCTTGCGGGCGGCAGGTTTCCGAGTCTCCCGGAAGTTTGCCATGTTCATCACCTTGTCC C AGATCACTCAGATGCTGATGGGCTGTGTGGTTAACTACCTGGTCTTCTGCTGGATGCAGCATGACCA G TGTCACTCTCACTTTCAGAACATCTTCTGGTCCTCACTCATGTACCTCAGCTACCTTGTGCTCTTCT G CCATTTCTTCTTTGAGGCCTACATCGGCAAAATGAGGAAAACAACGAAAGCTGAATAGTGTTGGAAC T GAGGAGGAAGCCATAGCTCAGGGTCATCAGGCACAAGGAATC A CACGTGGTGCAGCTAAAACAAAACAAAACATGAGCAAACACAAAACCCAAGGCAGCTTAGGGATAAT T AGGTTGATTTAACCCAGTAAGTTTATGATCCTTTTAGGGTGAGGACTCACTGAGTGCACCTCCATCT C CAAGCACTGCTGCTGGAAGACCCCATTCCCTCTTTATCTATCAACTCTAGGACAAGGGAGAACAAAA G CAAGCCAGAAGCAGAGGAGACTAATCAAAGGCAAACAAAGGCTATTAACACATAGGAAAATATGTAT T TACTAAGTGTCACATTTCTCTAAGATGAAAGATTTTTACTCTAGAAACTGTGCGAGCACAACACACA C AATCCTTTCTAACTTTATGGACACTAAACTGGAGCCAATAGAAAAGACAAAAATGAAAGAGACACAG G GTGTATATCTAGAACGATAATGCTTTTGCAGAAACTAAAGCCTTTTTAAGAAATGCCAGCTGCTGTA 183 WO 2004/013347 PCT/US2003/024504 G ACCCCATGAGAAAAGATGTCTTAATCATCCTTATGAAAACAGATGTAAACAACTATATTTCAACTAA C TTCATCTTCACTGCATAGCCTCAGGCTAGTGAGTTTGCCAAAACCAAAGGGGGTGAATACTTCCCCA A GATTCTTCCTGGGAGGATGGAAACAGTGCAGCCCAGGTCCCATGGGGGCAGCTCCATCCCAGAGCAT T TCTGATAGTTGAACTGTAATTTCTACTCTTAAGTGAGATATGAAGTATTATCCTTTTGTTCAGTTGC C CCGGGCTTTTGAACAGAAGAGTAAATACAGAATTGAAAAAGATAAACACTCAACCAAACAATGTGAA A ACGGGTTCTGTAGTATTTGTAAAAAGGCCCGGCCCAGGACCACTGTGAGCTGGAAAAGGGAGAAAGG C AGTGGGAAAAGAGGTGAGCCGAAGATCAATTCGACAGACAGACGGTGTGTATGCCCCTCCCTGTTTG A CTTCACACACACTCATAACTTTCCAAATGAAACCCCACAGTATAGCGCATATTTTCGATATTTTTGT G AATTCCAAAAGGAAATCACAGGGCTGTTCGAAATATTGGGGGAACACTGTGTTTCTGCATCATCTGC A TTTGCTCCCCAAGCAATGTAGAGGTGTTTAAAGGGCCCTCTGCTGGCTGAGTGGCAATACTACAACA A ACTTCAAGGCAAGTTTGGCTGAAAACAGTTGACAACAAAGGGCCCCCATACACTTATCCCTCAAATT T TAAGTGATATGAAATACTTGTCATGTCTTTGGCCAAATCAGAAGATATTCATCCTGCTTCAAGTCAG C TTCAGAAATGTTTTAAAAGCGACTTTAGCTCTGGAACTCAAAATCAATTTATTAAGAGCCATATTCT T TAAAAAAAAAAGCTGGATAATATTATCTGTAATATTTCAGTCCTTTACAAGCCAAATACATGTGTCA A TGTTTCTAGTATTTCAAAGAAGCAATTATGTAAAGTTGTTCAATGTGACATAATAGTATTATAATTG G TTAAGTAGCT TAATGATTAGGCAAACTAGATGAAAAGATTAGGGGCTTCCACACTGCATAGATCACA C GCACATAGCCACGCATACACACACAGACACACAGATGTGGGGTACACTGAATTTCAAAGCCCAAATG A ATAGAAACACATTTTCTGGCTAGCAGAAAAAAACAAAACAAAACTGTTGTTTCTCTTTCTTGCTTTG A GAGTGTACAGTAAAAGGGATTTTTTCGAATTATTTTTATATTATTTTAGCTTTAATTGTGCTGTCGT T CATGAAACAGAGCTGCTCTGCTTTTCTGTCAGAGATGGCAAGGGCTTTTTCAGCATCTCGTTTATGT G TGGAATTTAAAAAGAATAAAGTTTTATTCCATTCTGAAAAAAAAAAAAAAAAAGC NOV3a, CG180320-01 ',SEQDNO: 18 1265 aa MWat 31375.7kD Protein Sequence MNMSVLTLQEYEFEKQFNENEAIQWMQENWKKSFLFSALYAAFIFGGPHLMNKRAKFELRKPLVLWS L TLAVFSIFGALRTGAYMVYILMTKGLKQSVCDQGFYNGPVSKFWAYAFVLSKAPELGDTIFI ILRKQ K LIFLHWYHHITVLLYSWYSYKDMVAGGGWFMTMNYGVHAVMYSYYALRAAGFRVSRKFAMFITLSQI T QMLMGCVVNYLVFCWMQHDQCHSHFQNIFWSSLMYLSYLVLFCHFFFEAYIGKMRKTTKAE NOV3b, CG180320-02 ISEQ ID NO: 19 822 bp DNA Sequence OORF Start: at2 . ORF Stop: TAG at 809 CACCGGATCCACCATGAACATGTCAGTGTTGACTTTACAAGAATATGAATTCGAAAAGCAGTTCAAC G AGAATGAACCCATCCAATGGATGCAGGAAAACTGGAAGAAATCTTTCCTGTTTTCTGCTCTGTATGC T GCCTTTATATTCGGTGGTCGGCACCTAATGAATAAACGAGCAAAGTTTGAACTGAGGAAGCCATTAG T GCTCTOTCTCTGACCCTTGCAGTCTTCAGTATATTCGGTGCTCTTCGAACTGGTGCTTATATGGTG 184 WO 2004/013347 PCT/US2003/024504 T ACATTTTGATGACCAAAGGCCTGAAGCAGTCAGTTTGTGACCAGGGTTTTTACAATGGACCTGTCAG C AAATTCTGGGCTTATGCATTTGTGCTAAGCAAAGCACCCGAACTAGGAGATACAATATTCATTATTC T GAGGAAGCAGAAGCTGATCTTCCTGCACTGGTATCACCACATCACTGTGCTCCTGTACTCTTGGTAC T CCTACAAAGACATGGTTGCCGGGGGAGGTTGGTTCATGACTATGAACTATGGCGTGCACGCCGTGAT G TACTCTTACTATGCCTTGCGGGCGGCAGGTTTCCGAGTCTCCCGGAAGTTTGCCATGTTCATCACCT T GTCCCAGATCACTCAGATGCTGATGGGCTGTGTGGTTAACTACCTGGTCTTCTGCTGGATGCAGCAT G ACCAGTGTCACTCTCACTTTCAGAACATCTTCTGGTCCTCACTCATGTACCTCAGCTACCTTGTGCT C TTCTGCCATTTCTTCTTTGAGGCCTACATCGGCAAAATGAGGAAAACAACGAAAGCTGAATAGGCGG C CGCTAT NOV3b, CG180320-02 SEQ ID NO: 20 269 aa MW at 31722.lkD Protein Sequence TGSTMNMSVLTLQEYEFEKQFNENEAIQWMQENWKKSFLFSALYAAFIFGGRHLMNKRAKFELRKPL V LWSLTLAVFS IFGALRTGAYMVYILMTKGLKQSVCDQGFYNGPVSKFWAYAFVLSKAPELGDTIFII L RKQKLIFLHWYHHITVLLYSWYSYKDMVAGGGWFMTMNYGVHAVMYSYYALRAAGFRVSRKFAMFIT L SQITQMLMGCVVNYLVFCWMQHDQCHSHFQNIFWSSLMYLSYLVLFCHFFFEAYIGKMRKTTKAE NOV3c, CG180320-03 SEQ ID NO: 21 1834 bp DNA Sequence ORF Start: at 1 ORF Stop: TAG at 793 AACATGTCAGTGTTGACTTTACAAGAATATGAATTCGAAAAGCAGTTCAACGAGAATGAAGCCATCC A ATGGATGCAGGAAAACTGGAAGAAATCTTTCCTGTTTTCTGCTCTGTATGCTGCCTTTATATTCGGT G GTCGGCACCTAATGAATAAACGAGCAAAGTTTGAACTGAGGAAGCCATTAGTGCTCTGGTCTCTGAC C CTTGCAGTCTTCAGTATATTCGGTGCTCTTCGAACTGGTGCTTATATGGTGTACATTTTGATGACCA A AGGCCTGAAGCAGTCAGTTTGTGACCAGGGTTTTTACAATGGACCTGTCAGCAAATTCTGGGCTTAT G CATTTGTGCTAAGCAAAGCACCCGAACTAGGAGATACAATATTCATTATTCTGAGGAAGCAGAAGCT G ATCTTCCTGCACTGGTATCACCACATCACTGTGCTCCTGTACTCTTGGTACTCCTACAAAGACATGG T TGCCGGGGGAGGTTGGTTCATGACTATGAACTATGGCGTGCACGCCGTGATGTACTCTTACTATGCC T TGCGGGCGGCAGGTTTCCGAGTCTCCCGGAAGTTTGCCATGTTCATCACCTTGTCCCAGATCACTCA G ATGCTGATGGGCTGTGTGGTTAACTACCTGGTCTTCTGCTGGATGCAGCATGACCAGTGTCACTCTC A CTTTCAGAACATCTTCTGGTCCTCACTCATGTACCTCAGCTACCTTGTGCTCTTCTGCCATTTCTTC T TTGAGGCCTACATCGCCAAAATGAGGAAAACAACGAAAGCTGAATAGGCAGGTGCGGCCGCACTCGA G CACCACCACCACCACCAC NOV3c, CG180320-03 |SEQ ID NO: 22 264 aa MW at 31244.5kD Protein Sequence NMSVLTLQEYEFEKQFNENEAIQWMQENWKKSFLFSALYAAFIFGGRHLMNKRAKFELRKPLVLWSL T 185 WO 2004/013347 PCT/US2003/024504 LAVFSIFGALRTGAYMVYILMTKGLKQSVCDQGFYNGPVSKFWAYAFVLSKAPELGDTIFIILRKQK L IFLHWYHHITVLLYSWYSYKDMVAGGGWFMTMNYGVHAVMYSYYALRAAGFRVSRKFAMFITLSQIT Q MLMGCVVNYLVFCWMQHDQCHSHFQNIFWSSLMYLSYLVLFCHFFFEAYIGKMRKTTKAE NOV3d, CG180320-04 ISEQ ID NO: 23 801 bp DNA Sequence IORF Start: at 1 IORF Stop: TAG at 799 ACCATGAACATGTCAGTGTTGACTTTACAAGAATATGAATTCGAAAAGCAGTTCAACGAGAATGAAG C CATCCAATGGATGCAGGAAAACTGGAAGAAATCTTTCCTGTTTTCTGCTCTGTATGCTGCCTTTATA T TCGGTGGTCGGCACCTAATGAATAAACGAGCAAAGTTTGAACTGAGGAAGCCATTAGTGCTCTGGTC T CTGACCCTTGCAGTCTTCAGTATATTCGGTGCTCTTCGAACTGGTGCTTATATGGTGTACATTTTGA T GACCAAAGGCCTGAAGCAGTCAGTTTGTGACCAGGGTTTTTACAATGGACCTGTCAGCAAATTCTGG G CTTATGCATTTGTGCTAAGCAAAGCACCCGAACTAGGAGATACAATATTCATTATTCTGAGGAAGCA G AAGCTGATCTTCCTGCACTGGTATCACCACATCACTGTGCTCCTGTACTCTTGGTACTCCTACAAAG A CATGGTTGCCGGGGGAGGTTGGTTCATGACTATGAACTATGGCGTGCACGCCGTGATGTACTCTTAC T ATGCCTTGCGGGCGGCAGGTTTCCGAGTCTCCCGGAAGTTTGCCATGTTCATCACCTTGTCCCAGAT C ACTCAGATGCTGATGGGCTGTGTGGTTAACTACCTGGTCTTCTGCTGGATGCAGCATGACCAGTGTC A CTCTCACTTTCAGAACATCTTCTGGTCCTCACTCATGTACCTCAGCTACCTTGTGCTCTTCTGCCAT T TCTTCTTTGAGGCCTACATCGGCAAAATGAGGAAAACAACGAAAGCTGAATAG NOV3d, CG180320-04 SEQ ID NO: 24 266 aa IMW at 31476.8kD Protein Sequence TMNMSVLTLQEYEFEKQFNENEAIQWMQENWKKSFLFSALYAAFIFGGRHLMNKRAKFELRKPLVLW S LTLAVFSIFGALRTGAYMVYILMTKGLKQSVCDQGFYNGPVSKFWAYAFVLSKAPELGDTIFIILRK Q KLIFLHWYHHITVLLYSWYSYKDMVAGGGWFMTMNYGVHAVMYSYYALRAAGFRVSRKFAMFITLSQ I TQMLMGCVVNYLVFCWMQHDQCHSHFQNIFWSSLMYLSYLVLFCHFFFEAYIGKMRKTTKAE NOV3e, 305263028 SEQ ID NO: 25 834 bp DNA Sequence IORF Start: at 1 lORF Stop: TAG at 793 AACATGTCAGTGTTGACTTTACAAGAATATGAATTCGAAAAGCAGTTCAACGAGAATGAAGCCATCC A ATGGATGCAGGAAAACTGGAAGAAATCTTTCCTGTTTTCTGCTCTGTATGCTGCCTTTATATTCGGT G GTCGGCACCTAATGAATAAACGAGCAAAGTTTGAACTGAGGAAGCCATTAGTGCTCTGGTCTCTGAC C CTTGCAGTCTTCAGTATATTCGGTGCTCTTCGAACTGGTGCTTATATGGTGTACATTTTGATGACCA A AGGCCTGAAGCAGTCAGTTTGTGACCAGGGTTTTTACAATGGACCTGTCAGCAAATTCTGGGCTTAT G CATTTGTGCTAAGCAAAGCACCCGAACTAGGAGATACAATATTCATTATTCTGAGGAAGCAGAAGCT G ATCTTCCTGCACTGGTATCACCACATCACTGTGCTCCTGTACTCTTGGTACTCCTACAAAGACATGG T TGCCGGGGGAGGTTGGTTCATGACTATGAACTATGGCGTGCACGCCGTGATGTACTCTTACTATGCC T TGCGGGCGGCAGGTTTCCGAGTCTCCCGGAAGTTTGCCATGTTCATCACCTTGTCCCAGATCACTCA 186 WO 2004/013347 PCT/US2003/024504 G ATGCTGATGGGCTGTGTGGTTAACTACCTGGTCTTCTGCTGGATGCAGCATGACCAGTGTCACTCTC A CTTTCAGAACATCTTCTGGTCCTCACTCATGTACCTCAGCTACCTTGTGCTCTTCTGCCATTTCTTC T TTGAGGCCTACATCGGCAAAATGAGGAAAACAACGAAAGCTGAATAGGCAGGTGCGGCCGCACTCGA G CACCACCACCACCACCAC NOV3e, 305263028 SEQ ID NO: 26 264 aa MW at 31244.5kD Protein Sequence NMSVLTLQEYEFEKQFNENEAIQWMQENWKKSFLFSALYAAFIFGGRHLMNKRAKFELRKPLVLWSL T LAVFSIFGALRTGAYMVYILMTKGLKQSVCDQGFYNGPVSKFWAYAFVLSKAPELGDTIFIILRKQK L IFLHWYHHITVLLYSWYSYKDMVAGGGWFMTMNYGVHAVMYSYYALRAAGFRVSRKFAMFITLSQIT Q MLMGCVVNYLVFCWMQHDQCHSHFQNIFWSSLMYLSYLVLFCHFFFEAYIGKMRKTTKAE NOV3f, CG180320-05 SEQ ID NO: 27 834 bp DNA Sequence IORF Start: at 1 IORF Stop: TAG at 832 TCCACCATGGGTTACCCATATGACGTTCCAGACTACGCAAACATGTCAGTGTTGACTTTA GAAT A TGAATTCGAAAAGCAGTTCAACGAGAATGAAGCCATCCAATGGATGCAGGAAAACTGGAAGAAATCT T TCCTGTTTTCTGCTCTGTATGCTGCCTTTATATTCGGTGGTCGGCACCTAATGAATAAACGAGCAAA G TTTGAACTGAGGAAGCCATTAGTGCTCTGGTCTCTGACCCTTGCAGTCTTCAGTATATTCGGTGCTC T TCGAACTGGTGCTTATATGGTGTACATTTTGATGACCAAAGGCCTGAAGCAGTCAGTTTGTGACCAG G GTTTTTACAATGGACCTGTCAGCAAATTCTGGGCTTATGCATTTGTGCTAAGCAAAGCACCCGAACT A GGAGATACAATATTCATTATTCTGAGGAAGCAGAAGCTGATCTTCCTGCACTGGTATCACCACATCA C TGTGCTCCTGTACTCTTGGTACTCCTACAAAGACATGGTTGCCGGGGGAGGTTGGTTCATGACTATG A ACTATGGCGTGCACGCCGTGATGTACTCTTACTATGCCTTGCGGGCGGCAGGTTTCCGAGTCTCCCG G AAGTTTGCCATGTTCATCACCTTGTCCCAGATCACTCAGATGCTGATGGGCTGTGTGGTTAACTACC T GGTCTTCTGCTGGATGCAGCATGACCAGTGTCACTCTCACTTTCAGAACATCTTCTGGTCCTCACTC A TGTACCTCAGCTACCTTGTGCTCTTCTGCCATTTCTTCTTTGAGGCCTACATCGGCAAAATGAGGAA A ACAACGAAAGCTGAATAG NOV3f, CG180320-05 SEQID NO: 28 277 aa MW at 32705.1kD Protein Sequence I STMGYPYDVPDYANMSVLTLQE YEFEKQFNENEAIQWMQENTWKKSFLFSALYAAFIFGGRHLMNKRA K FELRKPLVLWSLTLAVFSIFGALRTGAYMVYILMTKGLKQSVCDQGFYNGPVSKFWAYAFVLSKAPE L GDTIFIILRKQKLIFLHWYHHITVLLYSWYSYKDMVAGGGWFMTMNYGVHAVMYSYYALRAAGFRVS R KFAMFITLSQITQMLMGCVVNYLVFCWMQHDQCHSHFQNIFWSSLMYLSYLVLFCHFFFEAYIGKMR K :TKAE A ClustalW comparison of the above protein sequences yields the following sequence 5 alignment shown in Table C5. 187 WO 2004/013347 PCT/US2003/024504 Table C5. Comparison of the NOV3 protein sequences. NOV3a ------------ MNMSVLTLQEYEFEKQFNENEAIQWMQENWKKSFLFSALYAAFIFGGR NOV3b ------- -TGSTMNMSVL TLQEYEFEKOFNENEAIQWMQENWKKSFLFSALYAAFIFGGR NOV3c ------------- NMSVLTLQEYEFEKQFNENEAIQWMQENWKKSFLFSALYAAFIFGGR NOV3d ----------- TMNMSVLTLQEYEFEKQFNENEAIQWMQENWKKSFLFSALYAAFIFGGR NOV3e ------------- NMSVLTLQEYEFEKQFNENEAIQWMQENWKKSFLFSALYAAFIFGGR NOV3f STMGYPYDVPDYANMSVLTLQEYEFEKQFNENEAIQWMQENMKKSFLFSALYAAFIFGGR NOV3a HLMNKRAKFELRKPLVLWSLTLAVFSIFGALRTGAYMVYILMTKGLKQSVCDQGFYNGPV NOV3b HLMNKRAKFELRKPLVLWSLTLAVFSIFGALRTGAYMVYILMTKGLKQSVCDQGFYNGPV NOV3c HLMNKRAKFELRKPLVLWSLTLAVFSIFGALRTGAYMVYILMTKGLKQSVCDQGFYNGPV NOV3d HLMNKRAKFELRKPLVLWSLTLAVFSIFGALRTGAYMVYILMTKGLKQSVCDQGFYNGPV NOV3e HLMNKRAKFELRKPLVLWSLTLAVFSIFGALRTGAYMVYILMTKGLKQSVCDQGFYNGPV NOV3f HLMNKRAKFELRKPLVLWSLTLAVFSIFGALRTGAYMVYILMTKGLKQSVCDQGFYNGPV NOV3a SKFWAYAFVLSKAPELGDTIFIILRKQKLIFLHWYHHITVLLYSWYSYKDMVAGGGWFMT NOV3b SKFWAYAFVLSKAPELGDTIFIILRKQKLIFLHWYHHITVLLYSWYSYKDMVAGGGWFMT NOV3c SKFWAYAFVLSKAPELGDTIFILRKQKLIFLHWYHHITVLLYSWYSYKDMVAGGGWFMT NOV3d SKFWAYAFVLSKAPELGDTIFIILRKQKLIFLHWYHHITVLLYSWYSYKDMVAGGGWFMT -NOV3e SKFWAYAFVLSKAPELGDTIFITLRKQKLIFLHWYHHITVLLYSWYSYKDMVAGGGWFMT NOV3f SKFWAYAFVLSKAPELGDTIFIILRKQKLIFLHWYHHITVLLYSWYSYKDMVAGGGWFMT NOV3a MNYGVHAVMYSYYALRAAGFRVSRKFAMFITLSQITQMLMGCVVNYLVFCWMQHDQCHSH NOV3b MNYGVHAVMYSYYALRAAGFRVSRKFAMFITLSQITQMLMGCVVNYLVFCWMQHDQCHSH NOV3c MNYGVHAVMYSYYALRAAGFRVSRKFAMFITLSQITQMLMGCVVNYLVFCWMQHDQCHSH NOV3d MNYGVHAVMYSYYALRAAGFRVSRKFAMFITLSQITQMLMGCVVNYLVFCWMQHDQCHSH NOV3e MNYGVHAVMYSYYALRAAGFRVSRKFAMFITLSQITQMLMGCVVNYLVFCWMQHDQCHSH NOV3 f MNYGVHAVMYSYYALRAAGFRVSRKFAMFITLSQITQMLMGCVVNYLVFCWMQHDQCHSH NOV3a FQNIFWSSLMYLSYLVLFCHFFFEAYIGKMRKTTKAE NOV3b FQNIFWSSLMYLSYLVLFCHFFFEAYIGKMRKTTKAE NOV3c FQNIFWSSLMYLSYLVLFCHFFFEAYIGKMRKTTKAE NOV3d FQNIFWSSLMYLSYLVLFCHFFFEAYIGKMRKTTKAE NOV3e FQNIFWSSLMYLSYLVLFCHFFFEAYIGKMRKTTKAE NOV3f FQNIFWSSLMYLSYLVLFCHFFFEAYIGKMRKTTKAE NOV3a (SEQ ID NO: 18) NOV3b (SEQ ID NO: 20) NOV3c (SEQ ID NO: 22) NOV3d (SEQ ID NO: 24) NOV3e (SEQ ID NO: 26) NOV3f (SEQ ID NO: 28) Further analysis of the NOV3a protein yielded the following properties shown in Table C6. Table C6. Protein Sequence Properties NOV3a SignalP analysis: Cleavage site between residues 47 and 48 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 10; pos.chg 0; neg.chg 1 H-region: length 1; peak value 0.00 PSG score: -4.40 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -1.00 possible cleavage site: between 46 and 47 188 WO 2004/013347 PCT/US2003/024504 >>> Seems to have no N-terminal signal peptide ALOM: Klein et all's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 3 Number of TMS(s) for threshold 0.5: 1 INTEGRAL Likelihood= -5.63 Transmembrane 63 - 79 PERIPHERAL Likelihood= 2.54 (at 116) ALOM score: -5.63 (number of TMSs: 1) MTOP: Prediction of membrane topology (Hartmann et al.) Center position for calculation: 70 Charge difference: -3.5 C( 2.0) -N( 5.5) N >= C: N-terminal side will be inside >>> membrane topology: type 2 (cytoplasmic tail I to 63) MITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment(75): 1.56 Hyd Moment(95): 3.11 G content: 0 D/E content: 2 S/T content: 2 Score: -7.42 Gavel: prediction of cleavage sites for mitochondrial preseq cleavage site motif not found NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 9.8% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: KKXX-like motif in the C-terminus: TTKA SKL: peroxisonal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern: none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: too long tail Dileucine motif in the tail: none 189 WO 2004/013347 PCT/US2003/024504 checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 94.1 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues Final Results (k = 9/23): 30.4 %: cytoplasmic 30.4 %: mitochondrial 13.0 %: Golgi 8.7 %: endoplasmic reticulum 4.3 %: extracellular, including cell wall 4.3 %: vacuolar 4.3 %: nuclear 4.3 %: vesicles of secretory system >> prediction for CG180320-01 is cyt (k=23) A search of the NOV3a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table C7. Table C7. Geneseq Results for NOV3a NOV3a Identities/ Geneseq Protein/Organism/Length [Patent #, Residues/ Similarities for Expect Identifier Date] Match the Matched Value Residues Region ABB82962 Human LCE related protein L..265 265/265 (100%) e-159 (GenBanK Identifier No. 1..265 265/265 (100%) GI#1 0440045) - Homo sapiens, 265 aa. [W0200299068-A2, 12-DEC 2002] ABB82961 Human LCE related protein 1..265 265/265 (100%) e-159 (GenBanK Identifier No. L..265 265/265 (100%) GI#13129088) - Homo sapiens, 265 aa. [W0200299068-A2, 12-DEC 2002] AAG79838 ADSL related polypeptide #2 - L..265 265/265 (100%) e-159 Homo sapiens, 265 aa. L..265 265/265 (100%)1 [W0200299038-A2, 12-DEC-2002] 190 WO 2004/013347 PCT/US2003/024504 AAU87832 Human elongase HS3 - Homo 1.265 265/265 (100%) e-159 sapiens, 265 aa. [W0200208401-A2, L..265 265/265 (100%) 31-JAN-2002] AAU00476 Human INTERCEPT 400 protein - 1..265 265/265 (100%) e-159 Homo sapiens, 265 aa. 1..265 265/265 (100%) [W0200118016-Al, 15-MAR-2001] _ .. _........._ In a BLAST search of public sequence databases, the NOV3a protein was found to have homology to the proteins shown in the BLASTP data in Table C8. Table C8. Public BLASTP Results for NOV3a Protein ProteinNOV3a Identities/ Residues/ Similarities for Expect Ac eo rMatch the Matched Value Residues Portion Q9H5J4 Hypothetical protein FLJ23378 - 1.265 265/265 (100%) e-158 Homo sapiens (Human), 265 aa. 1..265 265/265 (100%) Q920L5 Fatty acyl elongase (Long-chain 1..265 257/267 (96%) e-152 fatty-acyl elongase) (Myelination 1..267 262/267 (97%) associated SUR4-like protein) -Mus musculus (Mouse), 267 aa. Q920L6 Fatty acid elongase 2 - Rattus 1..265 256/267 (95%) e-152 norvegicus (Rat), 267 aa. 1..267 262/267 (97%) Q8CE45 Long chain fatty acyl elongase -Mus 1..265 256/267 (95%) e-151 musculus (Mouse), 267 aa. 1..267 261/267 (96%) Q8NCD1 Hypothetical protein FLJ90332 - 26..265 240/240 (100%) e-143 Homo sapiens (Human), 240 aa. 1..240 240/240 (100%) PFam analysis predicts that the NOV3a protein contains the domains shown in the Table C9. Table C9. Domain Analysis of NOV3a Identities/ Pfam Domain NOV3a Match Region Similarities Expect Value for the Matched Region ELO 10..265 85/327 (26%) 5.2e-46 168/327 (51%) 5 Example C3. Expression Profile of the Human Long Chain Fatty Acyl Elongase Gene The protocol for quantitative expression analysis is disclosed in Example Q9. 191 WO 2004/013347 PCT/US2003/024504 Expression of genes CG180320-01, CG180320-02, CG180320-03, and CG180320 04 was assessed using the primer-probe set Ag6596, described in Table C10. Results of the RTQ-PCR runs are shown in Tables Cl1 and C12. Table C10. Probe Name Ag6596 Primers Sequences Length Position No Forward 5'-caatggatgcaggaaaactg-3' 20 350 186 Probe TET-5 -tttcctgttttctgctctgtatgctg-3 - 26 379 187 5-ccgaccaccgaatataaagg-3I 20 405 188 5 Table C11. General screening panel vl.6 Rel. Exp.(%) Rel. Exp.(%) Tissue Name Ag6596, Run Tissue Name Ag6596, Run 277256790 277256790 Adipose 2.2 Renal ca. TK-10 14.4 Melanoma* Hs688(A).T 6.0 Bladder 5.1 IMelanoma* Hs688(B).T 11.9 JGastric ca. (liver met.) NCI- 28.1 Melanoma*____Hs688(B).T___11.9 _ N87 Melanoma* M14 11.0 Gastric ca. KATO II 55.5 Melanoma* LOXIMVI _ 26.1 Colon ca. SW-948 14.2 Melanoma* SK-MEL-5 29.1 Colon ca. SW480 10.4 Squamous cell carcinoma SCC- 24.1 Colon ca.* (SW480 met) 8.6 4 - SW620 Testis Pool 0.9 Colon ca. HT29 15.3 Prostate ca.* (bone met) PC-3 2.0 Colon ca. HCT-l 16 45.4 Prostate Pool 1.9 Colon ca. CaCo-2 22.2 Placenta 0.5 Colon cancer tissue 6.9 Uterus Pool j 0.7 Colon ca. SW1116 5.9 Ovarian ca. OVCAR-3 25.0 Colon ca. Colo-205 15.0 Ovarian ca. SK-OV-3 4.5 Colon ca. SW-48 10.4 Ovarian ca. OVCAR-4 3.6 Colon Pool 3.5 i ca. OVCAR-5 50.0 Small Intestine Pool 1.9 an ca. IGROV-1 12.0 Stomach Pool 2.1 Ovarian ca. OVCAR-8 14.4 Bone Marrow Pool 1.5 Ovary 2.4 Fetal Heart 2.9 Breast ca. MCF-7 20.7 Heart Pool Breast ca. MDA-MB-231 100.0 Lymph Node Pool 4.1 Breast ca. BT 549 47.3 Fetal Skeletal Muscle 4.1 Breast ca. T47D 4.8 Skeletal Muscle Pool 0.2 Breast ca. MDA-N 10.1 leen Pool 1.4 Breast Pool 1.7 Thymus Pool 3.5 Trachea 1. CNS cancer (glio/astro) U87- 31.2 192 WO 2004/013347 PCT/US2003/024504 MG Lung 0.4 CNS cancer (glio/astro) U- 45.1 118-MG Fetal Lung 5.6 CNS cancer (neuro;met) SK- 47.3 N-AS Lung ca. NCI-N417 8.2 CNS cancer (astro) SF-539 8.3 Lung ca. LX-1 15.7 CNS cancer (astro) SNB-75 10.3 Lung ca. NCI-H146 4.0 CNS cancer (glio) SNB-19 20.9 Lung ca. SHP-77 18.8 CNS cancer (glio) SF-295 28.7 Lung ca. A549 20.3 Brain (Amygdala) Pool 7.8 Lung ca. NCI-H526 6.4 Brain (cerebellum) 13.6 Lung ca. NCI-H23 8.6 Brain (fetal) 16.0 Lung ca. NCI-H460 12.1 Brain (Hippocampus) Pool 5.6 Lung ca. HOP-62 13.7 Cerebral Cortex Pool 9.8 Lung ca. NCI-H522 2.8 Brain (Substantia nigra) Pool 6.4 Liver 3.1 Brain (Thalamus) Pool 12.5 Fetal Liver 38.2 Brain (whole) 6.1 Liver ca. HepG2 10.9 Spinal Cord Pool 12.3 Kidney Pool 2.7 Adrenal Gland 9.7 Fetal Kidney 17.9 Pituitary gland Pool 1.9 Renal ca. 786-0 21.5 Salivary Gland 0.3 Renal ca. A498 17.1 Thyroid (female) 0.4 Renal ca. ACHN 7.7 Pancreatic ca. CAPAN2 32.5 Renal ca. UO-31 11.3 Pancreas Pool 1.5 Table C12. Panel 5 Islet Rel. Exp.(%) Rel. Exp.(%) Tissue Name Ag6596, Run Tissue Name Ag6596, Run 279518227 279518227 97457 Patient-02go adipose 1.5 94709_Donor 2 AM - 9.6 A-adipose 97476Patient-07skskeletal 0.0 94710_Donor 2 AM muscle B adipose 6.5 97477_Patient-07ututerus 1.6 94714-Donor 2 AM _ _ _ _ _ _ _C adipose 4.9 97478_Patient-07pl_placenta 0.5 94712_Donor 2 AD - 24.7 Akadipose 99167_Bayer Patient 1 13 94713Donor 2 AD - 29.3 B__adipose 97482Patient-08ut uterus 2.0 94714-Donor 2 AD - 22.2 Cadipose 97483_Patient-08p1_placenta 0.9 94742 -Donor 3 U - 4.8 AMesenchymal Stem Cells 9748 6_Patient-09sk-skeletal 06 94743 Donor 3 U -5. muscle 0. BMe-senchymal Stem Cells5. 97487_Patient-09ut-uterus L.4 94730 Donor 3 AM - 17.2 193 WO 2004/013347 PCT/US2003/024504 97488_Patient-09plplacenta 0.5 9473 1Donor 3 AM - 27.5 ____________B adipose 97492_Patient-10ut uterus 2.1 94732_Donor 3 AM - 17.2 C__adipose 97493_Patient-10plplacenta 1.4 94733_Donor 3 AD - 80.1 A adipose 97495 Patient-11go adipose 1.1 94734_Donor 3 AD- 74.2 _iBadipose 74.2 97496_Patient-ilsk skeletal 0.1 94735_Donor 3 AD - 24.8 muscle 0.1 C adipose 24.8 97497 Patient-ilut uterus 3.9 77138_Liver._HepG2untreated 100.0 97498 Patient-11p1 placenta 0.3 73556_Heart Cardiac stromal 1.5 cells (primary) 97500 Patient-12go adipose 1.2 81735_Small Intestine 4.0 97501_Patient-12sk skeletal 1.4 72409_KidneyProximal 33.2 muscle Convoluted Tubule 97502_Patient-12ut uterus 1.5 testne Duodenum 6.0 97503_Patient-l2plplacenta 0.8 90650 AdrenalAdrenocortica 2.2 1 adenoma 94721_Donor 2 U A.Mesenchymal Stem Cells 8.8 72410_KidneyHRCE1 947B senchyallU s 8.5 72411 _Kidney HRE 20.0 94723_Donor 2 U - 73139 Uterus Uterine smooth CMesenchymal Stem Cells 8.9 _ muscle cells -_16.6 General screening panel vl.6 Summary: (Ag6596) Moderate expression of this gene was detected ubiquitously in all tissues (CT=28-32). This ubiquitous pattern of expression indicates that this gene product is involved in homeostatic processes for these and other cell 5 types and tissues. Its expression was elevated in all the cancer cell lines (melanoma, ovarian cancer, breast cancer, lung cancer, renal cancer, colon cancer, pancreatic cancer, and CNS cancer) with CT=25.5-30. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product may be useful in the treatment of 10 melanoma, ovarian cancer, breast cancer, lung cancer, renal cancer, pancreatic cancer, and CNS cancer. In addition, the expression of this gene can be used as a detection marker for those cancers. This gene was expressed in adipose tissue (CT=30.98). Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene 15 product may be useful in the treatment of obesity and diabetes. 194 WO 2004/013347 PCT/US2003/024504 Panel 5 Islet Summary: (Ag6596) Expression of this gene was induced in adipose differentiated from Mesenchymal Stem cells (compare AD samples with U samples from Donor 2 (CT=30.46-30.86 vs. CT=32.18-32.24) and Donor 3 (CT=29.01-30.7 vs. CT=32.84 33.07). Thus therapeutic modulation of this gene, expressed protein and/or use of antibodies 5 or small molecule drugs targeting the gene or gene product can be useful in the treatment of obesity and diabetes. Example C4. Assays Screening for Modulators of Long Chain Fatty Acyl Elongase 10 A non-exhaustive list of cell lines that express the long chain fatty acyl elongase can be obtained from the differential gene expression (RTQ-PCR) results presented herein. Potential methods for Measurement of Fatty Acyl elongation reaction in microsomes 15 are described by Nagi et al., Evidence for two separate beta-ketoacyl CoA reductase components of the hepatic microsomal fatty acid chain elongation system in the rat, Biochem Biophys Res Commun. 1989 Dec 29;165(3):1428-34, and by Moon et al., Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins, J Biol Chem. 2001 Nov 30;276(48):45358-66. Epub 2001 Sep 20, followed by 20 HPLC separation of radio-labeled fatty acids by HPLC. Functional/mechanistic assay for the effectiveness of an administered modulator of Fatty Acyl Elongase could be performed by obesrving TG synthesis/accumulation in 3T3-L1 mouse adipocytes, human adipocytes or hepatocytes by Oil Red 0 staining. Alternatively 25 measurement could be made of post treatment TG accumulation in cells transfected with Fatty Acyl Elongase. Our results indicate that a modulator of Long Chain Fatty Acyl Elongase activity, such as an inhibitor, activator, antagonist, or agonist of Long Chain Fatty Acyl Elongase may 30 be useful for treatment of such disorders as obesity, diabetes, and insulin resistance, as well as for enhancement of insulin secretion. D. NOV4 - Acetyl-Coenzyme A acyltransferase 2 195 WO 2004/013347 PCT/US2003/024504 Acetyl-Coenzyme A acyltransferase 2 (ACAA2) is the last enzyme in mitochondrial fatty acid beta-oxidation. It is thought that fatty acid oxidation may interfere with glucose utilization in skeletal muscle and liver, thus causing insulin resistance and hyperglycemia. (Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid 5 cycle after 35 years. Diabetes Metab. Rev. 1998 14(4), 263-83 PMID: 10095997; Deems RO, Anderson RC, Foley JE. Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. Am. J. Physiol. 1998 274(2 Pt 2):R524-8; PMID: 9486313). GeneCalling@ studies showed significant up-regulation of ACAA2 in diabetic muscle. ACAA2 was also down-regulated in fast twitch versus slow twitch diabetic skeletal muscle 10 in response to vanadate, metformin and AICAR, compounds causing improvement of hypoglycemia and diabetes. GeneCalling@ data indicate that ACAA2 may make a good target for promoting skeletal muscle glucose utilization and improving diabetes. Shown below is the reaction catalyzed by human Acetyl-Coenzyme A acyltransferase 15 2. 3-oxoacyl CoA + CoA t Acyl CoA + Acetyl CoA Acetyl CoA - TCA cycle 20 Potential assay that may be used to screen for antibody therapeutics or small molecule drugs is the measurement of NAD+/NADH production in the outlined reaction coupled with the conversion reaction of 3-hydroxyacyl CoA to 3-oxoacyl CoA by the next mitochondrial enzyme. The general inhibitor for mitochondrial thiolases (4-bromocrotonic 25 acid) is described in literature (Schulz et al., Life Sci. (1987) 40, 1443). Cell lines expressing the Acetyl-Coenzyme A acyltransferase 2 can be obtained from the RTQ-PCR results shown herein. These and other Acetyl-Coenzyme A acyltransferase 2 expressing cell lines could be used for screening purposes. 30 ACAA2 catalyses the last step in acetyl-CoA production. Concerning accumulation of ACAA2 substrate, 3-oxoacyl-CoA has no reported toxicity and causes inhibition of two other enzymes in fatty acid oxidation cycle. The outcome of inhibiting the action of the human Acetyl-Coenzyme A acyltransferase 2 would be inhibition of fatty acid oxidation in skeletal muscle and liver, and promotion of glucose utilization. 35 Acetyl-Coenzyme A acyltransferase 2 (ACAA2) (3-oxoacyl-CoA thiolase) is up regulated in skeletal muscle in obese/diabetic skeletal muscle. The expression level of the 196 WO 2004/013347 PCT/US2003/024504 enzyme is down-regulated in gastrocnemius versus soleus muscle in response to vanadate, AICAR and Metformin treatments (all are known to improve glucose utilization in muscle). ACAA2 is the last enzyme in fatty acid beta-oxidation. Inhibition of ACAA2 would inhibit fatty acid oxidation in skeletal muscle and liver, promoting glucose utilization. Thus, an 5 inhibitor/antagonist of ACAA2 would be beneficial as an antihyperglycemic agent for the treatment of obesity and/or diabetes. Furthermore, we discovered that Acetyl-Coenzyme A acyltransferase 2 (ACAA2) is down-regulated in diabetic skeletal muscle of animals that respond favorably to rosiglitazone 10 treatment with improved glycemic control. However, the expression of Acetyl-Coenzyme A acyltransferase 2 was found to be not down-regulated in response to rosiglitazone treatment in diabetic animals that had no detectable improvement of hyperglycemia. Because acetyl Coenzyme A acyltransferase 2 expression is positively correlated with hyperglycemia, its down-regulation may account for the antidiabetic effect of rosiglitazone. Therefore, an 15 attenuation of Acetyl-Coenzyme A acyltransferase 2 total enzymatic activity might account for, and be sufficient to yield, favorable clinical effects comparable to that of rosiglitazone on hyperglycemia and skeletal muscle insulin sensitivity. Our data support the development of an antagonist of Acetyl-Coenzyme A acyltransferase 2 as a therapeutic agent to treat insulin resistance and diabetes. 20 Furthermore, our results indicate that a modulator of ACAA2 activity, such as an inhibitor, activator, antagonist, or agonist of ACAA2 may be useful for treatment of such disorders as obesity, diabetes, and insulin resistance, as well as for enhancement of insulin secretion. 25 Discovery Process The following sections describe the study design(s) and the techniques used to 30 identify the Acetyl-Coenzyme A acyltransferase 2 - encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for Obesity and Diabetes. Example D1. Mouse Dietary-Induced Obesity 197 WO 2004/013347 PCT/US2003/024504 A protocol for Mouse Dietary-Induced Obesity study is disclosed in Example Q1. The predominant cause for obesity in clinical populations is excess caloric intake. 5 This so-called diet-induced obesity (DIO) is mimicked in animal models (mouse strain C57BL) by feeding high fat diets of greater than 40% fat content. The DIO study was established to identify the gene expression changes contributing to the development and progression of diet-induced obesity. In addition, the study design sought to identify the factors that lead to the ability of certain individuals to resist the effects of a high fat diet and 10 thereby prevent obesity. The sample groups for the study had body weights +1 S.D., + 4 S.D. and + 7 S.D. of the chow-fed controls. In addition, the biochemical profile of the +7 S.D. mice revealed a further stratification of these animals into mice that retained a normal glycemic profile in spite of obesity and mice that demonstrated hyperglycemia. Tissues examined included hypothalamus, brainstem, liver, retroperitoneal white adipose tissue 15 (WAT), epididymal WAT, brown adipose tissue (BAT), gastrocnemius muscle (fast twitch skeletal muscle) and soleus muscle (slow twitch skeletal muscle). The differential gene expression profiles for these tissues revealed genes and pathways that can be used as therapeutic targets for obesity and/or diabetes. Protocol for differential gene expression analysis, GeneCalling@, is disclosed in Example Q7. 20 Results A fragment of the mouse Acetyl-Coenzyme A acyltransferase 2 gene was initially found to be up-regulated by 1.6 fold in the muscle of the obese, diabetic mice (hgsd7) on a 25 high fat diet as compared to mice on normal diet (chow) using CuraGen's GeneCalling@ method of differential gene expression. A differentially expressed mouse gene fragment migrating, at approximately 380.4 nucleotides in length was definitively identified as a component of the mouse Acetyl-Coenzyme A acyltransferase 2 cDNA. The method of competitive PCR was used for confirmation of the gene assessment. The electropherographic 30 peaks corresponding to the gene fragment of the mouse Acetyl-Coenzyme A acyltransferase 2 were ablated when a gene-specific primer (shown in Table Dl) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 380.4 nt in length were ablated in the sample from both the obese/diabetic and normal chow mouse. Table Dl. The direct sequence of the 380.4 nucleotide-long gene fragment and the gene 198 WO 2004/013347 PCT/US2003/024504 specific primers used for competitive PCR are indicated on the cDNA sequence of the Acetyl-Coenzyme A acyltransferase 2 fragment (SEQ ID NO: 189) and are shown in bold. The gene-specific primers at the 5' and 3' ends of the fragment are underlined. Competitive PCR Primer for the mouse Acetyl-Coenzyme A acyltransferase 2: Gene Sequence (fragment from 507 to 886 in bold. band size: 380) 1 AGAGCCCCGC GGAATAGCTG AGCTTCGCCA TGGCCCTGCT ACGAGGTGTG TTCATCGTCG 61 CTGCGAAGAG ACACCCTTTG GAGCTTACGG GGGCCTTCTC AAGGACTTCT CTGCCACCGA 121 TTTAACTGAA TTTGCTGCCA GGGCTGCTCT GTCTGCTGGC AAAGTTCCAC CTGAAACCAT 181 CGATAGTGTC ATCGTGGGCA ATGTCATGCA GAGCTCTTCA GATGCGGCAT ACCTGGCGAG 241 GCATGTGGGT TTGCGAGTGG GAGTCCCAAC AGAGACTGGG GCCCTTACCC TCAACAGGCT 301 CTGTGGCTCT GGTTTCCAGT CCATCGTGAG CGGATGTCAG GAAATCTGTT CTAAAGATGC 361 TGAGGTCGTC TTGTGTGGAG GAACAGAGAG CATGAGCCAG TCCCCCTACT GTGTCAGAAA 421 TGTGCGCTTC GGAACCAAAT TTGGATTAGA TCTCAAGCTG GAAGATACTT TGTGGGCAGG 481 ATTAACGGAT CAACATGTTA AGCTGCCCAT GGGAATGACT GCAGAGAACC TTGCTGCAAA 541 ATACAACATA AGCAGAGAAG ACTGTGACAG ATACGCCTTG CAGTCTCAGC AGAGGTGGAA 601 AGCTGCTAAC GAGGCTGGCT ACTrCAATGA GGAGATGGCA CCCATTGAGG TGAAGACGAA 661 GAAAGGCAAA CAGACCATGC AAGTGGACGA GCACGCTCGA CCCCAAACCA CCCTGGAGCA 721 ACTGCAGAAG CTCCCGTCCG TGTrCAAGAA AGACGGGACA GTCACAGCAG GGAACGCCTC 781 GGGGGTGTCT GACGGTGCTG GGGCCGTCAT CATAGCCAGC GAAGATGCTG TCAAAAAACA 841 TAACTYCACG CCCCTGGCCA GAGTCGTGGG CTACTrCGTG TCCGGATGCG ATCCTACTAT 901 CATGGGTATT GGTCCAGTCC CTGCTATCAA TGGAGCATTG AAGAAAGCTG GGCTGAGTCT 961 TAAGGACATG GATTTGATAG ACGTGAACGA AGCTTTTGCC CCTCAGTTCT TGTCTGTTCA 1021 GAAGGCCCTG GATCTTGACC CCAGCAAAAC CAATGTGAGT GGAGGCGCCA TTGCCCTGGG 1081 TCACCCGCTG GGAGGATCTG GCTCCAGAAT CACCGCACAC CTGGTTCATG AGTTAAGGCG 1141 TCGAGGTGGA AAGTACGCAG TGGGATCAGC TTOCATTGGA GGTGGCCAAG GCATCGCCTT 1201 GATCATCCAG AACACAGCCT GAAGGCATCA CAAGCACACT GCCCACACTT ACTGGGCCAG 1261 GCCACGGAAC ACAGGAGACC TTCGAGTCAG CCCTGCTGAG ACAGTGATTG TATGTGACCA 1321 AGCCTTGATG AGGCAAGATG CATTOGGTTC TGTCTACTTC ATACCTGTCT GACGTGTTAG 1381 AATAAAAACA CCAACCATCG GAGGCCITAA GAGAAATGGT ATCTGTCAGT AGTCACCACT 1441 GTATGCCTTC CATGGAGTAA TACAAACTGA ATAAATGTTG CCTTAACTCC AGCT Example D2. Insulin Sensitivity In Rat Skeletal Muscle 5 A protocol for Rat Insulin Sensitivity study is disclosed in Example Q3. 199 WO 2004/013347 PCT/US2003/024504 ZDF rats were treated with a variety of agents that are known to alter insulin sensitivity. Metformin, vanadate, and AICAR enhance tissue response to insulin, while the free fatty acids generated by Liposyn (intravenous lipid infusion) ZDF rats or their lean littermates were treated with a variety of agents that are known to alter insulin sensitivity. 5 Metformin, vanadate, and AICAR enhance tissue response to insulin, while the free fatty acids generated by Liposyn (intravenous lipid infusion) treatment reduces the response. A variety of tissues were-harvested, including gastrocnemius and soleus muscles, liver, retroperitoneal and epididymal WAT, and IBAT. Protocol for differential gene expression analysis, GeneCalling@, is disclosed in Example Q7. 10 Results A gene fragment of the rat Acetyl-Coenzyme A acyltransferase 2 was found to be down-regulated by 2.5 fold in gastrocnemius relative to soleus muscle in ZDF rats treated with vanadate, AICAR and Metformin using CuraGen's GeneCalling@ method of differential gene expression. A differentially expressed rat gene fragment migrating, at 15 approximately 353 nucleotides in length was definitively identified as a component of the rat Acetyl-Coenzyme A acyltransferase 2 cDNA. The method of competitive PCR was used for confirmation of the gene assessment. The electropherographic peaks corresponding to the gene fragment of the rat Acetyl-Coenzyme A acyltransferase 2 were ablated when a gene specific primer (shown in Table D2) competes with primers in the linker-adaptors during the 20 PCR amplification. The peaks at about 353 nt in length were ablated in the sample from both gastrocnemius and soleus muscle. Table D2. The direct sequence of the 353 nucleotide-long gene fragment and specific pnmers used for competitive PCR are indicated on the cDNA sequence of the Acetyl-Coenzyme A acyltransferase 2 fragment (SEQ ID NO: 190) and are shown in bold. The gene-specific primers at the 5' and 3'. ends of the fragment are underlined. Competitive PCR Primer for the rat Acetyl-Coenzyme A acyltransferase 2: Gene Sequence (fragment from 643 to 996 in bold. band size: 354) 162 GTCATGGCGC TGCTACGAGG TGTGTTTATC GTTGCTGCGA AGCGAACACC CTTTGGAGCT 222 TATGGGGGTC TrCTCAAGGA CTTCACTGCC ACTGACTTAA CTGAATTTGC TGCCAGGGCT 282 GCCCTGTCTG CTGGCAAAGT TCCACCGGAA ACCATCGATA GTGTCATCGT GGGCAATGTC 342 ATGCAGAGOCT CTTCAGATGC GGCGTACCTG GCAAGGCATG TGGGTTTACG TGTGGGAGTC 402 CCGACGGAGA CTGGGGCCCT CACCCTCAAC AGACTCTGTG GCTCTGGTTT CCAGTCCATC 462 GTGAGCGGAT GTCAGGAAAT CTGCTCGAAA GACGCTGAGG TCGTCTTATG TGGAGGAACC 522 GAGAGCATGA GCCAGTCCCC CTACTCTGTC AGAAATGTGC GCTTCGGAAC CAAATTTGGG 200 WO 2004/013347 PCT/US2003/024504 582 TrAGATCTCA AGCTGGAAGA TACTTTGTGG GCAGGATTAA CGGATCAACA CGTGAAGCTC 642 CCCATGGGGA TGACTGCAGA GAACCTGGCT GCAAAATACA ACATAAGCAG AGAAGACTGC 702 GACAGATACG CCCTGCAGTC CCAGCAGAGG TGGAAAGCCG CTAACGAGGC TGGCTACT 762 AATGAGGAGA TGGCCCCCAT TGAGGTGAAG ACCAAGAAGG GCAAACAGAC CATGCAAGTG 822 GATGAGCACG CCCGGCCCCA AACGACCCTG GAGCAGCTGC AGAACCTCCC GCCAGTGTTC 882 AAGAAAGAGG GGACGGTCAC AGCAGGGAAC GCCTCGGGCA TGTCTGACGG TGCTGGGGTC 942 GTCATCATAG CCAGCGAAGA TGCTGTCAAA AAACATAACT TCACACCACT GGCCAGAGTC 1002 GTGGGCTACT TTGTGTCTGG ATGTGACCCT GCTATCATGG GGATCGGTCC AGTCCCTGCC 1062 ATCACTGGAG CATTGAAGAA AGCTGGGCTG AGCCTTAAGG ACATGGATTT GATAGACGTG 1122 AATGAAGCAT TTGCTCCTCA GTTCTTGGCT GTTCAGAAGA GCTTGGATCT CGACCCCAGT 1182 AAAACCAACG TGAGTGGAGG TGCCATAGCC CTGGGTCACC CGCTGGGAGG ATCTGGATCC 1242 AGAATCACCG CACACCTGGT TCACGAGTTA AGGCGTCGAG GTGGAAAATA CGCAGTGGGA 1302 TCAGCTTGCA TTGGAGGTGG CCAAGGCATC TCCCTGATCA TCCAGAACAC AGCCTGAAGG 1362 GATTGCAAGC ATCCTACCCA CCCTCACTTG GCCAGGCTAC GGAACACAGG CGACCTTTGA 1422 GTCAGCCCTG CTGTGACAGT AAATGCATTT GACCAAGCCT TGATGGGTTC TGTCT Example D3. Mouse TZD Response Study .5 A protocol for Mouse TZD Response study is disclosed in Example Q4. The peroxisome proliferator-activated receptor gamma (PPARg) is the member of the nuclear hormone receptor subfamily of transcription factors that plays a major role in 10 regulation of metabolism (Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors.Endocrinology. 2003 Jun;144(6):2201-7. PMID: 12746275). The thiazolidinedione (TZD) drugs, including rosiglitazone, are synthetic agonists of PPARg receptors that can nonnalize elevated plasma glucose levels in obese, diabetic rodents and are often quite efficacious therapeutic agents for 15 the treatment of noninsulin-dependent diabetes mellitus in humans (Doggrell S. Do peroxisome proliferation receptor-gamma antagonists have clinical potential as combined antiobesity and antidiabetic drugs? Expert Opin Investig Drugs. 2003 Apr; 12(4):713-6., PMID: 12665425; Gurnell M, Savage DB, Chatteijee VK, O'Rahilly S. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. 20 J Clin Endocrinol Metab. 2003 Jun;88(6):2412-21 PMID: 12788836). Diabetic animals demonstrate differential responses to TZD treatment. To understand the basis for this differential response we compared changes in gene expression between diabetic animals that 201 WO 2004/013347 PCT/US2003/024504 responded favorably and that did not respond to TZD treatment. Female db/db mice were treated daily with 10mg per kilogram body weight rosiglitazone for 7 days. On day 8, the mice were bled for blood glucose. Treated mice were grouped into either a 'responder group' that demonstrated asignificant decrease of their hyperglycemia and a 'non-responder group' 5 that demonstrated no change in their blood glucose level. Gene expression in skeletal muscle and adipose tissues was compared between untreated diabetic mice and the two sub groups of TZD treated mice. Protocol for differential gene expression analysis, GeneCalling@, is disclosed in Example Q7. 10 Results Using CuraGen's GeneCalling@ method of differential gene expression, a fragment of the mouse Acetyl-Coenzyme A acyltransferase 2 gene was initially found to be down-regulated by 1.7 fold in the skeletal muscle of diabetic mice treated with rosiglitazone that 15 demonstrated improvement of hyperglycemia relative to mice treated with rosiglitazone, but failed to decrease blood glucose level. The same fragment has been found to be down regulated 1.9 fold in skeletal muscle of TZD treated mice with improved hyperglycemia relative to diabetic controls. A differentially expressed mouse gene fragment migrating at approximately 252 nucleotides in length on capillary gel electrophoresis was definitively 20 identified as a component of the mouse Acetyl-Coenzyme A acyltransferase 2 cDNA. The method of competitive PCR was used for confirmation of the gene assessment. The electropherographic peak corresponding to the gene fragment of mouse Acetyl-Coenzyme A acyltransferase 2 was ablated when a gene-specific primer (shown in Table D3) competes with primers in the linker-adaptors during the PCR amplification. These data are suggestive 25 of Acetyl-Coenzyme A acyltransferase 2 being involved in skeletal muscle insulin resistance and the progression of diabetes. Table D3. The sequence of the 252 nucleotide-long gene fragment and the gene-specific primers used for competitive PCR are indicated in bold on the cDNA sequence of the mouse ACCA2 gene fragment (SEQ ID NO:191). The gene-specific primers at the 5' and 3' ends of the fragment are underlined. Gene Sequence (fragment from 370 to 620 in bold. band size: 251) 1 TTTrrr=T GGAGTTAAGG CAACATTTAT TCAGTTGTA TTACTCCATG GAAGGCATAC 61 AGTGGTGACT ACTGACAGAT ACCATTTCTC TTAAGGCCTC CGATGGTTGG TGTTTATT 121 CTAACACGTC AGACAGGTAT GAAGTAGACA GAACCCAATG CATCTrGCCT CATCAAGGCT 181 TGGTCACATA CAATCACTGT CTCAGCAGGG CTGACTCGAA GGTCTCCTGT GTTCCGTGGC 241 CTGGCCCAGT AAGTGTGGGC AGTGTOCTTG TGATGCCTTC AGGCTGTGTT CTGGATGATC 202 WO 2004/013347 PCT/US2003/024504 301 AAGGCGATGC CTTGGCCACC TrCCATGCAA GCTGATTCCA CTGGGTACTT TCCACCTTGA 361 CGCCTrAACT CATGAACCAG GTGTGCGGTG ATrCTGGAGC CAGATCCTCC CAGCGGGTGA 421 CCCAGGGCAA TGGCGCCrCC ACTCACATTG GTTTGCTGG GGTCAAGATC CAGGGCCTrC 481 TGAACAGACA AGAACTGAGG GGCAAAAGCT TCGTTCACGT CTATCAAATC CATGTCCTTA 541 AGACrCAGCC CAGCTTTCTT CAATGCTCCA TTGATAGCAA GGACCTGACC AATACCCATG 601 ATAGTAGGAT CGCATCCGGA CACGAAGTAG CCCACGACTC TGGCCAAGGG CCGTGACGTT 661 TATGTTTTGA CAGCATCCTr GCTGGGCTTG ATGAGGGCCC CAGCACGTCA GACACCCCCG 721 AGGCGTATCC TTGTTTGACT GTCCCGTTT TTTTAAACAC TGAGGGGAGC TCTTGCAGTA 781 GCTCCAGGGT GGATTTGGA (gene length is 799, only region from 1 to 799 shown) Example D4. Identification of Human Acetyl-Coenzyme A acyltransferase 2 Gene Sequences 5 The sequence of Human Acetyl-Coenzyme A acyltransferase 2 Gene (Ace. No. CG1 81387-01) was derived by laboratory cloning of cDNA fragments, by in silico prediction of the sequence. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were cloned. In silico prediction was based on 10 sequences available in CuraGen's proprietary sequence databases or in the public human sequence databases, and provided either the full-length DNA sequence, or some portion thereof. The protocol for identification of human sequence(s) is disclosed in Example Q8. Table D4 shows an alignment (ClustalW) of the protein sequences of the human 15 (CG181387-01; SEQ ID NO:30), rat (P13437; SEQ ID NO:192) and mouse (BC028901; SEQ ID NO: 193) versions of the Acetyl-Coenzyme A acyltransferase 2. Table D5 shows protein sequences of rat (P13437; SEQ ID NO:192) and mouse (BC028901; SEQ ID NO: 193) versions of the Acetyl-Coenzyme A acyltransferase 2. 20 Table D4. An alignment (ClustalW) of the protein sequences of the human (CG181387-01; SEQ ID NO:30), rat (P13437; SEQ ID NO:192) and mouse (3C028901; SEQ ID NO:193) versions of the Acetyl-Coenzyme A acyltransferase 2. 203 WO 2004/013347 PCT/US2003/024504 AAH28901 CG181387-01 'MjRjjjM9 P13437 AMOM AAH2t991 CGIS1387-01 Wi P13437 OBM S AAH289O1 CGIS1387-01 Jil SIF STVI H-.'UM M P13437 AAH2890l1 1 CGIS1387-01 AAH28901 CGI81387-01 WIO P13437 EEJ Rat43 ActlGezMe A acylRanfrse2P337 E D O2 TableQ5.MproeinAsqu'eQLncLf aP134K~37;TAGNASGDGAGVVII)aEdAmouseHNFTPLARVVS Mous Acetyl-Coenyme A acyltransferase 2 (PA29 13437 9O; SEQ ID NO: 19 3) MALLRGVFIVAAKRTPFGAYGGLLKDFTAI7DLTEFAAR-AALSAGKVPPETIDSVIVGNVMQSSSDAAYLA RHVGLRVGVPTETGALTLNRLCGSGFQSIVSGCQEICSKDAEVVLCGGTESMSQSPYCVRNVRFGTKFGL DLKLEDTLWAGLTDQHVKLPMGMTAENLAAKYNISREDCDRYALQSQQRWKAANEAGYFNEEMAPIEVKT KKGKQTMQVDEHARPQTTLEQLQNLPSVFKKDGTVTAGNASGVSDGAGVIIASEDAVKKHNFTPLARVV GYFVSGCDPTIMGIGPVPAINGALKKAGLSLKDMDLIDVNEAFAPQFLSVQKALDLDPSKTINVSGGAIAL GHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGISLIIQNTV NoVs, ActlC181387A-Ocltafes 2(A891BC80 SEQ ID NO: 193) b RHGCGCCCCCACAAGCCGCCCCGALTNLGGQIS CCCAGCAGCVCGCAGTEQPCGCTCCGGTGL DGTTAGTCCAALGAACCCTTTGMTCTTAKNSECDRALGCCTTCTAAAGYTTCACTGCT CTPLGACTGTCITGAHATTTGCTGKAGCIGCTGTGTGGCAAGTTCCCTAACA ThCaoaoycoigwspromduin n rmr ftemtossmaie inExmleQ8 heNO loe a aalzdan henulotdead ncdd204pptd WO 2004/013347 PCT/US2003/024504 AGTGTGATTATGGGCAATGTCCTGCAGAGTTCTTCAGATGCTATATATTTGGCAAGGCATGTTGGTT T GCGTGTGGGAATCCCAAAGGAGACCCCAGCTCTCACGATTAATAGGCTCTGTGGTTCTGGTTTTCAG T CCATTGTGAATGGATGTCAGGAAATTTGTGTTAAAGAAGCTGAAGTTGTTTTATGTGGAGGAACCGA A AGCATGAGCCAAGCTCCCTACTGTGTCAGAAATGTGCGTTTTGGAACCAAGCTTGGATCAGATATCA A GCTGGAAGATTCTTTATGGGTATCATTAACAGATCAGCATGTCCAGCTCCCCATGGCAATGACTGCA G AGAATCTTACTGTAAAACACAAAATAAGCAGAGAAGAATGTGACAAATATGCCCTGCAGTCACAGCA G AGATGGAAAGCTGCTAATGATGCTGGCTACTTTAATGATGAAATGGCACCAATTGAAGTGAAGACAA A GAAAGGAAAACAGACAATGCAGGTAGACGAGCATGCTCGGCCCCAAACCACCCTGGAACAGTTACAG A AACTTCCTCCAGTATTCAAGAAAGATGGAACTGTTACTGCAGGGAATGCATCGGGTGTAGCTGATGG T GCTGGAGCTGTTATCATAGCTAGTGAAGATGCTGTTAAGAAACATAACTTCACACCACTGGCAAGAA T TGTGGGCTACTTTGTATCTGGATGTGATCCCTCTATCATGGGTATTGGTCCTGTCCCTGCTATCAGT G GGGCACTGAAGAAAGCAGGACTGAGTCTTAAGGACATGGATTTGGTAGAGGTGAATGAAGCTTTTGC T CCCCAGTACTTGGCTGTTGAGAGGAGTTTGGATCTTGACATAAGTAAAACCAATGTGAATGGAGGAG C CATTGCTTTGGGTCACCCACTGGGAGGATCTGGATCAAGAATTACTGCACACCTGGTTCACGAATTA A GGCGTCGAGGTGGAAAATATGCCGTTGGATCAGCTTGCATTGGAGGTGGCCAAGGTATTGCTGTCAT C ATTCAGAGCACAGCCTGAAGAGACCAGTGAGCTCACTGTGACCCATCCTTACTCTACTTGGCCAGGC C ACAGTAAAACAAGTGACCTTCAGAGCAGCTGCCACAACTGGCCATGCCCTGCCATTGAAACAGTGAT T AAGTTTGATCAAGCCATGGTGACACAAAAATGCATTGATCATGAATAGGAGCCCATGCTAGAAGTAC A TTCTCTCAGATTTGAACCAGTGAAATATGATGTATTTCTGAGCTAAAACTCAACTATAGAAGACATT A AAGAAATCGTATTCTTGCCAAGTAACCACCACTTCTGCCTTAGATAATATGATTATAAGGAAATCA A ATAAATGT TGCCT TAACT TC NOV4a, CG181387-01 SE DNO 0397aa IMW at42038.9kD Protein Sequence _IEIDN:3 MRLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVS PETVDSVIMGNVLQSSSDAI Y LARHVGLRVGIPKETPALTINRLCGSGFQS IVNGCQEICVKEAEVVLCGGTESMSQAPYCVRNVRFG T KLGSDIKLEDSLWVSLTDQHVQLPMAMTAENLTVKHKISREECDKYALQSQQRWKAANDAGYFNDEM A PIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFKKDGTVTAGNASGVADGAGAVIIASEDAVKKH N FTPLARIVGYFVSGCDPS IMGIGPVPAISGALKKAGLSLKDMDLVEVNEAFAPQYLAVERSLDLDIS K TNVNGGAIALGHPLGGSOSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA NOV4b, 282274427 SEQ ID NO: 31 11218 bp DNA Sequence JORF Start: at 2 JORF Stop: TGA at 1205 CACCGGATCCACCATGCGTCTGCTCCGAGGTGTGTTTGTAGTTGCTGCTAAGCGAACGCCCTTTGGA G CTTACGGAGGCCTTCTGAAAGACTTCACTGCTACTGACTTGTCTGAATTTGCTGCCAAGGCTGCCTT G 205 WO 2004/013347 PCT/US2003/024504 TCTGCTGGCAAAGTCTCACCTGAAACAGTTGACAGTGTGATTATGGGCAATGTCCTGCAGAGTTCTT C AGATGCTATATATTTGGCAAGGCATGTTGGTTTGCGTGTGGGAATCCCAAAGGAGACCCCAGCTCTC A CGATTAATAGGCTCTGTGGTTCTGGTTTTCAGTCCATTGTGAATGGATGTCAGGAAATTTGTGTTAA A GAAGCTGAAGTTGTTTTATGTGGAGGAACCGAAAGCATGAGCCAAGCTCCCTACTGTGTCAGAAATG T GCGTTTTGGAACCAAGCTTGGATCAGATATCAAGCTGGAAGATTCTTTATGGGTATCATTAACAGAT C AGCATGTCCAGCTCCCCATGGCAATGACTGCAGAGAATCTTGCTGTAAAACACAAAATAAGCAGAGA A GAATGTGACAAATATGCCCTGCAGTCACAGCAGAGATGGAAAGCTGCTAATGATGCTGGCTACTTTA A TGATGAAATGGCACCAATTGAAGTGAAGACAAAGAAAGGAAAACAGACAATGCAGGTAGACGAGCAT G CTCGGCCCCAAACCACCCTGGAACAGTTACAGAAACTTCCTCCAGTATTCAAGAAAGATGGAACTGT T ACTGCAGGGAATGCATCGGGTGTAGCTGATGGTGCTGGAGCTGTTATCATAGCTAGTGAAGATGCTG T TAAGAAACATAACTTCACACCACTGGCAAGAATTGTGGGCTACTTTGTATCTGGATGTGATCCCTCT A TCATGGGTATTGGTCCTGTCCCTGCTATCAGTGGGGCACTGAAGAAAGCAGGACTGAGTCTTAAGGA C ATGGATTTGGTAGAGGTGAATGAAGCTTTTGCTCCCCAGTACTTGGCTGTTGAGAGGAGTTTGGATC T TGACATAAGTAAAACCAATGTGAATGGAGGAGCCATTGCTTTGGGTCACCCACTGGGAGGATCTGGA T CAAGAATTACTGCACACCTGGTTCACGAATTAAGGCGTCGAGGTGGAAAATATGCCGTTGGATCAGC T TGCATTGGAGGTGGCCAAGGTATTGCTGTCATCATTCAGAGCACAGCCTGAGCGGCCGCTAT NOV4b, 282274427 SEQ ID NO: 32 401 aa MW at 42355.2kD Protein Sequence TGSTMRLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMGNVLQSS S DAIYLARHVGLRVGIPKETPALTINRLCGSGFQSIVNGCQEICVKEAEVVLCGGTESMSQAPYCVRN V RFGTKLGSDIKLEDSLWVSLTDQHVQLPMAMTAENLAVKHKISREECDKYALQSQQRWKAANDAGYF N DEMAPIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFKKDGTVTAGNASGVADGAGAVIIASEDA G KKNFTPLARIVGYFVSGCDPS IMGIGPVPAISGALKKAGLSLKDMDLVEVNEAFAPQYLAVERSLD L DISKTNVNGGAIALGHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA NOV4c, CG181387-02 (SEQ ID NO: 33 1218 bp DNA Sequence IORF Start: at 2 IORF Stop: TGA at 1205 CACCGGATCCACCATGCGTCTGCTCCGAGGTGTGTTTGTAGTTGCTGCTAAGCGAACGCCCTTTGGA G CTTACGGAGGCCTTCTGAAAGACTTCACTGCTACTGACTTGTCTGAATTTGCTGCCAAGGCTGCCTT G TCTGCTGGCAAAGTCTCACCTGAAACAGTTGACAGTGTGATTATGGGCAATGTCCTGCAGAGTTCTT C AGATGCTATATATTTGGCAAGGCATGTTGGTTTGCGTGTGGGAATCCCAAAGGAGACCCCAGCTCTC A CGATTAATAGGCTCTGTGGTTCTGGTTTTCAGTCCATTGTGAATGGATGTCAGGAAATTTGTGTTAA A GAAGCTGAAGTTGTTTTATGTGGAGGAACCGAAAGCATGAGCCAAGCTCCCTACTGTGTCAGAAATG T GCGTTTTGGAACCAAGCTTGGATCAGATATCAAGCTGGAAGATTCTTTATGGGTATCATTAACAGAT C 206 WO 2004/013347 PCT/US2003/024504 AGCATGTCCAGCTCCCCATGGCAATGACTGCAGAGAATCTTGCTGTAAAACACAAAATAAGCAGAGA A GAATGTGACAAATATGCCCTGCAGTCACAGCAGAGATGGAAAGCTGCTAATGATGCTGGCTACTTTA A TGATGAAATGGCACCAAT TGAAGTGAAGACAAAGAAAGGAAAACAGACAATGCAGGTAGACGAGCAT G CTCGGCCCCAAACCACCCTGGAACAGTTACAGAAATCTGATCCAGTATTCAAGAAAGATGGAACTGT T ACTGCAGGGAATGCATCGGGTGTAGCTGATGGTGCTGGAGCTGTTATCATAGCTAGTGAAGATGCTG T TAAGAAACATAACTTCACACCACTGGCAAGAATTGTGGGCTACTTTGTATCTGGATGTGATCCCTCT A TCATGGGTATTGGTCCTGTCCCTGCTATCAGTGGGGCACTGAAGAAAGCAGGACTGAGTCTTAAGGA C ATGGATTTGGTAGAGGTGAATGAAGCTTTTGCTCCCCAGTACTTGGCTGTTGAGAGGAGTTTGGATC T TGACATAAGTAAAACCAATGTGAATGGAGGAGCCATTGCTTTGGGTCACCCACTGGGAGGATCTGGA T CAAGAATTACTGCACACCTGGTTCACGAATTAAGGCGTCGAGGTGGAAAATATGCCGTTGGATCAGC T TGCATTGGAGGTGGCCAAGGTATTGCTGTCATCATTCAGAGCACAGCCTGAGCGGCCGCTAT NOV4c, CG181387-02 SEQ ID NO: 34 401 aa MW at 42355.2kD Protein Sequence TGSTMRLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAALSAGKVSPETSVIMGNVQSS S DAIYLARHVGLRVGI PKETPALTINRLCGSGFQS IVNGCQEICVKEAEVVLCGGTESMSQAPYCVRN RFGTKLGSDIKLEDSLWVSLTDQHVQLPMAMTAENLAVKHKISREECDKYALQSQQRWKAANDAGYF N DEMAPIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFKKDGTVTAGNASGVADGAGAVIIASEDA KKHNFTPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLKDMDLVEVNEAFAPQYLAVERSLD L DISKTNGGAIALGHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA NOV4d, 306268235 SEQ ID NO: 35 1248 bp DNA Sequence ORE Start: at 3 ORF Stop: TGA at 1224 ACGCGTCTCCCATGGGACATCATCACCACCATCACCGTCTGCTCCGAGGTGTGTTTGTAGTTGCTGC T AAGCGAACGCCCTTTGGAGCTTACGGAGGCCTTCTGAAAGACTTCACTGCTACTGACTTGTCTGAAT T TGCTGCCAAGGCTGCCTTGTCTGCTGGCAAAGTCTCACCTGAAACAGTTGACAGTGTGATTATGCGC A ATGTCCTGCAGAGTTCTTCAGATGCTATATATTTGGCAAGGCATGTTGGTTTGCGTGTGGGAATCCC A AAGGAGACCCCAGCTCTCACGATTAATAGGCTCTGTGGTTCTGGTTTTCAGTCCATTGTGAATGGAT G TCAGGAAATTTGTGTTAAAGAAGCTGAAGTTGTTTTATGTGGAGGAACCGAAAGCATGAGCCAAGCT C CCTACTGTGTCAGAAATGTGCGTTTTGGAACCAAGCTTGGATCAGATATCAAGCTGGAAGATTCTTT A TGGGTATCATTAACAGATCAGCATGTCCAGCTCCCATGGCAATGACTGCAGAGAATCTTGCTGTAA A ACACAAAATAAGCAGAGAAGAATGTGACAAATATGCCCTGCAGTCACAGCAGAGATGGAAAGCTGCT A ATGATGCTGGCTACTTTAATGATGAAATGGCACCAATTGAAGTGAAGACAAAGAAAGGAAAACAGAC A ATGCAGGTAGACGAGCATGCTCGGCCCCAAACCACCCTGGAACAGTTACAGAAACTTCCTCCAGTAT T CAAGAAAGATGGAACTGTTACTGCAGGGAATGCATCGGGTGTAGCTGATGGTGCTGGAGCTGTTATC A 207 WO 2004/013347 PCT/US2003/024504 TAGCTAGTGAAGATGCTGTTAAGAAACATAACTTCACACCACTGGCAAGAATTGTGGGCTACTTTGT A TCTGGATGTGATCCCTCTATCATGGGTATTGGTCCTGTCCCTGCTATCAGTGGGGCACTGAAGAAAG C AGGACTGAGTCTTAAGGACATGGATTTGGTAGAGGTGAATGAAGCTTTTGCTCCCCAGTACTTGGCT G TTGAGAGGAGTTTGGATCTTGACATAAGTAAAACCAATGTGAATGGAGGAGCCATTGCTTTGGGTCA C CCACTGGGAGGATCTGGATCAAGAATTACTGCACACCTGGTTCACGAATTAAGGCGTCGAGGTGGAA A ATATGCCGTTGGATCAGCTTGCATTGGAGGTGGCCAAGGTATTGCTGTCATCATTCAGAGCACAGCC T GAGCAGGTGCGGCCGGAGACGAAG NOV4d, 306268235 SEQ ID NO: 36 407 aa MW at 43144,0kD Protein Sequence ASPMGHHHHHHRLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMG N VLQSSSDAIYLARHVGLRVGIPKETPALTINRLCGSGFQS IVNGCQEICVKEAEVVLCGGTESMSQA P YCVRNVRFGTKLGSDIKLEDSLWVSLTDQHVQLPMAMTAENLAVKHKISREECDKYALQSQQRWKAA DAGYFNDEMAPIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFKKDGTVTAGNASGVADGAGAVI ASEDAVKKHNFTPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLKD3MDLVEVNEAFAPQYLA ERSLDLDISKTNVNGGAIALGHPLGGSGSRITAHLVHELPRRGGKYAVGSACIGGGQGIAVIIQSTA NOV4e, CG181387-03 SEQ ID NO: 37 1249 bp DNA Sequence jORF Start: at 2 |ORF Stop: TGA at 1208 ACATCATCACCACCATCACCGTCTGCTCCGAGGTGTGTTTGTAGTTGCTGCTAAGCGAACGCCCTTT G GAGCTTACGGAGGCCTTCTCAAAGACTTCACTGCTACTGACTTGTCTGAATTTOCTGCCAAGGCTGC C TTGTCTGCTGGCAAAGTCTCACCTGAAACAGTTGACAGTGTGATTATGGGCAATGTCCTGCAGAGTT C TTCAGATGCTATATATTTGGCAAGGCATGTTGGTTTGCGTGTGGGAATCCCAAAGGAGACCCCAGCT C TCACGATTAATAGGCTCTGTGGTTCTGGTTTTCAGTCCATTGTGAATGGATGTCAGGAAATTTGTGT T AAAGAAGCTGAAGTTGTTTTATGTGGAGGAACCGAAAGCATGAGCCAAGCTCCCTACTGTGTCAGAA A TGTGCGTTTTGGAACCAAGCTTGGATCAGATATCAAGCTGGAAGATTCTTTATGGGTATCATTAACA C ATCAGCATGTCCAGCTCCCCATGGCAATGACTGCAGAGAATCTTGCTGTAAAACACAAAATAAGCAG A GAAGAATGTGACAAATATGCCCTGCAGTCACAGCAGAGATGGAAAGCTGCTAATGATGCTGGCTACT T TAATGATGAAATGGCACCAATTGAAGTGAAGACAAAGAAAGGAAAACAGACAATGCAGGTAGACGAG C ATGCTCGGCCCCAAACCACCCTGGAACAGTTACAGAAACTTCCTCCAGTATTCAAGAAAGATGGAAC T GTTACTGCAGGGAATGCATCGGGTGTAGCTGATGGTGCTGGAGCTGTTATCATAGCTAGTGAAGATG C TGTTAAGAAACATAACTTCACACCACTGGCAAGAATTGTGGGCTACTTTGTATCTGGATGTGATCCC T CTATCATGGGTATTGGTCCTGTCCCTGCTATCAGTGGGGCACTGAAGAAAGCAGGACTGAGTCTTAA G GACATGGATTTCGTAGAGGTGAATGAAGCTTTTGCTCCCCAGTACTTGGCTGTTGAGAGGAGTTTGG A TCTTGACATAAGTAAAACCAATGTGAATGGAGGAGCCATTGCTTTGGGTCACCCACTGGGAGGATCT G 208 WO 2004/013347 PCT/US2003/024504 GATCAAGAATTACTGCACACCTGGTTCACGAATTAAGGCGTCGAGGTGGAAAATATGCCGTTGGATC A GCTTGCATTGGAGGTGGCCAAGGTATTGCTGTCATCATTCAGAGCACAGCCTGAGCAGGTGCGGCCG C ACTCGAGCACCACCACCACCACCAC NOV4e, CG1 81387-03 SEQ ID NO: 38 402 aa MW at 42700.5kD Protein Sequence I HHHHRLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMGNVLQS S SDAIYLARHVGLRVGIPKETPALTINRLCGSGFQSIVNGCQEICVKEAEVVLCGGTESMSQAPYCVR N VRFGTKLGSDIKLEDSLWVSLTDQHVQLPMAMTAENLAVKHKISREECDKYALQSQQRWKAANDAGY F NDEMAPIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFKKDGTVTAGNASGVADGAGAVIIASED A VKKHNFTPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLKDMDLVEVEAFAPQYLAVERSL D LDISKTNVNGGAIALGHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA NOV4fCG181387-04 SEQ ID NO: 39 1248 bp DNA Sequence IORF Start: at 1 IORF Stop: TGA at 1207 CGTCTGCTCCGAGGTGTGTTTGTAGTTGCTGCTAAGCGAACGCCCTTTGGAGCTTACGGAGGCCTTC T GAAAGACTTCACTGCTACTGACTTGTCTGAATTTGCTGCCAAGGCTGCCTTGTCTGCTGGCAAAGTC T CACCTGAAACAGTTGACAGTGTGATTATGGGCAATGTCCTGCAGAGTTCTTCAGATGCTATATATTT G GCAAGGCATGTTGGTTTGCGTGTGGGAATCCCAAAGGAGACCCCAGCTCTCACGATTAATAGGCTCT G TGGTTCTGGTTTTCAGTCCATTGTGAATGGATGTCAGGAAATTTGTGTTAAAGAAGCTGAAGTTGTT T TATGTGGAGGAACCGAAAGCATGAGCCAAGCTCCCTACTGTGTCAGAAATGTGCGTTTTGGAACCAA G CTTGGATCAGATATCAAGCTGGAAGATTCTTTATGGGTATCATTAACAGATCAGCATGTCCAGCTCC C CATGGCAATGACTGCAGAGAATCTTGCTGTAAAACACAAAATAAGCAGAGAAGAATGTGACAAATAT G CCCTGCAGTCACAGCAGAGATGGAAAGCTGCTAATGATGCTGGCTACTTTAATGATGAAATGGCACC A ATTGAAGTGAAGACAAAGAAAGGAAAACAGACAATGCAGGTAGACGAGCATGCTCGGCCCCAAACCA C CCTGGAACAGTTACAGAAACTTCCTCCAGTATTCAAGAAAGATGGAACTGTTACTGCAGGGAATGCA T CGGGTGTAGCTGATGGTGCTGGAGCTGTTATCATAGCTAGTGAAGATGCTGTTAAGAAACATAACTT C ACACCACTGGCAAGAATTGTGGGCTACTTTGTATCTGGATGTGATCCCTCTATCATGGGTATTGGTC C TGTCCCTGCTATCAGTGGGGCACTGAAGAAAGCAGGACTGAGTCTTAAGGACATGGATTTGGTAGAG G TGAATGAAGCTTTTGCTCCCCAGTACTTGGCTGTTGAGAGGAGTTTGGATCTTGACATAAGTAAAAC C AATGTGAATGGAGGAGCCATTGCTTTGGGTCACCCACTGGGAGGATCTGGATCAAGAATTACTGCAC A CCTGGTTCACGAATTAAGGCGTCGAGGTGGAAAATATGCCGTTGGATCAGCTTGCATTGGAGGTGGC C AAGGTATTGCTGTCATCATTCAGAGCACAGCCCATCATCACCACCATCACTGAGCAGGTGCGGCCGC A CTCGAGCACCACCACCACCACCAC NOV4f, CG181387-04 SEQ ID NO: 40 j402 aa MW at 42700.5kD Protein Sequence 209 WO 2004/013347 PCT/US2003/024504 RLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMGNVLQSSSDAIY L ARHVGLRVGIPKETPALTINRLCGSGFQSIVNGCQEICVKEAEVVLCGGTESMSQAPYCVRNVRFGT K LGSDIKLEDSLWVSLTDQHVQLPMAMTAENLAVKHKISREECDYYALQSQQRWKAANDAGYFNDEMA p IEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFKKDGTVTAGNASGVADGAGAVIIASEDAVKKHN F TPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLKDMDLVEVNEAFAPQYLAVERSLDLDISK T NVNGGAIALGHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTAHHHHHH NOV4g, CG181387-05 ISEQ ID NO: 41 1230 bp DNA Sequence ORF Start: at 1 JORF Stop: TGA at 1189 CGTCTGCTCCGAGGTGTGTTTGTAGTTGCTGCTAAGCGAACGCCCTTTGGAGCTTACGGAGGCCTTC T GAAAGACTTCACTGCTACTGACTTGTCTGAATTTGCTGCCAAGGCTGCCTTGTCTGCTGGCAAAGTC

T

CACCTGAAACAGTTGACAGTGTGATTATGGGCAATGTCCTGCAGAGTTCTTCAGATGCTATATATTT G GCAAGGCATGTTGGTTTGCGTGTGGGAATCCCAAAGGAGACCCCAGCTCTCACGATTAATAGGCTCT G TGGTTCTGGTTTTCAGTCCATTGTGAATGGATGTCAGGAAATTTGTGTTAAAGAAGCTGAAGTTGTT T TATGTGGAGGAACCGAAAGCATGAGCCAAGCTCCCTACTGTGTCAGAAATGTGCGTTTTGGAACCAA G CTTGGATCAGATATCAAGCTGGAAGATTCTTTATGGGTATCATTAACAGATCAGCATGTCCAGCTCC C CATGGCAATGACTGCAGAGAATCTTGCTGTAAAACACAAAATAAGCAGAGAAGAATGTGACAAATAT G CCCTGCAGTCACAGCAGAGATGGAAAGCTGCTAATGATGCTGGCTACTTTAATGATGAAATGGCACC A ATTGAAGTGAAGACAAAGAAAGGAAAACAGACAATGCAGGTAGACGAGCATGCTCGGCCCCAAACCA C CCTGGAACAGTTACAGAAACTTCCTCCAGTATTCAAGAAAGATGGAACTGTTACTGCAGGGAATGCA T CGGGTGTAGCTGATGGTGCTGGAGCTGTTATCATAGCTAGTGAAGATGCTGTTAAGAAACATAACTT C ACACCACTGGCAAGAATTGTGGGCTACTTTGTATCTGGATGTGATCCCTCTATCATGGGTATTGGTC C TGTCCCTGCTATCAGTGGGGCACTGAAGAAAGCAGGACTGAGTCTTAAGGACATGGATTTGGTAGAG G TGAATGAAGCTTTTGCTCCCCAGTACTTGGCTGTTGAGAGGAGTTTGGATCTTGACATAAGTAAAAC C AATGTGAATGGAGGAGCCATTGCTTTGGGTCACCCACTGGGAGGATCTGGATCAAGAATTACTGCAC A CCTGGTTCACGAATTAAGGCGTCGAGGTGGAAAATATGCCGTTGGATCAGCTTGCATTGGAGGTGGC C AAGGTATTGCTGTCATCATTCAGAGCACAGCCTGAGCAGGTGCGGCCGCACTCGAGCACCACCACCA C CACCAC NOV4g, CG181387-05 SEQ ID NO: 42 396 aa MW at 41877.6kD Protein Sequence RLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMGNVLQSSSDAIY L ARHVGLRVGIPKETPALTINRLCGSGFQS IVNGCQEICVKEAEVVLCGGTESMSQAPYCVRNVRFGT K LGSDIKLEDSLWVSLTDQHVQLPMAMTAENLAVKHKISREECDKYALQSQQRWKAANDAGYFNDEMA p IEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFKKDGTVTAGNASGVADGAGAVIIASEDAVKKHN F 210 WO 2004/013347 PCT/US2003/024504 TPLARIVGYFVSGCDPSIMGIGPVPAISGALKAGLSLKDMDLVEVNEAFAPQYLAVERSLDLDISK T NVNGGATALGHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA NOV4h, CG181387-06 ISEQ ID NO: 43 1221 bp DNA Sequence ORF Start: ATG at 4 JORF Stop: at 1195 ACCATGCGTCTGCTCCGAGGTGTGTTTGTAGTTGCTGCTAAGCGAACGCCCTTTGGAGCTTACGGAG G CCTTCTGAAAGACTTCACTGCTACTGACTTGTCTGAATTTGCTGCCAAGGCTGCCTTGTCTGCTGGC A AAGTCTCACCTGAAACAGTTGACAGTGTGATTATGGGCAATGTCCTGCAGAGTTCTTCAGATGCTAT A TATTTGGCAAGGCATGTTCGTTTGCGTGTGGGAATCCCAAAGGAGACCCCAGCTCTCACGATTAATA G GCTCTGTGGTTCTGGTTTTCAGTCCATTTGAATGGATGTCAGGAAATTTGTGTTAAAGAAGCTGAA G TTGTTTTATGTGGAGGAACCGAAAGCATGAGCCAAGCTCCCTACTGTGTCAGAAATGTGCGTTTTGG A ACCAAGCTTGGATCAGATATCAAGCTGGAAGATTCTTTATGGGTATCATTAACAGATCAGCATGTCC A GCTCCCCATGGCAATGACTGCAGAGAATCTTGCTGTAAAACACAAAATAAGCAGAGAAGAATGTGAC A AATATGCCCTGCAGTCACAGCAGAGATGGAAAGCTGCTAATGATGCTGGCTACTTTAATGATGAAAT G GCACCAATTGAAGTGAAGACAAAGAAAGGAAAACAGACAATGCAGGTAGACGAGCATGCTCGGCCCC A AACCACCCTGGAACAGTTACAGAAACTTCCTCCAGTATTCAAGAAAGATGGAACTGTTACTGCAGGG A ATGCATCGGGTGTAGCTGATGGTGCTGGAGCTGTTATCATAGCTAGTGAAGATGCTGTTAAGAAACA T AACTTCACACCACTGGCAAGAATTGTGGGCTACTTTGTATCTGGATGTGATCCCTCTATCATGGGTA T TGGTCCTGTCCCTGCTATCAGTGGGGCACTGAAGAAAGCAGGACTGAGTCTTAAGGACATGGATTTG G TAGAGGTGAATGAAGCTTTTGCTCCCCAGTACTTGGCTGTTGAGAGGAGTTTCGATCTTGACATAAG T AAAACCAATGTGAATGGAGGAGCCATTGCTTTGGGTCACCCACTGGGAGGATCTGGATCAAGAATTA C TGCACACCTGGTTCACGAATTAAGGCGTCGAGGTGGAAAATATGCCGTTGGATCAGCTTGCATTGGA G GTGGCCAAGGTATTGCTGTCATCATTCAGAGCACAGCCCATCATCACCACCATCACTGAGCAGGT NOV4h, CG181387-06 SEQ ID NO: 44 397 aa 1MW at 42008.8kD Protein Sequence MRLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMGNVLQSSSDAI Y LARHVGLRVGIPKETPALTINRLCGSGFQSIVNGCQEICVKEAEVVLCGGTESMSQAPYCVRNVRFG T KLGSDIKLEDSLWVSLTDQHVQLPMAMTAENLAVKHKISREECDKYALQSQQRWKAANDAGYFNDEM A PIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVKKDGTVTAGNASGVADGAGAVIIASEDAVKKH N FTPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLKDMDLVEVNEAFAPQYLAVERSLDLDIS K TNVNGGAIALGHPLGGSGBRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table D7. 211 WO 2004/013347 PCT/US2003/024504 Table D7. Comparison of the NOV4 protein sequences. NOV4a------------- MLRVVAKTFAGLKDTTLEAK LAKSE NOV4b--------TSMLRVVAIRPGYGLKFADSFAPLAKSE NOV4 -------- TGSTMRLLRGVFVVAAKRTPFGAYGGLLKFTATDLSEFKAASAGKVSPET NOV4d ASMMHHLRVVAKTFAGLKFADSFAALAKSE NOV4e-------HHHRLGFVARIF3YGLKFADSFA~ASGV E NOV4f-------------- RLGFVARPGYGLDFADSFAALAKSE NOV4g-------------- RLGFVARPGYGLDFADSFAALAKSE NOV4h------------- MLRVVAKTFArLKFADSFAALAKSE NOV4a VDSVIMGNhQSSSDAIYLAHVGLRVGIPKETPLTINLCGSGFQS IVNGCQEICVKE NOV4b VDVMNLSSAYAHGRGPKTATNLGGQINCECK NOV4c VDVMNLSSAYAHGRGPKTATNLGGQINCECK NQV4d VDSVIMGNVLQSSSDAIYLARHVGIJRVGIPKETPALJTINRLCGSGFQS EVNGCQEICVKE NOV4 a VDSVIMGNVLQSSSDAIYLAR.HVGLRVGIPKETPALTINRLCGSGFQS IVNGCQEICVKE NOV4f VDSVIMGNVLQSSSDAIYLARHVGLRVGIPKETPALTINRLCGSGFQS IVNGCQEICVKE NOV4g VDVMNLSSAYAHGRGPKTATNLGGQINCECK NOV4h VDSVIMGNLQSSSDAIYLRHVGLRVGIPKETPLTINRLCGSGQSTNGCQEIVK NOV4a AEVCGEMQPCRVPTLSILDLVLDIVLMMANT NOV4b AEVCGEMQPCRVFTLSILDLVLDHQPATNA 2JOV4c AEVCGEMQPCRVFTLSDKESWSTQVLMMANA NOV4d AFVCGEMQPCRVFTLSDKESWSTQVLMMANA NOV4e A-VLGTSSAYVNRGKGDILDLVLD~VLMMANA NOV4f ABVCGEMQPCRVFTLSILDLVLDHQPAT-NA NOV4g AEVCGEMQPCRVPTLSDKESWSTQVLMMANA NOV4h AEVCGEMQPCRVFTLSDKESWSTQVLMMANA NOV4 a KHIREDYLSQWANAYNDMPEKKGQMVEAPTL NOV4b KHIREDYLSQWANAYNDMPEKKGQMVEAPTL NOV4 c KHIREDYLSQWANAYNDMPEKKGQMVEAPTL NOV4d KEIREDYLSQWANAYNDMPEKKGQMVEAPTL NOV4 e K~KSECKAQQRKAIA3FNEAIVTK3QMVEAPTL NOT4f t IRECKAQQRWANAYNEAIVTKGQMVEAPTL NOV49 KHIREDYLSQWANAYNDMPEKKGQMVEAPTL NOV4h KRIREDYLSQWANAYNDMPEKKGQMVEAPTL NOV4 a QLKPVKDTTGAGAGGVIAEAKHFPAIGYSCP NOV4b QLQKLPPVFKKDGTVTAGNASGVAGAGAVIIASEDAVK = FTPLAIVGYFVSGCDPS NOV4 c QLQKLPPVFK1DGTVTAGNASGVADGAGAVIASEDAVKHFTPLARVGYFVSGCDPS NOV4d QLQKLPPVFKKDGTVTAGASGVDGAGAVIIASEDAVKFTPLAIVGYFVSGCDPS NOV~e QLQKLPPVFKDGTVTAGNASGVADGAGAVIIASEDAVJ(JNFTPLARIVGYFVSGCDPS N0V4 f QLQKLPPVFDGTVTAGNASGVADGAGAVIIASEDAVHFTPLARVGYFVSGCDPS NOV4g QIQKLPVFKDGTVTAGNASGVADGAGAVIIASEDAVKHFTPLAIVGYFVSGCDPS NOV4h QLQKLPPVFKDGTVTAGNAGVACAGAVIIASEDAVNFPLAIVGYFSGCDPS 1NOV4 a IMIPPIGLKGSKMLENEFPYAESDDSTVGAA NOV4b IMGIGPVPASGALKKAGLSLMDLVEVNEAFAPQY RSLDLDITNVGGAIAL NOV4c IMIPPIGLKALLDDVV AAQLVRLLDSTVGA NOV4d ITMGIGPVPAISGALKKAGLSLKDMDLVEVNEAFAPQYLAVERSLDLDISKTNGGAIAL NOV4e IMIPPIGLKGSKMLENEFPYAESDDSTVGAA NOV4 f IMGIGPVPAISGALKAGLSLKDMDLVEVNEAFAPQYLAVERSLDLDISKTNVNGGAIAL NOV4g IMGIGPVPAISGALKKAGLSLITMDLVEVNEAAPQYLAVERSLDISKVGGAIAL NOV4±i INGIGPVPAISGAL M GLSLKDMDLVEVNEAFAPQYLAERSLDLDISKTNJNGGAIALJ NOV4a GHPLGGSGSRITAflLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA- NOV4b GHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA- NOV4c GHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSA

-

NOV4d GHPIGGSGS3RITAHLvHEL1RRRGGKY7AVGSACIGGGQGIAVIIQSTA- NOV4e GHPLGGSGSRITAflLVHELRRRGGI(,YAVGSACIGGGQGIAVIIQSTA

--

NOV4f GHLGGRTHVERRGYAGAIGQIVISAMH 212 WO 2004/013347 PCT/US2003/024504 NOV4g GHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA----- NOV4h GHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA----- NOV4a (SEQ ID NO: 30) NOV4b (SEQ ID NO: 32) NOV4c (SEQ ID NO: 34) NOV4d (SEQ ID NO: 36) NOV4e (SEQ ID NO: 38) NOV4f (SEQ ID NO: 40) NOV4g (SEQ ID NO: 42) NOV4h (SEQ ID NO: 44) Further analysis of the NOV4a protein yielded the following properties shown in Table D8. Table D8. Protein Sequence Properties NOV4a SignalP analysis: Cleavage site between residues 19 and 20 PSORT R analysis: PSG: a new signal peptide prediction method N-region: length 5; pos.chg 2; neg.chg 0 Region: length 7; peak value 3.62 PSG score: -0.78 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -7.58 possible cleavage site: between 48 and 49 > Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 1 Number of TMS(s) for threshold 0.5: 0 PERIPHERAL Likelihood= 3.92 (at 279) ALOM score: -0.59 (number of TMSs: 0) MITDISC: discrimination of mitochondrial targeting seq R content: 3 Hyd Moment(75): 6.86 Hyd Moment(95): 13.09 G content: 4 D/E content: 1 S/T content: 1 Score: -2.94 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 24 KRT|PF NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 10.8% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: XXRR-like motif in the N-terminus: RLLR none 213 WO 2004/013347 PCT/US2003/024504 SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif irom cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 94.1 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues Final Results (k = 9/23): 47.8 %: mitochondrial 34.8 %: cytoplasmic 8.7 %: nuclear 4.3 %: vacuolar 4.3 %: peroxisomal >> prediction for CG181387-01 is mit (k=23) A search of the NOV4a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table D9. Table D9. Geneseq Results for NOV4a Geneseq Protein/Organism/Length [Patent NOV4a Identities/ f Expect Identifier #, Date] Residues/ Similarities for Value 214 WO 2004/013347 PCT/US2003/024504 Residues Region ABB89415 Human polypeptide SEQ ID NO 1.397 395/397 (99%) 0.0 1791 - Homo sapiens, 397 aa. 1.397 3951397(99%) [W0200190304-A2, 29-NOV-2001] AAU23202 Novel human enzyme polypeptide 1.397 395/397(99%) 0.0 #288 - Homo sapiens, 438 aa. 42..438 395/397 (99%) [WO200155301-A2, 02-AUG-2001] AAB53323 Human colon cancer antigen protein 1..397 395/397 (99%) 0.0 sequence SEQ ID NO:863 - Homo 42..438 395/397 (99%) sapiens, 438 aa. [W0200055351-A1, 21-SEP-2000] ABR48490 Human Ketothiolase - Homo sapiens, 4..397 391/394 (99%) 0.0 394 aa. [W0200294864-A2, 28- 1..394 392/394 (99%) NOV-2002] ABB60752 Drosophila melanogaster polypeptide 5..395 233/392 (59%) e-131 SEQ ID NO 9048 - Drosophila 6..397 292/392 (74%) melanogaster, 398 aa. [WO200171042-A2, 27-SEP-2001] In a BLAST search of public sequence databases, the NOV4a protein was found to have homology to the proteins shown in the BLASTP data in Table D10. Table D10. Public BLASTP Results for NOV4a Protein NOV4a Identities/ Accession Protein/Organism/Length Residues/ Similarities for Expect Number Match the Matched Value Residues Portion P42765 3-ketoacyl-CoA thiolase, 1..397 397/397 (100%) 0.0 mitochondrial (EC 2.3.1.16) (Beta- 1..397 397/397 (100%) ketothiolase) (Acetyl-CoA acyltransferase) (Mitochondrial 3 oxoacyl- CoA thiolase) (TI) - Homo sapiens (Human), 397 aa. Q9BUT6 Acetyl-coenzyme A acyltransferase 2 1..397 395/397 (99%) 0.0 (Mitochondrial 3 -oxoacyl-coenzyme 1..397 395/397 (99%) A thiolase) - Homo sapiens (Human), 397 aa. CAD67660 Sequence 75 from Patent 4..397 391/394 (99%) 0.0 W002094864 - Homo sapiens 1..394 392/394 (99%) (Human), 394 aa. Q8BWT1 3-ketoacyl-CoA thiolase - Mus 1..397 347/397 (87%) 0.0 musculus (Mouse), 397 aa. 1..397 381/397 (95%) Q8JZR8 0.0 215 WO 2004/013347 PCT/US2003/024504 acyltransferase 2 (Mitochondrial 3- 1.396 380/396 (95%) oxoacyl-coenzyme A thiolase) - Mus musculus (Mouse), 397 aa. PFam analysis predicts that the NOV4a protein contains the domains shown in the Table Dll. Table D11. Domain Analysis of NOV4a Identities/ Pfam Domain NOV4a Match Region Similarities Expect Value for the Matched Region thiolase 4..266 1271274 (46%) 1.4e-147 242/274 (88%) thiolaseC 271..395 81/142 (57%) 1.3e-77 119/142 (84%) ketoacyl-syntC 276..397 29/188 (15%) 0.31 76/188 (40%/) 5 Example D5. Human Acetyl-Coenzyme A acyltransferase 2 Gene Variants and SNIPs Variant sequences are included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can 10 arise in several ways. For example, a SNP maybe due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs 15 occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, however, in the case that a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered 20 regulation of the expression pattern for example, alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, stability of transcribed message. 216 WO 2004/013347 PCT/US2003/024504 Method of novel SNP Identification: SNPs are identified by analyzing sequence assemblies using CuraGen's proprietary SNPTool algorithm. SNPTool identifies variation in assemblies with the following criteria: SNPs are not analyzed within 10 base pairs on.both ends of an alignment; Window size (number of bases in a view) is 10; The allowed number of 5 mismatches in a window is 2; Minimum SNP base quality (PHRED score) is 23; Minimum number of changes to score an SNP is 2/assembly position. SNPTool analyzes the assembly and displays SNP positions, associated individual variant sequences in the assembly, the depth of the assembly at that given position, the putative assembly allele frequency, and the SNP sequence variation. Sequence traces are then selected and brought into view for manual 10 validation. The consensus assembly sequence is imported into CuraTools along with variant sequence changes to identify potential amino acid changes resulting from the SNP sequence variation. Comprehensive SNP data analysis is then exported into the SNPCalling database. Method of novel SNP Confirmation: SNPs are confirmed employing a validated method 15 know as Pyrosequencing. Detailed protocols for Pyrosequencing can be found in: Alderbom et al. Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. (2000). Genome Research. 10, Issue 8, August. 1249-1265. In brief, Pyrosequencing is a real time primer extension process of genotyping. This protocol 20 takes double-stranded, biotinylated PCR products from genomic DNA samples and binds them to streptavidin beads. These beads are then denatured producing single stranded bound DNA. SNPs are characterized utilizing a technique based on an indirect bioluminometric assay of pyrophosphate (PPi) that is released from each dNTP upon DNA chain elongation. Following Klenow polymerase-mediated base incorporation, PPi is released and used as a 25 substrate, together with adenosine 5'-phosphosulfate (APS), for ATP sulfurylase, which results in the formation of ATP. Subsequently, the ATP accomplishes the conversion of luciferin to its oxi-derivative by the action of luciferase. The ensuing light output becomes proportional to the number of added bases, up to about four bases. To allow processivity of the method dNTP excess is degraded by apyrase, which is also present in the starting 30 reaction mixture, so that only dNTPs are added to the template during the sequencing. The process has been fully automated and adapted to a 96-well format, which allows rapid screening of large SNP panels. Results 217 WO 2004/013347 PCT/US2003/024504 The DNA and protein sequences for the novel single nucleotide polymorphic variants of the Acetyl-Coenzyme A acyltransferase 2-like gene of CuraGen Acc. No. CGI 81387-01 are reported in Table D10. Variants are reported individually but any combination of all or a select subset of variants are also included. In Table D10, the positions of the variant bases 5 and the variant amino acid residues are underlined. In summary, there are 6 variants reported in Table D10. Variant 13380063 is an A to G SNP at 697 bp of the nucleotide sequence that results in a Met to Val change at amino acid 217 of protein sequence, variant 13380064 is an A to G SNP at 1250 bp of the nucleotide sequence that results in no change in the protein sequence since the SNP is not in the amino acid coding region, variant 13380065 is an A to 10 G SNP at 1451 bp of the nucleotide sequence that results in no change in the protein sequence since the SNP is not in the amino acid coding region, variant 13380066 is a C to T SNP at 1466 bp of the nucleotide sequence that results in no change in the protein sequence since the SNP is not in the amino acid coding region, variant 13380067 is an A to C SNP at 1525 bp of the nucleotide sequence that results in no change in the protein sequence since the 15 SNP is not in the amino acid coding region, and variant 13380068 is a T to C SNP at 1550 bp of the nucleotide sequence that results in no change in the protein sequence since the SNP is not in the amino acid coding region. Table D1O. Variants of nucleotide sequence Acc. No. CG181387-01 (SEQ ID NO:29) Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13380063 697 A G 217 Met Val 13380064 1250 A G 0 13380065 1451 A G 0 13380066 1466 C T 0 13380067 1525 A C 0 13380068 1550 T C 0 20 Table D11. Sequences of Variants Table D 11A1. Nucleotide sequence of variant 133 80063 NOV4aln (underlined). A/G (SEQ ID NO:155) 1 GCGTCCCCCACACCACAGACCCGCGCCCCGACGACCCAGCAGCCGCCATGCGTCTGCTCCGAGGTGTGTTTGTAGTTGC 81 TGCTAAGCGAACGCCCTTTGGAGCTTACGGAGGCCTTCTGAAAGACTTCACTGCTACTGACTTGTCTGAATTTGCTGCCA 161 AGGCTGCCTTGTCTGCTGGCAAAGTCTCACCTGAAACAGTTGACAGTGTGATTATGGGCAATGTCCTGCAGAGTTCTTCA 241 GATGCTATATATTTGGCAAGGCATGTTGGTTTGCGTGTGGGAATCCCAAAGGAGACCCCAGCTCTCACGATTAATAGGCT 321 CTGTGGTTCTGGTTTTCAGTCCATTGTGAATGGATGTCAGGAAATTTGTGTTAAAGAAGCTGAAGTTGTTTTATGTGGAG 401 GAACCGAAAGCATGAGCCAAGCTCCCTACTGTGTCAGAAATGTGCGTTTTGGAACCAAGCTTGGATCAGATATCAAGCTG 481 GAAGATTCTTTATGGGTATCATTAACAGATCAGCATGTCCAGCTCCCCATGGCAATGACTGCAGAGAATCTTACTGTAAA 561 ACACAAAATAAGCAGAGAAGAATGTGACAAATATGCCCTGCAGTCACAGCAGAGATGGAAAGCTGCTAATGATGCTGGCT 218 WO 2004/013347 PCT/US2003/024504 641 ACTTTAATGATGAAATGGCACCAATTGAAGTGAAGACAAAGAAAGGAAAAGAGACAGTGCAGGTAGACGAGCATGCTCOG 721 CCCCAAACCACCCTGGAACAGTTACAGAAACTTCCTCCAGTATTCAAGAAAGATGGAACTGTTACTGCAGGGAATGCATC 801 GGGTGTAGCTGATGGTGCTGGAGCTGTTATCATAGCTAGTGAAGATGCTGTTAAGAAACATAACTTCACACCACTGGCAA 881 GAATTGTGGGCTACTTTGTATCTGGATGTGATCCCTCTATCATGGGTATTGGTCCTGTCCCTGCTATC!AGTGGGGCACT 961 AAGAAAGCAGGACTGAGTCTTAAGGACATGGATTT TGGTGAATGAAGCTTTTGCTCCCCAGTACTTGGCTGTTGA 1041 GAGGAGTTTGGATCTTGACATAAGTAAAACCAATGTGAATGGAGGAGCCATTGCTTTGGGTCACCCACTGGGAGGATCTG 1121 GATCAAGAATTACTGCACACCTGGTTCACGAATTAAGGCGTCGAGGTCGAAAATATGCCGTTGGATCAGCTTGCATTGGA 1201 GGTGGCCAAGGTATTGCTGTCATCATTCAGAGCACAGCCTGAAGAGACCAGTGAGCTCACTGTGACCCATCCTTACTCTA 1281 CTTGGCCAGGCCACAGTAAAACAAGTGACCTTCAGAGCAGCTGCCACAACTGGCCATGCCCTGCCATTGAAACAGTGATT 1361 AAGTTTGATCAAGCCATGGTGACACAAAAATGCATTGATCATGAATAGGAGCCCATGCTAGAAGTACATTCTCTCAGATT 1441 TGAACCAGTGAAATATGATGTATTTCTGAGCTAAAACTCAACTATAGAAGACATTAAAAGAAATCGTATTCTTGCCAAGT 1521 AACCACCACTTCTGCCTTAGATAATATGATTATAAGGAAATCAAATAAATGTTGCCTTAACTTC Table D 11A2. Protein sequence of variant NOV4alp (underlined). (SEQ ID NO:156) 1 MRLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMGNVLQSSSDAIYLARHVGLRVGIP 81 KETPALTINRLCGSGFQSIVNGCQEICVKEABVVLCGGTESMSQAPYCVRNVRFGTKLGSDIKLEDSLWVSLTDQHVQLP 161 MAMTAENLTVKHKISREECDKYALQSQQRWKAANDAGYFNDEMAPIEVKTKKGKQTVQVDEHARPQTTLEQLQKLPPVFK 241 KDGTVTAGNASGVADGAGAVIIASEDAVKKHNFTPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLKDMDLVEVN 321 EAFAPQYLAVERSLDLDISKTNVNGGAIALGHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA Table D 1A3. Alteration effect Met to Val Table D1 1BI. Nucleotide sequence of variant 13380064 NOV4a2n (underlined). A/G (SEQ ID NO:157) 1 GCGTCCCCCACACCACAGACCCGCGCCGCCGACGACCCAGCAGCCGCCATGCGTCTGCTCCGAGGTGTGTTTGTAGTTGC 81 TGCTAAGCGAACGCCCTTTGGAGCTTACGGAGGCCTTCTGAAAGACTTCACTGCTACTGACTTGTCTGAATTTGCTGCCA 161 AGGCTGCCTTGTCTGCTGGCAAAGTCTCACCTGAAACAGTTGACAGTGTGATTATGGGCAATGTCCTGCAGAGTTCTTCA 241 GATGCTATATATTTGGCAAGGCATGTTGGTTTCCGTGTGGGAATCCCAAAGGAGACCCCAGCTCTCACGATTAATAGGCT 321 CTGTGGTTCTGGTTTTCAGTCCATTGTGAATGGATGTCAGGAAATTTGTGTTAAAGAAGCTGAAGTTGTTTTATGTGGAG 401 GAACCGAAAGCATGAGCCAAGCTCCCTACTGTCTCAGAAATTCTCGTTTTGGAACCAAGCTTGGATCAGATATCAAGCTG 481 GAAGATTCTTTATGGGTATCATTAACAGATCAGCATGTCCAGCTCCCCATGGCAATGACTGCAGAGAATCTTACTGTAAA 561 ACACAAAATAAGCAGAGAAGAATGTGACAAATATGCCCTGCAGTCACAGCAGAGATGGAAAGCTGCTAATGATGCTGGCT 641 ACTTTAATGATGAAATGGCACCAATTGAAGTGAAGACAAAGAAAGGAAAACAGACAATGCAGGTAGACGAGCATGCTCGG 721 CCCCAAACCACCCTGGAACAGTTACACAAACTTCCTCCAGTATTCAAGAAAGATGGAACTGTTACTGCAGGGAATGCATC 801 GGGTGTAGCTGATGGTGCTGGAGCTGTTATCATAGCTAGTGAAGATGCTGTTAAGAAACATAACTTCACACCACTGGCAA 881 GAATTGTGGGCTACTTTGTATCTGGATGTGATCCCTCTATCATGGGTATTGGTCCTGTCCCTGCTATCAGTGGGGCACTG 961 AAGAAAGCAGGACTGAGTCTTAAGGACATGGATTTGGTAGAGGTGAATGAAGCTTTTGCTCCCCAGTACTTGGCTGTTGA 1041 GAGGAGTTTGGATCTTGACATAAGTAAAACCAATGTGAATGGAGGAGCCATTGCTTTGGGTCACCCACTGGGAGGATCTG 1121 GATCAAGAATTACTGCACACCTGGTTCACGAATTAAGGCGTCGAGGTGGAAAATATGCCGTTGGATCAGCTTGCATTGGA 1201 GGTGGCCAAGGTATTGCTGTCATCATTCAGAGCACAGCCTCAAGAGACCGGTGAGCTCACTGTGACCCATCCTTACTCTA 1281 CTTGGCCAGGCCACAGTAAAACAAGTGACCTTCAGAGCAGCTGCCACAACTGGCCATGCCCTGCCATTGAAACAGTGATT 1361 AAGTTTGATCAAGCCATGGTGACACAAAAATGCATTGATCATGAATAGGAGCCCATGCTAGAAGTACATTCTCTCAGATT 1441 TGAACCAGTGAAATATGATGTATTTCTGAGCTAAAACTCAACTATAGAAGACATTAAAAGAAATCGTATTCTTGCCAAGT 1521 AACCACCACTTCTGCCTTAGATAATATGATTATAAGGAAATCAAATAAATGTTGCCTTAACTTC Table Dl 1B2. Protein sequence of variant NOV4a2p (underlined). (SEQ ID NO:158) 1 MRLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPE'VDSVIMGNVLQSSSDAIYLARHVGLRVGIP 81 KETPALTINRLCGSGFOSIVNGCQEICVKEAEVVLCGGTESMSQAPYCVRNVRFGTKLGSDIKLEDSLWVSLTDQHVQLD 161 MAMTAENLTVKHKISREECDKYALQSQQRWKAANDAGYFNDEMAPIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFK 241 KDGTVTAGNASGVADGAGAVIIASEDAVKKHNFTPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLKDMDLVEVN 321 EAFAPQYLAVERSLDLDISKTNVNGGAIALGHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA Table C 11B3. Alteration effect None Table D1 ICL. Nucleotide sequence of variant 13380065 NOV4a3n (underlined). A/G (SEQ ID NO:159) 1 GCGTCCCCCACACCACAGACCCGCGCCGCCGACGACCCAGCAGCCGCCATGCGTCTGCTCCGACGTGTGTTTGTAGTTGC 81 TGCTAAGCGAACGCCCTTTGGAGCTTACGGAGGCCTTCTGAAAGACTTCACTGCTACTGACTTGTCTGAATTTGCTGCCA 161 AGGCTGCCTTGTCTCCTGCCAAAGTCTCACCTGAAACAGTTGACAGTGTGATTATGGGCAATGTCCTGCAGAGTTCTTCA 241 GATGCTATATATTTGGCAAGGCATGTTGGTTTGCGTGTGGGAATCCCAAAGGAGACCCCAGCTCTCACGATTAATAGGCT 321 CTGTGGTTCTGGTTTTCAGTCCATTGTGAATCGATGTCAGGAAATTTGTGTTAAAGAAGCTGAAGTTGTTTTATGTGGAG 401 GAACCGAAAGCATGAGCCAACCTCCCTACTGTGTCAGAAATGTGCGTTTTGGAACCAAGCTTGGATCAGATATCAAGCTG 481 GAAGATTCTTTATGGGTATCATTAACAGATCAGCATGTCCAGCTCCCCATGGCAATGACTGCAGAGAATCTTACTGTAAA 561 ACACAAAATAAGCAGAGAAGAATGTGACAAATATGCCCTGCAGTCACAGCAGAGATGGAAAGCTGCTAATGATGCTGGCT 641 ACTTTAATGATGAAATGGCACCAATTGAAGTGAAGACAAAGAAAGGAAAACAGACAATGCAGGTAGACGAGCATGCTCGG 721 CCCCAAACCACCCTGGAACAGTTACAGAAACTTCCTCCAGTATTCAAGAAAGATGGAACTGTTACTGCAGGGAATGCATC 801 GGGTGTAGCTGATGGTGCTGGAGCTGTTATCATAGCAGTGAAGATGCTGTTAAGAACATAACTTCACACCACTGGCAA 219 WO 2004/013347 PCT/US2003/024504 881 GAATTGTGGGCTACTTTGTATCTGGATGTGATCCCTCTATCATGGGTATTGGTCCTGTCCCTGCTATCAGTGGGGCACTG 961 AAGAAAGCAGGACTGAGTCTTAAGGACATGGATTTGGTAGAGGTGAATGAAGCTTTTGCTCCCCAGTACTTGGCTGTTGA 1041 GAGGAGTTTGGATCTTGACATAAGTAAAACCAATGTGAATGGAGGAGCCATTGCTTTGGGTCACCCACTGGGAGGATCTG 1121 GATCAAGAATTACTGCACACCTGGTTCACGAATTAAGGCGTCGAGGTGGAAAATATGCCGTTGGATCAGCTTGCATTGGA 1201 GGTGGCCAAGGTATTGCTGTCATCATTCAGAGCACAGCCTGAAGAGACCAGTGAGCTCACTGTGACCCATCCTTACTCTA 1281 CTTGGCCAGGCCACAGTAAAACAAGTGACCTTCAGAGCAGCTGCCACAACTGGCCATGCCCTGCCATTGAAACAGTGATT 1361 AAGTTTGATCAAGCCATGGTGACACAAAAATGCATTGATCATGAATAGGAGCCCATGCTAGAAGTACATTCTCTCAGATT 1441 TGAACCAGTGGAATATGATGTATTTCTGAGCTAAAACTCAACTATAGAAGACATTAAAAGAAATCGTATTCTTGCCAAGT 1521 AACCACCACTTCTGCCTTAGATAATATGATTATAAGGAAATCAAATAAATGTTGCCTTAACTTC Table Dl1C2. Protein sequence of variant NOV4a3p (underlined). (SEQ ID NO:160) 1 MRLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMGNVLQSSSDAIYLARHVGLRVGIP 81 KETPALTINRLCGSGFQSIVNGCQEICVKEAEVVLCGGTESMSQAPYCVRNVRFGTKLGSDIKLEDSLWVSLTDQHVQLP 161 MAMTAENLTVKHKISREBCDKYALQSQQRWKAANDAGYFNDEMAPIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFK 241 KDGTVTAGNASGVADGAGAVIIASEDAVKKHNFTPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLKDMDLVEVN 321 EAFAPQYLAVERSLDLDISKTNVNGGAIALGHPLGGSGSRITAHLVHELRRGGKYAVGSACIGGGQGIAVIIQSTA Table D11 C3. Alteration effect None Table Dl D1. Nucleotide sequence of variant 13380066 NOV4a4n (underlined). C/T (SEQ ID NO:161) 1 GCGTCCCCCACACCACAGACCCGCGCCGCCGACGACCCAGCAGCCGCCATGCGTCTGCTCCGAGGTGTGTTTGTAGTTGC 81 TGCTAAGCGAACGCCCTTTGGAGCTTACGGAGGCCTTCTGAAAGACTTCACTGCTACTGACTTGTCTGAATTTGCTGCCA 161 AGGCTGCCTTGTCTGCTGGCAAAGTCTCACCTGAAACAGTTGACAGTGTGATTATGGGCAATGTCCTGCAGAGTTCTTCA 241 GATGCTATATATTTGGCAAGGCATGTTGGTTTGCGTGTGGGAATCCCAAAGGAGACCCCAGCTCTCACGATTAATAGGCT 321 CTGTGGTTCTGGTTTTCAGTCCATTGTGAATGGATGTCAGGAAATTTGTGTTAAAGAAGCTGAAGTTGTTTTATGTGGAG 401 GAACCGAAAGCATGAGCCAAGCTCCCTACTGTGTCAGAAATGTGCGTTTTGGAACCAAGCTTGGATCAGATATCAAGCTG 481 GAAGATTCTTTATGGGTATCATTAACAGATCAGCATGTCCAGCTCCCCATGGCAATGACTGCAGAGAATCTTACTGTAAA 561 ACACAAAATAAGCAGAGAAGAATGTGACAAATATGCCCTGCAGTCACAGCAGAGATGGAAAGCTGCTAATGATGCTGGCT 641 ACTTTAATGATGAAATGGCACCAATTGAAGTGAAGACAAAGAAAGGAAAACAGACAATGCAGGTAGACGAGCATGCTCGG 721 CCCCAAACCACCCTGGAACAGTTACAGAAACTTCCTCCAGTATTCAAGAAAGATGGAACTGTTACTGCAGGGAATGCATC 801 GGTGTAGCTGATGGTGCTGGAGCTGTTATCATAGCTAGTGAAGATGCTGTTAAGAAACATAACTTCACACCACTGGCAA 881 GAATTGTGGGCTACTTTGTATCTGGATGTGATCCCTCTATCATGGGTATTGGTCCTGTCCCTGCTATCAGTGGGGCACTG 961 AAGAAAGCAGGACTGAGTCTTAAGGACATGGATTTGGTAGAGGTGAATGAAGCTTTGCTCCCCAGTACTTGGCTGTTGA 1041 GAGGAGTTTGGATCTTGACATAAGTAAAACCAATGTGAATGGAGGAGCCATTGCTTTGGGTCACCCACTGGGAGGATCTG 1121 GATCAAGAATTACTGCACACCTGGTTCACGAATTAAGGCGTCGAGGTGGAAAATATGCCGTTGGATCAGCTTGCATTGGA 1201 GGTGGCCAAGGTATTGCTGTCATCATTCAGAGCACAGCCTGAAGAGACCAGTGAGCTCACTGTGACCCATCCTTACTCTA 1281 CTTGGCCAGGCCACAGTAAAACAAGTGACCTTCAGAGCAGCTGCCACAACTGGCCATGCCCTGCCATTGAAACAGTGATT 1361 AAGTTTGATCAAGCCATGGTGACACAAAAATGCATTGATCATGAATAGGAGCCCATGCTAGAAGTACATTCTCTCAGATT 1441 TGAACCAGTGAAATATGATGTATTTTTGAGCTAAAACTCAACTATAGAAGACATTAAAAGAAATCGTATTCTTGCCAAGT 1521 AACCACCACTTCTGCCTTAGATAATATGATTATAAGGAAATCAAATAAATGTTGCCTTAACTTC Table D 11D2. Protein sequence of variant NOV4a4p (underlined). (SEQ ID NO:162) 1 MRLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMGNVLQSSSDAIYLARHVGLRVGIP 81 KETPALTINRLCGSGFQSIVNGCQEICVKEAEVVLCGGTESMSQAPYCVRNVRFGTKLGSDIKLEDSLWVSLTDQHVQLP 161 MAMTAENLTVKHKISREECDKYALQSQQRWKAANDAGYFNDEMAPIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFK 241 KDGTVTAGNASGVADGAGAVIIASEDAVKKHNFTPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLKDMDLVEVN 321 EAFAPQYLAVERSLDLDISKTNVNGGAIALGHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA Table D 11D3. Alteration effect None Table Dl E1. Nucleotide sequence of variant 13380067 NOV4a5n (underlined). A/C (SEQ ]D NO:163) 1 GCGTCCCCCACACCACAGACCCGCGCCGCCGACGACCCAGCAGCCGCCATGCGTCTGCTCCGAGGTGTGTTTGTAGTTGC 81 TGCTAAGCGAACGCCCTTTGGAGCTTACGGAGGCCTTCTGAAAGACTTCACTGCTACTGACTTGTCTGAATTTGCTGCCA 161 AGGCTGCCTTGTCTGCTGGCAAAGTCTCACCTGAAACAGTTGACAGTGTGATTATGGGCAATGTCCTGCAGAGTTCTTCA 241 GATGCTATATATTTGGCAAGGCATGTTGGTTTGCGTGTGGGAATCCCAAAGGAGACCCCAGCTCTCACGATTAATAGGCT 321 CTGTGGTTCTGGTTTTCAGTCCATTGTGAATGGATGTCAGGAAATTTGTGTTAAAGAAGCTGAAGTTGTTTTATGTGGAG 401 GAACCGAAAGCATGAGCCAAGCTCCCTACTGTGTCAGAAATGTGCGTTTTGGAACCAAGCTTGGATCAGATATCAAGCTG 481 GAAGATTCTTTATGGGTATCATTAACAGATCAGCATGTCCAGCTCCCCATGGCAATGACTGCAGAGAATCTTACTGTAAA 561 ACACAAAATAAGCAGAGAAGAATGTGACAAATATGCCCTGCAGTCACAGCAGAGATGGAAAGCTGCTAATGATGCTGGCT 641 ACTTTAATGATGAAATGGCACCAATTGAAGTGAAGACAAAGAAAGGAAAACAGACAATGCAGGTAGACGAGCATGCTCGG 721 CCCCAAACCACCCTGGAACAGTTACAGAAACTTCCTCCAGTATTCAAGAAAGATGGAACTGTTACTGCAGGGAATGCATC 801 GGGTGTAGCTGATCGTGCTGGAGCTGTTATCATAGCTAGTGAAATGCTGTTAAAAACATAACTTCACACCACTGGCAA 881 GAATTGTGGGCTACTTTGTATCTGGATGTGATCCCTCTATCATGGGTATTGGTCCTGTCCCTGCTATCAGTGGGGCACTG 961 AAGAAAGCACACTGAGTCTTAAGGACATGGATTTGGTAGAGGTGAATGAAGCTTTTGCTCCCCAGTACTTGGCTGTTGA 1041 GAGGAGTTTGGATCTTGACATAAGTAAAACCAATGTGAATGGAGGAGCCATTGCTTTGGGTCACCCACTGGGAGGATCTG 220 WO 2004/013347 PCT/US2003/024504 1121 GATCAAGAATTACTGCACACCTGGTTCACGAATTAAGGCGTCGAGGTGGAAAATATGCCGTTGGATCAGCTTGCATTGGA 1201 GGTGGCCAAGGTATTGCTGTCATCATTCAGAGCACAGCCTGAAGAGACCAGTGAGCTCACTGTGACCCATCCTTACTCTA 1281 CTTGGCCAGGCCACAGTAAAACAAGTGACCTTCAGAGCAGCTGCCACAACTGGCCATGCCCTGCCATTGAAACAGTGATT 1361 AAGTTTGATCAAGCCATGGTGACACAAAAATGCATTGATCATGAATAGAGCCCATGCTAGAAGTACATTCTCTCAGATT 1441 TGAACCAGTGAAATATGATGTATTTCTGAGCTAAAACTCAACTATAGAAGACATTAAAAGAAATCGTATTCTTGCCAAGT 1521 AACCCCCACTTCTGCCTTAGATAATATGATTATAAGGAAATCAAATAAATGTTGCCTTAACTTC Table Dl 1E2. Protein sequence of variant NOV4a5p (underlined). (SEQ ID NO:164) 1 MRLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMGNVLQSSSDAIYLARHVGLRVGIP 81 KETPALTINRLCGSGFQSIVNGCQEICVKEAEVVLCGGTESMSQAPYCVRNVRFGTKLGSDIKLEDSLWVSLTDQHVQLP 161 MAMTAENLTVKHKISREECDKYALQSQQRWKAANDAGYFNDEMAPIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFK 241 KDGTVTAGNASGVADGAGAVIIASEDAVKKHNFTPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLDMDLVEVN 321 EAFAPQYLAVERSLDLDISKTNVNGGAIALGHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA Table D 11E3. Alteration effect None Table D1IF1. Nucleotide sequence of variant 13380068 NOV4a6n (underlined). T/C (SEQ ID NO:165) 1 GCGTCCCCCACACCACAGACCCGCGCCGCCGACGACCCAGCAGCCGCCATGCGTCTGCTCCGAGGTGTGTTTGTAGTTGC 81 TGCTAAGCGAACGCCCTTTGGAGCTTACGGAGGCCTTCTGAAAGACTTCACTGCTACTGACTTGTCTGAATTTGCTGCCA 161 AGGCTGCCTTGTCTGCTGGCAAAGTCTCACCTGAAACAGTTGACAGTGTGATTATGGGCAATGTCCTGCAGAGTTCTTCA 241 GATGCTATATATTTGGCAAGGCATGTTGGTTTGCGTGTGGGAATCCCAAAGGAGACCCCAGCTCTCACGATTAATAGGCT 321 CTGTGGTTCTGGTTTTCAGTCCATTGTGAATGGATGTCAGGAAATTTGTGTTAAAGAAGCTGAAGTTGTTTTATGTGGAG 401 GAACCGAAAGCATGAGCCAAGCTCCCTACTGTGTCAGAAATGTGCGTTTTGGAACCAAGCTTGGATCAGATATCAAGCTG 481 GAAGATTCTTTATGGGTATCATTAACAGATCAGCATGTCCAGCTCCCCATCGCAATGACTGCAGAGAATCTTACTGTAAA 561 ACACAAAATAAGCAGAGAAGAATGTGACAAATATGCCCTGCAGTCACAGCAGAGATGGAAAGCTCCTAATGATGCTGGCT 641 ACTTTAATGATGAAATGGCACCAATTGAAGTGAAGACAAAGAAAGGAAAACAGACAATGCAGGTAGACGAGCATGCTCGG 721 CCCCAAACCACCCTGGAACAGTTACAGAAACTTCCTCCAGTATTCAAGAAAGATGGAACTGTTACTGCAGGGAATGCATC 801 GGGTGTAGCTGATGGTGCTGGAGCTGTTATCATAGCTAGTGAAGATGCTGTTAAGAAACATAACTTCACACCACTGGCAA 881 GAATTGTGGGCTACTTTGTATCTGGATGTATCCCTCTATCATGGGTATTGGTCCTGTCCCTGCTATCAGTGGGGCACTG 961 AAGAAAGCAGGACTGAGTCTTAAGGACATGATTTGGTAGAGGTGAATGAAGCTTTTGCTCCCCAGTACTTGGCTGTTGA 1041 GAGGAGTTTGGATCTTGACATAAGTAAAACCAATGTGAATGGAGGAGCCATTGCTTTGGGTCACCCACTGGGAGGATCTG 1121 GATCAAGAATTACTGCACACCTGGTTCACGAATTAAGGCGTCGAGGTCAAAATATGCCGTTGGATCAGCTTGCATTGGA 1201 GGTGGCCAAGGTATTGCTGTCATCATTCAGAGCACAGCCTGAAGAGACCAGTGAGCTCACTGTGACCCATCCTTACTCTA 1281 CTTGGCCAGGCCACAGTAAAACAAGTGACCTTCAGAGCAGCTGCCACAACTGGCCATGCCCTGCCATTGAAACAGTGATT 1361 AAGTTTGATCAAGCCATGGTGACACAAAAATGCATTGATCATGAATAGGAGCCCATGCTAGAAGTACATTCTCTCAGATT 1441 TGAACCAGTGAAATATGATGTATTTCTGAGCTAAAACTCAACTATAGAAGACATTAAAAGAAATCGTATTCTTCCCAAGT 1521 AACCACCACTTCTGCCTTAGATAATATGACTATAAGGAAATCAAATAAATGTTGCCTTAACTTC Table D 1F2. Protein sequence of variant NOV4a6p (underlined). (SEQ ID NO:166) 1 MRLLRGVFVVAAKRTPFGAYGGLLKDFTATDLSEFAAKAALSAGKVSPETVDSVIMGNVLQSSSDAIYLARHVGLRVGIP 81 KETPALTINRLCGSGFQSIVNGCQEICVKEAEVVLCGGTESMSQAPYCVRNVRFGTKLGSDIKLEDSLWVSLTDQHVQLP 161 MAMTAENLTVKHKISREECDKYALQSQQRWKAANDAGYFNDEMAPIEVKTKKGKQTMQVDEHARPQTTLEQLQKLPPVFK 241 KDGTVTAGNASGVADGAGAVIIASEDAVKKHNFTPLARIVGYFVSGCDPSIMGIGPVPAISGALKKAGLSLKDMDLVEVN 321 EAFAPQYLAVERSLDLDISKTNVNGGAIALGHPLGGSGSRITAHLVHELRRRGGKYAVGSACIGGGQGIAVIIQSTA Table D 1F3. Alteration effect None Example D6. Expression Profile of the Human Acetyl-Coenzyme A acyltransferase 2 Gene 5 The protocol for quantitative expression analysis is disclosed in Example Q9. Expression of gene CG181387-01 and CG181387-02 was assessed using the primer probe set Ag6643, described in Table D13. Results of the RTQ-PCR runs are shown in Tables D14 and D15. Table D13. Probe Name Ag6643 221 WO 2004/013347 PCT/US2003/024504 Primers Sequences Length Position No Forwards -tactgtaaaacacaaaataagcagagaag-3' 29 552 194 Probe TET-5*-aatatgccctgcagtcacagcagaga-3 - 26 590 195 TAMRA__________ Reverse s5-atcattaaagtagccagcatattag-3' 26 626 196 Table D14. General screening panel vl.6 TRel. Exp.(%) Ag6643, Rel. Exp.(%) Ag6643, Tissue Name Run 277256952 Tissue Name Run 277256952 Adipose 12.8 Renal ca. TK-10 7.2 Melanoma* mBadr2. Hs688(A).T 5 Bladder 25.3 Melanoma* 18.4 Gastric ca. (liver met.) 13.6 Hs688(B).T NCI-N87 Melanoma* M14 11.5 Gastric ca. KATO III 100.0 Melanoma* 11.3 Colon ca. SW-948 9.5 LOXIMVI____ ___ Melanoma* SK- 17.1 Colon ca. SW480 22.4 MEL-S _______ _______ Squamous cell 0.5 Colon ca.* (SW480 14.9 carcinoma SCC-4 met) SW620 Testis Pool 6.0 Colon ca. HT29 13.9 Prostate ca.* (bone 4.3 Colon ca. HCT-1 16 5.4 met) PC-3 Prostate Pool 4.0 Colon ca. CaCo-2 45.1 Placenta 3.0 Colon cancer tissue 13.3 Uterus Pool 1.6 Colon ca. SW1116 2.7 Ovarian ca. 6.6 Colon ca. Colo-205 5.6 OVCAR-3 ______ ____________ Ovarian ca. SK-OV- 0.4 Colon ca. SW-48 15.0 3 Ovaran ca4.0 Colon Pool 5.1 Ovarn ca. 13.6 Small Intestine Pool 3.5 Ovarian ca. IGROV- 6.3 Stomach Pool 2.6 1 Ovarian ca 1.4 Bone Marrow Pool 2.6 OVCAR-8_______ _______ ____ ___ Ovary 5.3 Feta1 Heart 12.7 Breast ca. MCF-7 7.7 Heart Pool 11.0 Breast ca. MDA- 13.1 Lymph Node Pool 5.6 MB-2315 222 WO 2004/013347 PCT/US2003/024504 Breast ca. BT 549 28.3 Fetal Skeletal Muscle 7.2 Breast ca. T47D 4.9 Skeletal Muscle Pool 5.0 Breast ca. MDA-N 8.8 Spleen Pool 2.5 Breast Pool 5.4 Thymus Pool 3.9 Trachea 1.7 CNS cancer (glio/astro) 7.8 U87-MG Lung 1.7 CNS cancer (glio/astro) 21.3 U-118-MG Fetal Lung 9.3 CNS cancer 22.1 (neuro;met) SK-N-AS Lung ca. NCI-N417 6.2 CNS cancer (astro) SF- 9.3 539 Lung ca. LX-1 19.8 CNS cancer (astro) 32.5 SNB-75 Lung ca. NCI-H146 31.9 CNS cancer (glio) 5.8 SNB-19 Lung ca. SHP-77 35.6 CNS cancer (glio) SF- 9.2 295 Lung ca. A549 21.8 Brain (Amygdala) Pool 4.1 Lung ca. NCI-H526 9.0 Brain (cerebellum) 4.8 Lung ca. NCI-H23 12.9 Brain (fetal) 3.9 Lung ca. NCI-H460 10.0 Brain (Hippocampus) 5.7 Pool Lung ca. HOP-62 3.8 Cerebral Cortex Pool 4 Lung ca. NCI-H522 24.5 Brain (Substantia 3.4 nigra) Pool Liver 18.6 Brain (Thalamus) Pool 6.2 Fetal Liver 27.9 Brain (whole) 6.1 Liver ca. HepG2 9.3 Spinal Cord Pool 5.6 Kidney Pool 6.9 Adrenal Gland 11.9 Fetal Kidney 23.3 Pituitary gland Pool 2.1 Renal ca. 786-0 7.7 Salivary Gland 1.0 Renal ca. A498 1.1 Thyroid (female) 6.6 Renal ca. ACHN 4.2 Pancreatic ca. 10.9 Renal ca. UO-31 16.6 Pancreas Pool 6.3 Table D15. Panel 5 Islet Rel. Exp.(%) Rel. Exp.(%) Tissue Name Ag6643, Run Tissue Name Ag6643, Run 279519414 279519414 97457 Patient 02go adipose 22.5 honor 2 AM - A adipose 45.1 97476_Patient 0.0 94710 Donor 2 AM - B adipose 25.7 223 WO 2004/013347 PCT/US2003/024504 07sk skeletal muscle 97477 Patient- 6.0 94711 Donor 2 AM - Cadipose 21.3 O7ut uterus _______ -o adpos 977 atint- 9.8 94712 Donor 2 AD - A adipose 49.7 O7plplacenta _ 2A dps 9 99167 Bayer Pa t ien t 1 20.9 94713 Donor 2 AD -B adipose 70.7 97482 Patient- 3.5 94714 Donor 2 AD - Cjadipose 60.7 97483 Patient- 94742 Donor 3 U 08plplacenta 6.6 A Mesenchymal Stem Cells 12.2 97486 Patient- :94743_Donor 3 U - 12.7 09sk skeletal muscle BMesenchymal Stem Cells 9487 atient- 6.7 94730_Donor 3 AM - A adipose 65.5 O9ut-uterus 97488_Patient- 4.5 94731 Donor 3 AM - B adipose 68.3 O9plplacenta- 97492 Patient- 12.5 94732_Donor 3 AM - C adipose 74.2 out uterus _ _ _ _ _ _ _ _ _ _ _ _ _ _ 97493 Patient- 19.9 94733_Donor 3 AD - A adipose 100.0 'OPIAplacenta _______ ______________ ______ 97495 Patient- 9.6 94734 Donor 3 AD - B adipose 90.8 11 go adipose 996s ketentmuscle 15.4 94735_Donor 3 AD - C adipose 29.3 97497_Patient- 12.3 77138_Liver HepG2untreated 59.5 1 ut uterus_______ 97498 Patient- 73556 Heart Cardiac stromal 56 I p1_piacenta 3.1 cells (primary) 5.6 97500 Patient- 29.9 81735_Small Intestine 32.8 l2go adipose_______ _______________ _______ 97501_Patient- 51.4 72409_KidneyProximal 40.3 12sk skeletal muscle Convoluted Tubule 97502 Patient- 13.6 82685_Small intestine Duodenum 50.3 97503_Patient- 10.4 90650_Adrenal_Adrenocortical 6.0 l2plplacenta adenoma 94721_Donor 2 U A_Mesenchymal Stem 37.1 72410_Kidney HRCE 15.4 Cells 94722_Donor 2 U BMesenchymal Stem 24.5 7241 Kidney 16.0 Cells 94723_Donor 2 U - 73139UterusUterine smooth CMesenchymal Stem 36.1 7319_ers_ 5.1 Cells I muscle cells 224 WO 2004/013347 PCT/US2003/024504 General screening panel vl.6 Summary: Ag6643 Highest expression of this gene was detected in a gastric cancer KATO III cell line (CT=24.2). Moderate to high levels of expression of this gene were also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, melanoma and brain cancers. Thus, 5 expression of this gene could be used as a marker to detect the presence of these cancers. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product may be useful in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. 10 Among tissues with metabolic or endocrine function, this gene was expressed at moderate to high levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product may be useful in the treatment of endocrine/metabolically related diseases, such as obesity 15 and diabetes. In addition, this gene was expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product may be 20 useful in the treatment of central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression. Panel 5 Islet Summary: Ag6643 Highest expression of this gene was detected in differentiated adipose (CT=28.2). High expression of this gene was seen in midway and fully differentiated adipose tissue, in addition moderate levels of expression of this gene was also 25 detected in islet cells, skeletal muscle, small intestine and heart. Example D7. Assays for Modulators of Acetyl-Coenzyme A acyltransferase 2 One potential assay that may be used to screen for modulators of Acetyl-Coenzyme 30 A acyltransferase 2 is to measure acetoacetyl-CoA cleavage by an optical assay following the decrease of the enol and chelate form of acetoacetyl-CoA by absorption measurement at 305 nm as described Berndt H, Schlegel HG. Kinetics and properties of beta-ketothiolase 225 WO 2004/013347 PCT/US2003/024504 from Clostridium pasteurianum. Arch Microbiol. 1975 Mar 12;103(1):21-30, PMID: 240336). Another potential assay that may be used to screen for modulators of Acetyl 5 Coenzyme A acyltransferase 2 is the measurement of NAD+/NADH production in a reaction coupled with the conversion reaction of 3-hydroxyacyl CoA to 3-oxoacyl CoA by the next mitochondrial enzyme (Barycki JJ, O'Brien LK, Bratt JM, Zhang R, Sanishvili R, Strauss AW, Banaszak LJ. Biochemical characterization and crystal structure determination of human heart short chain L-3-hydroxyacyl-CoA dehydrogenase provide insights into catalytic 10 mechanism. Biochemistry. 1999 May 4;38(18):5786-98. PMID: 10231530). Our results indicate that a modulator of ACAA2 activity, such as an inhibitor, activator, antagonist, or agonist of ACAA2 may be useful for treatment of such disorders as obesity, diabetes, and insulin resistance, as well as for enhancement of insulin secretion. 15 E. NOV5 - PHOSPHOGLYCERATE MUTASE 2 Phosphoglycerate mutase is a dimeric enzyme containing, in different tissues, various proportions of a slow-migrating (PGM2) isoenzyme and a fast-migrating brain (PGMI) 20 isoenzyme, which are encoded by different genes. PGM1 is a ubiquitously expressed isoenzyme with highest expression in the brain. In contrast, PGM2 is expressed specifically in skeletal muscle. Phosphoglycerate mutase is an enzyme involved in the second step of glycolysis (conversion of glyceraldehydes 3-phopshate to pyruvate). Complete deficiency in PGM2 leads to a muscle phenotype associated with mild myopathy and exercise intolerance 25 (Tsujino S, Shanske S, Sakoda S, Fenichel G, DiMauro S. The molecular genetic basis of muscle phosphoglycerate mutase (PGAM) deficiency. (1993) Am. J. Hum. Genet. 52(3):472-7 PMID: 8447317). This phenotype may promote energy expenditure in a diabetic/obese condition. 30 We have found that most of the enzymes involved in the second step of glycolysis are up-regulated in diabetic skeletal muscle. This is consistent with the literature data which demonstrated an increase in glycolytic enzyme activity and a decrease in oxidative enzyme 226 WO 2004/013347 PCT/US2003/024504 activity in the skeletal muscle from diabetic/obese patients (Simoneau JA, Kelley DE. Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM. (1997) J. Apple. Physiol. 83(1):166-71 PMID: 9216960). Disbalance of glycolytic/oxidative capacity may increase the lipid content and consequentially lead to the 5 development of insulin resistance in skeletal muscle. Our differential expression (GeneCalling@) data shows the up-regulation of PGM1 in soleus muscle in diabetic compared to non-diabetic animals. PGMI was found expressed more in glycolytic then in oxidative muscle fiber. RTQ-PCR results demonstrate that PGM2 10 is specifically expressed in muscle tissue and up-regulated in insulin resistant skeletal muscle from patients with Gestational Diabetes. Up-regulation of both PGM1 and PGM2 detected in our studies would contribute to increase in glycolytic muscle capacity described in diabetic conditions. 15 Figure 3 suggests how alterations in expression of the human Phosphoglycerate mutase 2 and associated gene products function in the etiology and pathogenesis of obesity and/or diabetes. The scheme incorporates the unique findings of our studies in conjunction with what has been reported in the literature. Figure 4 summarizes the biochemistry surrounding the human Phosphoglycerate 20 mutase 2 and potential assays that may be used to screen for antibody therapeutics or small molecule drugs to treat obesity and/or diabetes. In the presence of 2,3-biphosphoglycerate, phosphoglycerate mutase catalyses the interconversion between 3-phosphoglycerate and 2 phosphoglycerate, the third step in conversion of glyceraldehydes-3-phosphate to pyruvate: 25 3-Phosphoglycerate U 2-phospoglycerate Activation of glycolysis can contribute to disproportional increase in glycolytic capacity in diabetic skeletal muscle and development of insulin resistance. Because of specific expression of PGM2 in skeletal muscle, its inhibition may restore the energy balance 30 and favor the oxidative muscle phenotype with minimal effect on glycolysis in other tissues. The outcome of inhibiting the action of the human Phosphoglycerate mutase 2 would be a reduction of Insulin Resistance, a major problem in obesity and/or diabetes. Thus, an antagonist or an inhibitor of PGM2 may be used for the treatment of obesity and/or diabetes. 227 WO 2004/013347 PCT/US2003/024504 Cell lines expressing the Phosphoglycerate mutase 2 are described in the RTQ-PCR results described herein. These and other Phosphoglycerate mutase 2 expressing cell lines could be used for screening purposes. The assay for measurement of phosphoglycerate mutase activity and the selective inhibitor for PGM2 have been described in literature (see 5 for example White MF, Fothergill-Gilmore LA.Development of a mutagenesis, expression and purification system for yeast phosphoglycerate mutase. Investigation of the role of active-site Hisl81.Eur J Biochem. 1992 Jul 15;207(2):709-14. PMID: 1386023, Rigden DJ, Walter RA, Phillips SE, Fothergill-Gilmore LA.Polyanionic inhibitors of phosphoglycerate mutase: combined structural and biochemical analysis.J Mol Biol. 1999 Jun 18;289(4):691-9. 10 PMID: 10369755). Furthermore, our results indicate that a modulator of Phosphoglycerate mutase 2 activity, such as an inhibitor, activator, antagonist, or agonist of Phosphoglycerate mutase 2 may be useful for treatment of such disorders as obesity, diabetes, and insulin resistance, as 15 well as for enhancement of insulin secretion. Discovery Process 20 The disregulation of PGMl isoform in diet induced obesity study suggests that the increase in phosphoglycerate mutase activity in skeletal muscle may contribute to the development of insulin resistance and diabetes. Based on expression data, we propose PGM2, major skeletal muscle isoform of phosphoglycerate mutase, CG186640-02 - encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an 25 antibody therapeutic and targets for a small molecule drugs for Obesity and Diabetes. Dysregulation of PGM1 gene in GeneCalling@ study described below is supportive for disease rationale for phosphoglycerate mutase isoform 2. The following sections describe the study design(s) and the techniques used to identify the Phosphoglycerate mutase 2 - encoded protein and any variants, thereof, as being 30 suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for Obesity and Diabetes. Example El. Mouse Dietary-Induced Obesity 228 WO 2004/013347 PCT/US2003/024504 A protocol for Mouse Dietary-Induced Obesity study is disclosed in Example Q1. The predominant cause for obesity in clinical populations is excess caloric intake. 5 This so-called diet-induced obesity (DIO) is mimicked in animal models (mouse strain C57BL/6J) by feeding high fat diets of greater than 40% fat content. The DIG study was established to identify the gene expression changes contributing to the development and progression of diet-induced obesity. In addition, the study design sought to identify the factors that lead to the ability of certain individuals to resist the effects of a high fat diet and 10 thereby prevent obesity. The sample groups for the study had body weights +1 S.D., + 4 S.D. and + 7 S.D. of the chow-fed controls. In addition, the biochemical profile of the +7 S.D. mice revealed a further stratification of these animals into mice that retained a normal glycemic profile in spite of obesity and mice that demonstrated hyperglycemia. Tissues examined included hypothalamus, brainstem, liver, retroperitoneal white adipose tissue 15 (WAT), epididymal WAT, brown adipose tissue (BAT), gastrocnemius muscle (fast twitch skeletal muscle) and soleus muscle (slow twitch skeletal muscle). The differential gene expression profiles for these tissues revealed genes and pathways that can be used as therapeutic targets for obesity. Protocol for differential gene expression analysis, GeneCalling@, is disclosed in Example Q7. 20 Results A fragment of the mouse Phosphoglycerate mutase 1 gene was initially found to be up-regulated by 2.7 fold in the soleus muscle of hyperglycemic (hgsd7, diabetic) mice 25 relative to euglycemic (sdl, normal control) mice using CuraGen's GeneCalling@ method of differential gene expression (Table El shows the alignment of the PGMl and PGM2 protein sequences with PGM1 protein sequence shown separately in Table E2). A differentially expressed mouse gene fragment migrating, at approximately 153 nucleotides in length was definitively identified as a component of the mouse Phosphoglycerate mutase 1 cDNA. The 30 method of comparative PCR was used for conformation of the gene assessment. The electropherographic peaks corresponding to the gene fragment of the mouse Phosphoglycerate mutase 1 were ablated when a gene-specific primer (shown in Table E3) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 153 nt in length were ablated in the sample from both the hyperglycemic and euglycemic 229 WO 2004/013347 PCT/US2003/024504 mice. A gene fragment of the mouse Phosphoglycerate mutase 1 was also found to be upregulated by approximately 2 fold in the gastrocnemius (glycolytic) muscle relative to slow twitch (oxidative) muscle fiber of obese hyperglycemic mice. These data show that phosphoglycerate mutase may be involved in the development of diabetes/obesity and its 5 modulation, such as inhibition, may be beneficial for the treatment of these diseases. Table El. Alignment (ClustalW) of the protein sequences of human Phosphoglycerate mutase 2 (CG1 86640-02; SEQ ID NO:46) and Phosphoglycerate mutase 1 (CGI 15294 02; SEQ ID NO:197). Table E2. Protein sequence of Phosphoglycerate mutase 1 (PGM1) (CGl115294-02; SEQ ID NO:197) G115294-02 (SEQ ID NO:197) AAYKLVLIRHGESAWNLENRFSGWYDADLSPAGHEEAKRGGQALRDAGYEFDIC FTSVQKRAIRTLWTVLDATDQMWLPVVRTWRLNERHYGGLTGLNKAETAAKHG EAQVKIWRRSYDVPPPPMEPDHPFYSNISKDRRYADLTEDQLPSCESLKDTIARAL PFWNEEIVPQIKEGKRVLIAAHGNSLRGIVKHLEGLSEEAIMELNLPTGIPIVYELD KNLKPIKPMQFLGDEETVRKAMEAVAAQGKAKK Table E3. The direct sequence of the 153 nucleotide-long gene fragment and the gene specific primers used for competitive PCR are indicated on the cDNA sequence of the Phosphoglycerate mutase 1 fragment (SEQ ID NO: 198) are shown below in bold. The gene-specific primers at the 5' and 3' ends of the fragment are underlined. Gene Sequence (fragment from 80 to 233 in bold. band size: 154) 1 AGGCGACGCG GCGGGCAGGC GTTGCGAGAT GCTGGCTATG AATTTGACAT CTGCTTCACC 62 TCTGTGCAGA AGAGAGCAAT CCGGACCCTC TGGACAGTCC TGGATGCCAT TGACCAGATG 121 TGGTTGCCAG TGGTCAGGAC TTGGCGCCTC AATGAGCGAC ACTATGGCGG TCTGACAGGT 181 CTCAACAAAG CAGAAACTGC TGCTAAGCAA TGGTGAGGCC CAGGTAAAGA TCTGGAAACG 241 ATCTTATGAT GTCCCACCGG CTCCCATTGG ACCCTGATTA ACCCTTTCTA CAGCAACATT 301 CAGCAAGGAA TCGCAGGTAC GCAGAACCTT ACTGAAAGAC CCGCTTCCCC TCCTGT (gene length is 356, only region from 1 to 356 shown) 230 WO 2004/013347 PCT/US2003/024504 Example E2. Identification of Human Sequence of Phosphoglycerate mutase 2 5 . The sequence of Human Phosphoglycerate mutase 2 (Acc. No. CG1 86640-02) was derived by laboratory cloning of cDNA fragments, by in silico prediction of the sequence. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were cloned. In silicon prediction was based on sequences available in CuraGen's proprietary sequence databases or in the public human sequence databases, and 10 provided either the full-length DNA sequence, or some portion thereof. Table E4 shows an alignment (ClustalW) of the protein sequences of the human (CG186640-02; SEQ ID NO:46), rat (M31835; SEQ ID NO:199) and mouse (AF029843; BC010750; SEQ ID NO:200) versions of the Phosphoglycerate mutase 2. Table E5 shows 15 sequences of rat (M31835; SEQ ID NO:199) and mouse (AF029843; BC010750; SEQ ID NO:200) versions of the Phosphoglycerate mutase 2. Table E4. An alignment (ClustalW) of the protein sequences of the human (CG86640-02; SEQ ID NO:46), rat (M31835; SEQ ID NO:199) and mouse (AF029843; BC010750; SEQ ID NO:200) versions of the Phosphoglycerate mutase 2. ERTLWTILDVTDQMWVPVVRTWRLNERHYGGLTOGLNKAETAAQKGEEQDPWRRSF AKRA -1 R. T LT I DTQW P 1 .V1RTWRLNERHYGGLT L... ETAAKH.E EQ.KI.WRR..D Kim PYPMDKHYSIS SKDRRYAGLKPEELPTCESLKDTIARALPFWNEEAP XGKVIAPKNSIKR VLAHNLGVHLEGMSDQAIMELNLPTGIPIVTELNQELKPTKPMRFLGDEETVR~MAAQK1 K A M E VAG A >PM os A094;BC010750; SEQ ID NO:200) vrin ftePopolcrt uae2 >PGM rat(M3135;SEQ D NO299 MATRLVVRGESWNQNRCGWDAESEGAEAKRAT IAIFCYSLRR >PGM2 moseune (Af029843 BC0175; SEQ D NO:0 ) admue(F28 >P rat(3183; SEQID N2319 WO 2004/013347 PCT/US2003/024504 MTTHRLVMVRHGESLWNQENRFCGWFDAELSEKGAEEAKRGATAIKDAKJEFDICYTSVLKRAIk TLWTILDVTDQMWVPVVRTWRLNERHYGGLTGLNKAETAAKHGEEQVKWRRSFDTPPPPMDE KHNYYTSISKDRRYAGLKPEELPTCESLKDTIARALPFWNEEIAPKIKAGQRVLIAAHGNSLRGIVK HLEGMSDQAIMELNLPTGIPIVYELDQNLKPTKPMRFLGDEETVRKAMEAVAAQGKAK The laboratory cloning was performed using one or more of the methods summarized in Example Q8. The NOV5 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table E6. 5 Table E6. NOV5 Sequence Analysis NOV5a, CG186640-02 SEQ ID NO: 45 834 bp DNA Sequence ORF Start: ATG at 36 ORF Stop: TGA at 1 795 CCCGTCCAGAGTCCTCTGTGGTCCCTGCTGCCACCATGGCCACTCACCGCCTCGTGATGGTCCGGCAC GGCGAGACGACATGGAACCAGGAGAACCGTTTCTGTGGCTGGTTCGATGCAGAGCTGAGTGAAAAGGG GACCGAGGAGGCCAAGCGGOGAGCCAAGGCCATCAAGGATGCCAAGATGGAGTTTGACATCTGCTACA CGTCAGTGCTGAAGCGGGCCATCCGAACCCTCTGGGCCATCCTGGACGGCACGGACCAGATGTGGCTG CCTGTGGTGCGCACTTGGCGCTTCAATGAGCGGCATTACGGGGGCCTCACAGGCTTCAACAAGGCAGA AACGGCCGCCAAGCACGGGGAGGAGCAGGTAAGATCTTGGAGGCGCTCCTTCGACATCCCGCCGCCCC CGATGGACGAGAAGCACCCCTACTACAACTCCATTAGCAAGGAGCGTCGGTACGCAGGCCTGAAGCCC GGGGAACTCCCCACCTGCGAGAGCCTCAAGGACACCATTGCCCGGGCCCTGCCCTTCTGGAACGAGGA GATTGTTCCCCAGATCAAGGCCGGCAAGCGAGTGCTCATTGCAGCCCACGGGAACAGCCTGCGGGGCA TTGTCAAGCACCTGGAAGGGATGTCAGACCAGGCGATCATGGAGCTGAACCTGCCCACGGGATCCCC ATTGTGTATGAGCTGAACAAGGAGCTGAAGCCCACCAAGCCCATGCAGTTCCTGGGTGATGAGGAAAC GGTGCGGAAGGCCATGGAGGCTGTGGCTGCCCAGGGCAAGGCCAAGTGAGGGGTGGGCTTTGGGCAAT AAAGGCACCTCCCCCAAC NOV5a, CG 186640-02 SEQ ID NO: 46 |253 aa IMW at 28849.9kD Protein Sequence I MATHRLVMVRHGET TWNQENRF CGWFDAELSEKGTEEAKRGAKAIKDAKMEFD ICYTSVLKRAIR TL W AILDGTDQMWLPVVRTWRFNERHYGGLTGFNKAETAAKHGEEQVRSWRRSFDIP PPPMDEKHPYYNS SKERRYAGLKPGELPT CESLKDT IARALPFWNEE IVPQ IKAGKRVL IAAHIGNSL RGIVEHLEGMSDQ A IMELNLPTGIPIVYELNKELKPTKPMQFLGDEETVRKAMEAVAAQGKAK NOV5b, 311980359 SEDN: 47 786 bp DNA Sequence OR trt: at I1R tp:TAa 784 ACCATGGGACATCATCACCACCATCACGCCACTCACCGCCTCGTGATGGTCCGGCACGGCGAGAGCA C ATGGAACCAGGAGAACCGTTTCTGTGGCTGGTTCGATGCAGAGCTGAGTGAAAAG3GGGACCGAGGAG G CCAACGGGGAGCCAAGGCCATCAAGGATGCCAAGATGGAGTTTGACATCTGCTACACGTCAGTGCT G AAGCGGGCCATCCGCACCCTCTGGGCCATCCTGGACGGCACGGACCAGATGTGGCTGCCTGTGGTGC G CACTTGGCGCCTCAATGAGCGGCATTACGGGGGCCTCACAGGCCTCAACAAGGCAGAAACGGCCGCC A AGCACGGGGAGGAGCAGGTGAAGATCTGGAGGCGCTCCT TCGACATCCCGCCGCCCCCGATGGACGA G AAGCACCCCTACTACAACTCCATTAGCAAGGAGCGTCGGTACGCAGGCCTGAAGCCCGGGGAACTCC C CACCTGCGAGAGCCTCAAGGACACCATTGCCCGGGCCCTGCCCT TCTGGAACGAG3GAGATTGTTCCC C AGATCAAGGCCGGCAAGCGAGTGCTCATTGCAGCCCACGGGAACAGCCTGCGGGG3CATTGTCAAGCA C ICTGGAAGGGATGTCAGACCAGGCGATCATGGAGCTGAACCTGCCCACGGGGATCCCCATTGTGTATG 232 WO 2004/013347 PCT/US2003/024504 A GCTGAACAAGGAGCTGAAGCCCACCAAGCCCATGCAGTTCCTGGGTGATGAGGAAACGGTGCGGAAG G CCATGGAGGCTGTGGCTGCCCAGGGCAAGGCCAAGTGA NOV5b, 311980359 SEQ ID NO: 48 261 aa MW at 29746.9kD Protein Sequence TMGHHHHHHATHRLVMVRHGESTWNQENRFCGWFDAELSEKGTEEAKRGAKAIKDAKMEFDICYTSV L KRAIRTLWAILDGTDQMWLPVVRTWRLNERHYGGLTGLNKAETAAKHGEEQVKIWRRSFDIPPPPMD E KHPYYNS ISKERRYAGLKPGELPTCESLKDTIARALPFWNEEIVPQIKAGKRVLIAAHGNSLRGIVK H LEGMSDQAIMELNLPTGIPIVYELNKELKPTKPMQFLGDEETVRKAMEAVAAQGKAK NOV5c, CG186640-01 SEQ ID NO: 49 898 bp DNA Sequence ORF Start: ATO at 67 ORF Stop: TGA at 826 AATTCGGTACGAGGGTTGGGAAGCAGCCGTCCCCGTCCAGAGTCCTCTGTGGTCCCTGCTGCCACCA T GGCCACTCACCGCCTCGTGATGGTCCGGCACGGCGAGAGCACATGGAACCAGGAGAACCGTTTCTGT G GCTGGTTCGATGCAGAGCTGAGTGAAAAGGGGACCGAGGAGGCCAAGCGOGGAGCCAAGGCCATCAA G GATGCCAAGATGGAGTTTGACATCTGCTACACGTCAGTGCTGAAGCGGCCCATCCGCACCCTCTGGG C CATCCTGGACGGCACGGACCAGATGTGGCTGCCTGTGGTGCGCACTTGGCGCCTCAATGAGCGGCAT T ACGGGGGCCTCACAGGCCTCAACAAGGCAGAAACGGCCGCCAAGCACGGGGAGGAGCAGGTGAAGAT C TGGAGGCGCTCCTTCGACATCCCGCCGCCCCCGATGGACGAGAAGCACCCCTACTACAACTCCATTA G CAAGGAGCGTCGGTACGCAGGCCTGAAGCCCGGGGAACTCCCCACCTGCGAGAGCCTCAAGGACACC A TTGCCCGGGCCCTGCCCTTCTGGAACGAGGAGATTGTTCCCCAGATCAAGGCCGGCAAGCGAGTGCT C ATTGCAGCCCACGGGAACAGCCTGCGGGGCATTGTCAAGCACCTGGAAGGGATGTCAGACCAGGCGA T CATGGAGCTGAACCTGCCCACGGGGATCCCCATTGTGTATGAGCTGAACAAGGAGCTGAAGCCCACC A AGCCCATGCAGTTCCTGGGTGATGAGGAAACGGTGCGGAAGGCCATGGAGGCTGTGGCTGCCCAGGG C AAGGCCAAGTGAGGGGTGGGCTTGGGCAATAAAGGCACCTCCCCCAACAAAA A A AAAAAAAAAAAAGC NOV5c, CG186640-01 SEQ ID NO: 50 253 aa MW at 28765.9kD Protein Sequence MATHRLVMVRHGESTWNQENRFCGWFDAELSEKGTEEAKRGAKAIKDAKMEFDICYTSVLKRAIRTL w AILDGTDQMWLPVVRTWRLNERHYGGLTGLNKAETAAKHGEEQVKIWRRSFDIPPPPMDEKHPYYNS T SKERRYAGLKPGELPTCESLKDTIARALPFWNEEIVPQIKAGKRVLIAAHGNSLRGIVKHLEGMSDQ A IMELNLPTGIPIVYELNKELKPTKPMQFLGDEETVRKAMEAVAAQGKAK NOV5d, CG186640-03 .SEQ ID NO: 51 763 bp DNA Sequence . ~.R Start: at 1 |ORF Stop: at 760 ACCATGGCCACTCACCGCCTCGTGATGGTCCGGCACGGCGAGAGCACATGGAACCAGGAGAACCGTT T CTGTGGCTGGTTCGATGCAGAGCTGAGTGAAAAGGGGACCGAGGAGGCCAAGCGGGGAGCCAAGGCC A TCAAGGATGCCAAGATGGAGTTTGACATCTGCTACACGTCAGTGCTGAAGCGGGCCATCCGCACCCT C 233 WO 2004/013347 PCT/US2003/024504 TGGGCCATCCTGGACGGCACGGACCAGATGTGGCTGCCTGTGGTGCGCACTTGGCGCCTCAATGAGC G GCATTACGGGGGCCTCACAGGCCTCAACAAGGCAGAAACGGCCGCCAAGCACGGGGAGGAGCAGGTG A AGATCTGGAGGCGCTCCTTCGACATCCCGCCGCCCCCGATGGACGAGAAGCACCCCTACTACAACTC C ATTAGCAAGGAGCGTCGGTACGCAGGCCTGAAGCCCGGGGAACTCCCCACCTGCGAGAGCCTCAAGG A CACCATTGCCCGGGCCCTGCCCTTCTGGAACGAGGAGATTGTTCCCCAGATCAAGGCCGGCAAGCGA G TGCTCATTGCAGCCCACGGGAACAGCCTGCGGGGCATTGTCAAGCACCTGGAAGGGATGTCAGACCA G GCGATCATGGAGCTGAACCTGCCCACGGGGATCCCCATTGTGTATGAGCTGAACAAGGAGCTGAAGC C CACCAAGCCCATGCAGTTCCTGGGTGATGAGGAAACGGTGCOGAAGGCCATGGAGGCTGTGGCTGCC C AGGGCAAGGCCAAGT NOV5d, CG186640-03 SEQ ID NO: 52 253 aa MW at 28738.8kD Protein Sequence TMATHRLVMVRHGESTWNQENRFCGWFDAELSEKGTEEAKRGAKAIKDAKMEFDICYTSVLKPAIRT L. WAILDGTDQMWLPVVRTWRLNERHYGGLTGLNKAETAAKHGEEQVKIWRRSFDIPPPPMDEKHPYYN S ISKERRYAGLKPGELPTCESLKDTIARALPFWNEEIVPQIKAGKRVLIAAHGNSLRGIVKHLEGMSD Q AIMELNLPTGIPIVYELNKELKPTKPMQFLGDEETVRKAMEAVAAQGKA NOV5e, C0186640-04 ISEQ ID NO: 53 786 bp DNA Sequence ORF Start: at S TGA at 784 ACCATGGGACATCATCACCACCATCACGCCACTCACCGCCTCGTGATGGTCCGGCACGGCGAGAG.CA C ATGGAACCAGGAGAACCGTTTCTGTGGCTGGTTCGATGCAGAGCTGAGTGAAAAGGGGACCGAGGAG G CCAAGCGGGGAGCCAAGGCCATCAAGGATGCCAAGATGGAGTTTGACATCTGCTACACGTCAGTGCT G AAGCGGGCCATCCGCACCCTCTGGGCCATCCTGGACGGCACGGACCAGATGTGGCTGCCTGTGGTGC G CACTTGGCGCCTCAATGAGCGGCATTACGGGGGCCTCACAGGCCTCAACAAGGCAGAAACGGCCGCC A AGCACGGGGAGGAGCAGGTGAAGATCTGGAGGCGCTCCTTCGACATCCCGCCGCCCCCGATGGACGA G AAGCACCCCTACTACAACTCCATTAGCAAGGAGCGTCGGTACGCAGGCCTGAAGCCCGGGGAACTCC C CACCTGCGAGAGCCTCAAGGACACCATTGCCCGGGCCCTGCCCTTCTGGAACGAGGAGATTGTTCCC C AGATCAAGGCCGGCAAGCGAGTGCTCATTGCAGCCCACGGGAACAGCCTGCGGGGCATTGTCAAGCA C CTGGAAGGGATGTCAGACCAGGCGATCATGGAGCTGAACCTGCCCACGGGGATCCCCATTGTGTATG A GCTGAACAAGGAGCTGAAGCCCACCAAGCCCATGCAGTTCCTGGGTGATGAGGAAACGGTGCGGAAG G CCATGGAGGCTGTGGCTGCCCAGGGCAAGGCCAAGTGA NOV5e, CG186640-04 SEQ ID NO: 54 261 aa MW at 29746.9kD Protein Sequence TMGHHHHHHATHRLVMVRHGESTWNQENRFCGWFDAELSEKGTEEAKRGAKAIKDAKMEFDICYTSV L KRAIRTLWAILDGTDQMWLPVVRTWRLNERHYGGLTGLNKAETAAKHGEEQVKIWRRSFDIPPPPMD E KHPYYNSISKERRYAGLKPGELPTCESLKDTIARALPFWNEEIVPQIKAGKRVLIAAHGNSLRGIVK H LEGMSDQAIMELNLPTGIPIVYELNKELKPTKPMQFLGDEETVRKAMEAVAAQGKAK 234 WO 2004/013347 PCT/US2003/024504 A ClustaiW comparison of the above protein sequences yields the following sequence alignment shown in Table E7. Table E7. Comparison of the NOV5 protein sequences. NOV5a -------- MATHRLVMVRHGETTWNQENRFCGWFDAELSEKGTEEAKRGAKAIKDAKMEF NOV5b TMGHHHHHHATHRLVMVRHGESTWNQENRFCGWFDAELSEKGTEEAKRGAKAIKDAKMEF NOV5c--- -------- MATHRLVMVRHGESTWNQENRFCGWFDAELSEKGTEEAKRGAKAIKDAKMEF NOV5d ------- TMATHRLVMVRHGESTWNQENRFCGWFDAELSEKGTEEAKRGAKAIKDAKMEF NOV5e TMGHHHHHHATHRLVMVRHGESTWNQENRFCGWFDAELSEKGTEEAKRGAKAIKDAKMEF NOV5a DICYTSVLKRAIRTLWAILDGTDQMWLPVVRTWRFNERHYGGLTGFNKAETAAKHGEEQV NOV5b DICYTSVLKRAIRTLWAILDGTDQMWLPVVRTWRLNERHYGGLTGLNKAETAAKHGEEQV NOV5c DICYTSVLKRAIRTLWAILDGTDQMWLPVVRTWRLNERHYGGLTGLNKAETAAKHGEEQV NOV5d DICYTSVLKRAIRTLWAILDGTDQMWLPVVRTWRLNERHYGGLTGLNKAETAAKHGEEQV NOV5e DICYTSVLKRAIRTLWAILDGTDQMWLPVVRTWRLNERHYGGLTGLNKAETAAKHGEEQV NOV5a RSWRRSFDIPPPPMDEKHPYYNSISKERRYAGLKPGELPTCESLKDTIARALPFWNEEIV NOV5b KIWRRSFDIPPPPMDEKHPYYNSISKERRYAGLKPGELPTCESLKDTIARALPFWNEEIV NOV5c KIWRRSFDIPPPPMDEKHPYYNSISKERRYAGLKPGELPTCESLKDTIARALPFWNEEIV NOV5d KIWRRSFDIPPPPMDEKHPYYNSISKERRYAGLKPGELPTCESLKDTIARALPFWNEEIV NOV5e KIWRRSFDIPPPPMDEKHPYYNSISKERRYAGLKPGELPTCESLKDTIARALPFWNEEIV NOVSa PQIKAGKRVLIAAHGNSLRGIVKHLEGMSDQAIMELNLPTGIPIVYELNKELKPTKPMQF NOV5b PQIKAGKRVLIAAHGNSLRGIVKHLEGMSDQAIMELNLPTGIPIVYELNKELKPTKPMQF NOV5c PQIKAGKRVLIAAHGNSLRGIVKHLEGMSDQAIMELNLPTGIPIVYELNKELKPTKPMQF NOV5d PQIKAGKRVLIAAHGNSLRGIVKHLEGMSDQAIMELNLPTGIPIVYELNKELKPTKPMQF NOVSe PQIKAGKRVLIAAHGNLRGIVKHLEGMSDQAIMELNLPTGIPIVYELNKELKPTKPMQF NOV5a LGDEETVRKAMEAVAAQGKAK NOV5b LGDEETVRKAMEAVAAQGKAK NOV5c LGDEETVRKAMEAVAAQGKAK NOVSd LGDEETVRKAMEAVAAQGKA NOV5e LGDEETVRKAMEAVAAQGKAK NOV5a (SEQ ID NO: 46) NOV5b (SEQ ID NO: 48) NOV5c (SEQ ID NO: 50) NOV5d (SEQ ID NO: 52) NOV5e (SEQ ID NO: 54) Further analysis of the NOV5a protein yielded the following properties shown in Table E8. Table E8. Protein Sequence Properties NOV5a SignalP analysis: I No Known Signal Sequence Predicted PSORT H analysis: PSG: a new signal peptide prediction method N-region: length 10; pos.chg 2; neg.chg 0 H-region: length 2; peak value -7.76 PSG score: -12.16 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -12.65 possible cleavage site: between 14 and 15 235 WO 2004/013347 PCT/US2003/024504 >>> Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood = 5.41 (at 204) ALOM score: 5.41 (number of TMSs: 0) MITDISC: discrimination of mitochondrial targeting seq R content: 2 Hyd Moment(75): 10.06 Hyd Moment(95): 6.20 G content: 1 D/E content: 2 S/T content: 3 Score: -4.24 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 20 VRHIGE NJCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none content of basic residues: 15.4% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: XXRR-like motif in the N-terminus: ATHR KKXX-like motif in the C-terminus: QGKA SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none 236 WO 2004/013347 PCT/US2003/024504 memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 89 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues Final Results (k = 9/23): 43.5 %: cytoplasmic 30.4 %: nuclear 26.1 %: mitochondrial >>prediction for CG1 86640-02 is cyt (k=23) A search of the NOV5a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table E9. Table E9. Geneseq Results for NOV5a NOV5a Identities/ Geneseq Protein/Organism/Length [Patent Residues/ Similarities for Expect Identifier #, Date] Match the Matched Value Residues Region ABG09674 Novel human diagnostic protein L..253 191/254 (75%) e-113 #9665 - Homo sapiens, 265 aa. ll..264 221/254 (86%) [W0200175067-A2, 11-OCT-2001] ABG05571 Novel human diagnostic protein 1..253 181/258 (70%) 7e-99 #5562 - Homo sapiens, 270 aa. 12..269 209/258 (80%) [W0200175067-A2, 11-OCT-2001] ABB64868 Drosophila melanogaster polypeptide 4..253 167/251 (66%) 2e-93 SEQ ID NO 21396 - Drosophila 42..292 196/251 (77%) melanogaster, 292 aa. .. __ ...... [W0200171042-A2, 27-SEP-2001] ...... 237 WO 2004/013347 PCT/US2003/024504 ABB66376 Drosophila melanogaster polypeptide 16.253 159/239 (66%) 6e-88 SEQ ID NO 25920 - Drosophila 33..271 185/239 (76%) melanogaster, 271 aa. [W0200171042-A2, 27-SEP-2001] ABG19326 Novel human diagnostic protein 4..251 161/256 (62%) 2e-84 #19317 - Homo sapiens, 333 aa. 35..290 198/256 (76%) [W0200175067-A2, 11-OCT-2001] I I I_ I In a BLAST search of public sequence databases, the NOV5a protein was found to have homology to the proteins shown in the BLASTP data in Table E10. Table E10. Public BLASTP Results for NOV5a Protein NOV5a Identities/ Accession Protein/Organism/Length Residues/ Similarities for Expect Number Match the Matched Value Residues Portion PMHUYM phosphoglycerate mutase (EC 5.4.2.1) 1..253 248/253 (98%) e-146 M - human, 253 aa. 1..253 250/253 (98%) P15259 Phosphoglycerate mutase 2 (EC 2..253 247/252 (98%) e-146 5.4.2.1) (EC 5.4.2.4) (EC 3.1.3.13) 1..252 249/252 (98%) (Phosphoglycerate mutase isozyme M) (PGAM-M) (BPG-dependent PGAM 2) (Muscle-specific phosphoglycerate mutase) - Homo sapiens (Human), 252 aa. PMRTYM phosphoglycerate mutase (EC 5.4.2.1) 1..253 232/253 (91%) e-136 M - rat, 253 aa. 1..253 241/253 (94%) P16290 Phosphoglycerate mutase 2 (EC 2..253 231/252 (91%) e-136 5.4.2.1) (EC 5.4.2.4) (EC 3.1.3.13) 1..252 240/252 (94%) (Phosphoglycerate mutase isozyme M) (PGAM-M) (BPG-dependent PGAM 2) (Muscle-specific phosphoglycerate mutase) - Rattus norvegicus (Rat), 252 aa. 070250 Phosphoglycerate mutase 2 (EC 3..253 227/251 (90%) e-134 5.4.2.1) (EC 5.4.2.4) (EC 3.1.3.13) 2..252 237/251 (93%) (Phosphoglycerate mutase isozyme M) (PGAM-M) (BPG-dependent PGAM 2) (Muscle-specific phosphoglycerate mutase) - Mus musculus (Mouse), 252 aa. PFam analysis predicts that the NOV5a protein contains the domains shown in the Table El 2. 238 WO 2004/013347 PCT/US2003/024504 Table Eli. Domain Analysis of NOV5a Identities/ Pfam Domain NOV5a Match Region Similarities Expect Value for the Matched Region PGAM 4..230 132/230 (57%) 1.3e-132 209/230 (91%) Example E3. Expression Profiles of the Human Phosphoglycerate mutase 2 (PGM2) and Human Phosphoglycerate mutase 1 (PGM1) Genes The protocol for quantitative expression analysis is disclosed in Example Q9. 5 Expression of genes CG186640-02 (PGM2) and CG115294-01 (PGM1) was assessed using the primer-probe sets Ag2379 and Ag6474 described in Tables E12 and E13. Results of the RTQ-PCR runs are shown in Tables E14 and E15. Ag2379 and Ag6474 are specific for CG1 15294-01 and CG1 86640-02 respectively. Table E12. Probe Name Ag2379 Primers Sequences Length Ntt oSEQ ID Forward 5 -ctacgagatgctggtatgagt-3' 22 164 201 Pbe TET-5'-ttgacatctgcttcacctcagtgcag-3 Poe TAMRA 2 8 0 Reverse 5'-gatcaatggcatctagcactgt-3' 22 236 203 10 Table E13. Probe Name Ag6474 Primers Sequences Length stat SE NoID Forward 5' -gyaggacaggtgaagatct-3' 20 327 204 Probe TET-5'-cgatggacgagaagcacccctactac-3 26 377 205 ITAMRA............ Reverse 5'-ccgacgctecttgctaa-3' 17 410 206 Table E14. Generalscreeningpanelv1.6 Rel. Rel. Exp.(%) Rel. Exp.(%) Rel. Exp.(%) Exp.(%) Tissue Name Ag6474, Run Ag2379, Run Tissue Name Ag6474, Run Ag2379, 277225783 277227794 277225783 Run 277227794 Adipose 3.1 30 Renal ca. TK-10 0.1 22.4 Melanoma* 0.0 52.1 Bladder 0.1 8.7 239 WO 2004/013347 PCT/US2003/024504 Hs688(A).T Melanoma* 0.1 42.3 Gastric ca. (liver 0.1 22.8 Hs688IB).T me0.) NCI-N87 Melanoma* M14 0.0 42.6 tne ca. 0.0 39.2 Melanoma* M4 0.0 42.6 KATO III ____ ____ Melanoma* 0.0 51.8 Colon ca. SW- 0.0 18.3 LOXIMVI 948 Melanoma* SK- 0.1 45.1 Colon ca. SW480 0.1 62.4 a. ell0Colon ca.* Squa ous cll 0.0 29.5 (SW480 met) 0.1 28.7 carcinoma SCC-4 SW620 ____ Tests Pool 6.1 4.6 Colon ca. HT29 0.1 26.2 Prostate ca.* 0.1 40.6 Colon ca. HCT- 0.1 79.6 (bone met) PC-3 116 Prostate Pool 1.0 3.2 Colon ca. CaCo-2 0.1 31.6 Placenta 0.0 6.6 Colon cancer 0.2 11.5 tissue Uterus Pool 0.1 2.1 Colon ca. 0.0 11.9 ________________SWI116______ ____ Ovarian ca. 0.8 39.8 Colon ca. Colo- 0.0 14.8 OVCAR-3 205 Ovarian ca. SK- 0.0 25.2 Colon ca. SW-48 0.0 14.8 OV-3 Ovarian ca. 0.1 32.1 Colon Pool 0.2 4.9 OVCAR-4 ____ _________ _______ Ovarian ca. 0.6 42.3 Small Intestine 0.4 3.6 OVCAR-5 Pool Ovarian ca. 1.4 32.8 Stomach Pool 0.0 3.6 Ovarian ca. 0.1 12.9 Bone Marrow 0.1 1.9 OVCAR-8 Pool Ovary 0.1 3.8 Fetal Heart 27.0 6.0 Breast ca. MCF-7 0.0 31.6 Heart Pool 31.0 1.9 Breast ca. MDA- 0.1 100.0 Lymph Node 01 6.5 MB-231 0.1 100.0 Pool0.1 Breast ca. BT 549 0.0 54.0 Fetal Skeletal 22.1 1.3 Muscle Breast ca. T47D 0.1 13.3 Skeletal Muscle 100.0 0.8 ________Pool Breast ca. MDA- 0.0 17.6 Spleen Pool 0.2 4.5 N I__ _ __ _ __ _ _ _ _ Breast Pool 0.0 4.5 Thymus Pool 0.7 5.6 CNS cancer Trachea 0.5 5.6 (glio/astro) U87- 0.0 64.2 MG 240 WO 2004/013347 PCT/US2003/024504 CNS cancer Lung 0.2 1.4 (glio/astro) U- 0.0 57.8 S118-MG CNS cancer Fetal Lung 0.3 7.5 (neuro;met) SK- 0.2 38.7 N-AS Lung ca. NCI- 0.4 18.8 CNS cancer 0.4 45.7 N417 (astro) SF-539 Lung ca. LX-1 0.4 27.4 CNS cancer 0.0 50.7 (astro) SNB-75 Lung ca. NCI- 6.3 80 CNS cancer H146 6.3 8.0 (glio) SNB-19 32.1 Lung ca. SHP-77 12.5 43.8 CNS cancer 0.2 55.9 (glio) SF-295 Lung ca. A549 0.1 43.2 Brain 1.0 13.6 (Amygdala) Pool Lung ca. NCI- 02 66 Brain 13.0 33.0 H526 _ (cerebellum) 1 Lung ca. NCI- 0.2 24.1 Brain (fetal) 0.9 Lung ca. NCI- Brain H460 0.0 18.6 (Hippocampus) 1.6 12.9 Lung ca. HOP-62 0.0 27.7 Cerebral Cortex 0.9 13.0 Lung ca. NCI- Brain (Substantia H522 0.1 19.8 nigra) Pool 2.1 11.3 Liver 1.0 2.1 Brain (Thalamus) 1.4 17.7 Fetal Liver 0.2 3.8 Brain (whole) 1.0 15.2 Liver ca. HepG2 0.5 18.3 Spinal Cord Pool 3.3 9.5 Kidney Pool 0.6 7.1 Adrenal Gland 0.3 11.0 Feta1Kidney 0.4 4.7 Pituitary gland 1.3 1.7 Pool Renal ca. 786-0 0.0 56.6 Salivary Gland 0.4 4.1 Renal ca. A498 0.0 21.8 Thyroid (female) 0.9 3.6 Renal ca. ACHN 0.0 25.7 Pancreatic ca. 0.0 19.5 CAPAN2 Renal ca. UO-31 0.0 33.2 IPancreas Pool 0.4 3.6 Table E15. Panel 5 Islet Rel. Exp.(%) Rel. Exp.(%) Rel. Tissue Name Ag6474, Run Exp.(%) Tissue Name Ag6474, Run Exp.(%) 268366291 Ag2379, 268366291 Ag2379, 1Run Run 241 WO 2004/013347 PCT/US2003/024504 263467358 ;i263467358 97457_Patient- 0.0 94709Donor 2 0.0 60.3 O2go adipose AM - A adipose 0.0 60.3 97476_Patient 07sk skeletal 8.3 4.7 94710__Donor 2 0.0 42.3 muscle AM - B adipose 97477 Patient- 94711 Donor 2 07uttit- 6.2 AM -C adipose 0.0 27.4 97478 Patient- 0.0 10.5 94712_Donor 2 0.2 35.8 07pl_iacenta _ AD - A_adipose 99167 Bayer 94713 Donor 2 Patient 1 AD - B-adipose 97482_Patient- 0.0 80 94714 Donor 2 I8ut uterus 0.0AD - Cadipose 97483 Patient- 94742_Donor 3 U 08pplatient- 0.0 8.4 - AMesenchymal 0.0 26.2 Stem Cells 97486_Patient- 94743_Donor 3 U 09sk_skeletal 17.6 1.2 - B Mesenchymal 0.0 36.1 muscle Stem Cells 97487_Patient- 0.1 9.7 94730 Donor 3 0.0 54.7 09ut uterus _ _AM - A adipose 97488 Patient- 0.0 55 94731 Donor 3 O9plplacenta 0_0_5_5_AM - B adipose 0.0 42.9 97492_Patient- 0.0 9.6 94732 Donor 3 0.0 51.1 1 Out uterus AM - C adipose 97493 Patient- 94733 Donor 3 0.0 1.4 -0.0 96.6 1 Oplplacenta 00 14 AD - A-adipose 97495 Patient- 0.0 94734 Donor 3 0.0 49.0 1Igoadipose 0.0 4.4 AD - Badipose 97496 Patient- 94735_Donor 3 11sk skeletal 69.7 2.2 D0.0 80.1 muscle AD - C_adipose 97497 Patient- 0.0 13.1 77138_LiverHep 0.2 46.3 1 ut uterus G2untreated 97498 Patient- 73556_Heart Card llpl_-acenta 0.0 8.9 iac stromal cells 0.0 12.8 _placenta _(primary) 97500 Patient- 0.0 9.7 81735_Small 0.2 11.0 12goadipose Intestine 97501 _Patient- 72409_Kidney Pro 12skskeletal 100.0 6.5 ximal Convoluted 0.0 18.4 muscle Tubule 97502 Patient- 82685_Small 12ut uterus 0.1 10.8 intestineDuodenu 0.0 10.9 242 WO 2004/013347 PCT/US2003/024504 90650 Adrenal A 97503_Patient- 0.0 9.1 drenocortical 0.0 14.6 12plplacenta adenoma 94721_Donor 2 U 0.0 35.6 72410_Kidney HR 0.2 72.7 A_Mesenchymal CE Stem Cells 94722 Donor 2 U 72411 Kidney HR - B Mesenchymal 0.0 32.5 E 0.1 34.2 Stem Cells 1 j 94723 Donor 2 U 73139 Uterus Ute - CMesenchymal 0.2 22.2 rine smooth muscle 0.0 19.1 Stem Cells cells General screening panel v1.6 Summary: PGM2 is specifically expressed in skeletal muscle, which is consistent with the literature data. PGM1 is ubiquitously expressed with 5 higher in expression in the cerebellum compared to PGM2 (CTs=26.8 vs. 29.5) and conversely is lower in skeletal muscle than PGM2 (CTs=32.2 vs 26.6). Specific expression of PGM2 in skeletal muscle suggests that a drug would target preliminary skeletal muscle and would not interfere significantly with glycolysis in other tissues, specifically in brain and pancreatic islets. 10 Panel 5 Islet Summary: In Panel 51, PGM2 is expressed only in skeletal muscle which is in agreement with the expression pattern of Panel 1.4. Moreover, PGM2 is significantly-up regulated in diabetic muscle (patient 12) relative to non-diabetic skeletal muscle (patients 7, patient 9, patient 11). These results further support the hypothesis that increases in phosphoglycerate mutase level/activity may contribute to the development of diabetes. 15 Therefore, inhibition of PGM2 may be beneficial for the treatment of diabetes. PGM1 is more widely expressed with high expression in islet cells (Bayer patient 1). Example E4. Assays for Modulators of Phosphoglycerate mutase 2 One potential assay that may be used to screen for modulators of Phosphoglycerate 20 mutase 2 is to measure the production of glycerate-3-phosphate formed in following reaction catalysed by phosphoglycerate mutase: 2-phospho-D-glycerate + 2,3-diphosphoglycerate <=> 3-phospho-D-glycerate + 2,3 diphosphoglycerate 243 WO 2004/013347 PCT/US2003/024504 Production of glycerate-3-phosphate could be measured by reaction coupled to phophoglycerate kinase and glyceraldehydephosphate dehydrogenase as described in Rosa R, Blouquit Y, Calvin MC, Prome D, Prome JC, Rosa J. Isolation, characterization, and 5 structure of a mutant 89 Arg----Cys bisphosphoglycerate mutase. Implication of the active site in the mutation. J Biol Chem. 1989 May 15;264(14):7837-43; PMID: 2542247. Our results indicate that a modulator of Phosphoglycerate mutase 2 activity, such as an inhibitor, activator, antagonist, or agonist of Phosphoglycerate mutase 2 may be useful for 10 treatment of such disorders as obesity, diabetes, and insulin resistance, as well as for enhancement of insulin secretion. F. NOV6 -- Adenosine Al Receptor 15 Adenosine Al receptor (Adoral) is a G-protein coupled receptor found at the plasma membrane of multiple cell types. Adoral is believed to be involved in heart contractility, adipose tissue lipolysis, glomerular filtration and tubulo-glomerular feedback in the kidney, and sympathetic and parasympathetic activity in the nervous system. (Fredholm BB, 20 Uzerman AP, Jacobson KA, Klotz KN, Linden J, International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001 Dec;53(4):527-52. Review. PMID: 11734617) It is a member of the adenosine receptor family comprised of adenosine Al, A2A, A2B and A3 receptors. Adenosine is the preferred endogenous ligand for these receptors. However, the adenosine receptors are not highly 25 homologous, with the greatest percent identity found between the Al and the A2B receptors (56% sequence identity at the protein level). The low level of sequence identity is illustrated by the fact that selective agonists and antagonists have been identified for the all of the adenosine receptors with the exception of A2B, which lacks a selective antagonist (Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J, International Union of 30 Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001 Dec;53(4):527-52. Review. PMID: 11734617) Adenosine is the main agonist for this receptor family. Under normal conditions, adenosine is continuously formed intracellularly in a variety of cell types, as well as 244 WO 2004/013347 PCT/US2003/024504 extracellularly in a variety of tissue compartments. The continuous synthesis and breakdown of adenosine in any cell type or tissue compartment varies with physiological circumstances, and this variance implies that the biology of adenosine receptors will be complicated, as well as tissue and cell-type specific. Adenosine Al receptor knockout mice that do not respond to 5 Adoral agonists have been reported (Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Gimenez-Llort L, Escorihuela RM, Femandez-Teruel A, Wiesenfeld-Hallin Z, Xu XJ, Hardemark A, Betsholtz C, Herlenius E, Fredholm BB. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine Al receptor. Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9407-12. PMID: 11470917). The mice were viable, 10 fertile and without any gross abnormalities. Although Adoral is hypothesized to be important for cardiovascular function, arterial blood pressure and heart rates were indistinguishable between Al receptor knockouts and wild type mice (Johansson et. al.). To date, our knowledge of the role of adenosine Al receptors in normal physiology is incomplete. 15 The distribution of Al receptors in tissues has been studied using selective radioligands (Fredholm et.al.). High expression has been reported in the brain (cortex, cerebellum, hippocampus), dorsal horn of the spinal cord, eye and adrenal gland (Fredhohn et.al.). Intermediate levels of Adoral were reported in other brain regions, skeletal muscle, 20 liver, kidney, adipose tissue, salivary glands, esophagus, colon and testis. The specific role of Adoral in all of these diverse cell types is not currently known. Insulin-secreting beta cells are located in the pancreatic islets of Langerhans. Insulin secretion can be measured while perfusing the isolated pancreas with glucose (the 25 physiologic signal). Structural analogues of adenosine have been used to perfuse the isolated rat pancreas, with a resultant decrease in insulin secretion. (Hillaire-Buys D, Chapal J, Bertrand G, Petit P, Loubatieres-Mariani MM. Purinergic receptors on insulin-secreting cells. Fundam Clin Pharmacol 1994 8(2):117-27. PMID: 8020870). However, this result did not confirm Adoral specificity (because adenosine acts on all adenosine receptor subtypes) 30 and was not specific for human islet cells. Aminophylline is a non-selective but potent adenosine receptor family antagonist. Intravenous administration of aminophylline stimulated insulin secretion in patients with Type 2 diabetes, suggesting that an adenosine receptor family antagonist may be involved in 245 WO 2004/013347 PCT/US2003/024504 turning on insulin secretion (Arias AM, Bisschop PH, Ackerman MT, Nijpels G, Endert E, Romijn JA, Sauerwein HP. Aminophylline stimulates insulin secretion in patients with Type 2 diabetes mellitus. Metabolism 2001 Sep;50(9):1030-5. PMID:1 1555834). The present invention is for the use of a specific Adoral antagonist to enhance insulin secretion and 5 lower blood glucose. US 6,407,076 describes compounds which are agonists of adenosine Al receptor and function as inhibitors of lipolysis and may also have the ability to lower elevated blood glucose. Adenosine Al receptor is coupled to the Gi family of G protein effector systems 10 that inhibit cAMP production (Fredholm et. al.). Cyclic AMP has long been known as a potentiator of neurotransmitter-induced insulin secretion (Harndahl L, Jing XJ, Ivarsson R, Degerman E, Ahren B, Manganiello VC, Renstrom E, Holst LS. hnportant role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin. J Biol Chem. 2002 Oct 4;277(40):37446-55. PMID: 12169692). The 15 present invention is for the use of a specific Adoral antagonist to enhance glucose stimulated insulin secretion (as opposed to neurotransmitter-stimulated insulin secretion). We have shown that Adoral is expressed in a wide variety of human tissues, with highest levels seen in brain and testis. We also documented that Adoral is expressed in 20 human pancreatic islet cells. Type 2 diabetes in man is characterized by increased fasting and post-prandial circulating free fatty acids, and by an insulin secretory defect. The increased levels of free fatty acids are hypothesized to be a major contributor to the insulin secretory defect. The 25 pancreatic islets of Langerhans contain beta cells that secrete insulin in response to increases in blood glucose. Culturing islet cells in vitro with oleate, one of the three most abundant circulating fatty acids in man, provides a means of studying the beta cell secretory defect in Type 2 diabetes. We discovered that islet cells cultured for 5 days in vitro with oleate have a significant deficit in glucose-stimulated insulin secretion and a 1.9-fold upregulation of 30 Adoral mRNA. Thus, the increased expression of Adoral in oleate-treated islets reflects increased receptor activation, decreased cAMP levels in the islet cell, and a resultant diminution of insulin secretion. A preferred method of the invention is the use of the adenosine Al receptor for identifying an antagonist that would be beneficial in the treatment of Type 2 diabetes. As such the current invention embodies the use of recombinantly 246 WO 2004/013347 PCT/US2003/024504 expressed and/or endogenously expressed protein in various screens to identify such therapeutic antibodies and/or therapeutic small molecules. In one embodiment, the present invention describes the specific upregulation of 5 Adoral mRNA in rat islet cells cultured in oleate. Islets cultured in oleate have a significant deficit in insulin secretion. The upregulation and activation of Adoral in oleate-cultured islets may be the cause of the suppressed insulin secretion. In particular the invention relates to the use of Adoral protein as a diagnostic and/or 10 target for small molecule drugs and antibody therapeutics. We documented that Adoral is expressed in a wide variety of human tissues, with highest expression in brain and testis. We also discovered novel expression of Adoral in human pancreatic islet cells. Furthermore, we have discovered that adenosine Al receptor mRNA is upregulated 1.9-fold in islets treated with oleate, which has been identified in the art to suppress glucose-stimulated 15 insulin secretion, versus control islets. The increased expression of Adoral in oleate-treated islets reflects increased receptor activation, decreased cAMP levels in the islet cell, and a resultant diminution of insulin secretion. Preferably, in one aspect, agonist activation of Adoral decreases cellular cAMP accumulation. Thus, the present invention describes a role for activation of Adoral in the inhibition of glucose-stimulated (but not neurotransmitter 20 stimulated) insulin secretion. Not to be limited by a particular mechanism of action, we have discovered that inhibition of Adoral may have beneficial effects for treating Type 2 diabetes. Specifically, Adoral is expressed in several metabolic tissues, including pancreatic islets of Langerhans. Thus, we have shown that culture of islets in 2mM oleate for 5 days results in increased 25 expression of islet cell Adoral. Increased expression and/or activation of Adoral may contribute to the insulin secretory defect in oleate-treated islets and patients with Type 2 diabetes. The finding that suppression of glucose-stimulated insulin secretion in islet cells is correlated with up-regulation of adenosine Al receptor mRNA in pancreatic islet cells, indicates a role for Adoral in insulin secretion and glucose homeostasis. Therefore, an 30 antagonist of Adoral is useful for the treatment of diabetes. In a particular embodiment of the invention, Adoral is a target for screening antagonists of Adoral expression or activity. As such the current invention embodies the use of recombinantly expressed and/or endogenously expressed protein in various screens to identify adenosine Al receptor 247 WO 2004/013347 PCT/US2003/024504 antagonist therapeutic antibodies and/or therapeutic small molecules beneficial in the treatment of Type 2 diabetes. Furthermore, our results indicate that a modulator of Adoral activity, such as an 5 inhibitor, activator, antagonist, or agonist of Adoral may be useful for treatment of such disorders as obesity, diabetes, and insulin resistance, as well as for enhancement of insulin secretion. Discovery Process 10 The following sections describe the study design(s) and the techniques used to identify the Adenosine Al receptor - encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for Obesity and Diabetes. 15 Example Fl. Rat Pancreatic Islets Study: A protocol Rat Pancreatic Islet study is disclosed in Example Q2. 20 Greater than 80% of Type 2 diabetes in man is associated with obesity. An important clinical goal in the early phases of Type II diabetes is to increase insulin secretion from the beta cells of the pancreas. Numerous agents have been identified that can modulate insulin secretion experimentally and in therapeutic situations. When applied to isolated rat 25 pancreatic islets, the changes in gene expression can be correlated with insulin secretion. In this study, acute and chronic changes in gene expression were examined from islets treated with an agent after short (4 hour) and long-term (5 days) exposure, respectively, compared with the basal state (11 mM glucose). The agents included elevated (25 mM) glucose, glucose (11 mM) and exendin-4 (1 nM), glucose (11 mM) and glybenclamide (50 uM) and 30 glucose (11 mM) and oleate (2 mM). A characteristic of obesity-related Type 2 diabetes is an increase in both fasting and post-prandial circulating free fatty acids, The increased levels of free fatty acids are hypothesized to be a major contributor to the insulin secretory defect seen in this disease. Culturing islet cells in vitro with oleate, one of the three most abundant circulating fatty acids in humans provides a means of studying the beta cell secretory defect 248 WO 2004/013347 PCT/US2003/024504 in Type 2 diabetes. Protocol for differential gene expression analysis, GeneCalling@, is disclosed in Example Q7. Results 5 A fragment of the rat Adenosine Al Receptor gene was initially found to be up regulated by 1.9 fold in a sample derived from oleate treated islet cells, 5 days after exposure to the oleate, a known suppressor of insulin secretion, relative to islet cells treated with glucose alone using CuraGen's GeneCalling@ method of differential gene expression. A 10 differentially expressed rat gene fragment migrating, at approximately 370 nucleotides in length was definitively identified as a component of the rat Adenosine Al Receptor cDNA. The method of competitive PCR was used for confirmation of the gene assessment. The electropherographic peaks corresponding to the gene fragment of the rat Adenosine Al Receptor were ablated when a gene-specific primer (shown Table Fl) competes with primers 15 in the linker-adaptors during the PCR amplification. The peaks at 370 nt in length were ablated in the sample from both the oleate treated and basal state islet cells. Table Fl. The sequence of the 370 nucleotide-long gene fragment and the gene-specific primers used for competitive PCR are indicated on the cDNA sequence of the rat adenosine Al receptor fragment (from 1003 to 2337; SEQ ID NO:207) and are shown below in bold. The gene specific primers at the 5' and 3' ends of the fragment are underlined. 1003 GCCAAGTCGC TGGCCCTCAT CCTCTTCCTC TTTGCCCTCA GCTGGCTGCC GCTGCATATC 1063 TTGAACTGTA TCACCCTCTT CTGCCCCACC TGCCAGAAAC CCAGCATTCT GATCTACATC 1123 GCCATCTTCC TCACACACGG CAACTCCGCC ATGAACCCCA TCGTCTATGC CTTCCGGATC 1183 CACAACTTCC GGGTCACCTT TCTGAAGATT TGGAATGACC ACTTCCGATG CCAGCCTAAG 1243 CCTCCCATCG ATGAAGACCT CCCAGAGGAG AAAGCTGAGG ACTAGACTCT GCCTTGCTCC 1303 GTCTAGCCCA TGCCCAGCGG CTCTCTGTTC AACTCCCACG TCCTCCCTGT CCCACCCTGT 1363 CCCACTGTCC CTCCTCAGTT TTCCCAGCTG GGGTGTAGGC TGTGGCATAG CGCGCATCTT 1423 TTCTTAAAGC TTTTACTTTG AGACGTCATG GAAAACTTAA GAGGTACACA TGGAGAAGAC 1483 ATGATCACAG AAGGGAAACA GCATAGAAGC ATCGATGCCT GCAGCTAGTG CTGGAGCTGG 1543 AGCTGGAGTT GAGTTTGACA TGATACAGGG ACTGCAGGAA TGAACTAGTA TTCCTCTCCT 1603 TCTTCCTCAC CCTCACCCTC CACAGAATCC. ACACCAACCT CCTCATAATC CTTCTCTAGG 1663 GCAGCCATGT CCTCACGGGC CTCAGAGAAC TCTCCCTCCT CCATGCCCTC ACCCACGTAC 1723 CAGTGCACAA AGGCACGCTT GGCATACATC AGATCAAACT TGTGATCCAG GCGAGCCcAA 1783 GCCTCAGCAA TGGCTGTGGT GTTGCTCAGC ATACACACAG CTCTCTGGAC CTTGGCCAGG 249 WO 2004/013347 PCT/US2003/024504 1843 TCGCCACCAG GTACCACAGT GGGAGGCTGG TAATTAATGC CAACCTTGAA GCCAGTGGGG 1903 CACCAGTCCA CAAACTGGAT GGTACGCTTG GTCTTGATGG TGGCAATGGC ACCATTGACA 1963 TCTTTGGGGA CCACATCACC ACGGTACAGC AGGCAGCAAG CCATGTATTT ACCATGGCGA 2023 GGGTCACATT TCACCATCTG GTTGGCTGGC TCAAAGCAGG CATTGGTGAT CTCTGCTACA 2083 GAAAGCTGTT CATGGTAGGC TTTCTCAGCA GAGATGACAG GGGCATAAGT GGCCAGAGGG 2143 AAGTGGATGC GAGGGTAGGG CACCAGGTTG GTCTGGAATT CTGTCAGATC AACATTCAGG 2203 GCCCCATCAA ATCTGAGGGA AGCAGTOATG GAAGACACAA TCTGGCTAAT AAGGCGGTTA 2263 AGGTTAGTGT AGGTTGGGCG CTCAATGTCG AGGTTTCTAC GACAGATGTC ATAGATGGCC 2323 TCATTGTCTA CCATG In addition, a second fragment of the rat Adenosine Al Receptor gene was found to be up-iegulated by 1.8 fold in the same sample of oleate treated islet cells above, (5 days after exposure to the oleate). This differentially expressed rat gene fragment migrating at 5 approximately 383.4 nucleotides in length was also definitively identified as a component of the rat Adenosine Al Receptor cDNa by the method of competitive PCR using a gene specific primer (shown Table F2) to compete with primers in the linker-adaptors during the PCR amplification. The electropherographic peaks corresponding to the gene fragment at 383 nt in length were ablated in the sample from both the oleate treated and basal state islet 10 cells. Table F2. The sequence of the 383 nucleotide-long gene fragment (from 2178 to 2559) and the gene-specific primers used for competitive PCR are indicated on the cDNA sequence of the rat adenosine Al receptor fragment (SEQ ID NO:208) are shown in bold. The gene specific primers at the 5' and 3' ends of the fragment are underlined. 1697 CCTCCTCCAT GCCCTCACCC ACGTACCAGT GCACAAAGGC ACGCTTGGCA TACATCAGAT 1757 CAAACTTOTG ATCCAGGCGA GCCCAAGCCT CAGCAATGGC TGTGGTGTTG CTCAGCATAC 1817 ACACAGCTCT CTGGACCTrG GCCAGGTCGC CACCAGOTAC CACAGTGGGA GGCTGGTAAT 1877 TAATOCCAAC CTTGAAGCCA GTGGGGCACC AGTCCACAAA CTGGATGGTA CGCTTGGTCT 1937 TGATGGTGGC AATGGCAGCA TTGACATCTT TGGGGACCAC ATCACCACGG TACAGCAGGC 1997 AGCAAGCCAT GTATTTACCA TGGCGAGGGT CACATTTCAC CATCTGGTrG GCTGGCTCAA 2057 AGCAGGCATT GGTGATCTCT GCTACAGAAA GCTGTTCATG GTAGGCTTTC TCAGCAGAGA 2117 TGACAGGGGC ATAAGTGGCC AGAGGGAAGT GGATGCGAGG GTAGGGCACC AGGT-rGGTCT 2177 GGAATTCTGT CAGATCAACA TTCAGGGCCC CATCAAATCT GAGGGAAGCA GTGATGGAAG 2237 ACACAATCTG GCTAATAAGG CGGTrAAGGT TAGTGTAGGT TGGGCGCTCA ATGTCGAGGT 2297 TTCTACGACA GATGTCATAG ATGGCCTCAT TGTCTACCAT GAAGGCACAA TCAGAGTGCT 2357 CCAGGGTGGT GTGGGTGGTG AGGATGGAAT TGTAGGGCTC AACCACAGCA GTGGAAACCT 250 WO 2004/013347 PCT/US2003/024504 2417 GGGGGGCTGG GTAAATGGAG AACTCCAGCT TGGACTrCTT TCCGTAGTCG ACAGAGACCC 2477 TCTCCATCAG CAGGGAGGTG AACCCAGAGC CAGTTCCCCC ACCAAAGCTG TGGAAAACCA 2537 AGAAGCCCTG GAGACCCGTG CACTGGTCAG CCAGCTrGCG AATT Example F2. Identification of Human Adenosine Al Receptor Gene Sequences 5 The sequence of Human Adenosine Al Receptor Gene (Acc. No. CG58655-01) was derived by laboratory cloning of cDNA fragments, by in silico prediction of the sequence. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were cloned. In silico prediction was based on sequences available in CuraGen's proprietary sequence databases or in the public human sequence databases, and 10 provided either the full-length DNA sequence, or some portion thereof. The protocol for identification of human sequence(s) is disclosed in Example Q8. Table F3 shows protein alignment (ClustalW) of the CG58655-01 (SEQ ID NO:56), and rat (scb-gb-m64299_1; SEQ ID NO:209) homologs of the Adenosine Al receptor. 15 Table F4 shows protein sequence of a rat (scbgb-m64299_1; SEQ ID NO:209) homolog of the Adenosine Al receptor. Table F3. Protein alignment (ClustalW) of the CG58655-01 (SEQ ID NO:56), and rat (sob gb-m64299 1I; SEQ ID NO:209) homologs of the Adenosine A1 receptor. 20 Table F4. Protein sequence of a rat (sebgb-mn64299_; SEQ ID NO:209) homolog ofthe Adenosine Al receptor. >m64299 Rat MPPYISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGALVIPLAILIN IGPQTYFH-TCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKTVVTQRRAAVAIAGCWILSLVVGL 251 WO 2004/013347 PCT/US2003/024504 TPMFGWNNLSVVEQDWRANGSVGEPVIKCEFEKVISMEYMVYFNFFVWVLPPLLLMVLIYLEVFYLIPK QLNKKVSASSGDPQKYYGKELKIAKSLALILFLFALSWLPLHILNCITLFCPTCQKPSILIYAIFLTHGN SAMNPIVYAFRIHKFRVTFLKIWNDHFRCQPKPPIDEDLPEEKAED The laboratory cloning was performed using one or more of the methods summarized in Example Q8. The NOV6 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table F5. 5 Table F5. NOV6 Sequence Analysis NOV6a, CG58655-01 'SEQ ID NO: 55 1003 bp DNA Sequence JORF Start: ATG at 5 1ORF Stop: TAG at 983 CGCCATGCCGCCCTCCATCTCAGCTTTCCAGGCCGCCTACATCGGCATCGAGGTGCTCATCGCCCTG G TCTCTGTGCCCGGGAACGTGCTGGTGATCTGGGCOGTGAAGTGAACCAGGCGCTGCGGGATGCCAC C TTCTGCTTCATCGTGTCGCTGGCCTCGCTGATGTGGCCGTGGGTGCCCTGGTCATCCCCCTCGCCA

T

CCTCATCAACATTGGGCCACAGACCTACTTCCACACCTGCCTCATGGTTGCCTGTCCGGTCCTCATC C TCACCCAGAGCTCCATCCTGGCCCTGCTGGCAATTGCGGTGGACCGCTACCTCCGGGTCAAGATCCC T CTCCGGTACAAGATGGTGGTGACCCCCCGGAGGGCGGCGGTGGCCATAGCCGGCTGCTGGATCCTCT C CT TCGTGGTGGGACTGACCCCTATGTTTGGCTGGAACAATCTGAGTGCGGTGGAGCGGGCCTGGGCA G CCAACGGCAGCATGGGGGAGCCCGTGATCAAGTGCGAGTTCGAGAAGGTCATCAGCATGGAGTACAT G GTCTACTTCAACTTCTTTGTGTGGGTGCTGCCCCCGCTTCTCCTCATGGTCCTCATCTACCTGGAGG T CTTCTACCTAATCCGCAAGCAGCTCAACAAGAAGGTGTCGGCCTCCTCCGGCGACCCGCAGAAGTAC T ATGGGAAGGAGCTGAAGATCGCCAAGTCGCTGGCCCTCATCCTCTTCCTCTTTGCCCTCAGCTGGCT G CCTTTGCACATCCTCAACTGCATCACCCTCTTCTGCCCGTCCTGCCACAAGCCCAGCATCCTTACCT A CATTGCCATCTTCCTCACGCACGGCAACTCGGCCATGAACCCCATTGTCTATGCCTTCCGCATCCAG A AGTTCCGCGTCACCTTCCTTAAGATTTGGAATGACCATTTCCGCTGCCAGCCTGCACCTCCCATTGA C GAGGATCTCCCAGAAGAGAGGCCTGATGACTAGACCCCGCCTTCCGCTCCC NOV6a, CG58655-01 SEQ ID NO: 56 326 aa MW at 36511.2kD Protein Sequence MPPS ISAFQAYIGIEVLIAVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGALVIPLAI L INIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKMVVTPRRAAVAIAGCWILS F VVGLTPMFGWNNLSAVERAWAANGSMGEPVIKCEFEKVISMEYMVYFNFFVWVLPPLLLMVLIYLEV F YLIRKQLNKKVSASSGDPQKYYGKELKIAKSLALILFLFALSWLPLHILNCITLFCPSCHKPSILTY I AIFLTHGNSAMNPIVYARIQKFRVTFLKIWNDHFRCQPAPPIDEDLPEERPDD NOV6b, 268368558 ISEQ ID NO: 57 1010bp DNA Sequence |ORE Start: at 3 ORF Stop: TAG at 993 CACCGAATTCCACCATGCCGCCCTCCATCTCAGCTTTCCAGGCCGCCTACATCGGCATCGAGGTGCT 252 WO 2004/013347 PCT/US2003/024504 ATCGCCCTGGTCTCTGTGCCCGGGAACGTGCTGGTGATCTGGGCGGTGAAGGTGAACCAGGCGCTGC G GGATGCCACCTTCTGCTTCATCGTGTCGCTGGCGGTGGCTGATGTGGCCGTGGGTGCCCTGGTCATC C CCCTCGCCATCCTCATCAACATTGGGCCACAGACCTACTTCCACACCTGCCTCATGGTTGCCTGTCC G GTCCTCATCCTCACCCAGAGCTCCATCCTGGCCCTGCTGGCAATTGCTGTGGACCGCTACCTCCGGG T CAAGATCCCTCTCCGGTACAAGATGGTGGTGACCCCCCGGAGGGCGGCGGTGGCCATAGCCGGCTGC T GGATCCTCTCCTTCGTGGTGGGACTGACCCCTATGTTTGGCTGGAACAATCTGAGTGCGGTGGAGCG G GCCTGGGCAGCCAACGGCAGCATGGGGGAGCCCGTGATCAAGTGCGAGTTCGAGAAGGTCATCAGCA T GGAGTACATGGTCTACTTCAACTTCTTTGTGTGGGTGCTGCCCCCGCTTCTCCTCATGGTCCTCATC T ACCTGGAGGTCTTCTACCTAATCCGCAAGCAGCTCAACAAGAAGGTGTCGGCCTCCTCCGGCGACCC G CAGAAGTACTATGGGAAGGAGCTGAAGATCGCCAAGTCGCTGGCCCTCATCCTCTTCCTCTTTGCCC T CAGCTGGCTGCCTTTGCACATCCTCAACTGCATCACCCTCTTCTGCCCGTCCTGCCACAAGCCCAGC A TCCTTACCTACATTGCCATCTTCCTCACGCACGGCAACTCGGCCATGAACCCCATTGTCTATGCCTT C CGCATCCAGAAGTTCCGCGTCACCTTCCTTAAGATTTGGAATGACCATTTCCGCTGCCACCCTGCAC C TCCCATTGACGAGGATCTCCCAGAAGAGAGGCCTGATGACTAGGGTGGCGGCCGCTAT NOV6b, 268368558 SEQ ID NO: 58 330 aa MW at 36910.6kD Protein Sequence PNSTMPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGALVI P LAILINIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYKMVVTPRRAAVAIAGC W ILSFVVGLTPMFGWNNSAVERAWAANGSMGEPVIKCEFEKVISMEYMVYFNFFVWVLPPLLLMVLI Y LEVFYLIRKQLNKKVSASSGDPQKYYGKELKIAKSLALILFLFALSWLPLHILNCITLFCPSCHKPS LTYIAIFLTHGNSAMNPIVYAFRIQKFRVTFLKIWNDHFRCQPAPPIDEDLPEERPDD A ClustaiW comparison of the above protein sequences yields the following sequence aligmnent shown in Table F6. Table F6. Comparison of the NOV6 protein sequences. NOV6a ---- MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADV NOV6b PNSTMPPSISAFQAAYIGIEVLIALSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADV NOV6a AVGALVIPLAILINIGPQTYFHTCLMVACPVLILTQSSILALLAAVDRYLRVKIPLRYK NOV6b AVGALVIPLAILINIGPQTYFHTCLMVACPVLILTQSSILALLAIAVDRYLRVKIPLRYK NOV6a MVVTPRRAAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAANGSMGEPVIKCEFEKVIS NOV6b MVVTPRRAAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAANGSMGEPVIKCEFEKVIS NOV6a MEYMVYFNFFVWVLPPLLLMVLIYLEVFYLIRKQLNKKVSASSGDPQKYYGKELKIAKSL NOV6b MEYMVYFNFFVWVLPPLLLMVLIYLEVFYLIRKQLNKKVSASSGDPQKYYGKELKIAKSL NOV6a ALILFLFALSWLPLHILNCITLFCPSCHKPSILTYIAIFLTHGNSAMNPIVYAFRIQKFR 253 WO 2004/013347 PCT/US2003/024504 NOV6b ALILFLFALSWLPLHILNCITLFCPSCHKPSILTYIAIFLTHGNSAMNPIVYAFRIQKFR NOV~a VTFLKIWNDHFRCQPAPPIDEDLPEERPDD NOV6b VTFLKIWNDHFRCQPAPPIDEDLPEERPDD NOV6a (SEQ ID NO: 56) NOV6b (SEQ ID NO: 58) Further analysis of the NOV6a protein yielded the following properties shown in Table F7. Table F7. Protein Sequence Properties NOV6a SignalP analysis: Cleavage site between residues 31 and 32 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 0; pos.chg 0; neg.chg 0 H-region: length 15; peak value 6.60 PSG score: 2.20 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -4.41 possible cleavage site: between 59 and 60 >>> Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 6 INTEGRAL Likelihood= -5.84 Transmembrane 15- 31 INTEGRAL Likelihood = -8.76 Transmembrane 53 - 69 INTEGRAL Likelihood = -7.22 Transmembrane 87-103 INTEGRAL Likelihood =-6.53 Transmembrane 124 -140 INTEGRAL Likelihood = -8.01 Transmembrane 185 - 201 INTEGRAL Likelihood =-6.05 Transmembrane 236 -252 PERIPHERAL Likelihood= 4.72 (at 267) ALOM score: -8.76 (number of TMSs: 6) MTOP: Prediction ofmembrane topology (Hartmann et al.) Center position for calculation: 22 Charge difference: 2.0 C( 1.0) - N(-1.0) C> N: C-terminal side will be inside >>>Caution: Inconsistent mtop result with signal peptide >>> membrane topology: type 3b MITDISC: discrimination of mitochondrial targeting seq R content: 0 Hyd Moment(75): 0.93 Hyd Moment(95): 4.05 G content 1 D/E content: 1 S/T content: 2 Score: -5.83 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motifat 133 RRAJAV NUCDISC: discrimination of nuclear localization signals pat4: none pat7: none bipartite: none 254 WO 2004/013347 PCT/US2003/024504 content of basic residues: 8.3% NLS Score: -0.47 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: none SKL: peroxisomal targeting signal in the C-terminus: none PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: none RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none NMYR: N-myristoylation pattern : none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 94.1 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues Final Results (k = 9/23): 55.6 %: endoplasmic reticulum 11.1 %: Golgi 11.1 %: vacuolar 11.1 %: vesicles of secretory system 11.1 %: mitochondrial >> prediction for CG58655-01 is end (k=9) A search of the NOV6a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table F8. 255 WO 2004/013347 PCT/US2003/024504 Table F8. Geneseq Results for NOV6a NOV6a Identities/ Geneseq Protein/Organism/Length [Patent Residues/ Similarities for Expect Identifier #, Date] Match the Matched Value Residues Region ABP96789 Human COPD related protein SEQ 1.326 326/326(100%) 0.0 ID NO:39 - Homo sapiens, 326 aa. 1.326 326/326 (100%) [W0200297127-A2, 05-DEC-2002] ABP81771 Human adenosine Al receptor 1..326 326/326 (100%) 0.0 protein SEQ ID NO:24 - Homo 1..326 326/326 (100%) sapiens, 326 aa. [W0200261087 A2, 08-AUG-2002] AAR84192 Human Al adenosine receptor - 1..326 326/326 (100%) 0.0 Homo sapiens, 326 aa. 1..326 326/326 (100%) [GB2289218-A, 15-NOV-1995] AAR87655 Human adenosine receptor Al 1..326 326/326 (100%) 0.0 subtype - Homo sapiens, 326 aa. 1..326 326/326 (100%) [GB2288733-A, 01-NOV-1995] AAR93989 Human ventricle Al adenosine 1..326 326/326 (100%) 0.0 receptor - Homo sapiens, 326 aa. 1..326 326/326 (100%) [W09511681-Al, 04-MAY-1995] II In a BLAST search of public sequence databases, the NOV6a protein was found to have homology to the proteins shown in the BLASTP data in Table F9. Table F9. Public BLASTP Results for NOV6a Protein NOV6a Identities/ Accession Protein/Organism/Length Residues/ Similarities for the Expect Number cues Matched Portion Value P30542 Adenosine Al receptor - Homo 1..326 326/326 (100%) 0.0 sapiens (Human), 326 aa. 1..326 326/326 (100%) P47745 Adenosine Al receptor - Cavia 1..326 311/326 (95%) 0.0 porcellus (Guinea pig), 326 aa. 1..326 318/326 (97%) A38144 adenosine receptor Al - bovine, 1..326 308/326 (94%) e-179 326 aa. 1..326 315/326 (96%) Q8BGU7 Adenosine Al receptor - Mus 1..326 309/326 (94%) e-179 musculus (Mouse), 326 aa. 1..326 315/326 (95%) P28190 Adenosine Al receptor - Bos 1..326 307/326 (94%) e-179 taurus (Bovine), 326 aa. 1..326 315/326 (96%) 256 WO 2004/013347 PCT/US2003/024504 PFam analysis predicts that the NOV6a protein contains the domains shown in the Table F10. Table F10. Domain Analysis of NOV6a Identities/ Pfam Domain NOV6a Match Region Similarities Expect Value for the Matched Region 7tm_5 4..278 46/347 (13%) 0.74 165/347 (48%) 7tm_1 26..288 81/287 (28%) 3.6e-65 204/287 (71%) 5 Example F3. Human Adenosine Al Receptor Gene Variants and SNPs Variant sequences are included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A 10 SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs 15 occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, however, in the case that a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered 20 regulation of the expression pattern for example, alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, stability of transcribed message. Method of novel SNP Identification: SNPs are identified by analyzing sequence assemblies 25 using CuraGen's proprietary SNPTool algorithm. SNPTool identifies variation in assemblies with the following criteria: SNPs are not analyzed within 10 base pairs on both ends of an alignment; Window size (number of bases in a view) is 10; The allowed number of 257 WO 2004/013347 PCT/US2003/024504 mismatches in a window is 2; Minimum SNP base quality (PHRED score) is 23; Minimum number of changes to score an SNP is 2/assembly position. SNPTool analyzes the assembly and displays SNP positions, associated individual variant sequences in the assembly, the depth of the assembly at that given position, the putative assembly allele frequency, and the 5 SNP sequence variation. Sequence traces are then selected and brought into view for manual validation. The consensus assembly sequence is imported into CuraTools along with variant sequence changes to identify potential amino acid changes resulting from the SNP sequence variation. Comprehensive SNP data analysis is then exported into the SNPCalling database. 10 Method of novel SNP Confirmation: SNIPs are confirmed employing a validated method know as Pyrosequencing. Detailed protocols for Pyrosequencing can be found in: Alderborn et al. Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. (2000). Genome Research. 10, Issue 8, August. 1249-1265. 15 In brief, Pyrosequencing is a real time primer extension process of genotyping. This protocol takes double-stranded, biotinylated PCR products from genomic DNA samples and binds them to streptavidin beads. These beads are then denatured producing single stranded bound DNA. SNPs are characterized utilizing a technique based on an indirect bioluminometric assay of pyrophosphate (PPi) that is released from each dNTP upon DNA chain elongation. 20 Following Klenow polymerase-mediated base incorporation, PPi is released and used as a substrate, together with adenosine 5'-phosphosulfate (APS), for ATP sulfurylase, which results in the formation of ATP. Subsequently, the ATP accomplishes the conversion of luciferin to its oxi-derivative by the action of luciferase. The ensuing light output becomes proportional to the number of added bases, up to about four bases. To allow processivity of 25 the method dNTP excess is degraded by apyrase, which is also present in the starting reaction mixture, so that only dNTPs are added to the template during the sequencing. The process has been fully automated and adapted to a 96-well format, which allows rapid screening of large SNP panels. 30 Results The DNA and protein sequences for the novel single nucleotide polymorphic variants of the Adenosine Al Recepto-like gene of CuraGen Acc. No. CG58655-01 are reported in Table F 11. Variants are reported individually but any combination of all or a select subset of variants are also included. In Table Fl 1, the positions of the variant bases and the variant 258 WO 2004/013347 PCT/US2003/024504 amino acid residues are underlined. In summary, there are 1 variants reported in Table Fl 1. Variant 13381538 is a T to C SNP at 717 bp of the nucleotide sequence that results in a Len to Pro change at amino acid 238 of protein sequence. 5 Table FI. Variant of nucleotide sequence Acc. No. CG58655-01 (SEQ ID NO:55) Variant Nucleotides Amino Acids Position Initial Modified Position Initial Modified 13381538 717 T C 238 Leu Pro Table F12. Sequence of Variants Table F12A1. Nucleotide sequence of variant 13381538 NOV6aln (underlined). T/C (SEQ ID NO:167) 1 CGCCATGCCGCCCTCCATCTCAGCTTTCCAGGCCGCCTACATCGGCATCGAGGTGCTCATCGCCCTGGTCTCTGTGCCCG 81 GGAACGTGCTGGTGATCTGGGCGGTGAAGGTGAACCAGGCGCTGCGGGATGCCACCTTCTGCTTCATCGTGTCGCTGGCG 161 GTGGCTGATGTGGCCGTGGGTGCCCTGGTCATCCCCCTCGCCATCCTCATCAACATTGGGCCACAGACCTACTTCCACAC 241 CTGCCTCATGGTTGCCTGTCCGGTCCTCATCCTCACCCAGAGCTCCATCCTGGCCCTGCTGGCAATTGCGGTGGACCGCT 321 ACCTCCGGGTCAAGATCCCTCTCCGGTACAAGATGGTGGTGACCCCCCGGAGGGCGGCGGTGGCCATAGCCGGCTGCTGG 401 ATCCTCTCCrTCGTGGTGGGACTGACCCCTATGTTTGGCTGGAACAATCTGAGTGCGGTGGAGCGGGCCTGGGCAGCCAA 481 CGGCAGCATGGGGGAGCCCGTGATCAAGTGCGAGTTCGAGAAGGTCATCAGCATGGAGTACATGGTCTACTTCAACTTCT 561 TTGTGTGGGTGCTGCCCCCGCTTCTCCTCATGGTCCTCATCTACCTGGAGGTCTTCTACCTAATCCGCAAGCAGCTCAAC 641 AAGAAGGTGTCGGCCTCCTCCGGCGACCCGCAGAAGTACTATGGGAAGGAGCTGAAGATCGCCAAGTCGCTGGCCCCCAT 721 CCTCTTCCTCTTTGCCCTCAGCTGGCTGCCTTTGCACATCCTCAACTGCATCACCCTCTTCTGCCCGTCCTGCCACAAGC 801 CCAGCATCCTTACCTACATTGCCATCTTCCTCACGCACGGCAACTCGGCCATGAACCCCATTGTCTATGCCTTCCGCATC 881 CAGAAGTTCCGCGTCACCTTCCTTAAGATTTGGAATGACCATTTCCGCTGCCAGCCTGCACCTCCCATTGACGAGGATCT 961 CCCAGAAGAGAGGCCTGATGACTAGACCCCGCCTTCCGCTCCC Table F12A2. Protein sequence of variant NOV6alp (underlined). (SEQ ID NO:168) 1 MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVSLAVADVAVGALVIPLAILINIGPQTYFHTC 81 LMVACPVLILTQSSILALLAIAVDRYLR.VKIPLRYKMVVTPRRAAVAIAGCWILSFVVGLTPMFGWNNLSAVERAWAANG 161 SMGEPVIKCEFEKVISMEYMVYFNFFVWVLPPLLLMtLIYLEVFYLIRKQLNKKVSASSGDPQKYYGRELKIAKSLAPIL 241 FLFALSWLPLILNCITLFCPSCHKPSILTYIAIFLTHGNSAMNPIVYAFRIQKFRVTFLKIWNDHFRCQPAPPIDEDLP 321 EERPDD Table F12A3. Alteration effect Leu to Pro Example F4. Expression Profile of the Human Adenosine Al Receptor Gene 10 (CG58655-01) The protocol for quantitative expression analysis is disclosed in Example Q9. Expression of gene CG58655-01 was assessed using the primer-probe set Ag6342, described in Table F13. Results of the RTQ-PCR runs are shown in Tables F14, F15, F16, and F17. 15 Table F13. Probe Name Ag6342 Primers Sequences Length Start S 259 WO 2004/013347 PCT/US2003/024504 IPosition No Forward 5i -ccaccgcactcagattgtt-3' 19 543 210 Probe TET-5'-agccaaacataggggtcagtcccac-3'- 25 564 211 TAMRA Reverse 5' -atagccggctgctggat-3' 17 602 212 Table F14. General screening panel v1.5 TRel. Exp.(%) Ag6342, . Rel. Exp.(%) Ag6342, Tissue Name Run 259475625 Tissue Name Run 259475625 Adipose 0.8 Renal ca. TK-10 73.7 Melanoma* 7.0 Bladder 11.4 Hs688(A).T Melanoma* 6.5 Gastric ca. (liver met.) 2.9 Hs688(B).T NCI-N87 Melanoma* M14 3.5 Gastric ca. KATO III 0.0 Melanoma* 0.3 Colon ca. SW-948 1.0 LOXIMVI Melanoma* SK- 0.9 Colon ca. SW480 5.8 MEL-5 Squamous cell Colon ca.* (SW480 0.7 carcinoma SCC-4 0.1 met) SW620 0.7 Testis Pool 29.3 Colon ca. HT29 0.1 Prostate ca.* (bone 0.0 Colon ca. HCT-116 6.3 met) PC-3 Prostate Pool 0.4 Colon ca. CaCo-2 17.8 Placenta 18.6 Colon cancer tissue 0.1 Uterus Pool 0.6 Colon ca. SW1 116 5.6 Ovarian ca. 61.1 Colon ca. Colo-205 0.0 OVCAR-3-_ Ovarian ca. SK-OV- 2.7 Colon ca. SW-48 0.0 3, Ovarian ca. 22.1 Colon Pool 1.0 OVCAR-4 Ovarian ca. Ovarin ca.24.5 Small Intestine Pool 0.5 OVCAR-5 Ovarian ca. IGROV- 36.3 Stomach Pool 0.3 Ovarian ca. 19.5 Bone Marrow Pool 0.3 OVCAR-8__________ ___ Ovary 0.2 Fetal Heart 9.4 Breast ca. MCF-7 7.9 Heart Pool 2.5 Breast ca. MDA- 0.8 Lymph Node Pool 2.2 MB-231 Breast ca. BT 549 0.3 Fetal Skeletal Muscle 1.6 260 WO 2004/013347 PCT/US2003/024504 Breast ca. T47D 1.0 Skeletal Muscle Pool 1.5 Breast ca. MDA-N 1.3 Spleen Pool 49 Breast Pool 0.6 Thymus Pool 2.0 Trachea 2.5 CNS cancer (glio/astro) 1.2 U87-MG Lung 0.2 CNS cancer (glio/astro) 3.0 U-118-MG Fetal Lung 2.5 CNS cancer 0.8 (neuro;met) SK-N-AS0 Lung ca. NCI-N417 4.5 CNS cancer (astro) SF- 10.5 539 Lung ca. LX-1 1.3 CNS cancer (astro) 45.4 SNB-75 Lung ca. NCI-H146 4.3 _cancer (glio) 36.6 _________SNB- .19 3. Lung ca. SHP-77 0.0 CNS cancer (glio) SF- 15.2 295 Lung ca. A549 1.7 Brain (Amygdala) Pool 60.3 Lung ca. NCI-H526 1.5 Brain (cerebellum) 75.3 Lung ca. NCI-H23 0.6 Brain (fetal) 22.4 Lung ca. NCI-H460 0.0 Brain (Hippocampus) 40.3 Pool Lung ca. HOP-62 3.1 Cerebral Cortex Pool 45.1 Lung ca. NCI-H522 2.5 Brain (Substantia 532 nigra) Pool Liver 0.5 Brain (Thalamus) Pool 56.6 Fetal Liver 1.0 Brain (whole) 32.3 Liver ca. HepG2 0.2 Spinal Cord Pool 47.3 Kidney Pool 0.6 Adrenal Gland 0.4 Fetal Kidney 2.9 Pituitary gland Pool 1.0 Renal ca. 786-0 67.4 Salivary Gland 3.6 Renal ca. A498 46.7 Thyroid (female) 4.3 Renal ca. ACHN 100.0 Pancreatic ca. 0.9 ___________CAPAN2 Renal ca. UO-31 13.7 Pancreas Pool 8.5 Table F15. General screening panel vl.7 Tissue Name Rel. Exp.(%) Ag6342, Tissue Name Rel. Exp.(%) Ag6342, Run 318350017 T Run 318350017 Adipose 21.2 Gastric ca. (liver met.) 0.2 NCI-N87 IHUVEC 0.0 Stomach 0.0 Melanoma* 0 C Hs688(A).T 00 Colon ca. SW-948 0.0 261 WO 2004/013347 PCT/US2003/024504 Melanoma* 0.2 Colon ca. SW480 0.1 Hs688(B).T Meanm )0.2 Colon ca. (SW480 met) SK-MEL-5 SW620 Tests j 17.0 Colon ca. HT29 0.1 Prostate ca. (bone 0.1 Colon ca. HCT-1 16 6.3 met) PC-3 Prostate ca. DU145 5.3 Colon cancer tissue 0.2 Prostate pool 0.2 Colon ca. SW1116 1.9 Uterus pool 0.0 Colon ca. Colo-205 0.0 Ovarian ca. 18.2 Colon ca. SW-48 0.0 OVCAR-3 Ovarian ca. 2.2 Colon 0.4 (ascites) SK-OV-3 Ovarian ca. 26.1 Small Intestine 0.0 OVCAR-4 Ovarian ca. 0.9 Fetal Heart 0.8 OVCAR-5 Ovarian ca. 100.0 Heart 0.6 IGROV-1 Ovarian ca. 6.8 Lymph Node pool 1 0.3 OVCAR-8 Ovary 0.2 Lymph Node pool 2 1.5 Breast ca. MC- 1.1 Fetal Skeletal Muscle 1.6 Breast ca. MDA- 3.1 Skeletal Muscle pool 0.2 MB-231 Breast ca. BT-549 0.1 Skeletal Muscle 0.6 Breast ca. T47D 1.2 Spleen 1.5 Breast pool 0.3 Thymus 0.2 Trachea I2.2 CNS cancer (glio/astro) 1.5 SF-268 Lung 1.4 CNS cancer (glio/astro) 1.4 T98G _ ' _ Fetal Lung 1.5 CNS cancer 0.0 (neuro;met) SK-N-AS Lung ca. NCI-N417 2.0 CNS cancer (astro) SF- 7.6 Lung ca. LX-1 0.3 CNS cancer (astro) 8.7 SNB-75 Lung ca. NCI- 64.1 CNS cancer (glio) 9.3 SNB-19 9.3 CNS cancer (glio) SF- 0 Lung ca. SHP-77 0.0 295 0.5 Lung ca. NCI-H23 11.2 Brain (Amygdla) 27.9 Lung ca. NCI-H460 1.8 jBrain (Cerebellum) 52.1 262 WO 2004/013347 PCT/US2003/024504 Lung ca. HOP-62 1.1 Brain (Fetal) 28.1 Lung ca. NCI-H522 3.6 Brain (Hippocampus) 20.6 Lung ca. DMS- 114 1.5 Cerebral Cortex pool 18.8 Liver 0.2 Brain (Substantia 10.3 nigra) Fetal Liver 0.2 Brain (Thalamus) 25.0 Kidney pool 7.2 Brain (Whole) 80.7 Fetal Kidney 3.0 Spinal Cord 12.8 Renal ca. 786-0 0.5 Adrenal Gland 0.3 Renal ca. A498 32.5 Pituitary Gland 0.6 Renal ca. ACHN 80.1 Salivary Gland 3.3 Renal ca. UO-31 8.1 Thyroid 1.8 Renal ca. TK-10 59.0 Pancreatic ca. PANC-1 2.8 Bladder 0.6 Pancreas pool 1.7 Table F16. Panel 5 Islet Rel. Exp.(%) Rel. Exp.(%) Rel. Exp.(%) Tissue Name Ag6342, Run Ag6342, Run Ag6342, Run 259472132 263594805 271406445 97457 Patient-02goadipose 34.4 9.6 8.4 97476 Patient-07sk skeletal muscle 0.0 1.4 1.9 97477 Patient-07ut uterus 0.0 3.1 0.9 97478 Patient-07plplacenta 88.9 79.0 68.8 99167 Bayer Patient 1 28.5 15.3 19.2 97482 Patient-08ut uterus -0.0 2.0 0.0 97483 Patient-08plplacenta 36.9 27.7 27.5 97486 Patient-09sk skeletal muscle 11.1 1.7 4.0 97487 Patient-09ut uterus 0.0 0.0 2.0 97488 Patient-09plplacenta 100.0 64.2 63.3 97492Paient-lOut uterus 8.2 1.9 3.8 97493 Patient-10plplacenta 96.6 100.0 100.0 97495 Patient-Ilgoadipose 34.4 3.3 4.1 97496 Patient-i lsk skeletal muscle 9.7 6.4 2.0 97497 Patient-11ut uterus 12.7 3.1 6.1 97498 Patient-11_plylacenta 52.9 67.4 62.0 97500_Patient-l2goadipose 28.1 24.0 18.6 97501 Patient-12sk skeletal muscle 20.0 9.9 10.1 97502 Patient-12ut uterus . 8.1 2.6 5.5 97503 Patient-12plplacenta 67.8 47.0 40.3 94721 Donor 2 U - A Mesenchymal Stem Cells 75.8 68.3 53.2 94722_Donor 2 U - B Mesenchymal 22.4 46.0 57.4 263 WO 2004/013347 PCT/US2003/024504 Stem Cells 94723_Donor 2 U - CMesenchymal 62.0 51.8 57.0 Stem Cells 94709_Donor 2 AM - Aadipose 3.1 21.8 14.3 94710_Donor 2 AM - Badipose 0.0 5.3 9.4 94711 Donor 2 AM - C adipose 8.7 14.8 8.2 94712 Donor 2 AD - Aadipose 19.1 17.7 14.0 94713_Donor 2 AD - B_adipose 13.0 29.7 22.5 94714 Donor 2 AD - C adipose 10.7 35.6 12.2 94742_Donor 3 U - AMesenchymal 23.3 29.1 5.9 Stem Cells 94743_Donor 3 U - BMesenchymal 33.0 8.9 28.3 Stem Cells 94730 Ionor 3 AM - A adipose 0.0 5.1 7.0 94731 Ionor 3 AM - B adipose 0.0 7.5 0.0 94732 Donor 3 AM - C adipose 4.3 3.3 3.7 94733 Donor 3 AD - A_adipose 0.0 1.1 12.4 94734 Donor 3 AD - Badipose 3.7 1.8 2.1 94735-Donor 3 AD - C adipose 23.2 2.6 7.0 77138_LiverHepG2untreated 0.0 1.7 3.8 73556_HeartCardiac stromal cells 0.0 0.0 0.0 (primary) 81735 Small Intestine 4.2 8.3 7.6 72409 KidneyProximal Convoluted 36.9 22.7 15.8 Tubule 82685_Small intestine Duodenum 0.0 3.8 0.0 90650_AdrenalAdrenocortical 0.0 0.0 2.0 adenoma 72410 KidneyHiRCE 48.3 32.3 44.1 72411 KidneyHRE 54.0 46.3 33.2 73139_UterusUterine smooth 12.1 14.5 9.8 muscle cells _ _4 Table F17. Human Metabolic Column A - Rel. Exp.(%) Ag6342, Run 324668027 Tissue Name A Tissue Name A 13757 psoas-AA.M.Diab.-hi 0.2 139523 pancreas-HI.M.Norm-hi BMI-31 0.3 135760 psoas-HI.M.Diab.-hi 4.1 139520 pancreas-CC.M.Nonn-hi BMI-29 0.5 BMI-2 1_____________ ___ 134827 psoas-CC.M.Diab.-hi 342 s0.2 142744 pancreas-HI.M.Norm-med BMI-35 0.4 137860 psoas-AA.M.Diab.- 0.6 139545 pancreas-AA.M.Nonn-med BMI-47 0.3 264 WO 2004/013347 PCT/US2003/024504 med BMI-8 137834 psoas-CC.M.Diab.- 0.5 139531 pancreas-AA.M.Norm-med BMI-37 0.0 med BMI-2 ________________ 137828 psoas-CC.M.Diab.

med828 M - . 0.7 137871 pancreas-CC.M.Norm-med BMI-26 1.5 med BMI-1 - I 135763 psoas-HI.M.Diab.- 0.9 139541 pancreas-Hi.M.Norm-low BMI-41 0.2 med BMI-23 142740 psoas-AS.M.Diab.- 0.4 139537 pancreas-CC.M.Norm-low BMI-40 6.7 low BMI-20___________________ 134834 psoas-AA.M.Diab.- 15193 w0.5 139533 pancreas-CC.M.Norm-low BMI-39 0.0 low BMI-17 137850 psoas-AS.M.Nonn-hi 1.7 137845 pancreas-AS.M.Norm-low BMI-28 1.0 135769 psoas-HI.M.Norm-hi 0.2 143530 small intestine-AA.M.Diab.-hi BMI-6 0.3 BMI-31 _______________ 135766psoas-AA.M.Norm-hi 0.2 143529 small intestine-CC.M.Diab.-hi BMI-4 0.2 1M-25 psoas-AA.M.Norm 142746 psoas-AA.M.Norm- 0.3 143538 small intestine-H.M.Diab.-med BMI-23 3.6 med.BMI-37 142745 psoas-HI.M.Norm- 0.1 143531 small intestine-AA.M.Diab.-med BMI-8 0.2 med BMI-35 I_______________ 137855 psoas-AA.M.Norm- 0.2 143528 small intestine-CC.M.Diab.-med BMI-2 0.3 mdBMI-47 _______________ 137844 psoas-CC.M.Norm- 0.1 143537 small intestine-H.M.Diab.-low BMI-22 0.3 med BMI-26 142742 psoas-CC.M.Konn- 0.7 143535 small intestine-AS.M.Diab.-low BMI-20 0.4 low BMI-40 137873 psoas-AS.M.Norm- 0.6 143534 small intestine-AA.M.Diab.-low BMI-17 0.2 low BMI-28 137853 psoas-HI.M.Norm- 0.7 143544 small intestine-AS.M.Nonn-hi BMI-34 0.2 low BMI-41 ____________________ 135775 psoas-CC.M.Norm- 0.6 143543 small intestine-HI.M.Norm-hi BMI-31 0.8 low BMI-39_____________________ 137858 diaphragm- 0.4 143542 small intestine-CC.M.Norm-hi BMI-29 0.1 AA.M.Diab.-hi BMI-6 135772 diaphragm- 0.3 143539 small intestine-AA.M.Norm-hi BMI-25 3.1 AS.M.Diab-hi BMI-9 135761 diaphragm- 1.3 143548 small intestine-AA.M.Norm-med BMI-47 0.1 HI.M.Diab.-hi BMI-21 134828 diaphragm- 0.3 143547 small intestine-AA.M.Norm-med BMI-37 0.1 CC.M.Diab.-lii BMI-4_______ _________ 137835 diaphragm 13783M.diaphrame I-2 0.2 143540 small intestine-CC.M.Norm-med BMI-26 0.1 CC.M.Diab.-med BMI-2 135764 diaphragm- 0.2 143550 small intestine-CC.M.Norm-low BMI-40 0.0 flI.M.Diab.-med BMI-23 _______________ 134835 diaphragm- :0.4 143549 small intestine-CC.M.Norm-low BMI-39 0.2 265 WO 2004/013347 PCT/US2003/024504 AA.M.Diab.-low BMI-17 1142738 diaphragm- 0.7 143546 small intestine-HI.M.Norn-low BMI-41 0.0 CC.M.Norm-hi BMI-29 139517 diaphragm- 0.9 143525 hypothalamus-HI.M.Diab.-hi BMI-21 0.2 AS.M.No -hr BM-34 11 137848 diaphragm- 0.4 143515 hypothalamus-CC.M.Diab.-hi BMI-4 0.0 HI.M.Norm-hi BMI-31 137843 diaphragm- 0.2 143513 hypothalamus-AA.M.Diab.-hi BMI-6 35.1 AA.M.Norm-hi BMI-25 ________________ 137879 diaphragm- 0.2 143507 hypothalamus-AS.M.Diab.-hi BMI-9 42.0 AA.M.Norm-med BMI-47 _______________ 137872 diaphragm- 0.2 143506 hypothalamus-CC.M.Diab.-med BMI-1 83.5 CC.M.Norm-med BMI-26 ________________ 135773 diaphragm- 0.7 143505 hypothalamus-HI.M.Diab.-med BMI-23 0.4 HI.M.Norm-med BMI-3 5 ______________ 139542 diaphragm- 1.5 143509 hypothalamus-AA.M.Diab.-low BMI-17 100.0 HI.M.Norm-low BMI-41 ________________ 137877 diaphragm- 0.7 143508 hypothalamus-CC.M.Diab.-low BMI-13 37.9 CC.M.Norm-low BMI-39 A ______________ 137874 diaphrag- 0.4 143503 hypothalamus-AS.M.Diab.-low BMI-20 60.3 AS.M.Norm-low BMI-28 ______________ 141340 subQadipose- 2.8 143522 hypothalamus-HI.M.Norm-hi BMI-31 0.0 AA.M.Diab.-hi BMI-6 II__________________ Il783 iai I- 0.1 143516 hypothalamus-AS.M.Nonn-hi BMI-34 0.0 135771ASDiai pMI9 0.2 143511 hypothalamus-CC.M.Norm-hi BMI-29 33.9 141329 ancrea MI-4 1.1 143504 hypothalamus-AA.M.Norm-hi BMI-25 19.9 C16 Diab d B1I-1 0.4 143517 hypothalamus-AA.M.Norm-med BMI-47 0.3 135762 su Qadipose- 0.0 143514 hypothalamus-HI.M.Norm-med BMI-35 16.8 HL.M.Diab.-med BMI-23 _______________ 141338 subQadipose- 0.1 143521 hypothalamus-AS.M.Norm-low BMI-28 0.1 AS.M.Diab.-low BMI-20 139547 subQadipose- 0.2 143512 hypothalamus-CC.M.Nonn-low BMI-40 0.1 HI.M.Diab.-low BMI-22______ __________ 135757 subQadipose- 0.1 145454 Patieit-25pl (CC.Diab.low BMI.no insulin) 17.6 CC.M.Diab.-low BMI-13 134832 subQadipose- 0.6 110916 Patient-18pl (HI.Diab.obese.no insulin) 6.0 AA.M.Diab.-low BMI-17 141332 subQadipose- 0.5 110913 Patient-18go (HI.Diab.obese.no insulin) 0.5 HI.M.Norm-hi BMI-31 135767 subQadipose- 0.1 110911 Patient-17pl (CC.Diab.low BMI.no insulin) 18.8 CC.M.Norm-hi BMI-29 I______________ I 135765 subQadipose- 1.1 110908 Patient-17go (CC.Diab.low BMI.no 1.7 266 WO 2004/013347 PCT/US2003/024504 AS.M.Norm-hi BMI-34 insulin) 14133 ubQad1pose-I3 0.8 100752 Patient-15sk (CC.Diab.obese.no insulin) 1.9 141339 subQadipose-08172 HI.M.Norm-med BMI-35 Ptetls(CDibbeenisun) j. 141334 subQadipose- 0.4 97828 Patient-13pl (CC.Diab.overwt.no insulin) 9.7 CC.M.Norm-med BMI-26 _ 139544 subQadipose- 1.5 160114 Patient 27-ut (CC.Diab.obese.insulin) 0.5 AA.M.Norm-med BMI-47 1.5 160114 Patient 27-ut (CC.Diab.obese.insulin) 0.5 137875 subQadipose- 0.5 160113 Patient 27-sk (CC.Diab.obese.insulin) 0.5 3 sum-adipB- 0.1 160111 Patient 27-go (CC.Diab.obese.insulin) 1.5 AS.M.Nonrn-low BMI-28 05101 ain 7s C.iboeeisln . 137878 subQadipose- 0.1 145461 Patient 27-go (CC.Diab.obese.insulin) 13 137876 subQadipose- 0. 1 145461 Patient-26sk (CC.Diab.obese.insulin) 2.1 CC.M.Norm-low BMI-39 137859Mi.Da-ipMI-6 0.0 145441 Patient-22sk (CC.Diab.low BMI.insulin) 6.8 AA.M.Diab.-hi BMI-6 135770 vis.adipose AS.MDiablii MI-90.4 145438 Patient-22pl (CC.Diab.low BMI.insulin) 14.8 AS.M.Diab-hi BMI-9 135759 vis.adipose- 0.1 145427 Patient-20pl (CC.Diab.overwt.insulin) 18.8 HI.M.Diab.-hi BMI-21 _Oll52 ain 143502 vis.adipose- 2.3 97503 Patient-12pl (CC.Diab.unknown 2.5 CC.M.Diab.-med BMI-2 BMI.insulin) 139510 vis.adipose 13950M.DimeB-8 0.1 145443 Patient-23pl (CC.Non-diab.overwt) 11.9 AA.M.Diab.-med BMI-8 137861 1sadipose- 0.2 145435 Patient-21pl (CC.Non-diab.overwt) 20.3 CC.M.Diab.-med-1____________________ 137839 vis.adipose 0.0 110921 Patient-19pl (CC.Non-diab.low BMI) 7.9 HI.M.Diab.-med BMI-23 IM 1iab.-dipo BI-22 0.2 110918 Patient-19go (CC.Non-diab.low BMI) 1.1 137831 vis.adipose- 0.0 97481 Patient-08sk (CC.Non-diab.obese) 0.9 CC.M.Diab.-low BMI-1 3 _______________ HIMN l ormi BMI-3 1 0.5 97478 Patient-07pl (CC.Non-diab.obese) 7.9 139516 vis.adipose A39516.M i. -ipBMI-4 0.1 160117 Human Islets-male, obese 0.2 AS.M.Norm-hi BMI-34 137846 vis. d 1I-29 0.1 145474 PANC1 (pancreas carcinoma) 1 2.0 AA 1M.81V -ipNB1MI-25 0.3 154911 Capan2 (pancreas adenocarcinoma) 2.8 139543 vis adipose 13943M.o-meBI-47 0.7 141190 SW579 (thyroid carcinoma) 0.1 AA.M.Norm-med BMI-47 139530 vis.adipose- 0.1 145489 SK-N-MC (neuroblastoma) 1 0.0 A1395o vis.adipose- M0.2 145495 SK-N-SH neuroblastomaa) 1 2.1 267 WO 2004/013347 PCT/US2003/024504 HI.M.Norm-med BMI-35 139539 vis.adipose- 0.0 145498 U87 MG (glioblastoma) 2 10.1 HLI.M.Norm-low BMI-41 C.535 vis.dipos M-40 0.1 145484 HEp-2 (larynx carcinoma) 1 0.2 37852 visdiposeMI-39 0.7 145479 A549 (lung carcinoma) 2.4 AS.M.Norm-1ow MI-28 0.1 145488 A427 (lung carcinoma) 2 4.0 1413271ivr-CC.Mia-hi 141327 liver-CC.M.Diab.-hi 0.1 145472 FHs 738Lu (normal lung) 1 8.1 BMI-4 139514 liver-HI.M.Diab.-hi i BMI-21 0.2 141187 SKW6.4 (B lymphocytes) 0.0 139526 liver-CC.M.Diab.- 0.3 154644 IM-9 (immunoglobulin secreting 0.0 med BMI-2 lymphoblast) 139511 liver-AA.M.Diab.- 154645 MOLT-4 (acute lymphoblastic leukemia 1.0 med BMI-8 0.4 derived from peripheral blood) 137840 liver-HI.M.Diab.-med 0.1 154648 U-937 (histiocystic lymphoma) 0.0 BMI-23 137827 liver-CC.M.Diab.- 0.0 154647 Daudi (Burkitt's lymphoma) 0.1 med BMI-1 137838 liver-HI.M.Diab.-low 0.0 145494 SK-MEL-2 (melanoma) 2 1.5 BMI-22 1 135758 liver-CC.M.Diab.-low 0.0 141176 A375 (melanoma) 3.4 BMI-13 0 139519 liver-CC.M.Norm-hi 0.4 154642 SW 1353 (humerus chondrosarcoma) 12.2 BMI-29 139518 liver-AA.M.Norm-ii 0.2 141179 HT-1080 (fibrosarcoma) 2.0 BMI-25 13749 liver-AS.M.Norm-hi 0.0 145491 MG-63 (osteosarcoma) 1 48.6 137847 liver-HI.M.Norn-hi 0.0 141186 MCF7 (breast carcinoma) 4.2 BMI-3v1er-AA.M.Norm 142741 liver-AA.M.Norn- 0.0 141193 T47D (breast carcinoma) 2.3 med BMI-37 141341 liver-HI.M.Norm-med 0.1 154641 BT-20 (breast carcinoma) 35.8 BMI-35 141335 liver-CC.M.Norm- 0.1 141175 293 (kidney transformed with adenovirus 5 0.7 med BMI-26 DNA) 139540 liver-HI.M.Norm-low 2.1 141182 HUH hepatoma 1 0.0 BMI-41 1 139534 liver-CC.M.Norm- 2.6 141184 HUH7 hepatoma 1 0.0 low BMI-39 139521 liver-AS.M.Norm-low 0.3 145478 HT1376 (bladder carcinoma) 3.6 BM I-28 _ _ 3.6 141328 pancreas- 1.6 145481 SCaBER (bladder carcinoma) 0.0 268 WO 2004/013347 PCT/US2003/024504 CC.M.Diab.-hi BMI-4 139525 pancreas-ASM.Diab 02 141192 SW620 (lymph node metastatsis, colon hi BMI-9 carcinoma) 2 1.6 137856 pancreas AA.M.Diab.-hi BMI-6 4.8 141180 HT29 (colon carcinoma) 1 0.0 137837 pancreas-HI.M.Diab.

hi BMI-21 1.8 141188 SW480 (colon carcinoma) 1 2.5 141337 pancreas CC.M.Diab.-med BMI-2 0.0 154646 CAOV-3 (ovary adenocarcinoma) 16.4 139527 pancreas CC.M.Diab.-med BMI-1 0.1 141194 HeLa (cervix carcinoma)- 2 6.2 139515 pancreas-HI.M.Diab.

med BMI-23 8.4 145482 HeLa S3 (cervix carcinoma) 1 0.3 139512 pancreas AA.M.Diab.-med BMI-8 3.9 145486 DU145 (prostate carcinoma) 53.6 142739 pancreas-AS.M.Diab- 0 low BMI-20 0.91154643 PC-3 (prostate adenocarcinoma) 0.0 139513 pancreas CC.M.Diab.-low BMI-13 0.91154649 HCT-8 (ileocecal adenocarcinoma) 8.3 124pancras 2.9 AA.M.Norm-hi BMI-25 General screening panel vl.7 Summary: (Ag6342) The highest expression of this gene was detected in the ovarian cancer cell line IGROV- 1 (CT=24). This gene is overexpressed in several ovarian cancer cell lines as compared to normal tissue. This gene was overexpressed in several renal cancer cell lines as compared to normal tissue. Therapeutic 5 modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product may be useful in the treatment of renal and ovarian cancers. Among tissues with metabolic or endocrine function, this gene was significantly expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal 10 muscle, heart, liver and the gastrointestinal tract. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product will be useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes. Human Metabolic Summary: (Ag6342) The highest expression of this gene was detected 15 in the hypothalamus of a diabetic patient. This gene is expressed at increased levels in hypothalamus of diabetic patients. This gene was expressed at low levels in visceral adipose, skeletal muscle and pancreas. Therapeutic modulation of this gene, expressed protein and/or 269 WO 2004/013347 PCT/US2003/024504 use of antibodies or small molecule drugs targeting the gene or gene product will be useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes. Panel 5 Islet Summary: (Ag6342) The expression of this gene was downregulated in mid differentiated and differentiated adipose cells. Therapeutic modulation of this gene, 5 expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product will be useful in the treatment of obesity. Pursuant to our invention, this data shows for the first time, that this receptor subtype is expressed in human islet cells (Bayer patient 1). 10 Example F5. Assays Screening for Modulators of Adenosine Al Receptor Adenosine Al receptor activation mediates the inhibition of cAMIP fonnation through Gi protein signalling. This is relevant for insulin secretion because an increase in intracellular cAMP potentiates insulin secretion. Type 2 diabetes is caused by too little 15 insulin secretion. Therefore, an antagonist of Adoral will act to increase insulin secretion and the antagonist would be suitable in treatment of Type 2 diabetes. Although the disclosed sequences of Adenosine Al receptor are the preferred isoforms, any of the other isoforms may be used for similar purposes. Furthennore, under 20 varying assay conditions, conditions may dictate that another isoform may supplant the listed isoforms. The CG58655-01 gene described herein, encoding the human Adenosine Al receptor, represents a full-length physical clone and may be used directly for expression and screening purposes. 25 Assays for screening for modulators of human Adoral can be formulated utilizing the non-exhaustive list of cell lines that express Adoral from the RTQ-PCR results shown herein. Adenosine Al receptor activation mediates the inhibition of adenylyl cyclase and 30 cAMP formation through Gi protein signalling. To assay the inhibition of adenosine Al receptor, the measurement of intracellular cAMP can be utilized. Cyclic AMP measurements can be made using the Biotrak cAMP assay system (Amersham Biosciences, Piscataway, NJ, USA). (Harndahl L, Jing XJ, Ivarsson R, Degerman E, Ahren B, 270 WO 2004/013347 PCT/US2003/024504 Manganiello VC, Renstrom E, Holst LS. Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin. J Biol Chem. 2002 Oct 4;277(40):37446-55. PMID: 12169692). An increase in cAMP would be indicative of a positive screen. To evaluate the efficacy of the compound(s) thus identified, 5 the effect on glucose-stimulated insulin secretion can be assayed in vitro with dispersed rat islets as used herein, or can be assayed in vivo by the effects on blood glucose in known rodent models of Type 2 diabetes. Our results indicate that a modulator of Adoral activity, such as an inhibitor, 10 activator, antagonist, or agonist of Adoral may be useful for treatment of such disorders as obesity, diabetes, and insulin resistance, as well as for enhancement of insulin secretion. G. NOV7 - 3-Hydroxy-3-Methylglutaryl Coenzyme A Lyase (HMG-CoA Lyase or HMG-CoA or HL) 15 3-Hydroxy-3-Methylglutaryl Coenzyme A Lyase catalyzes the final step of ketogenesis, an important pathway of mammalian energy metabolism. HIMG-CoA Lyase deficiency known as hydroxymethylglutaricaciduria is an autosomal recessive inborn error in man leading to episodes of hypoglycemia and coma. 20 HMG-CoA Lyase has the following catalytic activity: (s)-3-hydroxy-3-methylglutaryl-CoA = acetyl-CoA + acetoacetate HMG-CoA affects biochemical pathways relevant to the etiology and pathogenesis of 25 obesity and/or diabetes. The scheme incorporates the unique findings of these discovery studies in conjunction with what has been reported in the literature. The outcome of inhibiting the action of the human HMG CoA lyase would be a reduction of Insulin Resistance, a major problem in obesity and/or diabetes. HMG-CoA lyase uses HMG-CoA as a substrate to produce acetoacetate and acetyl-CoA. This is the final step in ketogenesis and 30 leucine metabolism. Importantly, acetyl-CoA from this reaction can be fed back into the TCA cycle but also into lipogenic pathways. We discovered that Mitochondrial 3-Hydroxy-3methylglutaryl coenzyme A lyase (nHMG-CoA lyase) is upregulated in the liver of SHR and WKY rats after triglitazone 271 WO 2004/013347 PCT/US2003/024504 treatment. mHMG-CoA lyase is the final step in ketogenesis and leucine catabolism which has 3-hydroxy-methylglutaryl-CoA as its substrate, and produces acetoacetate (ketone body) and acetyl-CoA. This process takes place in the liver especially during weight loss and the amount of acetyl-CoA produced during both fatty acid oxidation and ketogenesis often 5 exceeds the capacity of the TCA cycle. Moreover, excess citrate shunts acetyl-CoA back into the cytoplasm where it is used for cholesterol and fatty acid biosynthesis. Therefore, inhibiting this enzyme during weight loss may slow down ketone body formation and the generation of acetyl-CoA, and thus prevent the saturation of the TCA cycle. 10 The above formula summarizes the biochemistry surrounding the human HMG-CoA Lyase and potential assays that may be used to screen for antibody therapeutics or small molecule drugs to treat obesity and/or diabetes. Cell lines expressing the HMG-CoA Lyase can be obtained from the RTQ-PCR results shown herein. These and other JMG-CoA Lyase expressing cell lines could be used for screening purposes. 15 Furthermore, our results indicate that a modulator of 11MG CoA Lyase activity, such as an inhibitor, activator, antagonist, or agonist of HMG CoA Lyase may be useful for treatment of such disorders as obesity, diabetes, and insulin resistance, as well as for enhancement of insulin secretion. 20 Discovery Process The following sections describe the study design(s) and the techniques used to identify the HMG-CoA Lyase - encoded protein and any variants, thereof, as being suitable as diagnostic markers, targets for an antibody therapeutic and targets for a small molecule drugs for Obesity and Diabetes. 25 Example G1. Insulin Resistance Study A protocol Insulin Resistance study is disclosed in Example Q5. The spontaneously hypertensive rat (SHR) is a strain exhibiting features of the human Metabolic Syndrome X. The phenotypic features include obesity, hyperglycemia, 30 hypertension, dyslipidemia and dysfibrinolysis. Tissues were removed from adult male rats and a control strain (Wistar - Kyoto) to identify the gene expression differences that underlie the pathologic state in the SHR and in animals treated with various anti-hyperglycemic 272 WO 2004/013347 PCT/US2003/024504 agents such as tkoglitizone. Tissues included sub-cutaneous adipose, visceral adipose and liver. A gene fragment of the rat HMG-COA LYASE was initially found to be upregulated 5 by 1.6 fold in the liver of WKY rats treated with Troglitazone LD10 relative to WKY rats treated with 0.02% DMSO as control using CuraGen's GeneCalling@ method of differential gene expression. A differentially expressed rat gene fragment migrating at approximately 426.4 nucleotides in length.was definitively identified as a component of the rat HMG CoA Lyase cDNA in the Troglitazone treated and the untreated WKY control rats. The method of 10 competitive PCR was used for confirmation of the gene assessment. The chromatographic peaks corresponding to the gene fragment of the rat HMG CoA Lyase were ablated when a gene-specific primer (shown in Table GI) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 426.4 nt in length were ablated in the sample from both the Troglitazone treated and the untreated WKY control rats. The altered 15 expression of these genes in the animal model support the role of HMG CoA Lyase in the pathogenesis of obesity and/or diabetes. Table GI. The sequence of the 427 nucleotide-long gene fragment and the gene-specific primers used for competitive PCR are indicated on the cDNA sequence of the rat HMG CoA Lyase fragment (SEQ ID NO:213) and are shown below in bold. The gene-specific primers at the 5' and 3' ends of the fragment are underlined. Gene Sequence identified in WKY Troglitazone LD10 vs. 0.02% DMSO (Identified fragment from 612 to 1038 in bold. band size: 427) GGCCCCCGAG ATGGTCTGCA GAATGAAAAG AGTATCGTGC CGACGCCAGT GAAAATCAAA CTGATAGACA TGCTATCCGA AGCAGGGCTC CCGGTCATCG AGGCCACCAG CTTTGTCTCT CCCAAGTGGG TGCCGCAGAT GGCTGACCAC TCTGACGTCT TGAAGGGCAT TCAGAAGTTT CCCGGCATCA ACTACCCGGT CCTGACACCA AACATGAAAG GCTTTGAGGA AGCGGTAGCT GCAGGTGCCA AGGAAGTGAG CATCTTTGGG GCTGCGTCCG AGCTCTTCAC CCGGAAGAAT GTGAACTGCT CTATAGAGGA GAGTTTCCAG CGCTTTGATG GGGTCATGCA GGCCGCGAGG GCTGCCAGCA TCTCTGTGAG AGGGTATGTC TCCTGTGCCC TCGGATGTCC CTACGAGGGG AAGGTCTCCC CGGCTAAAGT TGCTGAGGTC GCCAAGAAGT TGTACTCAAT GGGCTCCTAT GAGATCTCCC TTGGGACAC CATTGGCGTA GGCACGCCAG GACTCATGAA AGACATGCTG ACTGCTGTCC TGCATGAAGT GCCTGTGGCC GCATTGGCTG TCCACTGCCA TGACACCTAT GGCCAAGCTC TGGCCAACAC GTTGGTGGCC CTGCAGATGG GAGTGAGCGT TGTGGACTCC TCGGTGGCAG GACTCGGAGG CTGTCCCTAT GCAAAGGGGG CGTCAGGAAA CTTGGCTACC GAGGACCTGG TCTACATGCT GACTCCTTA GOGATTCACA CGGGTGTGAA CCTCCAGAAG CTCCTAGAAG CCGGGOACTT CATCTGTCAA GCCCTGAACA GAAAAACCAG TTCCAAAGTG GCACAGGCCA CCTGCAAACT CTGAGCCCCT TGTTCACCTA AACCGGAACT GTGGGAGTTG GGTGTACACA ATGATTCCTG GATGGGGAAA TGGAATGAAG GCAAATGAGC CGGCCTCACA GAGGTCCCTC TCCTACATAG AAGGGCTAGA GCTGCCAGCA CGCCCGGACC AGCTCCCCAG AGCTGCGTGC CTAAGCACTG CTTGGCTGGC CCTGGGTGAG TCCACTAGCC AGCAGAGCTG ACATCCATGT GCCACGACCG CGGGTCCCAT GTTCTACCTC TGAGGACAGC AGCGCCTTTG CTGAAATGGT GGGCTCAATC TACTGCGGTG GCCGACTGCC AACTCCAGCG TCTCTGGGAA ATCTCTGTAC GTGATTCTTG AAAACAGCTT ATGTAATTAA AGGTTTAATT TTCTAATATC Additionally, a gene fragment of the rat HMG CoA Lyase was initially found to be upregulated by 2.6 fold in the liver of SHR rats treated with Troglitazone LD10 relative to 20 SHR rats treated with 0.02% DMSO as control using CuraGen's GeneCalling@ method of 273 WO 2004/013347 PCT/US2003/024504 differential gene expression. A differentially expressed rat gene fragment migrating at approximately 48.2 nucleotides in length was definitively identified as a component of the rat HMG CoA Lyase cDNA in the Troglitazone treated and the untreated SHR control rats. The method of competitive PCR was used for confirmation of the gene assessment. The 5 chromatographic peaks corresponding to the gene fragment of the rat HMG CoA Lyase were ablated when a gene-specific primer (shown in Table G2) competes with primers in the linker-adaptors during the PCR amplification. The peaks at 48.2 nt in length were ablated in the sample from both the Troglitazone treated and the untreated WKY control rats. The altered expression of these genes in the animal model support the role of HMG CoA Lyase 10 in the pathogenesis of obesity and/or diabetes. Table G2. The sequence of the 48 nucleotide-long gene fragment and the gene-specific primers used for competitive PCR are indicated on the cDNA sequence of the rat H1MG CoA Lyase fragment (SEQ ID NO:214) and are shown below in bold. The gene-specific primers at the 5' and 3' ends of the fragment are underlined. Gene Sequence identified in SHR Troglitazone LD1O vs. 0.02% DMSo (Identified fragment from 612 to 659 in bold. band size: 48) GGCCCCCGAGATGGTCTGCAGAATGAAAAGAGTATCGTGCCGACGCCAGTGAAAATCAAACTGATAGACATGCTATCCGA AGCAGGGCTCCCGGTCATCGAGGCCACCAGCTTTGTCTCTCCCAAGTGGGTGCCGCAGATGGCTGACCACTCTGACGTCT TGAAGGGCATTCAGAAGTTTCCCGGCATCAACTACCCGGTCCTGACACCAAACATGAAAGGCTTTGAGGAAGCGGTAGCT GCAGGTGCCAAGGAAGTGAGCATCTTTGGGGCTGCGTCCGAGCTCTTCACCCGGAAGAATGTGAACTGCTCTATAGAGGA GAGTTTCCAGCGCTTTGATGGGGTCATGCAGGCCGCGAGGGCTGCCAGCATCTCTGTGAGAGGGTATGTCTCCTGTGCCC TCGGATGTCCCTACGAGGGGAAGGTCTCCCCGGCTAAAGTTGCTGAGGTCGCCAAGAAGTTGTACTCAATGGGCTGCTAT GAGATCTCCCTTGGGGACACCATTGGCGTAGGCACGCCAGGACTCATGAAAGACATGCTGACTGCTGTCCTGCATGAAGT GCCTGTGGCCGCATTGGCTGTCCACTGCCATGACACCTATGGCCAAGCTCTGGCCAACACGTTGGTGGCCCTGCAGATGG GAGTGAGCGTTGTGGACTCCTCGGTGGCAGGACTCGGAGGCTGTCCCTATGCAAAGGGGGCGTCAGGAAACTTGGCTACC GAGGACCTGGTCTACATGCTGACTGGCTTAGGGATTCACACGGGTGTGAACCTCCAGAAGCTCCTAGAAGCCGGGGACTT CATCTGTCAAGCCCTGAACAGAAAAACCAGTTCCAAAGTGGCACAGGCCACCTGCAAACTCTGAGCCCCTTGTTCACCTA AACCGGAACTGTGGGAGTTGGGTGTACACAATGATTCCTGGATGGGGAAATGGAATGAAGGCAAATGAOCCGGCCTCACA GAGGTCCCTCTCCTACATAGAAGGGCTAGAGCTGCCAGCACGCCCGGAC Example G2. Identification of Human HMG CoA Lyase Sequence 15 The sequence of Human HMG CoA Lyase (Acc. No CG96859-03) was derived by laboratory screening of cDNA library by the two-hybrid approach. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were sequenced. In silico prediction was based on sequences available in CuraGen Corporation's proprietary sequence databases or in the public human sequence databases, and provided 20 either the full-length DNA sequence, or some portion thereof. The protocol for identification of human sequence(s) is disclosed in Example Q8. 274 WO 2004/013347 PCT/US2003/024504 Table G3 shows an alignment (ClustalW) of the protein sequences of CG96859-03 (SEQ ID NO:60), another public form of HMG CoA lyase with one aa difference (P35914; SEQ ID NO:215), a novel splice form of HMG CoA lyase (CG96859-02; SEQ ID NO:66), and the mouse (S65036.1; SEQ ID NO:216) and rat (Y10054; SEQ ID NO:217) orthologues 5 of HMG CoA Lyase. Table G4 shoes protein sequences of the public form of HMG CoA lyase (P35914; SEQ ID NO:215), the mouse (S65036.1; SEQ ID NO:216), and rat (Y10054; SEQ ID NO:217) orthologues of HMG CoA Lyase. Table G3. Alignment (ClustalW) of the protein sequences of CG96859-03 (SEQ UD NO:60), another public form of HMG CoA lyase with one aa difference (P35914; SEQ ID NO:215), a novel splice form of H1MG CoA lyase (CG96859-02; SEQ ID NO:66), and the mouse (S65036.1; SEQ ID NO:216) and rat (Y10054; SEQ ID NO:217) orthologues of HMG CoA Lyase. C096859-03 REVCOMP I - IvLQ 55 P35914_HMGCoAlyase I ----- VE CG96859-02_REVCOMP 1 -I55 y10054_HMGCoAlysase_rat I RLRAKI F 60 S65036.1 mouse MG lyse ---- I S F 55 C096859.03_REVCOMP 56 115 P35914_HMG_CoA yse 56 115 CG96859-02 REVCOMP 56 CIKLILGLSIE SH QL 115 y1054_HMGCoA_1ysse_mat 61 PE S65036.1_mouseHMG lyrse 56 ILID GPI C096859-03_REVCOMP 116 75 P35914_HMGCoA_lye 116 * EI A 175 CG96859-02 REVCOMP 116 A IK---.------.- 119 y1O054_HMGCoA_1yssea_mt 121 S F A L C E S M RAMS ISO S65036.1_mouseHMGiyese 116 S AL 175 CG96859-03 REVCOMP 176 E P K E ID A A 235 P35914_HMGCoA lyes 176 E P A F E GA 235 C096859-02 REVCOMP 120 --- - EGV164 y10054_HMG.CoAlysse _mt 181 L 240 S65036.1_mouse_HMGlyese 176 EKNSAKAfM 235 CG96859-03_REVCOMP 236 T 295 P35914_HMGCoA Lyse 236 295 C096859-02 REVCOMP 165 224 y10054_HMGCoAiyeserat 241 T L DLM D A T LH 300 S65036.1_mouseHMGlyese 236 I 1 M3GI 295 C096859.03 REVCOMP 296 LQKLLEAIA AT325 P35914_HMGCoAlyese 296 325 CG96859-02_REVCOMP 225 L 254 ylO154_HMGCoAlysasermt 31 L D 330 S65036.1_mouseHMGlyes 296 Q L D A325 Table G4. Protein sequences of the public form of HMG CoA lyase (P35914; SEQ ID NO:215), the mouse (S65036.1; SEQ ID NO:216), and rat (Y10054; SEQ ID NO:217) orthologues of HMG CoA Lyase. >P35914 HMG CoA lyase (SEQ ID NO:215) MAAMRKALPRRLVGLASLRAVSTSSMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLIDMLSEAGLSV IETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAGAKEVVIFGAASELFTKKNIN CSIEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKISPAKVAEVTKKFYSMGCYEISLGDTIGVGT PGIMKDMLSAVMQEVPLAALAVHCHDTYGQALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATED LVYMLEGLGIHTGVNLQKLLEAGNFICQALNRKTSSKVAQATCKL >S65036.1 mouse HMG lyase (SEQ ID NO:216) MASVRKAFPRRLVGLTSLRAVSTSSMGTLPKQVKIVEVGPRDGLQNEKSIVPTPVKIRLIDMLSEAGLPV IEATSFVSPNWVPQMADHSDVLKGIQKFPGINYPVLTPNMKGFEEAVAAGAKEVSVFGAVSELFTRKNAN CSIEESFQRFAGVMQAAQAASISVRGYVSCALGCPYEGKVSPAKVAEVAKKLYSMGCYEISLGDTIGVGT PGLMKDMLTAVMHEVPVTALGVHCHDTIGQALANTLVALQMGVSVVDSSVAGLGGCPYAKGASGNLATED LVYMLNGLGIHTGVNLQKLLEAGDFICQALNRKTSSKVAQATCKL >y1005 4 HMG CoA lyase rat (SEQ ID NO:217) 275 WO 2004/013347 PCT/US2003/024504 RLRAKMATVRKAFPQRLVGLASLRAASTSSMGTLPKRVKIVEVGPRDGLQNEKSIVPTPVKIKLIDMLSEAGLPV IEATSFVSPKWVPQMADHSDVLKGIQKFPGINYPVLTPNMKGFEEAVAAGAKEVSIFGAASELFTRKNVN CSIEESFQRFDGVMQAARAASISVRGYVSCALGCPYEGKVSPAKVAEVAKKLYSMGCYEISLGDTIGVGT PGLMKDMLTAVLHEVPVAALAVHCHDTYGQALANTLVALQMGVSVVDSSVAGLGGCPYAKGASGNLATED LVYMLTGLGIHTGVNLQKLLEAGDFICQALNRKTSSKVAQATCKL In addition to the human version of the HMG CoA Lyase identified as being differentially expressed in the experimental study, other variants have been identified by direct sequencing of cDNAs derived from many different human tissues and from sequences 5 in public databases. Two splice-form variants have been identified at CuraGen. The two alternative spliced forms are CG96859-02 and CG96859-05. The preferred variant of all those identified, to be used for screening purposes, is CG96859-03. The laboratory cloning was performed using one or more of the methods summarized in Example Q8. The NOV7 clone was analyzed, and the nucleotide and encoded polypeptide 10 sequences are shown in Table G5. Table G5. NOV7 Sequence Analysis NOV7a, CG96859-03 SEQ ID NO: 59 1041 bp DNA Sequence IORE Start: ATG at 15 -ORF Stop: TGA at 990 AAATTCCGGCCAAGATGGCAGCAATGAGGAAGGCGCTTCCGCGGCGACTGGTGGGCTTGGCGTCCCT C CGGGCTGTCAGCACCTCATCTATGGGCACTTTACCAAAGCGGGTGAAAATTGTGGAAGTTGGTCCCC G AGATGGACTACAAAATGAAAAGAATATCGTATCTACTCCAGTGAAAATCAAGCTGATAGACATGCTT T CTGAAGCAGGACTCTCTGTTATAGAAACCACCAGCTTTGTGTCTCCTAAGTGGGTTCCCCAGATGGG T GACCACACTGAAGTCTTGAAGGGCATTCAGAAGTTTCCTGGCATCAACTACCCAGTCCTGACCCCAA A TTTGAAAGGCTTCGAGGCAGCGGTTGCTGCTGGAGCCAAGGAAGTAGTCATCTTTGGAGCTGCCTCA G AGCTCTTCACCAAGAAGAACATCAATTGTTCCATAGAGGAGAGTTTTCAGAGGTTTGACGCAATCCT G AAGGCAGCGCAGTCAGCCAATATTTCTGTGCGGGGGTACGTCTCCTGTGCTCTTGGCTGCCCTTATG A AGGGAAGATCTCCCCAGCTAAAGTAGCTGAGGTCACCAAGAAGTTCTACTCAATGGGCTGCTACGAG A TCTCCCTGGGGGACACCATTGGTGTGGGCACCCCAGGGATCATGAAAGACATGCTGTCTGCTGTCAT G CAGGAAGTGCCTCTGGCTGCCCTGGCTGTCCACTGCCATGACACCTATGGTCAAGCCCTGGCCAACA C CTTGATGGCCCTGCAGATGGGAGTGAGTGTCGTGGACTCTTCTGTGGCAGGACTTGGAGGCTGTCCC T ACGCACAGCGGGCATCAGGAAACTTGGCCACAGAAGACCTGGTCTACATGCTAGAGGGCTTGGGCAT T CACACGGGTGTGAATCTCCAGAAGCTTCTGGAAGCTGGAAACTTTATCTGTCAAGCCCTGAACAGAA A AACTAGCTCCAAAGTGGCTCAGGCTACCTGTAAACTCTGAGCCCCTTGCCCACCTGAAGGCCTGGGG A TGATGTGGAAATAAGGGGCAT 276 WO 2004/013347 PCT/US2003/024504 NOV7a, CG96859-03 SEQ ID NO: 60 325 aa MW at 34359.8kD Protein Sequence MAAMRKALPRRLVGASLRAVSTSSMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLIDMLSEAG L SVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAGAKEVVIFGAASELPT K KNINCSIEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKISPAKVAEVTKKFYSMGCYEISLG D TIGVGTPGIMDMLSAVMQEVPLAALAVHCHDTYGQALANTLMALQMGVSVVDSSVAGLGGCPYAQG A SGNLATEDLVYMLEGLGIHTGVNLQKLLEAGNFICQALNRKTSSKVAQATCKL NOV7b, 223317153 SEQ ID NO: 61 1982 bp DNA Sequence PORF Start: at 64 Stop:TGAat 967 TAACTTTATTATTAAAAATTAAAGAGGTATATATTAATGTATCGATTAAATAAGGAGGAATAAACCA T GGGCACTTTACCAAAGCGGGTGAAAATTGTGGAAGTTGGTCCCCGAGATGGACTACAAAATGAAAAG A ATATCGTATCTACTCCAGTGAAAATCAAGCTGATAGACATGCTTTCTGAAGCAGGACTCTCTGTTAT A GAAACCACCAGCTTTGTGTCTCCTAAGTGGGTTCCCCAGATGGGTGACCACACTGAAGTCTTGAAGG G CATTCAGAAGTTTCCTGGCATCAACTACCCAGTCCTGACCCCAAATTTGAAAGGCTTCGAGGCAGCG G TTGCTGCTGGAGCCAAGGAAGTAGTCATCTTTGGAGCTGCCTCAGAGCTCTTCACCAAGAAGAACAT C AATTGTTCCATAGAGGAGAGTTTTCAGAGGTTTGACGCAATCCTGAAGGCAGCGCAGTCAGCCAATA T TTCTGTGCGGGGGTACGTCTCCTGTGCTCTTGGCTGCCCTTATGAAGGGAAGATCTCCCCAGCTAAA G TAGCTGAGGTCACCAAGAAGTTCTACTCAATGGGCTGCTACGAGATCTCCCTGGGGGACACCATTGG T GTGGGCACCCCAGGGATCATGAAAGACATGCTGTCTGCTGTCATGCAGGAAGTGCCTCTGGCTGCCC T GGCTGTCCACTGCCATGACACCTATGGTCAAGCCCTGGCCAACACCTTGATGGCCCTGCAGATGGGA G TGAGTGTCGTGGACTCTTCTGTGGCAGGACTTGGAGGCTGTCCCTACGCACAGGGGGCATCAGGAAA C TTGGCCACAGAAGACCTGGTCTACATGCTAGAGGGCTTGGGCATTCACACGGGTGTGAATCTCCAGA A GCTTCTGGAAGCTGGAAACTTTATCTGTCAAGCCCTGAACAGAAAAACTAGCTCCAAAGTGGCTCAG G CTACCTCTAAACTCTGATCTAGAACAAAAA NOV7b, 223317153 SEQ ID NO: 62 301 aa MW at 31819.7kD Protein Sequence TMGTLPKRVKIVEVGPRDGLONEKNIVSTPVKIKLIDMLSEAGLSVIETTSFVSPKWVPQMGDHTEV L KGIQKFPGINYPVLTPNLKGFEAAVAAGAKEVVIFGAASELFTKKNINCS IEESFQRFDAILKAAQS A NISVRGYVSCALGCPYEGKISPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPL A ALAVHCHDTYGQALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVN L QKLLEAGNFICQALNRKTSSKVAQATSKL SEQ ID NO: 63 1568 bp 277 WO 2004/013347 PCT/US2003/024504 NOV7c, CG96859-01 SEQ ID NO: 63 1568 bp DNA Sequence GAATTCCGGCCAAGATGGCAGCAAT LC'TSGCG ]qG ( C ,GGGGGC-TQAGGAGWGATT-AGG SGAGT-TAGAAAGGGGGTGA WAAT-G-TGGAAG-T-TGGWGGG G AGATGGACTACAAAATGAAAAGAATATCGTATCTACTCCAGTGAAAATCAAGCTGATAGACATGCTT T CTGAAGCAGGACTCTCTGTTATAGAAACCACCAGCTTTGTGTCTCCTAAGTGGGTTCCCCAGATGGG T GACCACACTGAAGTCTTGAAGGGCATTCAGAAGTTTCCTGGCATCAACTACCCAGTCCTGACCCCAA A TTTGAAAGGCTTCGAGGCAGCGGTTGCTGCTGGAGCCAAGGAAGTAGTCATCTTTGGAGCTGCCTCA G AGCTCTTCACCAAGAAGAACATCAATTGTTCCATAGAGGAGAGTTTTCAGAGGTTTGACGCAATCCT G AAGGCAGCGCAGTCAGCCAATATTTCTGTGCGGGGGTACGTCTCCTGTGCTCTTGGCTGCCCTTATG A AGGGAAGATCTCCCCAGCTAAAGTAGCTGAGGTCACCAAGAAGTTCTACTCAATGGGCTGCTACGAG A TCTCCCTGGGGGACACCATTGGTGTGGGCACCCCAGGGATCATGAGACATGCTATCTGCTGTCAT G CAGGAAGTGCCTCTGGCTGCCCTGGCTGTCCACTGCCATGACACCTATGGTCAAGCCCTGACCAACA C CTTGATGGCCCTGCAGATGGGAGTGAGTGTCGTGGACTCTTCTGTGGCAGGACTTGGAGGCTGTCCC T ACGCACAGGGGGCATCAGGAAACTTGGCCACAGAAGACCTGGTCTACATGCTAGAGGGCTTGGGCAT T CACACGGGTGTGAATCTCCAGAAGCTTCTGGAAGCTGGAAACTTTATCTGTCAAGCCCTGAACAGAA A AACTAGCTCCAAAGTGGCTCAGGCTACCTGTAAACTCTGAGCCCCTTGCCCACCTGAAGCCCTGGGG A TGATGTGGAAATAGGGGCACACACAGATGATTCATGGATGGGGACATGGAAATGAGAATAGGTTAAA T GGTGCAGGTACCTCATAGCCAGCTCTACACAGAGGTCTCTCCTGGCAGAAAGCAGGCGAAGGGCAGG A GaAGCTGCTTGGCAGAAGGACCTCCTGCCCAGACCTGAGGAGTGAGAGGCTTTGAGGGCTGAAGTCT C CCTTTGTTACGGACCCTGGCCCAGGAGTTGAATGCCTGAGGACGTGTGGGAACCCCGTTCCCTACTT A GCATGATCCTTGAGTCTCCTCTCTGGATGGAATCCGCGAGCTGGCCACCTGGCCACCCTCTACACGG C TCCACCCTGCCATGGCCGTGGGGCCCTTGCTCTCTGACTTCTCAGGACACAGGTCATGGAGGTTCTT C CCAAGCTGGCAGAGGCCATTTGTGGAAAGTGGAGAGCTACGTGGTGGCCGTCTGCCAACTCCAGCAT C TCTGGAAAATCTCCACGCTGAATGTGATTTTTGAAAACAGCTTATGTAATTAAAGGTTGAATGGCAC A TCAT NOV7c, CG96859-01 SEQ ID NO: 64 325 aa MW at 34389.8kD Protein Sequence MAAMRKALPRRVGLASLRAVSTSSMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLIDMLSEAG L SVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAGAKEVVIFGAASELFT K KNINCSIEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKISPAKVAEVTKKFYSMGCYEISLG D TIGVGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQALTNTLMALQMGVSVVDSSVAGLGGCPYAQG A 278 WO 2004/013347 PCT/US2003/024504 SGNLATEDLVYMLEGLGIHTGVNLQKLLEAGNFICQALNRKTSSKVAQATCKL .. .. NOV7d, CG96859-02 SEQ ID NO: 65 1355 bp DNA Sequence ORF Start: ATG at 15 |ORF Stop: TGA at 777 GAATTCCGGCCAAGATGGCAGCAATGAGGAAGGCGCTTCCGCGGCGACTGGTGGGCTTGGCGTCCCT C CGGGCTGTCAGCACCTCATCTATGGGCACTTTACCAAAGCGGGTGAAAATTGTGGAAGTTGGTCCCC G AGATGGACTACAAAATGAAAAGAATATCGTATCTACTCCAGTGAAAATCAAGCTGATAGACATCCTT T CTGAAGCAGGACTCTCTGTTATAGAAACCACCAGCTTTGTGTCTCCTAAGTGGGTTCCCCAGATGGG T GACCACACTGAAGTCTTGAAGGGCATTCAGAAGTTTCCTGGCATCAACTACCCAGTCCTGACCCCAA A TTTGAAAGGCTTCGAGGCAGCGGTCACCAAGAAGTTCTACTCAATGGGCTGCTACGAGATCTCCCTG G GGGACACCATTGGTGTGGGCACCCCAGGGATCATGAAAGACATGCTGTCTGCTGTCATGCAGGAAGT G CCTCTGGCTGCCCTGGCTGTCCACTGCCATGACACCTATGGTCAAGCCCTGGCCAACACCTTGATGG C CCTGCAGATGGGAGTGAGTGTCGTGGACTCTTCTGTGGCAGGACTTGGAGGCTGTCCCTACGCACAG G GGGCATCAGGAAACTTGGCCACAGAAGACCTGGTCTACATGCTAGAGGGCTTGGGCATTCACACGGG T GTGAATCTCCAGAAGCTTCTGGAAGCTGGAAACTTTATCTGTCAAGCCCTGAACAGAAAAACTAGCT C CAAAGTGGCTCAGGCTACCTGTAAACTCTGAGCCCCTTGCCCACCTGAAGCCCTGGGGATGATGTGG A AATAGGGGCACACACAGATGATTCATGGATGGGGACATGGAAATGAGAATAGGTTAAATGGTGCAGG T ACCTCATAGCCAGCTCTACACAGAGGTCTCTCCTGGCAGAAAGCAGGCGAAGGGCAGGAGGAGCTGC T TGGCAGAAGGACCTCCTGCCCAGACCTGAGGAGTGAGAGGCTTTGAGGGCTGAAGTCTCCCTTTGTT A CGGACCCTGGCCCAGGAGTTGAATGCCTGAGGACGTGTGGGAACCCCGTTCCCTACTTAGCATGATC C TTGAGTCTCCTCTCTGGATGGAATCCGCGAGCTGGCCACCTGGCCACCCTCTACACGGCTCCACCCT G CCATGGCCGTGGGGCCCTTGCTCTCTGACTTCTCAGGACACAGGTCATGGAGGTTCTTCCCAAGCTG

G

CAGAGGCCATTTGTGGAAAGTGGAGAGCTACGTGGTGGCCGTCTGCCAACTCCAGCATCTCTGGAAA A TCTCCACGCTGAATGTGATTTTTGAAAACAGCTTATGTAATTAAAGGTTGAATGGCACATCAT NOV7d, CG96859-02 SEQ ID NO: 66 |254 aa MW at 26909.3kD Protein Sequence MAAMRKALPRRLVGLASLRAVSTSSMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLIDMLSEAG SVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVTKKFYSMGCYEISLGDTI G VGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQALANTLMALQMGVSVVDSSVAGLGGCPYAQGASG N LATEDLVYMLEGLGIHTGVNLQKLLEAGNFICQALNRKTSSKVAQATCKL NOV7e, CG96859-04 ISEQ ID NO: 67 1788 bp DNA Sequence ORF Start: ATG at 2 ORF Stop: TGA at 764 GATGGCAGCAATGAGGAAGGCGCTTCCGCGGCGACTGGTGGGCTTGGCGTCCCTCCGGGCTGTCAGC 279 WO 2004/013347 PCT/US2003/024504 CCTCATCTATGGGCACTTTACCAAAGCGGGTGAAAATTGTGGAAGTTGGTCCCCGAGATGGACTACA A AATGAAAGGAATATCGTATCTACTCCAGTGAAAATCAAGCTGATAGACATGCTTTCTGAAGCAGGAC T CTCTGTTATAGAAACCACCAGCTTTGTGTCTCCTAAGTGGGTTCCCCAGATGGGTGACCACACTGAA G TCTTGAAGGGCATTCAGAAGTTTCCTGGCATCAACTACCCAGTCCTGACCCCAAATTTGAAAGGCTT C GAGGCAGCGGTCACCAAGAAGT TCTACTCAATGGGCTGCTACGAGATCTCCCTGGGGG.ACACCATTG G TGTGGGCACCCCAGGGATCATGAAAGACATGCTGTCTGCTGTCATGCAGGAAGTGCCTCTGGCTGCC C TGGCTGTCCACTGCCATGACACCTATGGTCAAGCCCTGGCCAACACCTTGATGGCCCTGCAGATGGG A GTGAGTGTCGTGGACTCTTCTGTGGCAGGACTTGGAGGCTGTCCCTACGCACAGGGGGCATCAGGAA A CTTGGCCACAGAAGACCTGGTCTACATGCTAGAGGGCTTGGGCATTCACACGGGTGTGAATCTCCAG AGCTTCTGGAAGCTGGAAACTTTATCTGTCAAGCCCTGAACAGAAAACTAGCTCCAAAGTGGCTCA G GCTACCTGTAAACTCTGAGCCCCTTGCCCACCTGAAGCCC NOV7e, CG96859-04 SEQ ID NO: 69 MW .3kD Protein Sequence MAAMRKALPRRLVGLASLRAVSTSSMGTLPKRVKIVEVGPRDGLQNERNIVSTPVKIKLIDMLSEAG L SVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVTKKFYSMGCYEISLGDTI G VGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQALANTLMALQMGVSVVDSSVAGLGGCPYAQGASG N LATEDLVYMLEGLGIHTGVNLQKLLEAGNFICQALNRKTSSKVAQATCKL NOV7f, CG96859-05 , SEQ ID NO: 69 1893 bp DNA Sequence JORF Start: AT a 2 ORF Stop: TGA at 869 GATGGCAGCAATGAGAGGCGCTTCCGCGGCGACTGGTGGGCTTGGCGTCCCTCCGGGCTGTCAGC A CCTTATCTATGGGCACTTTACCAA.AGCGGGTGAAAATTGTGGAAGTTGGTCCCCGAGATGGACTACA A AATGAAAAGAATATCGTATCTACTCCAGTGAAAATCAAGCTGATAGACATGCTTTCTGAAGCAGGAC T CTCTGTTATAGAAACCACCAGCTTTGTGTCTCCTAAGTGGGTTCCCCAGATGGGTGACCACACTGAA G TCTTGAAGGGCATTCAGAAGTTTCCTGGCATCAACTACCCAGTCCTGACCCCAAATTTGAAAGGCTT C GAGGCAGCGGTTGCTGCTGGAGCCAAGGAAGTAGTCATCTTTGGAGCTGCCTCAGAGCTCTTCACCA A GAAGAACATCAATTGTTCCATAGAGGAGAGTTTTCAGAGGTTTGACGCAATCCTGAAGGCAGCGCAG T CAGCCAATATTTCTGTGCGAGGGTACGTCTCCTGTGCTCTTGGCTGCCCTTATGAAGGGAAGATCTC C CCAGCTAAAGTAGCTGAGGAAGTGCCTCTGGCTGCCCTGGCTGTCCACTGCCATGACACCTATGGTC A AGCCCTGGCCAACACCTTGATGGCCCTGCAGATGGGAGTGAGTGTCGTGGACTCTTCTGTGGCAGGA C TTGGAGGCTGTCCCTACGCACAGGGGGCATCAGGAAACTTGGCCACAGAAGACCTGGTCTACATGCT A GAGGGCTTGGGCATTCACACGGGTGTGAATCTCCAGAAGCTTCTGGAAGCTGGAAACTTTATCTGTC A 280 WO 2004/013347 PCT/US2003/024504 AGCCCTGAACAGAAAAACTAGCTCCAAAGTGGCTCAGGCTACCTGTAAACTCTGAGCCCCTTGCCCA C CTGAAGCCC NOV7f, CG96859-05 SEQ ID NO: 70 289 aa MW at 30531.3kD Protein Sequence MAAMRKALPRRLVGLASLRAVSTLSMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLIDMLSEAG SVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAGAKEVVIFGAASELFT K KININCS IEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKISPAKVAEEVPLAALAVHCHDTYG Q ALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLLEAGNFIC Q ALNRKTSSKVAQATCKL NOV7g, CG96859-06 SEQ ID NO: 71 1353 bp DNA Sequence IORF Start: ATG at 202 ORF Stop: at 1171 CCCCAAAATTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTC T ATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGAC T CACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGGATCCACCAT G GCAGCAATGAGGAAGGCGCTTCCGCGGCGACTGGTGGGCTTGGCGTCCCTCCGGGCTGTCAGCACCT C ATCTATGGGCACTTTACCAAAGCGGGTGAAAATTGTGGAAGTTGGTCCCCGAGATGGACTACAAAAT G AAAAGAATATCGTATCTACTCCAGTGAAAATCAAGCTGATAGACATGCTTTCTGAAGCAGGACTCTC T GTTATAGAAACCACCAGCTTTGTGTCTCCTAAGTGGGTTCCCCAGATGGGTGACCACACTGAAGTCT T GAAGGGCATTCAGAAGTTTCCTGGCATCAACTACCCAGTCCTGACCCCAAATTTGAAAGGCTTCGAG G CAGCGGTTGCTGCTGGAGCCAAGGAAGTAGTCATCTTTGGAGCTGCCTCAGAGCTCTTCACCAAGAA G AACATCAATTGTTCCATAGAGGAGAGTTTTCAGAGGTTTGACGCAATCCTGAAGGCAGCGCAGTCAG C CAATATTTCTGTGCGGGGGTACGTCTCCTGTGCTCTTGGCTGCCCTTATGAAGGGAAGATCTCCCCA G CTAAAGTAGCTGAGGTCACCAAGAAGTTCTACTCAATGGGCTGCTACGAGATCTCCCTGGGGGACAC C ATTGGTGTGGGCACCCCAGGGATCATGAAAGACATGCTGTCTGCTGTCATGCAGGAAGTGCCTCTGG C TGCCCTGGCTGTCCACTGCCATGACACCTATGGTCAAGCCCTGGCCAACACCTTGATGGCCCTGCAG A TGGGAGTGAGTGTCGTGGACTCTTCTGTGGCAGGACTTGGAGGCTGTCCCTACGCACAGGGGGCATC A GGAAACTTGGCCACAGAAGACCTGGTCTACATGCTAGAGGGCTTGGGCATTCACACGGGTGTGAATC T CCAGAAGCTTCTGGAAGCTGGAAACTTTATCTGTCAAGCCCTGAACAGAAAAACTAGCTCCAAAGTG G CTCAGGCTACCTGTAAACTCTGAGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCAG C CTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTG G AAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAG 281 WO 2004/013347 PCT/US2003/024504 NOV7g, CG96859-06 SEQ ID NO: 72 323 aa MW at 34118.4kD Protein Sequence MAAMRKALPRRLVGLASLRAVSTSSMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLIDMLSEAG L SVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAGAKEVVIFGAASELFT K KNINCS IEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKISPAKVAEVTKKFYSMGCYEISLG D TIGVGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQALANTLMALQMGVSVVDSSVAGLGGCPYAQG A SGNLATEDLVYMLEGLGIHTGVNLQKLLEAGNFICQALNRKTSSKVAQATC NOV7h, CG96859-07 SEQ ID NO: 73 969 bp DNA Sequence ORF Start: at 64 ORF Stop: TGA at 967 TAACTTTATTATTAAAAATTAAAGAGGTATATATTAATGTATCGATTAAATAAGGAGGAATAAACCA T GGGCACTTTACCAAAGCGGGTGAAAATTGTGGAAGTTGGTCCCCGAGATGGACTACAAAATGAAAAG A ATATCGTATCTACTCCAGTGAAAATCAAGCTGATAGACATGCTTTCTGAAGCAGGACTCTCTGTTAT A GAAACCACCAGCTTTGTGTCTCCTAAGTGGGTTCCCCAGATGGGTGACCACACTGAAGTCTTGAAGG G CATTCAGAAGTTTCCTGGCATCAACTACCCAGTCCTGACCCCAAATTTGAAAGGCTTCGAGGCAGCG G TTGCTGCTGGAGCCAAGGAAGTAGTCATCTTTGGAGCTGCCTCAGAGCTCTTCACCAAGAAGAACAT C AATTGTTCCATAGAGGAGAGTTTTCAGAGGTTTGACGCAATCCTGAAGGCAGCGCAGTCAGCCAATA T TTCTGTGCGGGGGTACGTCTCCTGTGCTCTTGGCTGCCCTTATGAAGGGAAGATCTCCCCAGCTAAA G TAGCTGAGGTCACCAAGAAGTTCTACTCAATGGGCTGCTACGAGATCTCCCTGGGGGACACCATTGG T GTGGGCACCCCAGGGATCATGAAAGACATGCTGTCTGCTGTCATGCAGGAAGTGCCTCTGGCTGCCC T GGCTGTCCACTGCCATGACACCTATGGTCAAGCCCTGGCCAACACCTTGATGGCCCTGCAGATGGGA G TGAGTGTCGTGGACTCTTCTGTGGCAGGACTTGGAGGCTGTCCCTACGCACAGGGGGCATCAGGAAA C TTGGCCACAGAAGACCTGGTCTACATGCTAGAGGGCTTGGGCATTCACACGGGTGTGAATCTCCAGA A GCTTCTGGAAGCTGGAAACTTTATCTGTCAAGCCCTGAACAGAAAAACTAGCTCCAAAGTGGCTCAG G CTACCTGTAAACTCTGA NOV7h, CG96859-07 SEQD NO: 74 301 aa |MWat31835.7kD Protein Sequence I TMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLIDMLSEAGLSVIETTSFVSPKWVPQMGDHTEV L KGIQKFPGINYPVLTPNLKGFEAAVAAGAKEVVIFGAASELFTKKNINCSIEESFQRFDAILKAAQS A NISVRGYVSCALGCPYEGKISPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPL A ALAVHCHDTYGQALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVN L QKLLEAGNFICQALNRKTSSKVAQATCKL SEQ ID NO: 75 969 bp 282 WO 2004/013347 PCT/US2003/024504 NTOV7i, CG96859-08 SEQ ID NO: 75 969 bp DNA Sequence M4VT/T"W~g dyTTAAAGAG JUAATrWp3tg'ATCG) gENJ8'gGq44fj)@!MCCA kUAWS AGGGGG-TGAA b-GTGAAGTTGGWGGG CAGA GGGAGAGAAATAAA ATATCGTATCTACTCCAGTGAAAATCAAGCTGATAGACATGCTT TCTGAAGCAGGACTCTCTGTTAT GAAACCACCAGCTTTGTGTCTCCTAAGTGGGTTCCCCAGATGGGTGACCACACTGAAGTCTTGAAGG CATTCAGAAGTTTCCTGGCATCAACTACCCAGTCCTGACCCCAAATTTGAAAGGCTTCGAGGCAGCG G TTGCTGCTGGAGCCAAGGAAGTAGTCATCTTTGGAGCTGCCTCAGAGCTCTTCACCAAGAAGAACAT C AATTGTTCCATAGAGGAGAGTTTTCAGAGGTTTGACGCAATCCTGAAGGCAGCGCAGTCAGCCAATA T TTCTGTGCGGGGGTACGTCTCCTGTGCTCTTGGCTGCCCTTATGAAGGGAAGATCTCCCCAGCTAAA G TAGCTGAGGTCACCAAGAAGTTCTACTCAATGGGCTGCTACGAGATCTCCCTGGGGGACACCATTGG T GTGGGCACCCCAGGGATCATGAAAGACATGCTGTCTGCTGTCATGCAGGAAGTGCCTCTGGCTGCCC T GGCTGTCCACTGCCATGACACCTATGGTCAAGCCCTGGCCAACACCTTGATGGCCCTGCAGATGGGA G TGAGTGTCGTGGACTCTTCTGTGGCAGGACTTGGAGGCTGTCCCTACGCACAGGGGGCATCAGGAAA C TTGGCCACAGAAGACCTGGTCTACATGCTAGAGGGCTTGGGCATTCACACGGGTGTGAATCTCCAGA A GCTTCTGGAAGCTGGAAACTTTATCTGTCAAGCCCTGAACAGAAAAACTAGCTCCAAAGTGGCTCAG G CTACCTGTAAACTCTGA NOV7i, CG96859-08 SEQ ID NO: 76 301 aa MW at 31835.7kD Protein Sequence TMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLIDMLSEAGLSVIETTSFVSPKWVPQMGDHTEV L KGIQKFPGINYPVLTPNLKGFEAAVAAGAKEVVIFGAASELFTKKNINCSIEESFQRFDAILKAAQS A NISVRGYVSCALGCPYEGKISPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPL A ALAVHCHDTYGQALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVN L QKLLEAGNFICQALNRKTSSKVAQATCKL jSEQ ID NO:77 1987 bp JORF Start: at 64 JORF Stop: TGA at 985 TAACTTTATTATTAAAAATTAAAGAGGTATATATTAATGTATCGATTAAATAAGGAGGAATAAACCA T GGGCCACCATCACCACCATCACACTTTACCAAAGCGGGTGAAAATTGTGGAAGTTGGTCCCCGAGAT G GACTACAAAATGAAAAGAATATCGTATCTACTCCAGTGAAAATCAAGCTGATAGACATGCTTTCTGA A GCAGGACTCTCTGTTATAGAAACCACCAGCTTTGTGTCTCCTAAGTGGGTTCCCCAGATGGGTGACC A CACTGAAGTCTTGAAGGGCATTCAGAAGTTTCCTGGCATCAACTACCCAGTCCTGACCCCAAATTTG A AAGGCTTCGAGGCAGCGGTTGCTGCTGGAGCCAAGGAAGTAGTCATCTTTGGAGCTGCCTCAGAGCT C 283 WO 2004/013347 PCT/US2003/024504 TTCACCAAGAAGAACATCAATTGTTCCATAGAGGAGAGTTTTCAGAGGTTTGACGCAATCCTGAAGG C AGCGCAGTCAGCCAATATTTCTGTGCGGGGGTACGTCTCCTGTGCTCTTGGCTGCCCTTATGAAGGG A AGATCTCCCCAGCTAAAGTAGCTGAGGTCACCAAGAAGTTCTACTCAATGGGCTGCTACGAGATCTC C CTGGGGGACACCATTGGTGTGGGCACCCCAGGGATCATGAAAGACATGCTGTCTGCTGTCATGCAGG A AGTGCCTCTGGCTGCCCTGGCTGTCCACTGCCATGACACCTATGGTCAAGCCCTGGCCAACACCTTG A TGGCCCTGCAGATGGGAGTGAGTGTCGTGGACTCTTCTGTGGCAGGACTTGGAGGCTGTCCCTACGC A CAGGCGGCATCAGGAAACTTGGCCACAGAAGACCTGGTCTACATGCTAGAGGGCTTGGGCATTCACA C GGGTGTGAATCTCCAGAAGCTTCTGGAAGCTGGAAACTTTATCTGTCAAGCCCTGAACAGAAAAACT A GCTCCAAAGTGGCTCAGGCTACCTGTAAACTCTGA NOV7j, CG96859-09 EQ D NO: 78 307 aa MW at 32658.6kD Protein Sequence TMGHHHHHHTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLIDMLSEAGLSVIETTSFVSPKWVPQM G DHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAGAKEVVIFGAASELFTKKNINCSIEESFQRFDAI L KAAQSANISVRGYVSCALGCPYEGKISPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAV M QEVPLAALAVHCHDTYGQALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLG HTGVNLQKLLEAGNFICQALNRKTSSKVAQATCKL A ClustaiW comparison of the above protein sequences yields the following sequence alignment shown in Table G6. Table G6. Comparison of the NOV7 protein sequences. NOV7a MAAMRKALPRRLVGLASLRAVSTSSMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLI NOV7b ------------------------- TMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLI NOV7c MAAMRKALPRRLVGLASLRAVSTSSMGTLPKRVKIVEVGPRDGLQNEKIVSTPVKIKLI NOV7d MAAMRKALPRRLVGLASLRAVSTSSMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLI NOV7e MAAMRKALPRRLVGLASLRAVSTSSMGTLPKRVKIVEVGPRDGLQNERNIVSTPVKIKLI NOV7f MAAMRKALPRRLVGLASLRAVSTLSMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLI NOV7g MAAMRKALPRRLVGLASLRAVSTSSMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLI NOV7h ------------------------ TMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLI NOV7i ------------------------ TMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLI NOV7j ------------------ TMGHHHHHHTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLI NOV7a DMLSEAGLSVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAG NOV7b DMLSEAGLSVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAG NOV7c DMLSEAGLSVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAG NOV7d DMLSEAGLSVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVTK NOV7e DMLSEAGLSVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVTK NOV7f DMLSEAGLSVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAG NOV7g DMLSEAGLSVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAG NOV7h DMLSEAGLSVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAG NOV7i DMLSEAGLSVIETTSFVSPKVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAG NOV7j DMLSEAGLSVIETTSFVSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAG 284 WO 2004/013347 PCT/US2003/024504 NOV7a AKEVVIFGAASELFTKKNINCSIEESFQRFDAILKAAQSANISVGYVSCALGCPYEGKI NOV7b AKEVVIFGAASELFTKKNINCSIEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKI NOV7c AKEVVIFGAASELFTKKNINCSIEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKI NOV7d --- ---- NOV7e --------------------------------------------------------- NOV7f AKEVVIFGAASELFTKKNINCSIEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKI NOV7g AKEVVIFGAASELFTKKNINCSIEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKI NOV7h AKEVVIFGAASELFTKKNINCSIEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKI NOV7i AKEVVIFGAASELFTKKNINCSIEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKI NOV7j AKEVVIFGAASELFTKKNINCSIEESFQRFDAILKAAQSANISVRGYVSCALGCPYEGKI NOV7a SPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQ NOV7b SPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQ NOV7c SPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQ NOV7d ---------- KFYSMGCYEISLGDTIGVGTPGIMDMLSAVMQEVPLAALAVHCHDTYGQ NOV7e ---------- KFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQ NOV7f SPAKVAE------------------------------------EVPLAALAVHCHDTYGQ NOV7g SPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQ NOV7h SPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQ NOV7i SPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQ NOV7j SPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQ NOV7a ALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLL NOV7b ALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLL NOV7c ALTNTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLL NOV7d ALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLL NOV7e ALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLL NOV7f ALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLL NOV7g ALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLL NOV7h ALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLL NOV7i ALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLL NOV7j ALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLL NOV7a EAGNFICQALNRKTSSKVAQATCKL NOV7b EAGNPICQALNRKTSSKVAQATSKL NOV7c EAGNFICQALNRKTSSKVAQATCKL NOV7d EAGNFICQALNRKTSSKVAQATCKL NOV7e EAGNFICQALNRKTSSKVAQATCKL NOV7f EAGNFICQALNRKTSSKVAQATCKL NOV7g EAGNFICQALNRKTSSKVAQATC- NOV7h EAGNFICQALNRKTSSKVAQATCKL NOV7i EAGNFICQALNRKTSSKVAQATCKL NOV7j EAGNFICQALNRKTSSKVAQATCKL NOV7a (SEQ ID NO: 60) NOV7b (SEQ ID NO: 62) NOV7c (SEQ ID NO: 64) NOV7d (SEQ ID NO: 66) NOV7e (SEQ ID NO: 68) NOV7f (SEQ ID NO: 70) NOV7g (SEQ ID NO: 72) NOV7h (SEQ ID NO: 74) NOV7i (SEQ ID NO: 76) NOV7j (SEQ ID NO: 78) Further analysis of the NOV7a protein yielded the following properties shown in Table G7. 285 WO 2004/013347 PCT/US2003/024504 Table G7. Protein Sequence Properties NOV7a SignalP analysis: Cleavage site between residues 25 and 26 PSORT II analysis: PSG: a new signal peptide prediction method N-region: length 11; pos.chg 4; neg.chg 0 H-region: length 7; peak value 0.99 PSG score: -3.41 GvH: von Heijne's method for signal seq. recognition GvH score (threshold: -2.1): -2.69 possible cleavage site: between 23 and 24 >>> Seems to have no N-terminal signal peptide ALOM: Klein et al's method for TM region allocation Init position for calculation: 1 Tentative number of TMS(s) for the threshold 0.5: 0 number of TMS(s) .. fixed PERIPHERAL Likelihood= 1.80 (at 115) ALOM score: 1.80 (number of TMSs: 0) MITDISC: discrimination of mitochondrial targeting seq R content: 5 Hyd Moment(75): 10.64 Hyd Moment(95): 9.40 G content: 2 D/E content: 1 S/T content: 6 Score: 1.44 Gavel: prediction of cleavage sites for mitochondrial preseq R-2 motif at 42 KRVIKI NUCDISC: discrimination of nuclear localization signals pat4: none pat7: PKRVKIV (5) at 30 bipartite: none content of basic residues: 9.8% NLS Score: -0.04 KDEL: ER retention motif in the C-terminus: none ER Membrane Retention Signals: XXRR-like motif in the N-terminus: AAMR KKXX-like motif in the C-terminus: ATCK SKL: peroxisomal targeting signal in the C-terminus: CKL PTS2: 2nd peroxisomal targeting signal: none VAC: possible vacuolar targeting motif: found TLPK at 28 RNA-binding motif: none Actinin-type actin-binding motif: type 1: none type 2: none 286 WO 2004/013347 PCT/US2003/024504 NMYR: N-myristoylation pattern: none Prenylation motif: none memYQRL: transport motif from cell surface to Golgi: none Tyrosines in the tail: none Dileucine motif in the tail: none checking 63 PROSITE DNA binding motifs: none checking 71 PROSITE ribosomal protein motifs: none checking 33 PROSITE prokaryotic DNA binding motifs: none NNCN: Reinhardt's method for Cytoplasmic/Nuclear discrimination Prediction: cytoplasmic Reliability: 94.1 COIL: Lupas's algorithm to detect coiled-coil regions total: 0 residues Final Results (k= 9/23): 87.0 %: mitochondrial 4.3 %: Golgi 4.3 %: cytoplasmic 4.3 %: nuclear >> prediction for CG96859-03 is mit (k=23) A search of the NOV7a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table G8. Table G8. Geneseq Results for NOV7a NOV7a Identities/ Geneseq Protein/Organism/Length [Patent Residues/ Similarities for Expect Identifier #, Date] Match the Matched Value Residues Region ABB99771 Protein related to 1..325 324/325 (99%) 0.0 hydroxymethylglutaryl-CoA lyase- 1..325 324/325 (99%) like enzyme - Homo sapiens, 325 aa. [W0200299093-A2, 12-DEC-20021 AAU75774 Human 3-hydroxy-3-methylglutaryl 1..325 324/325 (99%) 0.0 coenzyme A lyase (HMGCL) protein 1..325 324/325 (99%) - Homo sapiens, 325 aa. [W0200198315-A2, 27-DEC-2001] . 287 WO 2004/013347 PCT/US2003/024504 AAU01613 Gene #24 human secreted protein 30..321 234/292 (80%) e-137 homologous amino acid sequence - 1..292 266/292 (90%) Homo sapiens, 293 aa. [W0200123547-A1, 05-APR-2001] ABB99772 Sequence of human 20.322 215/303 (70%) e-126 hydroxymethylglutaryl-CoA lyase- 50..352 259/303 (84%) like enzyme - Homo sapiens, 355 aa. [W0200299093-A2, 12-DEC-2002] ABB99770 Sequence of human 20..322 215/303 (70%) e-126 hydroxymethylglutaryl-CoA lyase- 35..337 259/303 (84%) like enzyme - Homo sapiens, 340 aa. [WO200299093-A2, 12-DEC-2002] In a BLAST search of public sequence databases, the NOV7a protein was found to have homology to the proteins shown in the BLASTP data in Table G9. Table G9. Public BLASTP Results for NOV7a Protein NOV7a Identities/ Accession Protein/Organism/Length Residues/ Similarities for Expect Number Match the Matched Value Residues Portion P35914 Hydroxymethylglutaryl-CoA lyase, 1..325 325/325 (100%) 0.0 mitochondrial precursor (EC 4.1.3.4) 1..325 325/325 (100%) (HMG-CoA lyase) (HL) (3-hydroxy 3-methylglutarate-CoA lyase) Homo sapiens (Human), 325 aa. A45470 hydroxymethylglutaryl-CoA lyase 1..325 324/325 (99%) 0.0 (EC 4.1.3.4) - human, 325 aa. 1..325 324/325 (99%) Q8HXZ6 3-hydroxymethyl-3-methylglutaryl- 1..325 313/325 (96%) e-176 coenzyme A lyase - Macaca 1..325 315/325 (96%) fascicularis (Crab eating macaque) (Cynomolgus monkey), 325 aa. CAB40160 DJ886K2.2 (Hydroxymethylglutaryl- 21..325 305/305 (100%) e-172 CoA lyase) - Homo sapiens (Human), 1..305 305/305 (100%) 305 aa (fragment). P97519 Hydroxymethylglutaryl-CoA lyase, 1..325 289/325 (88%) e-167 mitochondrial precursor (EC 4.1.3.4) 1..325 311/325 (94%) (HMG-CoA lyase) (HL) (3-hydroxy 3-methylglutarate-CoA lyase) Rattus norvegicus (Rat), 325 aa. 288 WO 2004/013347 PCT/US2003/024504 PFam analysis predicts that the NOV7a protein contains the domains shown in the Table G10. Table GI0. Domain Analysis of NOV7a Identities/ Pfam Domain NOV7a Match Region Similarities Expect Value for the Matched Region HMGL-like 41..314 103/307 (34%) 4.le-118 249/307 (81%) 5 Example G3. Single Nucleotide Polymorphisms (SNPs) of CG96859-03 Variant sequences are included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for 10 another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at 15 the position of the SNP. Intragenic SNPs may also be silent, however, in the case that a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern for example, alteration in temporal expression, 20 physiological response regulation, cell type expression regulation, intensity of expression, stability of transcribed message. Method of novel SNP Identification: SNPs are identified by analyzing sequence assemblies using CuraGen's proprietary SNPTool algorithm. SNPTool identifies variation in assemblies 25 with the following criteria: SNPs are not analyzed within 10 base pairs on both ends of an alignment; Window size (number of bases in a view) is 10; The allowed number of mismatches in a window is 2; Minimum SNP base quality (PHRED score) is 23; Minimum number of changes to score an SNP is 2/assembly position. SNPTool analyzes the assembly and displays SNP positions, associated individual variant sequences in the assembly, the 289 WO 2004/013347 PCT/US2003/024504 depth of the assembly at that given position, the putative assembly allele frequency, and the SNP sequence variation. Sequence traces are then selected and brought into view for manual validation. The consensus assembly sequence is imported into CuraTools along with variant sequence changes to identify potential amino acid changes resulting from the SNP sequence 5 variation. Comprehensive SNP data analysis is then exported into the SNPCalling database. Method of novel SNP Confirmation: SNPs are confirmed employing a validated method know as Pyrosequencing. Detailed protocols for Pyrosequencing can be found in: Alderborn et al. Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA 10 Sequencing. (2000). Genome Research. 10, Issue 8, August. 1249-1265. In brief, Pyrosequencing is a real time primer extension process of genotyping. This protocol takes double-stranded, biotinylated PCR products from genomic DNA samples and binds them to streptavidin beads. These beads are then denatured producing single stranded bound 15 DNA. SNPs are characterized utilizing a technique based on an indirect bioluminometric assay of pyrophosphate (PPi) that is released from each dNTP upon DNA chain elongation. Following Klenow polymerase-mediated base incorporation, PPi is released and used as a substrate, together with adenosine 5'-phosphosulfate (APS), for ATP sulfurylase, which results in the formation of ATP. Subsequently, the ATP accomplishes the conversion of 20 luciferin to its oxi-derivative by the action of luciferase. The ensuing light output becomes proportional to the number of added bases, up to about four bases. To allow processivity of the method dNTP excess is degraded by apyrase, which is also present in the starting reaction mixture, so that only dNTPs are added to the template during the sequencing. The process has been fully automated and adapted to a 96-well format, which allows rapid 25 screening of large SNP panels. Results The DNA and protein~sequences for the novel single nucleotide polymorphic variants of the 30 HYDROXYMETHYLGLUTARYL-COA LYASE-like gene of CuraGen Ace. No. CG96859-03 are reported in Table GI1. Variants are reported individually but any combination of all or a select subset of variants are also included. In Table G1l, the positions of the variant bases and the variant amino acid residues are underlined. In summary, there are 1 variants reported in Table G11. Variant 13379476 is a C to T SNP at 725 bp of the 290 WO 2004/013347 PCT/US2003/024504 nucleotide sequence that results in no change in the protein sequence (silent). Table GIl. Variant of nucleotide sequence Acc. No. CG96859-03 (SEQ ID NO:59) Nucleotides Amino Acids Variant Position Initial Modified Position Initial Modified 13379476 725 C T 237 Thr Thr 5 Table G12. Variant Sequences TableG12AL. Nucleotide sequence of variant 13379476 NOV7aln (underlined). C/T (SEQ ID NO:169) 1 AAATTCCGGCCAAGATGGCACCAATGAGGAAGGCGCTTCCGCGGCGACTGGTGGGCTTGGCGTCCCTCCGGGCTGTCAGC 91 ACCTCATCTATGGGCACTTTACCAAAGCGGGTGAAAATTCTGGAAGTTGGTCCCCGAGATGGACTACAAAATGAAAAGAA 161 TATCGTATCTACTCCAGTGAAAATCAAGCTGATAGACATGCTTTCTGAAGCAGGACTCTCTGT.TATAGAAACCACCAGCT 241 TTGTGTCTCCTAAGTGGGTTCCCCAG3ATGGGTGACCACACTGAAGTCTTGAAGGGCATTCAGAAGTTTCCTGGCATCAAC 321 TACCCAGTCCTGACCCCAAATTTGAAACGCTTCGAGGCAGCGGTTGCTGCTGAGCCAAGGAAGTAGTCATCTTTGGAGC 401 TGCCTCAGAGCTCTTCACCAAG.AAGAACATCAATTGTTCCATAGAGGAOAGTTTTCAGAGGTTTGACGCAATCCTGAAGG 481 CAGCGCAGTCAGCCAATATTTCTGTGCGGGGGTACGTCTCCTGTGCTCTTGGCTGCCCTTATGAAGGGAAGATCTCCCCA 561 GCTAAAGTAGCTGAGGTCACCAAGAAGTTCTACTCAATGGGCTGCTACGAGATCTCCCTGGCGGACACCATTGGTGTGGG . 641 CACCCCAGGGATCATGAAAGACATGCTGTCTGCTGTCATGCAGGAAGTGCCTCTGGCTGCCCTGGCTGTCCACTGCCATg 721 ACACTTATGGTCAAGCCCTGGCCAACACCTTGATGGCCCTGCAGATGGGAGTGAGTGTCGTGGACTCTTCTGTGGCAGGA 801 CTTG GAGGCTGTCCCTACGCACAGGGGGCATCAGGAAACTTGGCCACAGAAGACCTGGTCTACATGCTAGAGGGCTTGGG 881 CATTCACACGGGTGTGAATCTCCAGAAGCTTCTGGAAGCTGGAAACTTTATCTGTCAAGCCCTGAACAGAAAAACTAGCT 961 CCAAAGTGGCTCAGGCTACCTGTAAACTCTGAGCCCCTTGCCCACCTGAAGGCCTGGG3GATGATGTCGAAATAAGGGGCA 1041 T TableGl2A2. Protein sequence of variant NOV7aln (underlined). (SEQ ID NO:170) 1 MAAMRKALPRRLVGLASLRAVSTSSMGTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLIDMLSEAGLSVIETTSFVSPK 81 WVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAGAKEVVIFGAASELFTKKNINCSIEESFQRFDAILKAAQSA 161 NISVRGYVSCALGCPYEGKISPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVPLAALAVHCHDTYGQ 241 ALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNLATEDLVYMLEGLGIHTGVNLQKLLEAGNFICQALNRKTSSKVAQ 321 ATCKL TableG12A3. Alteration effect No change. Example G4. Expression Profiles of HMG CoA Lyase (CG96859-03) - like protein The protocol for quantitative expression analysis is disclosed in Example Q9. Expression of gene CG96859-03 was assessed using the primer-probe set Ag8471, described 10 in Table G13. Results of the RTQ-PCR runs are shown in Table G14. Table G13. Probe Name Ag8471 Start SEQ ID Primers Sequences Length Position No Forward s -aagctggtggtttctataaCagaga-3' 25 801 218 Probe TET-5' -tcctgcttcagaaagCatgtCtatCagC-31- 28 827 219 Poe TAM4RA Reverse 5 1aagaatatcgtatCtaCtCCagtgaaaat-3 29 858 220 291 WO 2004/013347 PCT/US2003/024504 Table G14. Generalscreeningpanelvl.7 Column A - Rel. Exp.(%) Ag8471, Run 406009117 Tissue Name A Tissue Name A Adipose 42.3 Gastric ca. (liver met.) NCI-N87 0.4 HUVEC 25.7 Stomach 1.4 Melanoma* Hs688(A).T 0.0 Colon ca. SW-948 12.9 Melanoma* Hs688(B).T 54.7 Colon ca. SW480 0.2 Melanoma (met) SK-MEL-5 28.7 Colon ca. (SW480 met) SW620 33.0 Testis 12.1 Colon ca. HT29 57.8 Prostate ca. (bone met) PC-3 0.9 Colon ca. HCT-1 16 40.3 Prostate ca. DU145 32.8 Colon cancer tissue 1.4 Prostate pool 9.2 Colon ca. SW1116 11.2 Uterus pool 3.1 Colon ca. Colo-205 26.4 Ovarian ca. OVCAR-3 8.4 Colon ca. SW-48 14.4 Ovarian ca. (ascites) SK-OV-3 1.6 Colon 22.5 Ovarian ca. OVCAR-4 0.0 Small Intestine 4.1 Ovarian ca. OVCAR-5 40.6 Fetal Heart 6.0 Ovarian ca. IGROV--1 0.0 Heart 7.4 Ovarian ca. OVCAR-8 44.4 Lymph Node pool 2 35.6 Ovary 14.6 Fetal Skeletal Muscle 9.8 Breast ca. MCF-7 31.0 Skeletal Muscle pool 5.4 Breast ca. MDA-MB-231 28.5 Skeletal Muscle 42.6 Breast ca. BT 549 30.4 Spleen 16.6 Breast ca. T47D 35.4 Thymus 9.9 Breast pool 0.0 CNS cancer (glio/astro) SF-268 9.4 Trachea 30.8 CNS cancer (glio/astro) T98G 13.9 Lung 38.4 CNS cancer (neuro;met) SK-N-AS 0.3 Fetal Lung 22.4 CNS cancer (astro) SF-539 88.9 Lung ca. NCI-N417 6.3 CNS cancer (astro) SNB-75 44.1 Lung ca. LX-1 10.7 CNS cancer (glio) SNB-19 33.9 Lung ca. NCI-H146 4.7 CNS cancer (glio) SF-295 9.1 Lung ca. SHP-77 29.9 Brain (Amygdala) 10.2 Lung ca. NCI-H23 31.2 IBrain (Cerebellum) 27.7 Lung ca. NCI-H460 13.4 Brain (Fetal) 14.9 Lung ca. HOP-62 100.0 Brain (Hippocampus) 13.3 Lung ca. NCI-H522 23.2 Cerebral Cortex pool 9.2 Lung ca. DMS-I 14 7.6 Brain (Substantia nigra) 4.0 Liver 71.7 Brain (Thalamus) 17.1 Fetal Liver (Whole) Kidney pool 8 Spial Cord 11.8 Fetal Kidney189 Aenal Gland 292 WO 2004/013347 PCT/US2003/024504 Renal ca. 786-0 64.2 Pituitary Gland 17.6 Renal ca. A498 10.5 Salivary Gland 151 Renal ca. ACHN 24.0 Thyroid 59.0 Renal ca. UO-31 48.0 Pancreatic ca. PANC-1 19.9 Renal ca. TK-10 24.0 Pancreas pool 6.1 Bladder 14.9 Panels 1, 1.1, 1.2, and 1.3D Panels 1, 1.1, 1.2 and 1.3D included 2 control wells (genomic DNA control and chemistry control) and 94 wells of cDNA samples from cultured cell lines and primary normal tissues. Cell lines were derived from carcinomas (ca) including: lung, small cell (s cell var), non 5 small cell (non-s or non-sm); breast; melanoma; colon; prostate; glioma (glio), astrocytoma (astro) and neuroblastoma (neuro); squamous cell (squam); ovarian; liver; renal; gastric and pancreatic from the American Type Culture Collection (ATCC, Bethesda, MD). Normal tissues were obtained from individual adults or fetuses and included: adult and fetal skeletal muscle, adult and fetal heart, adult and fetal kidney, adult and fetal liver, adult and fetal lung, 10 brain, spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. The following abbreviations are used in reporting the results: metastasis (met); pleural effusion (pl. eff or pl effusion) and * indicates established from metastasis. 15 Generalscreeningpanel vl.4, v1.5, v1.6 and v1.7 Panels 1.4, 1.5, 1.6 and 1.7 were as described for Panels 1, 1.1, 1.2 and 1.3D, above except that normal tissue samples were pooled from 2 to 5 different adults or fetuses. Generalscreeningpanel_v1.7 Summary: Ag8471 The highest expression of this gene was detected in a lung cancer sample (CT=26). This gene is widely expressed. Among 20 tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therapeutic modulation of this gene, expressed protein and/or use of antibodies or small molecule drugs targeting the gene or gene product will useful in the treatment of endocrine/metabolically related diseases, such as obesity and 25 diabetes. 293 WO 2004/013347 PCT/US2003/024504 Example G5. Screening Assays for Modulators of HMG CoA Lyase A non-exhaustive list of cell lines that express the HMG CoA Lyase can be obtained from the differential gene expression (RTQ-PCR) results presented herein. 5 Potential methods for measurement of HMG-CoA lyase enzymatic activity include citrate synthase-coupled assay of Stegink and Coon, (Stereospecificity and other properties of highly purified beta-hydroxy-beta-methylglutaryl coenzyme A cleavage enzyme from bovine liver, 10 J Biol Chem. 1968 Oct 25;243(20):5272-9), further modified by Kramer and Miziorko (Purification and characterization of avian liver 3-hydroxy-3-methylglutaryl coenzyme A lyase, J Biol Chem. 1980 Nov 25;255(22):11023-8). Our results indicate that a modulator. of HMG CoA Lyase activity, such as an inhibitor, activator, antagonist, or agonist of HMG CoA Lyase may be useful for treatment of 15 such disorders as obesity, diabetes, and insulin resistance, as well as for enhancement of insulin secretion. Protocols 20 Following Examples describe procedures, protocols and technologies described in this application. Example Q1. Mouse Diet-Induced Obesity (DIO) Study (BP24.02) Overview 25 The predominant cause for obesity in clinical populations is excess caloric intake. This so-called diet-induced obesity (DIO) is mimicked in animal models by feeding high fat diets of greater than 40% fat content. The DIO study was established to identify the gene expression changes contributing to the development and progression of diet-induced obesity. 30 In addition, the study design sought to identify the factors that led to the ability of certain individuals to resist the effects of a high fat diet and thereby prevent obesity. The sample groups for the study normally had body weights +1 S.D.,+ 4 S.D. and + 7 S.D. of the chow-fed controls. In addition, the biochemical profile of the + 7 S.D. mice 35 normally revealed a further stratification of these animals into mice that retained a normal glycemic profile in spite of obesity and mice that demonstrated hyperglycemia. Tissues 294 WO 2004/013347 PCT/US2003/024504 examined included hypothalamus, brainstem, liver, retroperitoneal white adipose tissue (WAT), epididymal WAT, brown adipose tissue (BAT), gastrocnemius muscle (fast twitch skeletal muscle) and soleus muscle (slow twitch skeletal muscle). The differential gene expression profiles for these tissues revealed genes and pathways that can be used as 5 therapeutic targets for obesity and/or diabetes. Protocol 5 groups of mice were used with 3 mice per group. Occasionally, more than 3 mice 10 were used in a single group in order to preserve correct parameters for the study. In such case only 3 mice would be sacrificed for tissues. The groups were grouped based on the following parameters: Group 1. Chow fed mice Group 2. Mice fed a high fat diet who were 1 standard deviation in weight above the chow 15 fed mice. Group 3. Mice fed a high fat diet who were 4 standard deviations in weight above the chow fed mice. Group 4. Mice fed a high fat diet who were 7 standard deviations in weight above the chow fed mice and who had normal glucose levels. 20 Group 5. Mice fed a high fat diet who were 7 standard deviation in weight above the chow fed mice and who were hyperglycemic. In each group of mice, there were 3 mice that were sacrificed and tissues harvested for the study. 25 Example Q2. Rat Pancreatic Islet Study (BP24.03) Overview An important clinical goal in the early phases of Type II diabetes is to increase insulin secretion from the beta cells of the pancreas. Numerous agents have been identified 30 that can modulate insulin secretion experimentally and in therapeutic situations. When applied to isolated rat pancreatic islets, the changes in gene expression can be correlated with insulin secretion. In this study, acute and chronic changes in gene expression were examined from islets treated with an agent after short (4 hour) and long-term (5 days) exposure, respectively, compared with the basal state (11 mM glucose). The agents included elevated 35 (25 mM) glucose, glucose (11 mM) and exendin-4 (1 nM), glucose (11 mM) and glybenclamide (50 uM) and glucose (11 mM) and oleate (2 mM). Protocol All samples were isolated rat islets. They differed only in the treatment that they received. The following samples were in the 4 hour group: 40 1) 11 mM glucose 2) 25 mM glucose 295 WO 2004/013347 PCT/US2003/024504 3) 11 mM glucose & JTT 608 4) 11 mM glucose & Carbacol 5) 11 mM glucose & Exendin-4 5 Isolated rat islets were treated with either 11mM glucose (basal state) or 25mM glucose (elevated glucose.). Then there were 3 additional sets of rat islets that were treated with 1 1mM glucose and one of the 3 agents: JTT 608, Carbacol, or Exendin-4. The following samples were in the 5 day group: 10 1) 11 mM glucose 2) 25 mM glucose 3) 11 mM glucose &lnM Exendin 4) 11 mM glucose & 5OuM Glybenclamide 5) 11 mMglucose & 2mM Oleic Acid 15 Isolated rat islets were treated with either 1mM glucose (basal state) or 25mM glucose (elevated glucose.). Then there were 3 additional sets of rat islets that were treated with 1 lmM glucose and one of the 3 agents: exendin, glybenclamide, or oleic acid. 20 From all 10 samples, each was split into 2 replicates. The 2 replicates were run for differential gene expression analysis (GeneCalling@). Example Q3. Rat Insulin Sensitivity Study (BP24.05) 25 Protocol ZDF rats or their lean littermates were treated with a variety of agents that are known to alter insulin sensitivity. Metformin, vanadate, and AICAR enhance tissue response to insulin, while the free fatty acids generated by Liposyn (intravenous lipid infusion) treatment 30 reduces the response. A variety of tissues were harvested, including gastrocnemius and soleus muscles, liver, retroperitoneal and epididymal WAT, and IBAT. Only gastrocnemius and soleus muscles were processed for differential gene expression analysis (GeneCalling@). 35 There were 5 groups of samples: 1) Metformin vehicle (vehicle M) 2) Metformin treated rats 3) AICAR and vanadate vehicle (vehicle AV) 40 4) AICAR treated rats 5) Vanadate treated rats 296 WO 2004/013347 PCT/US2003/024504 Treatment was for 4 hours and glucose values before and after treatment were obtained. Each sample was done in triplicate (5 groups X 3 rats X 2 tissues). In the second part of the study rats were given an intravenous lipid infusion which 5 should reduce tissue response to insulin in treated rats. In the intravenous lipid infusion part of the study 2 groups were used: 1) Rats treated with lipid infusion vehicle. 2) Rats treated with lipid infusion. 10 In each group, there were 3 rats (done in triplicate) and soleus and gastrodnemius samples were processed for differential gene expression analysis (GeneCalling@) (2 groups X 3 samples X 2 tissues). 15 Example Q4. Mouse TZD Response Study (BP24.07) Overview and Protocol The peroxisome proliferator-activated receptor gamma (PPARg) is the member of the 20 nuclear hormone receptor subfamily of transcription factors that plays a major role in regulation of metabolism. The thiazolidinedione (TZD) drugs, including rosiglitazone, are synthetic agonists of PPARg receptors that can normalize elevated plasma glucose levels in obese, diabetic rodents and are often quite efficacious therapeutic agents for the treatment of noninsulin-dependent diabetes mellitus in humans. Diabetic animals demonstrate differential 25 responses to TZD treatment. To understand the basis for this differential response we compared changes in gene expression between diabetic animals that responded favorably and that did not respond to TZD treatment. Female db/db mice were treated daily with 10mg per kilogram body weight rosiglitazone for 7 days. On day 8, the mice were bled for blood glucose. Treated mice were grouped into either a responder group that demonstrated a 30 significant decrease of their hyperglycemia and a non-responder group that demonstrated no change in their blood glucose level. Gene expression in skeletal muscle and adipose tissues was compared between untreated diabetic mice and the two sub-groups of TZD treated mice. 3 tissues were collected for differential gene expression analysis (GeneCalling@): 35 liver, thigh muscle, and uterine white adipose. 3 groups of samples were used: 1) Vehicle treated 2) Rosiglitazone responders 297 WO 2004/013347 PCT/US2003/024504 3) Rosiglitazone non-responders Each group had 3 mice in it. Total of 27 samples were processed for differential gene expression analysis (GeneCalling@). 5 Example Q5. Insulin Resistance Study (MB.01) The spontaneoulsy hypertensive rat (SHR) is a strain exhibiting features of the human Metabolic Syndrome X. The phenotypic features include obesity, hyperglycemia, 10 hypertension, dyslipidemia and dysfibrinolysis. Tissues were removed from adult male rats and a control strain (Wistar _ Kyoto) to identify the gene expression differences that underlie the pathologic state in the SHR and in animals treated with various anti-hyperglycemic agents such as troglitizone. Tissues included sub-cutaneous adipose, visceral adipose, brain, muscle, and liver. Each tissue was collected in triplicate for differential gene expression 15 analysis (GeneCalling@). Example Q6. Genetically Obese Mice vs Genetically Lean Mice Study (MB.04) Overview 20 A number of genetic models of obesity have been studied, most prominently in mouse and rat, but only a few causative genes have been identified. In this study, a set of mouse genetic models were studied in order to identify by positional expression cloning the genes for obesity in mice, which genes may be relevant to human obesity. 25 Protocol 7 strains of mice were used. Some exhibited a lean phenotype, some were normal weight mice, and some of the mice were genetically obese. 30 The following strains of mice used in the study: 1) CAST/EI - lean phenotype 2) SM/J black - lean phenotype 3) SWR/J - normal phenotype 35 4) C57L/J - normal phenotype 5) C571BL/6J - normal phenotype 6) AKR/J - obese phenotype 7) NZB/BINJ - obese phenotype 298 WO 2004/013347 PCT/US2003/024504 Various tissues were processed for differential gene expression analysis (GeneCalling@): brain, liver, muscle, and adipose. Samples were processed in triplicate (i.e. 3 brain samples from 3 CAST/EL mice). 5 Total of 7 strains X 4 tissues X 3 samples = 84 samples were used. Example Q7. Method of Identifying the Differentially Expressed Gene and Gene Product (GeneCalling@) 10 The GeneCalling@ technology is a proprietary method of performing differential gene expression profiling between two or more samples developed at CuraGen and described by Shimkets, et al., "Gene expression analysis by transcript profiling coupled to a gene database query" Nature Biotechnology 17:198-803 (1999). GeneCalling@ technology is also 15 disclose in U.S. Pat. No. 5,871,697. cDNA was derived from various samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or 20 steroids. The cDNA thus derived was then digested with up to as many as 120 pairs of restriction enzymes and pairs of linker-adaptors specific for each pair of restriction enzymes were ligated to the appropriate end. The restriction digestion generates a mixture of unique cDNA gene fragments. Limited PCR amplification is performed with primers homologous to the linker adapter sequence where one primer is biotinylated and the other is fluorescently 25 labeled. The doubly labeled material is isolated and the fluorescently labeled single strand is resolved by capillary gel electrophoresis. A computer algorithm compares the electropherograms from an experimental and control group for each of the restriction digestions. This and additional sequence-derived information is used to predict the identity of each differentially expressed gene fragment using a variety of genetic databases. The 30 three methods routinely used to confirm the identity of the gene fragment found to have altered expression in models of or patients with obesity and/or diabetes are described below. A). Direct Sequencing The differentially expressed gene fragment is isolated, cloned into a plasmid, and sequenced. 35 Afterwards, the sequence information is used to design an oligonucleotide corresponding to 299 WO 2004/013347 PCT/US2003/024504 either or both termini of the gene fragment. This oligonucleotide, when used in a competitive PCR reaction, will ablate the electropherographic band from which the sequence is derived. B). Competitive PCR 5 In competitive PCR, the electropherographic peaks corresponding to the gene fragment of the gene of interest are ablated when a gene-specific primer (designed from the sequenced band or available databases) competes with primers in the linker-adaptors during the PCR amplification. 10 C). PCR with Perfect or Mismatched 3' Nucleotides (TraPping) This method utilizes a competitive PCR approach using a degenerate set of primers that extend one or two nucleotides into the gene-specific region of the fragment beyond the flanking restriction sites. As in the competitive PCR approach, primers that lead to the ablation of the electropherographic band add additional sequence information. In conjunction 15 with the size of the gene fragment and the 12 nucleotides of sequence derived from the restriction sites, this additional sequence data can uniquely define the gene after database analysis. TraPping is disclosed in a published PCT application Pub. No. WO 01/49886. 20 Example Q8. Identification of Human Sequences The laboratory cloning was performed using one or more of the methods summarized below: SeqCallingTMTechnology: cDNA was derived from various human samples representing 25 multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then sequenced using CuraGen Corporation's 30 SeqCalling technology that is disclosed in full in U. S. Ser. Nos. 09/417,386 filed Oct. 13, 1999 (as well as in PCT application Pub. No.: WO 00/40757), and 09/614,505 filed July 11, 2000. Sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatics programs to produce a consensus sequence for each 300 WO 2004/013347 PCT/US2003/024504 assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes infonnation on variants, such as splice forms single nucleotide polymorphisms 5 (SNPs), insertions, deletions and other sequence variations. Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a 10 cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site, at which one allele bears a gap with respect to a particular nucleotide in another allele. 15 SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression 20 pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message. Information associated with genomic clones, public genes and ESTs sharing 25 sequence identity with the disclosed sequences and CuraGen Corporation's Electronic Northern bioinformatic tool. RACE: Techniques based on the polymerase chain reaction such as rapid amplification of cDNA ends (RACE), were used to isolate or complete the predicted sequence of the cDNA 30 of the invention. Usually multiple clones were sequenced from one or more human samples to derive the sequences for fragments. Various human tissue samples from different donors were used for the RACE reaction. The sequences derived from these procedures were included in the SeqCalling Assembly process described in preceding paragraphs. 301 WO 2004/013347 PCT/US2003/024504 Exon Linking: The cDNA coding for the CG101190-01 sequence was cloned by the polymerase chain reaction (PCR) using the primers designed based on known cDNA sequences or in silico predictions of the full length or some portion (one or more exons) of the cDNA/protein sequence of the invention. These primers were used to amplify a cDNA 5 from a pool containing expressed human sequences derived from the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma -Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, 10 stomach, testis, thyroid, trachea and uterus. Physical Clone: The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2.1 vector from Invitrogen to provide clones used for expression and screening purposes. 15 Example Q9. Quantitative expression analysis (RTQ-PCR) of clones in various cells and tissues The quantitative expression of various NOV genes was assessed using microtiter plates 20 containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ-PCR) performed on an Applied Biosystems (Foster City, CA) ABI PRISM@ 7700 or an ABI PRISM@ 7900 HT Sequence Detection System. RNA integrity of all samples was determined by visual assessment of agarose gel 25 electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s: 18s) and the absence of low molecular weight RNAs (degradation products). Control samples to detect genomic DNA contamination included RTQ-PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon. 30 RNA samples were normalized in reference to nucleic acids encoding constitutively expressed genes (i.e., p-actin and GAPDH). Alternatively, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen 302 WO 2004/013347 PCT/US2003/024504 Corporation, Carlsbad, CA, Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 10 pg of total RNA in a volume of 20 sl or were scaled up to contain 50 pg of total RNA in a volume of 100 pl and were incubated for 60 minutes at 42*C. sscDNA samples were then normalized in reference to 5 nucleic acids as described above. Probes and primers were designed according to Applied Biosystems Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default reaction condition settings and the following parameters were set before selecting primers: 250 nM primer concentration; 58* 10 60* C primer melting temperature (Tm) range; 59* C primer optimal Tm; 20 C maximum primer difference (if probe does not have 5' G, probe Tm must be 10' C greater than primer Tm; and 75 bp to 100 bp amplicon size. The selected probes and primers were synthesized by Synthegen (Houston, TX). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to 15 the 5' and 3' ends of the probe, respectively. Their final concentrations were: 900 nM forward and reverse primers, and 200nM probe. Normalized RNA was spotted in individual wells of a 96 or 384-well PCR plate (Applied Biosystems, Foster City, CA). PCR cocktails included a single gene-specific probe and primers set or two multiplexed probe and primers sets. PCR reactions were done using 20 TaqMan@ One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer's instructions. Reverse transcription was performed at 480 C for 30 minutes followed by amplification/PCR cycles: 950 C 10 min, then 40 cycles at 950 C for 15 seconds, followed by 600 C for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) and plotted using a log scale, with 25 the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression was the reciprocal of the RNA difference multiplied by 100. CT values below 28 indicate high expression, between 28 and 32 indicate moderate expression, between 32 and 35 indicate low expression and above 35 reflect levels of expression that were too low to be 30 measured reliably. 303 WO 2004/013347 PCT/US2003/024504 Normalized sscDNA was analyzed by RTQ-PCR using 1X TaqMan@ Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. PCR amplification and analysis were done as described above. Panels 1, 1.1, 1.2, and 1.3D 5 Panels 1, 1.1, 1.2 and 1.3D included 2 control wells (genomic DNA control and chemistry control) and 94 wells of cDNA samples from cultured cell lines and primary normal tissues. Cell lines were derived from carcinomas (ca) including: lung, small cell (s cell var), non small cell (non-s or non-sm); breast; melanoma; colon; prostate; glioma (glio), astrocytoma (astro) and neuroblastoma (neuro); squamous cell (squam); ovarian; liver; renal; gastric and 10 pancreatic from the American Type Culture Collection (ATCC, Bethesda, MD). Normal tissues were obtained from individual adults or fetuses and included: adult and fetal skeletal muscle, adult and fetal heart, adult and fetal kidney, adult and fetal liver, adult and fetal lung, brain, spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, 15 uterus, placenta, prostate, testis and adipose. The following abbreviations are used in reporting the results: metastasis (met); pleural effusion (pl. eff or pl effusion) and * indicates established from metastasis. General_screeningpanel-v1.4, v1.5, v1.6 and vl.7 Panels 1.4, 1.5, 1.6 and 1.7 were as described for Panels 1, 1.1, 1.2 and 1.3D, above except 20 that normal tissue samples were pooled from 2 to 5 different adults or fetuses. Panels 2D, 2.2, 2.3 and 2.4 ' Panels 2D, 2.2, 2.3 and 2.4 included 2 control wells and 94 wells containing RNA or cDNA from human surgical specimens procured through the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative 25 (NDRI), Ardais (Lexington, MA) or Clinomics BioSciences (Frederick, MD). Tissues included human malignancies and in some cases matched adjacent normal tissue (NAT). Information regarding histopathological assessment of tumor differentiation grade as well as the clinical stage of the patient from which samples were obtained was generally available. Normal tissue RNA and cDNA samples were purchased from various commercial sources 30 such as Clontech (Palo Alto, CA), Research Genetics and Invitrogen (Carlsbad, CA). 304 WO 2004/013347 PCT/US2003/024504 HASS Panel v 1.0 The HASS Panel vI.0 included 93 cDNA samples and two controls including: 81 samples of cultured human cancer cell lines subjected to serum starvation, acidosis and anoxia according to established procedures for various lengths of time; 3 human primary cells; 9 5 malignant brain cancers (4 medulloblastomas and 5 glioblastomas); and 2 controls. Cancer cell lines (ATCC) were cultured using recommended conditions and included: breast, prostate, bladder, pancreatic and CNS. Primary human cells were obtained from Clonetics (Walkersville, MD). Malignant brain samples were gifts from the Henry Ford Cancer Center. ARDAIS Panel v1.0 and v1.1 10 The ARDAIS Panel v1.0 and v1. 1 included 2 controls and 22 test samples including: human lung adenocarcinomas, lung squamous cell carcinomas, and in some cases matched adjacent normal tissues (NAT) obtained from Ardais (Lexington, MA). Unmatched malignant and non-malignant RNA samples from lungs with gross histopathological assessment of tumor differentiation grade and stage and clinical state of the patient were obtained from Ardais. 15 ARDAIS Prostate v1.0 ARDAIS Prostate v1.0 panel included 2 controls and 68 test samples of human prostate malignancies and in some cases matched adjacent normal tissues (NAT) obtained from Ardais (Lexington, MA). RNA from unmatched malignant and non-malignant prostate samples with gross histopathological assessment of tumor differentiation grade and stage and 20 clinical state of the patient were also obtained from Ardais. ARDAIS Kidney vl.0 ARDAIS Kidney v1.0 panel included 2 control wells and 44 test samples of human renal cell carcinoma and in some cases matched adjacent normal tissue (NAT) obtained from Ardais (Lexington, MA). RNA from unmatched renal cell carcinoma and normal tissue with gross 25 histopathological assessment of tumor differentiation grade and stage and clinical state of the patient were also obtained from Ardais. ARDAIS Breast v1.0 305 WO 2004/013347 PCT/US2003/024504 ARDAIS Breast v1.0 panel included 2 control wells and 71 test samples of human breast malignancies and in some cases matched adjacent normal tissue (NAT) obtained from Ardais (Lexington, MA). RNA from unmatched malignant and non-malignant breast samples with gross histopathological assessment of tumor differentiation grade and stage and clinical state 5 of the patient were also obtained from Ardais. Panel 3D, 3.1 and 3.2 Panels 3D, 3.1, and 3.2 included two controls, 92 cDNA samples of cultured human cancer cell lines and 2 samples of human primary cerebellum. Cell lines (ATCC, National Cancer Institute (NCI), German tumor cell bank) were cultured as recommended and were derived 10 from: squamous cell carcinoma of the tongue, melanoma, sarcoma, leukemia, lymphoma, and epidennoid, bladder, pancreas, kidney, breast, prostate, ovary, uterus, cervix, stomach, colon, lung and CNS carcinomas. Panels 4D, 4R, and 4.1D Panels 4D, 4R, and 4. 1D included 2 control wells and 94 test samples of RNA (Panel 4R) or 15 cDNA (Panels 4D and 4.1D) from human cell lines or tissues related to inflammatory conditions. Controls included total RNA from normal tissues such as colon, lung (Stratagene, La Jolla, CA), thymus and kidney (Clontech, Palo Alto, CA). Total RNA from cirrhotic and lupus kidney was obtained from BioChain Institute, Inc., (Hayward, CA). Crohn's intestinal and ulcerative colitis samples were obtained from the National Disease Research Interchange 20 (NDRI, Philadelphia, PA). Cells purchased from Clonetics (Walkersville, MD) included: astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, and human umbilical vein endothelial. These primary cell types were activated by incubating with 25 various cytokines (IL-I beta ~1 -5 ng/ml, TNF alpha -5-10 ng/ml, IFN gamma ~20-50 ng/ml, IL-4 -5-10 ng/ml, IL-9 -5-10 ng/ml, IL-13 5-10 ng/ml) or combinations of cytokines as indicated. Starved endothelial cells were cultured in the basal media (Clonetics, Walkersville, MD) with 0.1% serum. Mononuclear cells were prepared from blood donations using Ficoll. LAK cells were 30 cultured in culture media [DMEM, 5% FCS (Hyclone, Logan, UT), 100 mM non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1 mM sodium pyruvate (Gibco), 306 WO 2004/013347 PCT/US2003/024504 mercaptoethanol 5.5 x 10- M (Gibco), and 10 mM Hepes (Gibco)] and interleukin 2 for 4-6 days. Cells were activated with 10-20 ng/ml PMA and 1-2 ig/ml ionomycin, 5-10 ng/ml IL 12, 20-50 ng/ml IFN gamma or 5-10 ng/ml IL-18 for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in culture media with ~5 mg/ml PHA (phytohemagglutinin) 5 or PWM (pokeweed mitogen; Sigma-Aldrich Corp., St. Louis, MO). Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing them 1:1 at a final concentration of-2x10 6 cells/ml in culture media. The MLR samples were taken at various time points from 1-7 days for RNA preparation. 10 Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culturing in culture media with 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culturing monocytes for 5-7 days in culture media with ~50 ng/ml 10% type AB 15 Human Serum (Life technologies, Rockville, MD) or MCSF (Macrophage colony stimulating factor; R&D, Minneapolis, MN). Monocytes, macrophages and dendritic cells were stimulated for 6 or 12-14 hours with 100 ng/ml lipopolysaccharide (LPS). Dendritic cells were also stimulated with 10 pg/ml anti-CD40 monoclonal antibody (Pharmingen, San Diego, CA) for 6 or 12-14 hours. 20 CD4+ lymphocytes, CD8+ lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions. CD45+RA and CD45+RO CD4+ lymphocytes were isolated by depleting mononuclear cells of CD8+, CD56+, CD14+ and CD19+ cells using CD8, CD56, CD14 and CD19 Miltenyi 25 beads and positive selection. CD45RO Miltenyi beads were then used to separate the CD45+RO CD4+ lymphocytes from CD45+RA CD4+ lymphocytes. CD45+RA CD4+, CD45+RO CD4 +and CD8+ lymphocytes were cultured in culture media at 106 cells/ml in culture plates precoated overnight with 0.5 mg/ml anti-CD28 (Pharmingen, San Diego, CA) and 3 pLg/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested 30 for RNA preparation. To prepare chronically activated CD8+ lymphocytes, isolated CD8+ lymphocytes were activated for 4 days on anti-CD28, anti-CD3 coated plates and then harvested and expanded in culture media with IL-2 (1 ng/ml). These CD8+ cells were activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as 307 WO 2004/013347 PCT/US2003/024504 described above. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. Isolated NK cells were cultured in culture media with 1 ng/ml IL-2 for 4-6 days before RNA was prepared. B cells were prepared from minced and sieved tonsil tissue (NDRI). Tonsil cells were 5 pelleted and resupended at 106 cells/mi in culture media. Cells were activated using 5 pg/ml PWM (Sigma-Aldrich Corp., St. Louis, MO) or-10 pg/ml anti-CD40 (Pharmingen, San Diego, CA) and 5-10 ng/ml IL-4. Cells were harvested for RNA preparation after 24, 48 and 72 hours. To prepare primary and secondary Thl/Th2 and Tr cells, umbilical cord blood CD4+ 10 lymphocytes (Poietic Systems, German Town, MD) were cultured at 10 5 -10 6 cells/ml in culture media with IL-2 (4 ng/ml) in 6-well Falcon plates (precoated overnight with 10 pg/ml anti-CD28 (Pharmingen) and 2 pg/ml anti-CD3 (OKT3; ATCC) then washed twice with PBS). To stimulate Thl phenotype differentiation, IL-12 (5 ng/ml) and anti-IL4 (1 pg/ml) were 15 used; for Th2 phenotype differentiation, IL-4 (5 ng/ml) and anti-IFN gamma (1 [tg/ml) were used; and for Tr phenotype differentiation, IL-10 (5 ng/ml) was used. After 4-5 days, the activated Thl, Th2 and Tr1 lymphocytes were washed once with DMEM and expanded for 4-7 days in culture media with IL-2 (1 ng/ml). Activated Thl, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/CD3 and cytokines as described above with 20 the addition of anti-CD95L (1 pg/ml) to prevent apoptosis. After 4-5 days, the Thl, Th2 and Tr1 lymphocytes were washed and expanded in culture media with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate-bound anti-CD3 and anti-CD28 mAbs and 4 days 25 into the second and third expansion cultures. Leukocyte cells lines Ramos, EOL-1, KU-812 were obtained from the ATCC. EOL-1 cells were further differentiated by culturing in culture media at 5 x10 5 cells/ml with 0.1 mM dbcAMP for 8 days, changing the media every 3 days and adjusting the cell concentration to 5 X105 cells/ml. RNA was prepared from resting cells or cells activated with PMA (10 30 ng/ml) and ionomycin (I pig/ml) for 6 and 14 hours. RNA was prepared from resting CCD 1106 keratinocyte cell line (ATCC) or from cells activated with -5 ng/ml TNF alpha and 1 ng/ml IL-1 beta. RNA was prepared from resting NCI-H292, airway epithelial tumor cell 308 WO 2004/013347 PCT/US2003/024504 line (ATCC) or from cells activated for 6 and 14 hours in culture media with 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13, and 25 ng/ml IFN gamma. RNA was prepared by lysing approximately 107 cells/ml using Trizol (Gibco BRL) then adding 1/10 volume of bromochloropropane (Molecular Research Corporation, Cincinnati, 5 OH), vortexing, incubating for 10 minutes at room temperature and then spinning at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was placed in a 15 ml Falcon Tube and an equal volume of isopropanol was added and left at -20' C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min and washed in 70% ethanol. The pellet was redissolved in 300 pl of RNAse-free water with 35 ml buffer (Promega, Madison, WI) 5 pl 10 DTT, 7 pl RNAsin and 8 p1 DNAse and incubated at 370 C for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3 M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down, placed in RNAse free water and stored at -80' C. AI_comprehensive panel vl.O 15 Autoimmunity (AI) comprehensive panel v1.0 included two controls and 89 cDNA test samples isolated from male (M) and female (F) surgical and postmortem human tissues that were obtained from the Backus Hospital and Clinomics (Frederick, MD). Tissue samples included : normal, adjacent (Adj); matched normal adjacent (match control); joint tissues (synoyial (Syn) fluid, synovium, bone and cartilage, osteoarthritis (OA), rheumatoid arthritis 20 (RA)); psoriatic; ulcerative colitis colon; Crohns disease colon; and emphysmatic, asthmatic, allergic and chronic obstructive pulmonary disease (COPD) lung. Pulmonary and General inflammation (PGI) panel vl.O Pulmonary and General inflammation (PGI) panel v1.0 included two controls and 39 test samples isolated as surgical or postmortem samples. Tissue samples include: five normal 25 lung samples obtained from Maryland Brain and Tissue Bank, University ofMaryland (Baltimore, MD), International Bioresource systems, IBS (Tuscon, AZ), and Asterand (Detroit, MI), five normal adjacent intestine tissues (NAT) from Ardais (Lexington, MA), ulcerative colitis samples (UC) from Ardais (Lexington, MA); Crohns disease colon from NDRI, National Disease Research Interchange (Philadelphia, PA); emphysematous tissue 30 samples from Ardais (Lexington, MA) and Genomic Collaborative Inc. (Cambridge, MA), asthmatic tissue from Maryland Brain and Tissue Bank, University of Maryland (Baltimore, 309 WO 2004/013347 PCT/US2003/024504 MD) and Genomic Collaborative Inc (Cambridge, MA) and fibrotic tissue from Ardais (Lexinton, MA) and Genomic Collaborative (Cambridge, MA). Cellular OA/RA Panel Cellular OA.RA panel includes 2 control wells and 35 test samples comprised of cDNA 5 generated from total RNA isolated from human cell lines or primary cells representative of the human joint and its inflammatory condition. Cell types included normal human osteoblasts (Nhost) from Clonetics (Cambrex, East Rutherford, NJ), human chondrosarcoma SW1353 cells from ATCC (Manossas, VA)), human fibroblast-like synoviocytes from Cell Applications, Inc. (San Diego, CA) and MH7A cell line (a rheumatoid fibroblast-like 10 synoviocytes transformed with SV40 T antigen) from Riken Cell bank ( Tsukuba Science City, Japan). These cell types were activated by incubating with various cytokines (IL-I beta ~1-10 ng/ml, TNF alpha -5-50 ng/ml, or prostaglandin E2 for Nhost cells) for 1, 6, 18 or 24 h. All these cells were starved for at least 5 h and cultured in their corresponding basal medium with - 0.1 to 1 % FBS. 15 Minitissue OA/RA Panel The OA/RA mini panel includes two control wells and 31 test samples comprised of cDNA generated from total RNA isolated from surgical and postmortem human tissues obtained from the University of Calgary (Alberta, Canada), NDRI (Philadelphia, PA), and Ardais Corporation (Lexington, MA). Joint tissue samples include synovium, bone and cartilage 20 from osteoarthritic and rheumatoid arthritis patients undergoing reconstructive knee surgery, as well as, normal synovium samples (RNA and tissue). Visceral normal tissues were pooled from 2-5 different adults and included adrenal gland, heart, kidney, brain, colon, lung, stomach, small intestine, skeletal muscle, and ovary. AI.05 chondrosarcoma 25 AI.05 chondrosarcoma plates included SW1353 cells (ATCC) subjected to serum starvation and treated for 6 and 18 h with cytokines that are known to induce MMP (1, 3 and 13) synthesis (e.g. ILlbeta). These treatments included: IL-1beta (10 ng/ml), IL-1beta + TNF alpha (50 ng/ml), IL-1beta + Oncostatin (50 ng/ml) and PMA (100 ng/ml). Supernatants were collected and analyzed for MMP 1, 3 and 13 production. RNA was prepared from these 30 samples using standard procedures. 310 WO 2004/013347 PCT/US2003/024504 Panels 5D and 51 Panel SD and 51 included two controls and cDNAs isolated from human tissues, human pancreatic islets cells, cell lines, metabolic tissues obtained from patients enrolled in the Gestational Diabetes study (described below), and cells from different stages of adipocyte 5 differentiation, including differentiated (AD), midway differentiated (AM), and undifferentiated (U; human mesenchymal stem cells). Gestational Diabetes study subjects were young (18 - 40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. Uterine wall smooth muscle (UT), visceral (Vis) adipose, skeletal muscle (SK), placenta (P1) 10 greater omentum adipose (GO Adipose) and subcutaneous (SubQ) adipose samples (less than 1 cc) were. collected, rinsed in sterile saline, blotted and flash frozen in liquid nitrogen. Patients included: Patient 2, an overweight diabetic Hispanic not on insulin; Patient 7-9, obese non-diabetic Caucasians with body mass index (BMI) greater than 30; Patient 10, an overweight diabetic Hispanic, on insulin; Patient 11, an overweight nondiabetic African 15 American; and Patient 12, a diabetic Hispanic on insulin. Differentiated adipocytes were obtained from induced donor progenitor cells (Clonetics, Walkersville, MD). Differentiated human mesenchymal stem cells (HuMSCs) were prepared as described in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr 2 1999: 143-147. mRNA was isolated and sscDNA 20 was produced from Trizol lysates or frozen pellets. Human cell lines (ATCC, NCI or German tumor cell bank) included: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells and adrenal cortical adenoma cells. Cells were cultured, RNA extracted and sscDNA was produced using standard procedures. 25 Panel 51 also contains pancreatic islets (Diabetes Research Institute at the University of Miami School of Medicine). Human Metabolic RTQ-PCR Panel Human Metabolic RTQ-PCR Panel included two controls (genomic DNA control and chemistry control) and 211 cDNAs isolated from human tissues and cell lines relevant to 30 metabolic diseases. This panel identifies genes that play a role in the etiology and 311 WO 2004/013347 PCT/US2003/024504 pathogenesis of obesity and/or diabetes. Metabolic tissues including placenta (PI), uterine wall smooth muscle (Ut), visceral adipose, skeletal muscle (Sk) and subcutaneous (SubQ) adipose were obtained from the Gestational Diabetes study (described above). Included in the panel are: Patients 7 and 8, obese non-diabetic Caucasians; Patient 12 a diabetic 5 Caucasian with unknown BMI, on insulin (treated); Patient 13, an overweight diabetic Caucasian, not on insulin (untreated); Patient 15, an obese, untreated, diabetic Caucasian; Patient 17 and 25, untreated diabetic Caucasians of normal weight; Patient 18, an obese, untreated, diabetic Hispanic; Patient 19, a non-diabetic Caucasian of normal weight; Patient 20, an overweight, treated diabetic Caucasian; Patient 21 and 23, overweight non-diabetic 10 Caucasians; Patient 22, a treated diabetic Caucasian of normal weight; Patient 23, an overweight non-diabetic Caucasian; and Patients 26 and 27, obese, treated, diabetic Caucasians. Total RNA was isolated from metabolic tissues including: hypothalamus, liver, pancreas, pancreatic islets, small intestine, psoas muscle, diaphragm muscle, visceral (Vis) adipose, 15 subcutaneous (SubQ) adipose and greater omentum (Go) from 12 Type II diabetic (Diab) patients and 12 non diabetic (Norm) at autopsy. Control diabetic and non-diabetic subjects were matched where possible for: age; sex, male (M); female (F); ethnicity, Caucasian (CC); Hispanic (HI); African American (AA); Asian (AS); and BMI, 20-25 (Low BM), 26-30 (Med BM) or overweight (Overwt), BMI greater than 30 (Hi BMI) (obese). 20 RNA was extracted and ss cDNA was produced from cell lines (ATCC) by standard methods. CNS Panels CNS Panels CNSD.01, CNS Neurodegeneration VL.O and CNS Neurodegeneration V2.0 included two controls and 46 to 94 test cDNA samples isolated from postmortem human 25 brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital). Brains were removed from calvaria of donors between 4 and 24 hours after death, and frozen at -80' C in liquid nitrogen vapor. Panel CNSD.01 Panel CNSD.01 included two specimens each from: Alzheimer's disease, Parkinson's 30 disease, Huntington's disease, Progressive Supernuclear Palsy (PSP), Depression, and 312 WO 2004/013347 PCT/US2003/024504 normal controls. Collected tissues included: cingulate gyrus (Cing Gyr), temporal pole (Temp Pole), globus palladus (Glob palladus), substantia nigra (Sub Nigra), primary motor strip (Brodman Area 4), parietal cortex (Brodman Area 7), prefrontal cortex (Brodman Area 9), and occipital cortex (Brodman area 17). Not all brain regions are represented in all cases. 5 Panel CNS Neurodegeneration V1.O The CNS Neurodegeneration V1.0 panel included: six Alzheimer's disease (AD) brains and eight normals which included no dementia and no Alzheimer's like pathology (control) or no dementia but evidence of severe Alzheimer's like pathology (Control Path), specifically senile plaque load rated as level 3 on a scale of 0-3; 0 no evidence of plaques, 3 severe AD 10 senile plaque load. Tissues collected included: hippocampus, temporal cortex (Brodman Area 21), parietal cortex (Brodman area 7), occipital cortex (Brodman area 17) superior temporal cortex (Sup Temporal Ctx) and inferior temporal cortex (Inf Temproal Ctx). Gene expression was analyzed after normalization using a scaling factor calculated by subtracting the Well mean (CT average for the specific tissue) from the Grand mean (average 15 CT value for all wells across all runs). The scaled CT value is the result of the raw CT value plus the scaling factor. Panel CNS Neurodegeneration V2.0 The CNS Neurodegeneration V2.0 panel included sixteen cases of Alzheimer's disease (AD) and twenty-nine normal controls (no evidence of dementia prior to death) including fourteen 20 controls (Control) with no dementia and no Alzheimer's like pathology and fifteen controls with no dementia but evidence of severe Alzheimer's like pathology (AH3), specifically senile plaque load rated as level 3 on a scale of 0-3; 0 no evidence of plaques, 3 severe AD senile plaque load. Tissues from the temporal cortex (Brodman Area 21) included the inferior and superior temporal cortex that was pooled from a given individual (Inf & Sup 25 Temp Ctx Pool). Example Q1O. PathCalling) Technology 30 The sequence of NOVX was derived by laboratory screening of cDNA library by the two-hybrid approach. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, were sequenced. In silico prediction was based on sequences 313 WO 2004/013347 PCT/US2003/024504 available in CuraGen Corporation's proprietary sequence databases or in the public human sequence databases, and provided either the full-length DNA sequence, or some portion thereof. The laboratory screening was performed using the methods that follow. cDNA 5 libraries were derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The 10 cDNA thus derived was then directionally cloned into the appropriate two-hybrid vector (Gal4-activation domain (Gal4-AD) fusion). Such cDNA libraries as well as commercially available cDNA libraries from Clontech (Palo Alto, CA) were then transferred from E.coli into a CuraGen Corporation proprietary yeast strain (disclosed in U. S. Patents 6,057,101 and 6,083,693, incorporated herein by reference in their entireties). 15 Gal4-binding domain (Gal4-BD) fusions of a CuraGen Corportion proprietary library of human sequences was used to screen multiple Gal4-AD fusion cDNA libraries resulting in the selection of yeast hybrid diploids in each of which the Gal4-AD fusion contains an individual cDNA. Each sample was amplified using the polymerase chain reaction (PCR) using non-specific primers at the cDNA insert boundaries. Such PCR product was 20 sequenced; sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation's database. Sequences were included as components for assembly when the extent of identity with 25 another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations. Physical clone: the cDNA fragment derived by the screening procedure, covering the entire open reading frame is, as a recombinant DNA, cloned into pACT2 plasmid (Clontech) 30 used to make the cDNA library. The recombinant plasmid is inserted into the host and selected by the yeast hybrid diploid generated during the screening procedure by the mating 314 WO 2004/013347 PCT/US2003/024504 of both CuraGen Corporation proprietary yeast strains N106' and YULH (U. S. Patents 6,057,101 and 6,083,693). OTHER EMBODIMENTS 5 While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. 315

Claims (36)

1. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:2n-1, wherein n is an integer between 1 and 85.

2. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 85.

3. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 85.

4. An isolated polypeptide of claim 3, wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:96, SEQ ID NO:98, SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ ID NO:108, and SEQ ID NO:110.

5. An isolated polypeptide of claim 3, wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:130, SEQ ID NO:136, SEQ ID NO:138, SEQ UD NO:144, SEQ ID NO:148, SEQ ID NO:152, and SEQ ID NO:154.

6. An isolated polypeptide of claim 3, wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, and SEQ ID NO:28.

7. An isolated polypeptide of claim 3, wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, and SEQ I) NO:156

8. An isolated polypeptide of claim 3, wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, and SEQ ID NO:54.

9. An isolated polypeptide of claim 3, wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:56, SEQ ID NO:58, and SEQ ID NO:168.

10. An isolated polypeptide of claim 3, wherein the isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ TID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, and SEQ ID NO:170. 316 WO 2004/013347 PCT/US2003/024504

11. A method for identifying compounds that modulate target polypeptide activity compnsmg: (a) combining a test compound with a target polypeptide and a substrate of the target polypeptide; and (b) determining whether the test compound modulates the activity of the target polypeptide; wherein the target polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 85, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at least 95% identical to the at least one domain of SEQ ID NO:2n.

12. The method of claim 11, further comprising a step of identifying the test compound that modulates the target polypeptide activity by inhibiting the target polypeptide activity as an inhibitor of the target polypeptide activity.

13. The method of claim 11, further comprising a step of identifying the test compound that modulates the target polypeptide activity by inhibiting the target polypeptide activity as an antagonist of the target polypeptide.

14. The method of claim 11, further comprising a step of identifying the test compound that modulates the target polypeptide activity by activating the target polypeptide activity as an activator of the target polypeptide activity.

15. The method of claim 11, further comprising a step of identifying the test compound that modulates the target polypeptide activity by activating the target polypeptide activity as an agonist of the target polypeptide.

16. The method of claim 11, further comprising a step of identifying the test compound that modulates the target polypeptide activity as an enhancer of insulin secretion.

17. The method of claim 11, further comprising a step of identifying the test compound that modulates the target polypeptide activity as a therapeutic for treatment of insulin resistance.

18. The method of claim 11, further comprising a step of identifying the test compound that modulates the target polypeptide activity as a therapeutic for treatment of obesity.

19. The method of claim 11, further comprising a step of identifying the test compound that modulates the target polypeptide activity as a therapeutic for treatment of diabetes.

20. The method of claim 11, wherein the target polypeptide is an isolated polypeptide.

21. The method of claim 11, wherein the target polypeptide is produced by a process comprising culturing a recombinant host cell, the recombinant host cell comprising a nucleic acid encoding the target polypeptide, under conditions promoting expression of the target polypeptide. 317 WO 2004/013347 PCT/US2003/024504

22. The method of claim 21, wherein the nucleic acid comprises a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:2n-1, wherein n is an integer between 1 and 85; (b) nucleotides encoding an amino acid sequence of the at least one domain of SEQ ID NO:2n; and c) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO:2n, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at least 95% identical to the at least one domain of SEQ ID NO:2n.

23. The method of claim 11, wherein the target polypeptide is produced by expression of a recombinant vector comprising a nucleic acid, the nucleic acid encoding an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 85, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at least 95% identical to the at least one domain of SEQ ID NO:2n.

24. The method of claim 23, wherein the test compound is combined with the target polypeptide in a mammalian cell grown in culture.

25. The method of claim 23, wherein the test compound is combined with the target polypeptide in vitro.

26. The method of claim 23, wherein the nucleic acid comprises a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:2n-1, wherein n is an integer between 1 and 85; (b) nucleotides encoding an amino acid sequence of the at least one domain of SEQ ID NO:2n; and c) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO:2n, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at least 95% identical to the at least one domain of SEQ ID NO:2n.

27. The method of claim 11, wherein the target polypeptide is produced by expression of an endogenous nucleic acid, the endogenous nucleic acid encoding an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 85, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at least 95% identical to the at least one domain of SEQ ID NO:2n.

28. The method of claim 27, wherein the test compound is combined with the target polypeptide in a mammalian cell grown in culture.

29. The method of claim 27, wherein the test compound is combined with the target 318 WO 2004/013347 PCT/US2003/024504 polypeptide in vitro.

30. The method of claim 27, wherein the endogenous nucleic acid comprises a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:2n-1, wherein n is an integer between 1 and 85; (b) nucleotides encoding an amino acid sequence of the at least one domain of SEQ ID NO:2n; and (c) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO:2n, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at least 95% identical to the at least one domain of SEQ ID NO:2n.

31. An antibody that immunospecifically binds to the target polypeptide, wherein the target polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 85, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at least 95% identical to the at least one domain of SEQ ID NO:2n.

32. The antibody of claim 31, wherein the antibody is a monoclonal antibody.

33. The antibody of claim 31, wherein the antibody is a humanized antibody.

34. The antibody of claim 31, wherein the antibody is a human antibody.

35. A method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of a target polypeptide, the method comprising: (a) providing a cell expressing the target polypeptide and having a property or function ascribable to the target polypeptide; (b) contacting the cell with a composition comprising a candidate test compound; and (c) determining whether the test compound alters the property or function ascribable to the target polypeptide; whereby, if an alteration observed in the presence of the test compound is not observed when the cell is contacted with the composition in the absence of the test compound, the test compound is identified as a potential therapeutic agent; and wherein the target polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 85, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at least 95% identical to the at least one domain of SEQ ID NO:2n. 319 WO 2004/013347 PCT/US2003/024504

36. A method for screening for a modulator of activity of or of latency or predisposition to a pathology associated with a target polypeptide, the method comprising: (a) administering a test compound to a test animal at an increased risk for a pathology associated with the target polypeptide, wherein the test animal recombinantly expresses the target polypeptide; (b) measuring the activity of the target polypeptide in the test animal after administering the test compound of step (a); and (c) comparing the activity of the target polypeptide in the test animal with the activity of the target polypeptide in a control animal not administered the test compound, wherein a change in the activity of the target polypeptide in the test animal relative to the control animal indicates that the test compound is a modulator of activity of or of latency or predisposition to, a pathology associated with the target polypeptide; wherein the target polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 85, the amino acid sequence that is at least 95% identical to SEQ ID NO:2n, the amino acid sequence of at least one domain of SEQ ID NO:2n, and the amino acid sequence that is at least 95% identical to the at least one domain of SEQ ID NO:2n. 320